
The HKU Scholars Hub




Title	Life science academic output in predominantly Chinese communities, 1990 to 2001: China, Hong Kong, Singapore and Taiwan
Other Contributor(s)	University of Hong Kong. Faculty of Medicine.
Author(s)	Karlberg, J
Citation	
Issued Date	2003
URL	http://hdl.handle.net/10722/54813
Rights	Creative Commons: Attribution 3.0 Hong Kong License


In Predominantly Chinese Communities 1990 to 2001


China, Hong Kong, Singapore and Taiwan







Clinical Science





Pre-clinical Science





Clinical and Pre-clinical Science









Table of Contents

	4000	
- 1		Foreword
1		TOTEWOLD

- 7 Introduction
- 10 Research Output and Research Impact
- Global Research Impact given by the Number of Publications
- 14 Research Output and Public Health
- 16 Asian Research Impact given by the Number of Publications
- 18 Research Impact given by the Number of Very High Impact Publications
- 22 Citation Index
- 24 Surgery as an Example of Area Adjusted Journal Impact Factor
- 26 Medline Listed Journals with No Impact Factor
- 32 Hong Kong Total Academic Output
- 34 Hong Kong Area Specific Academic Output
- 38 Area Specific Publication Impact
- 40 Summary of Area Specific Publication Impact
- 48 Summary
- 50 Appendix
- (51) Multidisciplinary Sciences
- (52) Biochemistry and Molecular Biology
- (58) Biotechnology and Applied Microbiology
- (61) Cardiac and Cardiovascular Systems
- (63) Cell Biology
- (67) Clinical Neurology
- (70) Critical Care Medicine
- (72) Dentistry, Oral Surgery and Medicine
- (74) Emergency Medicine

Table of Contents (continued)

- (76) Endocrinology and Metabolism
- 79 Gastroenterology and Hepatology
- (81) Genetics and Heredity
- (84) Geriatrics and Gerontology
- (86) Hematology
- (88) Immunology
- 91 Infectious Diseases
- 95 Materials Science and Biomaterials
- 97 Medicine, General and Internal
- 100 Microbiology
- (103) Neurosciences
- (105) Nutrition and Dietetics
- Obstetrics and Gynecology
- (109) Oncology
- (112) Ophthalmology
- (114) Orthopedics
- (116) Otorhinolaryngology
- 118 Pathology
- (121 Pediatrics
- 124 Peripheral Vascular Disease
- 126 Pharmacology and Pharmacy
- 130 Physiology
- 133 Psychiatry
- 136 Public, Environmental and Occupational Health
- (139) Radiology, Nuclear Medicine and Medical Imaging
- (142) Reproductive Biology
- Respiratory System
- (146) Rheumatology
- 148 Surgery
- (151) Toxicology
- 154) Transplantation
- (156) Urology and Nephrology
- (158) Virology

Foreword

In 1998, the Faculty of Medicine at The University of Hong Kong, Hong Kong SAR established a Clinical Trials Centre to act as an interface between the industry and investigator teams at the university and affiliated hospitals. Trial activities have since focused on evaluating new clinical treatments, procedures, devices and diagnostic tools -- commonly developed by large international pharmaceutical companies from North America, Europe and Japan. Reasons for involvement in such research are both academic and financial, in addition to the possibility of improving the care of trial participants.

Most clinical trials of new treatments are of the highest quality; with a good study design, sufficient number of trial participants and sufficient resources to conduct essential investigations and laboratory tests. Since trials aim to provide evidence for both treatment efficacy and treatment safety of new medical treatments, the results are of interest not only locally, but also to clinical researchers and clinicians world-wide. Since the likelihood is high of having results published in international clinical research journals of high repute, the trial results can therefore have a high impact on the global medical scientific community. For this reason, clinical trials on new medical treatments generally have a high academic value, or what we usually call HIGH IMPACT RESEARCH.

A pharmaceutical or biotechnology company usually funds all parts of a clinical trial -- including drug cost, clinical investigations, laboratory tests processing, investigator and nursing fees, data management, statistical analysis and medical writing. Since the trial results are commonly reviewed by drug regulatory authorities in the US, Europe or Japan, trial costs affecting the quality of the data collected cannot be cut, or acceptance would be jeopardised. Clinical trials not only embrace patient treatment costs, but also provide investigator teams with extra funding for staff employment. In an academic medical institution, the investigator trial fee provided by the sponsor for the work conducted by the clinical research team is commonly used to enhance other research activities that are not easily funded by other means. One important by-product of trial involvement is thus that the investigator team may be able to produce additional, independent research. More funding leads to more research, which leads to an increasing number of studies published in international publications -- and ultimately HIGHER IMPACT and greater prestige for the team and its institution.

The question posed by this book is simple – how HIGH IMPACT is CLINICAL RESEARCH in HONG KONG in comparison with other predominantly Chinese communities like China, Taiwan and Singapore, and to some extent also with the rest of the world? The Clinical Trials Centre at HKU is keen to attract more clinical trials to Hong Kong – an initiative which both encourages the biotechnology industry in Hong Kong and establishes Hong Kong as a bridge to biotechnology development in mainland China. The ambition is also to attract more research and development teams from the international pharmaceutical industry to Hong Kong.

Johan Karlberg, MD, PhD

Professor and Director

Clinical Trials Centre

Faculty of Medicine

The University of Hong Kong

February 2003

Introduction

Several emerging regions in Asia, Eastern Europe, Africa, and South and Latin America are conducting clinical trials on new drugs, devices and diagnostic tools. This study does not attempt to present a 'big picture' addressing the possibilities or problems concerning the conduct of clinical trials across these regions. Instead, it focuses on a single location in one region -- Hong Kong in Asia. The question being addressed is: What is needed in an emerging region to strive for excellence in order to become a competitive location for the conduct of biotechnology research, when compared with established regions, in say North America, the European Commission and Japan? Many interacting factors are important when striving for excellence. In biotechnology, these not only include the need for long-term financial support from governments and the industry. Also critical is the establishment of an infrastructure that makes the region attractive to large international pharmaceutical companies and researchers of a high international standard. The required infrastructure ranges from access to office space and well-trained local researchers and research support staff to implementing and complying with international guidelines.

Involvement in global clinical trials is certainly a first important step to becoming a player in the biotechnology arena. But that is not enough if the aim is to establish a self-financed local biotechnology industry. The way is long and the investment is large from early discovery of a molecule in the laboratory of a pre-clinical research through clinical trials to the market. But many well-known international pharmaceutical companies were established on the strength of university researchers making important new medical discoveries. With the backing of investors, they were able to develop their molecule into a new medical therapy -- to the benefit of patients and society at large. This has happened many times in North America, Europe, Japan and other developed regions -- and it can be emulated in new emerging biotechnology regions as well.

Before 1996, very few Phase I-III trials for global registration purposes were conducted in Asia outside of Japan. It was hard to name a single local research and development team of an international pharmaceutical company represented in the region. But since then Hong Kong, along with other countries in Asia, has suddenly become an important hub for global clinical trials. Consider, for instance, the quantum leap in clinical trial certificates for phase I-III clinical trials that have been approved by Hong Kong's Department of Health. Between 1988 and 1995, the annual number of certificates approved was 22. This number increased to 56 between 1996 and 1999 -- and to 113 between 2000 and 2001. There were five times more clinical trials of new pharmaceutical entities initiated in 2001 than over the previous five years – and the pace of growth was 500% over 10 years, or 50% per year. Growth in clinical trial activities will certainly continue for decades. How do we know this trend will continue in Hong Kong and in Asia? Well, firstly, it's a global trend – more compounds need to be

developed, so more trials per compound need to be conducted, so more patients will be required for each clinical trial. Secondly, Asia has a large patient population and many potential investigators, which are two important selection criteria for a trial site. Thirdly, some diseases are much more prevalent in Asia than in other continents. Fourthly, the potential market for a new treatment can be large in Asia. Finally, the Asian biotechnology industry is developing very rapidly and also needs to conduct its own trials.

However, some important factors will eventually lead to a negative impact on the expected increase in clinical trial activities and biotechnology development in Hong Kong and Asia if they are not addressed effectively and in a timely manner. Governments, including the Hong Kong SAR Government, must listen, understand and take initiatives to meet the needs of the industry. With the anticipated increase in trial activities will be a growing requirement for well-qualified study site personnel and well-trained personnel working locally for international pharmaceutical companies. It is also important to understand and establish various quality assurance programmes, including international accreditation(s) of clinical laboratory tests, standardisation and audits of the operation of ethics committees, the acceptance and enforcement of international clinical trial guidelines, and the operation of other clinical trial support services.

But who should take the lead to start the transition towards a clinical trial environment up to acceptable international standards? Government institutions, private entities, or both? It is the author's view that this will only happen if there is sufficient 'critical mass' involved -- in both pre-clinical and as well as clinical phases of drug development. In addition, a drug regulatory authority is essential in the region, to advise the industry during various drug development phases and ensure recognition of study results by drug regulatory authorities oversees. If a new drug is not accepted overseas, it cannot be marketed overseas.

The Hospital Authority of the Hong Kong SAR Government is responsible for patient care of most citizens in Hong Kong. The Authority has been very successful in its work, as implied by one of the world's lowest infant mortality rates (about 3 in 1000) and highest life expectancy (about 80 years). A high standard of medical care is, of course, an important aspect when a new therapy enters the clinical testing phase. Hong Kong has two universities with medical faculties — The University of Hong Kong and the Chinese University of Hong Kong — and six other universities.

By outlining academic output over the past 12 years (1990-2001) in the medical and biology, or life science area by various institutions in Hong Kong, this report aims to identify strengths as well as weaknesses from a

pre-clinical and clinical research point of view. Since interest is growing in understanding the differences between ethnic groups in response to medical treatments and safety are becoming more and more interesting, it is also important to compare Hong Kong research with output from three other regions with predominantly Chinese populations — namely China, Singapore and Taiwan. Some comparison with other countries in Asia, as well as countries in other continents, is also relevant as a measure of international recognition and competence.

Reference

Clinical Trial Reporter, Lippincott Williams & Wilkins, Asia Ltd, Hong Kong SAR 2002;1:9.

Research Output and Research Impact

There is no universally accepted and adopted way to describe academic research output, despite demand for such a generally accepted instrument, even at the level of deciding appropriate resource allocation to universities or individual university departments, or for staff promotion purposes. The number of publications is a simple way of measuring academic output. But from a scientific point of view, not all publications carry the same weight or make the same impact. A research report reviewed and accepted by a scientific journal - peer reviewed - is commonly seen as having a higher scientific value than a 'non-peer reviewed' published research report. However, one peer-reviewed journal may have a higher impact factor – i.e. a larger number of citations for each individual paper published in the journal – than another peer-reviewed journal. A further complicating factor is that only a few papers represent most citations in any journal, so a study is not necessarily important even if it is published in a journal with a high impact factor. Comparing the impact factors of journals is meaningless, for instance, if they serve different disciplines in which widely different citation practices may prevail. However, for better or worse, the global trend is for academic publication citation statistics to be increasingly used as a standard metric to assess the quality of scientific work. Both the citation statistics of an individual paper and the 'impact factor' of the journal publishing it is being taken more and more seriously.

This study presents a general comparison of the academic output in life science from January 1990 to November 2001 between Hong Kong institutions, and between Hong Kong and other regions. The results are not presented for funding purposes, staff promotion or for comparison of individual departments. The aim is rather to identify the strengths and weaknesses of clinical research in Hong Kong as an emerging centre for biotechnology development. For this reason, a rather simple method is adopted -- based partly on some common assumptions and practices.

- Database: Publications published in peer-reviewed journals are usually seen as having high impact compared to other types of scientific communication, such as abstracts from meetings, book chapters and departmental reports. This is why only publications listed in the Medline data-base are included.
- Years: The Medline data-base lists publications over the last four decades. But this analysis is restricted to the last 12 years: between January 1990 and November 2001.
- Full-publications: Only full publications (original or review articles, not letters) are included.
- Corresponding Address: The corresponding address in the address field of the Medline data-base was used to identify the country and institution of each individual publication. This address virtually always represents the institution that contributed to the majority of research behind the publication, i.e. hypotheses generation, study design, study conduct, funding, data management, medical statistics and medical writing.

• Citation Report: Publications included in local scientific journals can be listed in the Medline data-base, but

they may not be included in the Journal Citation Reports (JCR) data-base, if they have a low overall impact on

the international community. Only publications found both in the Medline data-base and listed in the 2000

version of the JCR data-base were included for most comparisons

• Adjusted Impact Factor: Some areas of research have an average a much lower Impact Factor than other

areas, due to a tradition or custom of including either few or many citations in individual publications. All

journals in a specific area of the (JCR) data-base are rated in terms of their Impact Factor in relation to each

other, rather than in relation to all journals for all areas taken together. This provides an Area Specific or Subject

Category Impact Factor; in other words, an Adjusted Impact Factor as illustrates on page 22 - "Impact Factor

by Area".

• Very High Impact Factor: The number of publications found in a few general medical scientific journals of

very high impact and high repute are also presented in isolation. Four journals were deemed to represent High

Impact Clinical Science - The Lancet, New England Journal of Medicine (N Engl J Med), Journal of the

American Medical Association (JAMA) and British Medical Journal (BMJ). Two additional journals were chosen

to represent High Impact Basic Science: Nature and Science.

• Population Statistics: The population size, infant mortality rate and life expectancy of some countries are

used in some analyses, from figures published elsewhere.

References

Medline - Available at: http://www.medline.com.

Journal Citation Reports - ISI. Available at: http://www.isinet.com/isi/products/citation/jcr.

Jemec GBE. Impact factor to assess academic output [correspondence]. - The Lancet 2001; 358:1373.

Horgan A. BMJ's impact factor increases by 24% [new roundup]. - BMJ 2002; 325:8.

Vital Statistics World Health Organisation - Available at : http://www.who.int/country/en

11

Global Research Impact given by the Number of Publications

A simple and easy measure of the research impact of a country is the total number of publications. Figure 1 gives the number of full publications — excluding letters as the mode of communication — in Medline between January 1990 and November 2001 for the top 50 countries globally. Disregarding population density, it is not surprising that the United States has the largest number, followed by Japan and United Kingdom. The figures in Figure 1 should be regarded with some caution since about 25% of all full publications in Medline during the years of observation could not be linked to any particular country. Some publications do not give the country in the address of correspondence field; others used local languages such as Italian, German or Swedish to identify the country. Two countries, namely the US and UK, were often identified by individual states or institutions. Despite of this relatively high drop-out rate, the overall picture is nevertheless deemed realistic since the drop-out rate can be assumed to be quite similar between countries. When all the countries previously belonging to "western" Europe were combined, the number of publications increased to 1.22 million — similar to the US tally of 1.29 million. Note, that 18th position is taken by Taiwan, 24th by China, 31st by Hong Kong and 35th by Singapore when the total number of publications are taken as the measure for comparison. About 62,000 publications were identified from the four predominantly Chinese communities combined over the 12 years of study.

The overall aim of medical research is to find new treatments or preventive measures for proper management of disease in the community. It is thus be appropriate to incorporate publication density measure as an index of research activity in a population -- such as the number of publications per million people in a population. Figure 1 includes this index, along with the top 50 countries ranked in this way. The top five countries are: Sweden, Israel, Finland, Denmark and Switzerland. Singapore, Hong Kong and Taiwan are 21st, 23rd and 25th, respectively. China, understandably given its huge population, is not among the top 50 countries based on the population density publication index.

Virtually all countries with a sizeable biotechnology industry rank among the top 20 countries in both listings in Figure 1. Countries rated between places 21 and 30 on the population adjusted listing in Figure 1 may be considered representative of emerging countries with the 'know how' to develop competitive international biotechnological industries in the next few decades.

Global 1990 to 2001

Number of full papers in Medline Top 50 countries

Number of publications 1990-2001




Figure 1. The number of publications in Medline between January,1990 and November, 2001 for the top 50 countries globally; the total number of publications (left) and the total number of publications per million population (right).

Research Output and Public Health

The number of publications in medical and biology fields should be of importance for the health care of a population, since a highly active academic staff certainly enhances both the teaching quality of medical professionals and the health of the population at large. Figure 2A shows the association between infant mortality rate (the number of deaths during the first year of life per 1,000 live births) and the number of publications per million populations. There is no association between infant mortality rate and among the countries with a low publication density, but there is a significant (non-linear regression, p<0.01) trend from a value of 20 publications per million inhabitants. A similar significant (p<0.05) pattern can be noted for life expectancy in relation to the publication density number (Figure 2B). Clearly, there is an association between vital health statistics and the number of publications in life science. Consequently, it can be argued that scientific publications in life science not only have an impact on the international academic community, but also on the health of local populations where research is conducted.




Figure 2. The number of publications in Medline per million population between January 1990 and November 2001 for 153 countries all having a population above 0.5 million inhabitants and at least two publications per million inhabitants, plotted in relation to (A) infant mortality rate (number of deaths during the first year of life of 1000 live births) and (B) life expectancy in years, respectively. A logarithmic scale with the base of 10 has been used for the publication rate and the infant mortality rate for an improved visual display of the data.

Asian Research Impact given by the Number of Publications

Figure 3 shows the number of Medline publications for Asian countries, ranked by total number of publications and number of publications per million population. In Asia, there are about 10 countries with a significant academic output in life science. Based on the population-adjusted publication tally, Israel is on top followed by Japan, Singapore, Hong Kong and Taiwan. However, based on total publications, a few other countries emerge among Asia's top 10 countries, namely India, South Korea, China, Turkey and Thailand. There is thus a significant difference in academic activity among the 53 Asian countries, with very low activity for the majority.

Asia 1990 to 2001

Number of full papers in Medline All countries in Asia

Number of publications 1990-2001




Figure 3. The number of publications in Medline between January 1990 and November 2001 for all Asian countries (n=53); the total number of publications (left) and the total number of publications per million population (right).

Research Impact given by the Number of Very High Impact Publications

Instead of counting the number of full publications found in Medline, the level of high impact medical research can identified by the number of studies published in those few journals with both a very high impact factor and a wide readership. In this presentation, four such journals – The Lancet, New England Journal of Medicine (N Engl J Med), Journal of the American Medical Association (JAMA) and the British Medical Journal (BMJ) – were selected to represent the most important and prestigious publications in Clinical Science. Two other journals – Nature and Science – were chosen to represent Pre-clinical Science. Arguably, other journals of very high impact might have been considered as well, so readers should draw their own conclusions from the following results.

Table 1 provides the number of publications between 1990 and 2001 in the six selected journals with a very high impact having an address of the corresponding author in China, Hong Kong, Singapore or Taiwan. For comparison, the corresponding figures for the five countries with the highest number of Medline publications per million populations as shown in Figure 1 are provided in Table 1 as well. Among the latter group of countries Sweden has the highest number of publications (n=321) in the very high impact Clinical Science area, while Denmark proportionately has the highest number (0.90%) of Medline publications of very high impact Clinical Science papers. In the Pre-clinical Science area, Switzerland has a significantly higher number of publications (n=331) than any of the others giving comparable high proportion (0.61%) of such important publications in relation to the total number of Medline publications from Switzerland.

Figure 4 and Table 1 show the corresponding numbers for the four predominantly Chinese communities. Hong Kong accounts for 55% of all publications in the four very high impact factor Clinical Science journals, while China accounts for 55% of the very high impact Pre-clinical Science publications. In proportion to the number of Medline publications, Hong Kong and China are comparable with the "top" five countries with 0.58% in Clinical Science (Table 1). In this comparison, neither Singapore nor Taiwan emerge in a favourable position. Since Hong Kong is part of China — 'one country, two systems' — the two combined are arguably perfectly matched, with one strong in Clinical Science and the other in Pre-clinical Science.

Table 1. The number of publications between 1990 and 2001 in some selected general journals with a very high impact representing Clinical and Pre-clinical Science with the corresponding address of the author in China, Hong Kong, Singapore or Taiwan. For comparison, the corresponding figures for the five countries with the highest number of Medline publications per million population (Figure 1) are included as well.

			Total I	Number of I	Publications				
	Sweden	Israel	Finland	Denmark	Switzerland	China	Hong Kong	Singapore	Taiwan
	n	n	n	n	n	n	n	n	n
Clinical Science									
The Lancet	160	76	92	118	62	4	13	6	4
N Engl J Med	42	104	32	24	64	4	30	9	9
JAMA	16	59	21	13	73	3	7	1	4
ВМЈ	103	34	102	134	24	2	15	0	6
Total	321	273	247	289	223	13	65	16	23
Pre-clinical Science									
Nature	77	81	19	21	161	14	3	6	1
Science	59	72	16	15	170	15	3	8	2
Total	136	153	35	36	331	29	6	14	3
Grand Total	457	426	282	325	554	42	71	30	26
Total Publication*	70387*	55745	32317	32276	54078	16127	11213	8126	26593
Very High Impact, %	0.65**	0.76	0.87	1.01	1.02	0.26	0.63	0.37	0.10
Clinical Science, %	0.49***	0.49	0.76	0.90	0.41	0.08	0.58	0.20	0.09
Pre-clinical Science, %	6 0.19****	0.27	0.11	0.11	0.61	0.18	0.05	0.17	0.01

numbers taken from Figure 1

^{** 457/70387*100}

^{*** 321/70387*100}

^{**** 136/70387*100}

Very High Impact Research Output

Number of full papers in six major journals by country

12 year period - 1990 to 2001

China Hong Kong Singapore Taiwan




Figure 4. Very High Impact research output in China, Hong Kong, Singapore and Taiwan. Very High Clinical Science impact is here represented by the number of publications between 1990 and 2001 in four major general journals, i.e. The Lancet, New England Journal of Medicine (N Engl J Med), Journal of the American Medical Association (JAMA) and the British Medical Journal (BMJ). High Pre-clinical Science impact is here represented by the number of publications in two major journals, i.e. Science and Nature.

Table 2 provides similar figures for the various parties in Hong Kong. Most (63/65) of the very high impact Clinical Science publications are from the two Medical University Faculties, with a similar contribution. The very few (n=6) Hong Kong publications in Pre-clinical Science published in Nature or Science are from The University of Hong Kong (n=2) and other Academic Institutions in Hong Kong (n=4), but none from the Chinese University of Hong Kong.

From these results, it can be concluded that Hong Kong holds a strong position in Clinical Science in relation to the other three predominantly Chinese communities, as well as in relation to the globally top five countries, while very high impact in Pre-clinical Science falls short in Hong Kong.

Table 2. The number of publications in some selected general journals with a very high impact representing Clinical Science and Pre-clinical Science with the corresponding address of the author in Hong Kong; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other Hong Kong Universities (Academia) and other institutions including Government and private hospitals (Other).

HUNN	No of Pub	dications in Very I	tigh tropact tournals, i	1	
Journal	CUHK	нки	Academia	Other	Total
Clinical Science	THE RESIDENCE OF THE PROPERTY			en e	
The Lancet	14	15	1	0	30
N Engl J Med	8	7	0	0	15
JAMA	0	6	0	1	7
ВМЈ	9	3	0	1	13
Total	31	31	1	2	65
Pre-clinical Science	angus yang yang dimensionan managan personal mendelah dibahan yang personal mendelah dibahan yang serimi dibahan dibah	ada matika di dahi-tirka tida matika dahir dahir dahir dari dari dari melalari dalam dalam dalam da dalam dalam	and although control of the control	idead managagaga mas Arlanda maren — ya mas gantada Paran er er ta Mada malan ya ten ye ta shika a	
Nature	0	2	1	0	3
Science	0	0	3	0	3
Total	0	2	4	0	6
Grand Total	31	33	5	2	71

Citation Index

The Journal Citation Reports is an essential and comprehensive resource for journal evaluation, using citation data drawn from over 8,400 journals worldwide. Coverage is both multidisciplinary and international, and incorporates journals from over 3,000 publishers in 60 nations. The JCR is the only source of citation data on journals, and includes virtually all specialties in the areas of science, technology and the social sciences. JCR Web shows the relationship between citing and cited journals in a clear, easy-to-use framework. JCR Web is available annually in two editions: a) the Science Edition contains data from roughly 5,000 science and technology journals; b) the Social Sciences Edition contains data from roughly 1,500 social sciences journals.

This analysis is based on the Science Edition year 2000 version and no part of the Social Sciences Edition.

Impact Factor

The journal impact factor is a measure of the frequency with which the average article in a journal has been cited in a particular year. The impact factor is calculated by dividing the number of current citations to articles published in the two previous years by the total number of articles published in the two previous years.

Impact Factor by Area

The Science Edition of the Journal Citation Reports of year 2000 includes 169 different areas, as listed in Table 3. The areas are given in alphabetical order. The median impact factor (IF) is given for each area, computed over all the individual journals listed in a certain area. The number of journals listed under each area is also provided in Table 3. Some journals are included in more than one area. Note that many of the clinical areas such as Anesthesiology, Cardiac and Cardiovascular Systems, Clinical Neurology, General and Internal Medicine, Obstetrics and Gynecology, Orthopedics, Pediatrics and Surgery have a median IF of 0.6 to 1.1. A higher median IF (1.5 to 2.0) can be seen in other areas such as Endocrinology and Metabolism, Gastroenterology and Hepatology, Hematology, Immunology, Infectious Diseases, Neurosciences and Oncology. Obviously, the practice of citation is different in the various areas -- making if virtually impossible to compare a journal's IF belonging to one area with the IF of a journal belonging to another area.

Table 3. The listing includes all areas (n=169) of the year 2000 Science Edition of the Journal Citation Reports. The median impact factor (IF) of the area specific journals and the number of journals (N) are given for each area. Note that a journal can be included in more than one area.

urit dan dan dahadan kerapatan dan dan gamanggal	Area		THE RESERVE AND ADDRESS OF THE PARTY OF THE	Area	Section (Mark Propriet Control of
	Median	Journals			Journals
Area	IF	n	Area	IF	n
Acoustics Agricultural Economics & Policy	0 650 0 423	2- 5	Limnology	0.891	12
Agricultural Engineering	0 550	9	Marine & Freshwater Biology Materials Science: Learnatorials	0.894	71 10
Agriculture Dairy & Animal Science	0.521	14	Materials Science Curamics	0 120	24
Agriculture Multidisciplinary	0.319	28	Materials Science Charaction & Testing	0 166	21
Agriculture Soil Science	u 754	29	Materials Science, Criatings & Films	0.629	16
Agronomy	0 507	57	Materials Science Composites	0.411	19
Allergy	1 292	15	Materials Science, Multidisciplinary	0.562	167
An stomy & Morphology	U 896	20	Materials Science, Paper & Wood	0.310	20
Andrology	1 337	4 23	Materials Science Textiles	0.313	14
Anesthosiology Astronomy & Astrophysics	1 417	37	Mathematics Mathematics Applied	0.415 0.559	156
Automation & Control Systems	0.400	44	Mathematics Applied Mathematics Miscelfineous	0 923	144 20
Behavioral Sciences	1 498	39	Mechanics	0 531	91
Biochemical Research Methods	1 594	43	Mudical Ethics	0 8 10	5
Biochemistry & Molecular Biology	1 39*	310	Medical Informatics	0.893	16
Biodiversity Conservation	U 839	16	Medical Laboritory Technology	1.063	24
Biology	0.835	51	Medicine Geni ml & Internal	0.583	105
Biology Miscellaneous	1 293	62	Medicine Legal	0.939	9
Biophysics Participation C. Aughard Marrahadan	0 094	6b	Mcdicine Research & Experimental	1 422	74
Biotechnology & Applied Microbiology	0 973 1 099	134	Metallursy & Metallurgical Engineering	0 304	65
Cardiac & Cardiovascular Systems Cell Biology	2 145	62 147	Meteorology & Atmospheric Sciences Microbiology	1 262	40 83
Chemistry Analytical	1 24"	65	Microscopy	1 249	10
Chemistry Applied	0.641	55	Mineralogy	0.961	24
Chemistry Inorganic & Nuclear	1 142	38	Mining & Mineral Processing	0.178	18
Chemistry Mcdicinal	1 39"	35	Multidisciplinary Sciences	0.366	49
Chemistry Multidisciplinary	0 735	110	Micology	0 921	14
Chemistry Organic	1 605	46	Neuroimasine	0 997	15
Chemistry Physical	1 317	41	Neurosciences	1 758	203
Clinical Neurology Computer Science Artificial Intelligence	1 113 0 5**5	136 "1	Nuclear Science & Technology Nutrition & Dietetics	0.470	30 50
Computer Science Cybernetics	0 45"	19	Obstetrics & Gynecology	1 220 0 950	57
Computer Science Hardware & Architecture	0 441	49	Oceanography	U 753	38
Computer Science Information Systems	0.483	67	Oncologs	1 626	102
Computer Science Interdisciplinary Applications	0.469	75	Operations Research & Management Sciences	0 400	51
Computer Science Software Graphics Programming	0 498	74	Ophthalmology	0 773	41
Computer Science Theory & Methods	0 585	67	Optics	0 684	57
Construction & Building Technology	0 319	28	Ornithology	0 625	14
Critical Care Medicine	1 407	15	Orthopedics	U 795	39
Crystallography	1 364 0 890	17	Otorhinolaryngology	0.818	29 27
Dentistry Oral Surgery & Medicine Dermatology Oral Surgery & Venereal Diseases	0.921	46 36	Paleontology Parasitology	0 793 0 818	21
Developmental Biology	2 353	33	Pathology	1 174	67
Ecology	1 025	100	Pediatrics	0.812	71
Education Scientific Disciplines	0 301	13	Peripheral Vascular Disease	1 596	45
Electrochemistry	1 326	16	Pharmacology & Pharmacy	1.279	181
Emergency Medicine	0 739	12	Physics Applied	0.823	69
Endocrinology & Metabolism	1 996	89	Physics Atomic Molecular & Chemical	1 442	30
Energy & Fuels	0.352	6h	Physics Condensed Matter	0 898	54
Engineering Aerospace	0 225	26	Physics Fluids & Plasmas Physics Mathematical	1 227 1 008	19 29
Engineering Biomedical Engineering Chemical	0 982 0 455	41 117	Physics Multidisciplinary	0 671	69
Engineering Civil	0 330	63	Physics Nuclear	1 419	20
Engineering Electrical & Electronic	0 495	204	Physics Particles & Fields	1 284	19
Engineering Environmental	0 464	36	Physiology	1 391	7 6
Engineering Geological	0 367	1~	Plant Sciences	0.816	137
Engineering Industrial	0 296	31	Polymer Science	0.641	69
Engineering Manufacturing	0 309	35	Psychiatry	1 556	82
Engineering Marine	0 127	4	Psychology	1 323	56
Engineering Mechanical	0 350	102	Public Environmental & Occupational Health Radiology Nuclear Medicine & Medical Imaging	1 271	88 80
Engineering Multidisciplinary	0 306 0 336	58 14	Radiology Nuclear Medicine & Medical Imaging Rehabilitation	1 017 0 909	80 20
Engineering Ocean Engineering Petroleum	0 135	26	Renabilitation Remote Sensing	0 783	9
Entomology	0 585	65	Reproductive Biology	1 952	23
Environmental Sciences	0 822	127	Respiratory System	1 575	29
Fisheries	0 766	35	Rheumatology	1 398	23
Food Science & Technology	0 660	94	Robotics	0 385	12
Forestry	0.576	29	Spectroscopy	1 39"	37
Gastroenterology & Hepatology	1 699	44	Sport Sciences	0 732	61
Genetics & Heredity	1 965	114	Statistics & Probability Substance Abuse	0 459 1 495	69 9
Geochemistry & Geophysics	0 932	45		0 810	136
Geography Geology	0 868 0 831	23 36	Surgery Telecommunications	0 400	47
Geosciences Interdisciplinary	0 691	117	Thermodynamics	0 393	37
Geriatrics & Gerontology	1 413	22	Toxicology	1 308	77
Health Care Sciences & Services	0 963	44	Transplantation	2 093	16
Hematology	1 473	60	Transportation Science & Technology	0 175	17
History & Philosophy of Science	0 333	31	Tropical Medicine	0 894	12
Horticulture	0 543	19	Urology & Nephrology	1 370	43
	0 431	14	Veterinary Sciences	0 446	126
Imaging Science & Photographic Technology					
Immunology	1 943	116	Virology	2 219	28
	1 943 1 872 0 480	116 36 52	Virology Water Resources Zoology	0 579 0 717	28 47 111

Surgery as an Example of Area Adjusted Journal Impact Factor

As an illustration, one single area, Surgery, was selected to illustrate the variation in IF among journals listed under one and the same area. Table 4 includes all journals in Surgery with an IF information in the Science Edition of year 2000 Journal Citation Reports. The journals are listed according to the IF and are all ranked (%) in relation to their position in the Surgery research area. The IF figures range from 0.059 to 5.987. This analysis simply codes each journal in three Impact Factor (IF) Codes: A, B and C. All A IF code represents the top 1/3 journals in relation to their IF within the area the journal is listed. This means that all journals with a ranking between 100.0% and 66.7% are given an IF code A. An IF code B is consequently given for journals ranking between 66.6% and 33.3%, and an IF code C to the lowest 1/3 ranked journals, i.e. area adjusted journal impact factor. The same procedure was used in the following description of all 168 areas, as listed in Table 3.

In the following figures we have divided the bars representing the number of publications into three groups; i.e. High Impact (IF code A), Good Impact (IF code B) and Low Impact (IF code C).

Table 4. All journals in Surgery listed in the Science Edition of year 2000 Journal Citation Reports. The journals are listed according to the Impact Factor (IF) and ranked (%) in relation to their position in the Surgery research area. The top 1/3 ranked journals - 100% to 66.7% - are given an 'A' Impact Code, the mid 1/3 ranked journals - 66.6% to 33.3% - are given a 'B' Impact Code and the low 1/3 ranked journals - 66.6% to 33.3% - are given a 'C' Impact Code. The medium Impact Factor in the Surgery research area is 0.81.

Journal Name	IF	Ranking %	Impact Factor Code	Journal Name	IF	Ranking %	Impact Factor Code
		70	Couc	and regulation are considerable formwidth. Washington included the particular property within processing	d solutions of the solution of		Code
ANN SURG	5 957	00 0	Α	J BURN CARE REHABIL	0.810	50 ~	В
AM I SURG PATHOL	4 269	99 3	A	MINIM INVAS NEUROSUR	0.803	49 3	В
TRANSPLANTATION	4 0 3 5	98 5	A	J HAND SURG AM	U 795	48.5	В
J ENDOVASC SURG	3 276	97 8	A	LAPAROENDOSC ADV A	0.783	4" 8	В
J VASC SURG	3 114	97 1	Α	OPHTHALMIC SURG LAS	U 775	471	В
J THORAC CARDIOV SUR	3 057	96 3	A	BRIT I ORAL MAX SURG	17" מ	46 3	В
BRIT J SURG	2 935	95 6	4	I INVEST SURG	0.756	45.6	В
J NEUROSURG	2 918	94 9	A	EUR SURG RES	0 754	44 9	В
NEUROSURGERY I NEUROL NEUROSUR PS	2 899 2 846	94 1 93 4	A A	CHIRURG	0 "21 0 718	44 1 43 4	8
I AM COLL SURGEONS	2 805	92 6	Ä	CLEFT PALATE CRAN SURG LAPARO ENDO PER	0 691	42.6	8 B
ANN SURG ONCOL	2 799	91 9	Â	TRANSPLANT P	0 678	41 9	В
SHOCK	2 785	91 2	Ä	BRIT J PLAST SURG	0.675	41 2	В
ARCH SURG CHICAGO	2 629	90 4	A	EUR I SURG	0.663	40.4	В
SURGERY	2 456	89 7	A	STEREOT FUNCT NEUROS	0 657	39 7	В
LASER SURG MED	2 348	89 0	A	J CRANIO MAXILL SURG	0 636	19.0	В
I BONE JOINT SURG AM	2 222	88 2	4	AUST NZ J SURG	0 627	38 2	В
LIVER TRANSPLANT	2 150	87 5	\	I RECONSTR MICROSURG	0 621	3" 5	8
AM I YURG	2 116	86 8	A	LASER MED SCI	0 620	36.8	В
I CATARACT REFR SURG	2 071	86 0	A	CLIN NEUROL NEUROSUR	0.619	36 0	В
I REFRACT SURG	2 061	85 3	A	OPER TECHN SPORT MED	0.606	35 3	В
SURG ENDOSC ULTRAS TRANSPLANT INT	2 056 2 049	84 6 83 8	``	I C ARDIOVASC SURG PHLEBOLOGY	0 573 0 5°1	34 6 33 8	В В
WORLD I SURC	2 049	83 I	Α.	CHILD NERV SYST	0.563	33.0	Č
HEAD NECK-J SCI SPEC	1 917	82.4	A.	ANN CHIR GYNAECOL	0.550	32.4	Č
CLIN TRANSPLANT	1.841	81 6	À	ANN CHIR	0 545	31.6	č
ANN THORAC SURG	1 428	80 9	A	J CRANIOFAC SURG	0.541	30.9	č
CURR PROB SURG	1 826	80 1	A	BRIT I NEUROSURG	0.539	30.1	Č
ENDOSCOPY	181**	79 4	A	MICROSURG	0.517	29 4	c c
LANGENBECK ARCH SURG	1 770	78 7	\	J ROY COLL SUPG EDIN	0.510	28 7	C
INT I COLORECTAL DIS	1 707	77 9	A	ARCH ORTHOP TRAUM SU	0 507	27 9	C
DIS COLON RECTUM	1 690	77 2	A	NEUROSURG QUART	0 500	27 2	Ċ
I SURG RES	1 674	76 5	Ą	UNFALLCHIRURG	0 496	26 5	c
SEMIN SURG ONCOL	650 64"	75 7	Ž.) HAND SURG BRIT EUR PEDIATR SURG INT	0 495 0 191	25 7 25 0	C C
DERMATOL SURC I BONE JOINT SURG BR	1 612	75 O 74 3		INT SURG	0 488	24 3	č
EUR I VASC ENDOVASC	1 565	73.5	A A	GINAECOL ENDOSC	0 485	23 5	c
I SURG ONCOL	1 541	72.8	Ä	INT I SURG PATHOL	0 463	22.8	č
ARCH OTOLARYNGOL	1 527	72 1	Ä	SCAND PLAST RECONS	0 450	22 1	č
TRAUMA	1 498	71.3	A	ANN ROY COLL SURG	0 439	21 3	Ċ
OBES SURG	1 464	70 6	A	J ENDOVASC THER	0.425	20 6	С
EUR J SURG ONCOL	1 43‡	69 9	A	CAN J SURG	0.422	19 9	C
PLAST RECONSTR SURC	1 42'	69 1	A	AESTHET PLAST SURG	0 114	19 1	c
NEUROSURG CLIN N AM	1 265	68 4	A	NEUROCHIRURGIE	0 390	18 4	ç
SURG CLIN N AM	1 252	67 6	Ą	NEUROL MED CHIR	0 387	17 6 16 9	c c
ARTHROSCOPY I PEDIATR SURC	1 217 1 216	66 9 66 2	A B	INJURY NEUROSURG REV	0 363 0 358	16.2	c
I CLIN LASER MED SUR	1 205	65 4	8	SURG TODAY	0 356	15 4	č
EUR I CARDIO THORAC	1 187	64 7	В	EUR J PEDIATR SURG	0 350	14 7	č
CLIN ORTHOP RELAT R	1 182	64 0	8	SURG RADIOL ANAT	0.314	14.0	č
AM SURGEON	1 101	63 2	В	ZBL CHIR	0 302	13.2	Ċ
ANN VASC SURG	1 0"3	62 5	В	SURG ONCOL	0 293	12.5	C.
SURG NEUROL	1 018	61 8	В	MINIM INVASIV THER	0 291	11.8	С
OTOLARYNG HEAD NECK	0 977	61 0	В	ACTA CHIR BELG	0 270	11 0	Ç
SHOULDER ELB SURG	0 973	60 3	В	KNEE	0 255	10 3	c
ZBL NEUROCHIR	0 939	59 6	В	CRIT REV NEUROSURG	0 233	96	C
NEUROSURG ANESTH	0 937	58 8	В	CLIN TECH SMALL AN P	0 228 0 224	8 8 8 1	c c
INT J ORAL MAY SURG	0 932 0 905	58 1 57 4	8 8	J CARDIAC SURG TECH NEUROSURG	0 224	7.4	Č
HEPATO GASTROENTEROL ORAL SURG ORAL MED O	0 905 0 865	57 4 56 6	B B	J CHIR-PARIS	0 213	66	c
ANN PLAS SURG	0 864	55 9	В	REV CHIR ORTHOP	0 212	5 9	č
CARDIOVASC SURG	0 862	55 1	В	SKULL BASE SURG	0 185	5 1	С
BURNS	0 856	54 4	В	5 AFR SURG	0 159	4.4	С
THORAC CARDIOV SURG	0 850	53 7	В	EUR J PLAST SURG	0 159	3.7	С
ACTA NEUROCHIR	0 817	52 9	В	NEUROL SURG TOKYO	0 156	2 9	C
CLIN PLAST SURG	0.816	52 2	В	NEUROCIRUGIA	0 154	2 2	C
PEDIATR NEUROSURG	0 811	51 5	В	CHIR GASTROENTEROL	0 078	1 5	c
DIGEST SURG	0.810	50 0	R	CESK SLOV NEUROL N	0 059	0.7	С

Medline Listed Journals with No Impact Factor

There are a few journals included in Medline that have no IF information given in the Science Edition of Journal Citation Reports. Many of these journals have entered the Medline data-base in recent years, thus not providing enough current information to be counted in terms of the IF evaluation. Other journals have been listed in Medline for a longer period, but for various reasons have not been given an IF. Table 5 lists some journals found in Medline but not included in the Science Edition of Journal Citation Reports in year 2000. The publications identified here had corresponding addresses in China, Hong Kong, Singapore or Taiwan and were published from January 1990 to November 2001. As noted from the listing in Table 5, almost all journals are local, i.e. published in one of the four predominantly Chinese regions.

Such local journals have little or no impact on the scientific community from a global perspective. Perhaps publications accepted in local journals did not initially stand up to international standards. It seems thus reasonable to omit the non-IF journals and related publications when describing research output between regions and institutions. The following only counts Medline publications published in journals with an IF ranking.

We have to acknowledge that publications occurring in local journals – being listed or not listed in Medline – counts for a significant position of the life science research output. However, such publications are not easily accessed to the international research community due to that the journal is only available in local libraries and/or that non-English language is used. The standard of the papers published in local journal are commonly not received by an international board of scientist also affecting the quality of the research communication. It may however be important that health information distributed to the local health practitioners in the local language through local journals, but they are commonly based on results already appearing in international journals.


Table 5. Journals included in Medline with no Impact Factor information in the Science Edition of year 2000 Journal Citation Reports. The list includes those journals with 80 identified publications or more with the corresponding address in China, Hong Kong, Singapore or Taiwan during 1990 to 2001.

Journal Name	Number of publications		
ANN ACAD MED SINGAPO	1643		
ZHONGHUA YI XUE ZA Z	1492		
SINGAPORE MED J	1312		
GAOXIONG YI XUE KE X	584		
ZHONGHUA MIN GUO XIA	584		
KAOHSIUNG J MED SCI	545		
BIOCHIM BIOPHYS ACTA	380		
YAN KE XUE BAO	372		
PROC NATL SCI COUNC	309		
YI CHUAN XUE BAO	297		
ZHONGHUA MIN GUO WEI	265		
ACTA ANAESTHESIOL SI	260		
CHIN J BIOTECHNOL	255		
ZHONGHUA YI XUE YI C	250		
ZHONGGUO ZHONG YAO Z	221		
SOUTHEAST ASIAN J TR	163		
ZHONGGUO XIU FU CHON	160		
J TRADIT CHIN MED	151		
WEI SHENG YAN JIU	142		
ZHONGHUA GAN ZANG BI	140		
YAO XUE XUE BAO	132		
MA ZUI XUE ZA ZHI	125		
ZHEN CI YAN JIU	117		
HUAN JING KE XUE	103		
CHIN J DENT RES	102		
HONG KONG MED J	96		
SHENG WU GONG CHENG	94		
ZHONGGUO ZHONG XI YI	90		
J CHROMATOGR B BIOME	87		
ZHONGHUA ZHONG LIU Z	85		
J ADV NURS	83		
J SINGAPORE PAEDIATR	83		
AUSTRALAS RADIOL	82		
ZHONGHUA WAI KE ZA Z	81		
HUA XI KOU QIANG YI	80		

Figure 5 gives the number of Medline publications for China, Hong Kong, Singapore and Taiwan for the twelve years (1990-2001) and four three-year periods (e.g. 1990-1992, etc.) The lower panel of Figure 5 gives the same numbers but divided by the population of the respective region, in millions. The bars have been divided into four parts, each representing the type of publications from an Area Adjusted Impact Factor point of view, a low IF corresponds to the Impact Factor Code 'C' (Please Lefel to page 24), a good Impact Factor corresponds to the Impact Factor Code 'A' No Impact Factor means that the journal where the publication was printed is not listed in the Journal Citation Reports for year 2000.

Medline Research Output

Number of full papers in Medline by country



Number of full papers in Medline by country / million population




Figure 5. Number of Medline publications published between 1990 and 2001. The number is given for China, Hong Kong, Singapore and Taiwan for all 12 years together, and for four three-year periods (eg. 1990-1992, etc). The total number of publications is given in the upper panel and per million population in the lower panel. Each bar has been divided into four groups of publications — no impact factor and a low, good or high Area Adjusted IF, as described on page 24.

Figure 6 gives the same numbers as Figure 5, with the exception that publications included in journals with no Impact Factor have been omitted for logical reasons as discussed on page 26. Taiwan has the largest number of publications tollowed by China, Hong Kong and Singapore. However, adding the figures for China and Hong Kong results in a number close to that of Taiwan


The increase in the total number of Medline publications with an Impact Factor from 1990-1992 to 1999-2001 is similar in the four regions, i.e. 255 0% for China, 231 7% for Hong Kong, 217 8% for Singapore and 262 8% for Taiwan

The proportion of the publications with an Impact Factor Code 'A', or High Impact Factor, is 50 0% for Hong Kong, 48 5% for Singapore, 45 5% for Taiwan and 36 9% for China

After adjustment of the underlying population in each region, Hong Kong stands out to be most productive, followed by Singapore and Taiwan China for obvious reasons scores very low for the number of Medline publications adjusted for the underlying population

Impact Research Output

Number of full papers (with impact factor) in Medline by country



Number of full papers (with impact factor) in Medline by country / million population




Figure 6. Number of Medline publications published between 1990 and 2001. The number is given for China, Hong Kong, Singapore and Taiwan for all 12 years together, and for four three-year periods (eg. 1990-1992, etc). The total number of publications is given in the upper panel and per million population in the lower panel. Each bar has been divided into three groups of publications — a low, good and high Area Adjusted IF, as described on page 24.

Hong Kong Total Academic Output


In Figure 7 the total number of Medline publications (1990-2001) among Hong Kong institutions divided into the three IF categories, i.e. low, good and high (upper panel). The percentage above each bar represents the contribution made by each institution to the total Hong Kong publication number. The lower panel of Figure 7 gives the corresponding figures for the last three years (1999-2001) of comparison.

Among the various institutions in Hong Kong, The University of Hong Kong rates as number one considering the total number of Medline full publications from 1990 to 2001, representing 42.2%, i.e. 3.8% more than the runner-up, the Chinese University of Hong Kong. The remaining number of publications comes from non-academic institutions or organizations such as governmental hospitals and private hospitals (9.3%), with another 8.6% from other Hong Kong academic institutions. A similar rate of publication is also seen among the various Hong Kong institutions over the last three years (1999-2001), although the three universities without a Medical Faculty all increased their publication rate slightly against the two medical schools. However, the two medical schools together still account for the vast majority (77.7%) of the total number of Hong Kong publications.

The proportion of high Area Adjusted Impact Factor publications (Impact Factor Code 'A') among Hong Kong Institutions for the whole period of observation (1990-2001) is 70.9% for the Hong Kong University of Science and Technology (HKUST), 51.1% for HKU, 47.2% for Chinese University of Hong Kong (CUHK), 44.3% for Hong Kong Baptist University (HKBU), 43.5% for other and 34.1% for The Hong Kong Polytechnic University (PolyU). This percentages increased over the last three years (1999-2001) for all institutions except for the non-academic institutions (Other), showing a decreasing trend in the proportion of high Area Adjusted Impact Factor. The calculations are all based on the numbers provided in Figure 7.

Hong Kong Institutions

Number of full papers (with impact factor) in Medline






Figure 7. The total number of Medline publications (1990-2001) among Hong Kong institutions divided into the three Area Adjusted IF categories, i.e. low, good and high (upper panel). The percentage above each bars represents the contribution made by each institution to the total Hong Kong publication number. The lower panel gives the corresponding figures for the last three years (1999-2001) of comparison. The institutions correspond to Hong Kong Baptist University (HKBU), Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), non-academic institutions/organizations (Other), Hong Kong Polytechnic University (PolyU) and the Hong Kong University of Science and Technology (HKUST).

Hong Kong Area Specific Academic Output

Figure 8 gives two different area listings in descending order; the number of publications with an IF value and the median Impact Factor for all Clinical and Pre-clinical publications identified. For definition of Clinical and Pre-clinical publication see Table 6, pages 38-39. The publications are those having 'Hong Kong' in the corresponding address field from 1999-2001. The number of publications is an important factor when considering the impact that a certain area has on the international scientific community. From this viewpoint, Surgery, Pharmacology and Pharmacy, and Oncology emerge on top. However, based on the rating of the median Impact Factor of those journals where the identified publications have appeared, the picture becomes quite different with Peripheral Vascular Disease, Virology and Reproductive Biology being the top three rated, while Surgery is relegated to 26th position with a median IF of 1.434.

Hong Kong 1990 to 2001

Clinical and Pre-clinical Research Areas




Figure 7. The left graph gives the various areas in descending order, sorted by the number of publications with an IF with 'Hong Kong' in the corresponding address during the period 1990-2001. The right graph includes the areas in descending order sorted by the median Impact Factor of all Hong Kong publications between 1990 and 2001. The area listed are those given in bold in Table 6.

Figure 9 includes the same graph (lett) as in Figure 8, i.e. the total number of Medline full Hong Kong Clinical and Pre-clinical publications with an Impact Factor sorted in descending order. The right graph in Figure 9 gives the descending order of the Median Area Adjusted Impact Factor, i.e. the Median of the ranking % of all publications identified for Hong Kong in a certain area. The three top areas are Orthopedics, Reproductive Biology and Anesthesiology with Median Area Adjusted Impact Factors of 92 3%, 87 1% and 86 4%, respectively. These figures form a better basis for comparison between areas than a direct comparison of the Impact Factor, as provided by the Science Edition of the Journal Citation Reports.

The recommendation made here is that the overall impact of an area should be based on both the total number of publications and the value of the Area Adjusted Impact Factor

Hong Kong 1990 to 2001

Clinical and Pre-clinical Research Areas

Number of published papers




Figure 9. The left graph gives in descending order the number of Hong Kong publications in Medline with an Impact Factor during the period 1990-2001. The right graph includes the areas sorted in descending order after the Median Area Adjusted IF, as previously described on page 24. The areas listed are given in bold in Table 6.

Area Specific Publication Impact

The remaining part of this report includes information about each of the areas listed with bold text in Table 6, representing the major areas in clinical and pre-clinical science research. One additional area has been included: the Multidisciplinary Sciences subject category. The reason for including this table is because the two most important journals in Pre-clinical Science — Nature and Science — are listed in this subject category.

The information of five other areas are not given in tables since the number of publications was still relatively small to provide any useful information. The five areas are Allergy, Aneshesiology, Biochemical Research Methods, Medical Laboratory Technology and Medicine, Research and Experimental.

The remaining selected areas are described in alphabetical order both by Table and Figures in the Appendix.

Table 6. This table gives all details for all Area specific publications identified in Medline between 1990 and 2001 with 'Hong Kong' in the corresponding address. All publications counted here were published in a journal listed in the Science Edition of the Journal Citation Reports for year 2000. The table gives the median Impact Factor given in various ways and the number of category A, B and C publications as well as the total number of publications. The areas given in bold represent the major areas of publication and are mostly clinically and pre-clinically oriented; these areas are the focus of the remaining part of this report.

	Glo	bal		Hong Kong								
	All Areas	Area	Area	Adjusted	Publ	lications	Publ	ıcations	Publi	cations	Public	cations
	IF	IF	IF	IF	Α	type	В	type	C	type	To	otal
Area of Research	Median	Median	Median	Median	n	%	n	%	n	%	n	%
Acoustics	0.783	0 650	1 366	84 6	10	100.0	0	0.0	0	0.0	10	100.
Agriculture, Dairy & Animal Science	0.783	0 521	1.823	100.0	1	100 0	0	0.0	0	0.0	1	100.
Allergy	0.783	1 858	2 978	70 6	86	61.9	22	15.8	31	22.3	139	100
Anatomy & Morphology	0.783	0 896	1 385	737	21	84.0	3	12.0	1	4.0	25	100
Andrology	0.783	1 357	1 357	66.7	9	69 2	4	30.8	0	0.0	13	100
Anesthesiology	0.783	0 927	2 027	86 4	150	88 8	12	7.1	7	4 1	169	100
Behavioral Sciences	0.783	1 498	1 419	44 7	2	33.3	4	66.7	0	0.0	6	100
Biochemical Research Methods	0.783	1 594	1 756	59 5	7	36.8	11	57.9	1	5.3	19	100
Biochemistry & Molecular Biology	0.783	1 882	2 852	68 4	86	55 5	37	23.9	32	20.6	155	100
Biology	0 783	0.835	1 989	72.5	5	71.4	2	28.6	0	0.0	7	100
Biology, Miscellaneous	0.783	1 293	2.002	66.9	2	50.0	2	50.0	0	0.0	4	100
Biophysics	0.783	2 094	3 055	72,7	64	77.1	16	19.3	3	3.6	83	100
Biotechnology & Applied Microbiology	0.783	0.973	1.311	61.9	18	42.9	24	57.1	0	0.0	42	100
Cardiac & Cardiovascular Systems	0.783	1.099	2 144	73.0	86	50.9	68	40.2	15	8.9	169	100
Cell Biology	0.783	2.145	2 775	63.9	62	37.1	87	52.1	18	10.8	167	100
Chemistry, Analytical	0.783	1.247	1.976	76.9	36	83.7	7	16.3	0	0.0	43	100
Chemistry, Applied	0.783	0.641	1.368	81.8	1	100.0	0	0.0	Õ	0.0	1	100
Chemistry, Inorganic & Nuclear	0.783	1,142	2.712	76.3	13	76.5	3	17.6	1	5.9	17	100
Chemistry, Medicinal	0.783	1.397	4.134	91.4	4	80.0	Õ	0.0	1	20.0	5	100
Chemistry, Multidisciplinary	0.783	0.735	6.025	94.9	17	89.5	2	10.5	ò	0.0	19	100
Chemistry, Organic	0.783	1.605	3.689	91.7	21	72.4	8	27.6	ő	0.0	29	100
Clinical Neurology	0.783	1.113	2.611	81.0	31	57.4	22	40.7	1	1.9	54	100
Computer Science, Artificial Intelligence	0.783	0.575	2.702	98.6	9	100.0	0	0.0	ò	0.0	9	100
Computer Science, Information Systems	0.783	0.483	0.699	65.7	Õ	0.0	1	100.0	õ	0.0	1	100
Computer Science, Interdisciplinary Applications		0.468	3.409	100.0	5	83.3	i	16.7	ő	0.0	6	100
Construction & Building Technology	0.783	0.319	1.221	100.0	1	100.0	ò	0.0	Õ	0.0	1	100
Critical Care Medicine	0.783	1.407	0.770	40.0	16	17.6	75	82.4	0	0.0	91	100
Crystallography	0.783	1.364	0.543	29.4	1	33.3	0	0.0	2	66.7	3	100
Dentistry, Oral Surgery & Medicine	0.783	0.890	0.773	39.1	64	24.5	72	27.6	125	47.9	261	100
Dermatology, Oral Surgery & Venereal Diseases	0.783	0.921	0.876	45.8	13	31.0	18	42.9	11	26.2	42	100
Developmental Biology	0.783	2.353	3.131	66.7	16	51.6	14	45.2	1	3.2	31	100

Table	6.	(continu	red)
	•	CONTIN	1001

		<u>bal</u>			Hong Kong Publications Publications Publications				eternitude resultinose			
	All Areas			Adjusted	Publ	ıcations			Publ	ications	Publi	cations
	IF	IF	IF	IF	Α	type	В	type	С	type	To	otal
Area of Research	Median	Median	Median	Median	n	%	n	%	n	%	n	%
Ecology	0.783	1.025	2.769	88.0	2	100.0	0	0.0	0	0.0	2	100.0
Emergency Medicine Endocrinology & Metabolism	0.783 0.783	0. 7 39 1.886	1.054 2.732	66.7 73.0	12 136	52.2 60.4	11 71	47.8 31.6	0 18	0.0 8.0	23 225	100.0
Energy & Fuels	0.783	0.352	0.700	81.8	130	100.0	0	0.0	0	0.0	1	100.0 100.0
Engineering, Biomedical	0.783	0.982	1.600	75.6	52	80.0	9	13.8	4	6.2	65	100.0
Engineering, Electrical & Electronic	0.783	0.495	1.640	92.2	3	100.0	0	0.0	0	0.0	3	100.0
Engineering, Environmental	0.783	0.464	1.221	91.7	3	100.0	0	0.0	0	0.0	3	100.0
Engineering, Industrial Entomology	0.783 0.783	0.296 0.585	0.642 0.763	90.3	2 0	100.0	0	0.0	0	0.0	2	100.0
Environmental Sciences	0.783	0.822	1.033	57.6 59.8	23	0.0 34.8	1 41	100.0 62.1	0 2	0.0 3.0	1 66	100.0 100.0
Food Science & Technology	0.783	0.660	1.560	92.6	30	93.8	2	6.3	ō	0.0	32	100.0
Gastroenterology & Hepatology	0.783	1.699	2.820	82.2	153	54.6	115	41.1	12	4.3	280	100.0
Genetics & Heredity	0.783	1.965	2.462	63.2	29	36.7	38	48.1	12	15.2	79	100.0
Geriatrics & Gerontology	0.783	1.413	1.549	63.6	13	43.3	15	50.0	2	6.7	30	100.0
Health Care Sciences & Services Hematology	0.783 0.783	0.963 1.473	1.078 1.744	56.8 56.7	10 60	22.7 46.5	33 38	75.0 29.5	1 31	2.3 24.0	44 129	100.0 100.0
Immunology	0.783	1.943	1.995	51.7	37	39.8	37	39.8	19	20.4	93	100.0
Infectious Diseases	0.783	1.872	1.254	33.3	11	16.2	24	35.3	33	48.5	68	100.0
Integrative & Complementary Medicine	0.783	0.579	0.930	87.5	1	100.0	0	0.0	0	0.0	1	100.0
Marine & Freshwater Biology	0.783	0.894	1.625	87.3	6	85.7	1	14.3	0	0.0	7	100.0
Materials Science, Biomaterials	0.783	0.653	1.016	70.0	15	68.2	2	9.1	5	22.7	22	100.0
Mathematics, Applied	0.783	0.559	1.900	98.6	1	100.0	0	0.0	0	0.0	1	100.0
Mathematics, Miscellaneous Medical Ethics	0.783 0.783	0.923 0.810	1.059 0.955	75.0 80.0	3 1	75.0 100.0	1 0	25.0 0.0	0	0.0	4 1	100.0 100.0
Medical Informatics	0.783	0.893	0.699	43.8	13	40.6	11	34.4	8	25.0	32	100.0
Medical Laboratory Technology	0.783	1.063	1.327	62.5	35	42.2	39	47.0	9	10.8	83	100.0
Medicine, General & Internal	0.783	0.583	0.413	40.0	124	37.2	48	14.4	161	48.3	333	100.0
Medicine, Legal	0.783	0.939	0.829	33.3	0	0.0	21	100.0	0	0.0	21	100.0
Medicine, Research & Experimental	0.783	1.422	0.973	37.8	10	21.7	20	43.5	16	34.8	46	100.0
Microbiology	0.783	1.511	2.972	81.9	70	57.9	44	36.4	7	5.8	121	100.0
Microscopy Multidisciplinary Sciences	0.783 0.783	1.249 0.366	1.746 1.381	80.0 83. <i>7</i>	9 25	90.0 100.0	1	10.0 0.0	0	0.0 0.0	10 25	100.0 100.0
Mycology	0.783	0.921	0.708	50.0	0	0.0	4	100.0	Ö	0.0	4	100.0
Neuroimagine	0.783	0.997	2.984	66.7	1	50.0	1	50.0	ő	0.0	2	100.0
Neurosciences	0.783	1.758	2.526	67.5	164	55.6	117	39.7	14	4.7	295	100.0
Nutrition & Dietetics	0.783	1.220	1.914	74.5	64	78.0	15	18.3	3	3.7	82	100.0
Obstetrics & Gynecology	0.783	0.950	1.000	54.4	107	35.0	95	31.0	104	34.0	306	100.0
Oncology Ophthalmology	0.783 0.783	1.626 0.773	1.716 1.015	53.4 58.5	183 55	33.8 35.0	287 57	53.0 36.3	72 45	13.3 28.7	542 157	100.0
Optics	0.783	0.773	1.481	80.7	1	100.0	0	0.0	0	0.0	137	100.0
Orthopedics	0.783	0.795	1.843	92.3	55	75.3	ž	9.6	11	15.1	73	100.0
Otorhinolaryngology	0.783	0.818	0.482	20.7	23	21.9	18	17.1	64	61.0	105	100.0
Parasitology	0.783	0.988	1.657	71.4	10	55.6	8	44.4	0	0.0	18	100.0
Pathology	0.783	1.174	1.755	74.6	284	63.4	152	33.9	12	2.7	448	100.0
Pediatrics	0.783	0.812	0.982	56.3	115	42.3	132	48.5	25 13	9.2 16.7	272 78	100.0 100.0
Peripheral Vascular Disease Pharmacology & Pharmacy	0.783 0.783	1.596 1.279	3.386 1.808	82.2 65.7	54 266	69.2 46.3	11 223	14.1 38.9	85	14.8	574	100.0
Physics, Atomic, Molecular & Chemical	0.783	1.442	2.150	76.7	6	100.0	0	0.0	0	0.0	6	100.0
Physics, Mathematical	0.783	1.008	2.142	96.6	3	100.0	Ö	0.0	Ō	0.0	3	100.0
Physics, Multidisciplinary	0.783	0.671	6.462	94.2	10	100.0	0	0.0	0	0.0	10	100.0
Physiology	0.783	1.391	2.203	68.4	61	54.5	42	37.5	9	8.0	112	100.0
Plant Sciences	0.783	0.816	1.831	82.5	39	75.0	13 92	25.0	0 8	0.0 6.2	52 130	100.0 100.0
Psychiatry Psychology	0.783 0.783	1.556 1.323	1.625 1.252	54.3 48.2	30 12	23.1 28.6	19	70.8 45.2	11	26.2	42	100.0
Public, Environmental & Occupational Health		1.271	1.606	63.1	61	43.0	46	32.4	35	24.6	142	100.0
Radiology, Nuclear Medicine & Medical Imag		1.017	0.951	41.3	149	31.6	243	51.6	79	16.8	471	100.0
Rehabilitation	0.783	0.809	0.535	42.9	9	29.0	15	48.4	7	22.6	31	100.0
Reproductive Biology	0.783	1.952	2.997	87.0	94	82.5	1	0.9	19	16.7	114	100.0
Respiratory System	0.783	1.575	2.451	75.9	77	65.8	31	26.5	9	7.7	117	100.0
Rheumatology	0.783	1.398	2.514	78.3	58 11	78.4	12	16.2	4	5.4	74 11	100.0
Spectroscopy Sport Sciences	0.783 0.783	1.397 0.732	2.638 0.843	83.8 59.0	11 19	100.0 31.7	0 41	0.0 68.3	0	0.0	11 60	100.0 100.0
Sport Sciences Statistics & Probability	0.783	0.732	1.257	87.0	22	91.7	2	8.3	0	0.0	24	100.0
Substance Abuse	0.783	1.495	0.687	11.1	1	25.0	ō	0.0	3	75.0	4	100.0
Surgery	0.783	0.810	1.434	69.9	553	51.3	384	35.6	141	13.1	1078	100.0
Toxicology	0.783	1.308	1.437	61.0	29	41.4	28	40.0	13	18.6	70	100.0
Transplantation	0.783	2.093	0.678	12.5	48	37.2	5	3.9	76	58.9	129	100.0
Tropical Medicine	0.783	0.894	1.114	66.7	15	51.7	8	27.6	6	20.7	29	100.0
Urology & Nephrology	0.783	1.370	1.842	67.4 86.7	136	57.9	83 19	35.3 39.6	16 0	6.8 0.0	235 48	100.0 100.0
Virology	0.783 0.783	0.446 2.219	1.236 3.289	86.7 75.0	29 33	60.4 66.0	15	39.6	2	4.0	48 50	100.0
Virology Water Resources	0.783	0.579	1.285	97.9	33 9	75.0	3	25.0	ó	0.0	12	100.0
Zoology	0.783	0.717	1.249	82.1	33	84.6	6	15.4	Õ	0.0	39	100.0

Summary of Area Specific Publication Impact

Table 7 indicates the number of Medline publications produced by China, Hong Kong, Singapore, Taiwan with an impact factor published between January 1990 and November 2001. Only the major Clinical and Preclinical Science research areas, shown in bold in Table 6, have been listed and are in two groups -- namely Clinical Science and Pre-clinical Science. Each area is described in more detail in the Appendix in alphabetical order. As seen in Table 7, there is a large variation in the number of publications for each area, and a large variation of the proportion of the publications published in each region. However, Figure 10 gives the percentage for all Clinical Science publications and Pre-clinical Science publications, respectively, and the two combined for the region in Table 8. As can be seen from Figure 10, Taiwan had the largest proportion (49.8%) of identified publications in the Clinical Science area, followed by Hong Kong (24.3%), China (15.5%) and Singapore (10.4%). The findings are slightly different for the Pre-clinical Science area, where Taiwan made the largest contribution (42.3%) followed by China (33.7%), Hong Kong (15.0%) and Singapore (9.0%). Taking all areas together (Table 7 and Figure 10), Taiwan accounted for about 50 publications out of 100, China and Hong Kong had 20 publications each, and Singapore the remaining 10 publications.




Figure 10. The three charts include the percentage of all Clinical Science publications, Pre-clinical Science publications, and the two combined, respectively, for the four dominant Chinese populated regions. The details of the results are in Table 7.

Table 7. The number of Medline publications with an impact factor published between January 1990 and November 2001 from China, Hong Kong, Singapore, Taiwan.

	Total	Ch	ına	Hong	g Kong	Chi Hong	na + g Kong	Sing	apore	Taiwan		
Area	Ν	Ν	%	Ν	%	N	%	Ν	%	Ν	%	
CONTRACTOR OF THE PROPERTY OF					* *************************************							
Clinical Science												
Anesthesiology	408	32	7.8	169	41.4	201	49 3	61	15 ()	146	37.8	
Cardiac & Cardiovascular Systems	866	93	10.7	169	195	262	30 3	41	4.7	563	65.0	
Clinical Neurology	297	39	13.1	54	18.2	93	31.3	20	6 7	184	62.0	
Critical Care Medicine	162 743	8 100	49	91	56.2	99	61 1	34	21.0	29	1" 9	
Dentistry Oral Surgery & Medicine Emergency Medicine	97	100	13.5 5.2	261 23	35 1 23 7	361 28	48.6	151	20.3	231	31 1	
Endocunology & Metabolism	765	9h	12.5	225	29.4	2n 321	28 9 42 0	10 120	10 ±	59 324	60 8	
Gastrounterology & Hepatology	1225	89	7 3	280	22 9	369	30 1	94	13	762	42 4 62 2	
Genatrics & Gerontology	88	21	23 9	30	34 1	51	58 U	4	4.5	33	373	
Hematology	458	89	19 4	129	28 2	218	47.6	29	6.3	211	46.1	
Immunology	586	131	22 4	93	15.9	224	38 2	7-	13 1	285	48 6	
Intectious Diseases	278	2.2	79	68	24.5	90	32.4	41	14.7	147	52 9	
Medicine General & Internal	3228	340	16 7	333	10.3	873	2-0	63	2.0	2292	71.0	
Microbiology	800	132	16.5	121	15.1	253	31.6	105	13 1	442	55.3	
Nutrition & Dietetics	37b	117	31.1	82	21.8	199	52 9	23	6.1	154	41.0	
Obstetrics & Gynecology	930	93	10.0	306	32 9	399	42 9	142	15 3	389	41.8	
Oncology	2147	408	190	542	25.2	950	44 2	157	7 3	1040	48 4	
Ophthalmology	458	62	13.5	157	34 3	219	47.8	97	21.2	142	31.0	
Orthopedics	255	3.5	12 9	*3	28 6	106	41.6	18	7.1	131	51.4	
Otorhinolary ngology	425	107	25.2	103	24 7	212	49 9	52	12.2	161	379	
Pathology	903	78	26	448	49 6	526	58 3	126	14 0	251	27.8	
Pediatrics	784	53	6.8	273	14.8	326	41.6	132	16.8	326	41.6	
Peripheral Vascular Disease	547	125	22 9	78	14 3	203	371	25	4.6	319	58 3	
Psychiatry	352	52	14 9	130	36 9	182	51 7	44	12.5	126	35 8	
Public Environmental & Occ Health	900	343	J8 I	142	15.8	485	53 9	126	14.0	289	32 1	
Reproductive Biology	411	80	19.5	114	27 "	194	4" 2	72	175	145	35 3	
Respiratory System	433	57	11.8	117	24 2	174	36.0	51	10.6	258	53.4	
Rheumatology	235	7	3.0	74	31.5	81	34.5	42	179	112	47.7	
Surgery	3847	623	16.2	1079	28.0	1702	44.2	418	10 9	1727	44 9	
Transplantation	612	67	14.2	129	21 1	216 331	35 3 32 8	68	11 1	328 595	536 590	
Urology & Nephrology	1008 730	96 128	9 5 17 5	235 50	23 3 6 8	331 178	32 8 24 4	82 105	8 I 14 4	595 447	61.2	
Virology Total	25404	3946	15 5	6180	24.3	10126	39.9	2630	10.4	12648	49.8	
Pre-clinical Science												
Biochemistry & Molecular Biology	1621	507	31.3	155	96	bh2	40 8	260	16.0	699	431	
Biotechnology & Applied Microbiology	352	155	44 0	42	11.9	19~	56.0	36	10.2	119	318	
Cell Biology	893	231	25 9	167	18 7	198	44 6	169	18 9	326	36.5	
Genetics & Heredity	757	249	32.9	-9	10.4	328	43 3	124	16.4	305	40 3	
Materials Science Biomaterials	311	89	28 6	22	71	111	35 7	44	14.1	156	50 2	
Neurosciences	1937	705	0 اد	295	15.1	1000	51 1	169	46	788	40 3	
Pharmacology & Pharmacy	3869	1830	47 3	574	14.8	2404	62 1	197	5 1 2 ~	1268	328 659	
Physiology Parkeless Market Andrews	671	99	14.8	112 471	16.7 26.0	211 715	31 4 39 5	18 82	4.5	442 1013	56 O	
Radiology Nuclear Medicine	1810 979	244	13 5 35 1	#11 70	7.2	414	39 5 42 3	82 91	93	1013 474	55 U 48 4	
Toxicology Total	13220	344 4453	33 7	1987	15 0	6440	48 7	1190	9.0	5590	42.3	

Table 8 indicates the number of Medline publications with an impact factor published between January 1990 and November 2001 by Hong Kong institutions: namely the Chinese University of Hong Kong, The University of Hong Kong, other academic institutions and non-academic institutions or organizations. Each area is described in more detail in the Appendix in alphabetical order. Figure 11 indicates the proportions of Clinical Science publications and Pre-clinical Science publication areas respectively for each institutional group. The two institutions with medical faculties together account for 85.5% of Clinical Science output and 79.9% of Pre-clinical Science academic output in Hong Kong. The University of Hong Kong is rated number one in Clinical Science with 47.4% of the Hong Kong publications while the Chinese University of Hong Kong is the leading institution in Pre-clinical Science with 44.3% of the output. Table 8 indicates that The University of Hong Kong accounted for the largest number of publications in 19 out of 33 Clinical Science areas (57.6%) versus 9 for the Chinese University and one each for the other two institutional groups. The Chinese University had the largest number of publications in 6 out of 10 Pre-clinical Science areas (60.0%) versus three for The University of Hong Kong and one for other academic institutions. Taking all areas together (Table 8 and Figure 11) The University of Hong Kong accounted for 45 Hong Kong publications out of 100, the Chinese University of Hong Kong for 40 publications, other academic institutions for 6 and non-academic institutions for the remaining 9 publications.




Figure 11. The three charts include the percentages of all Clinical Science publications and the Pre-clinical Science publications, and the two combined, respectively, for Hong Kong institutions: namely the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia), and non-academic institutions or organizations (Other). Details of the results are in Table 8.

Table 8. The number of Medline publications with an impact factor published between January 1990 and November 2001 for Hong Kong institutions: the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other). Only life science areas are listed and they are given in two groups, namely Clinical Science and Preclinical Science. Bold figures represent the highest percentage within each area.

	Total CUHK			Н	KŲ	Aca	Academia		Other	
Area	Ν	Ν	%	Ν	%	Ν	%	Ν	%	
Clinical Science	- ANTONOMER PROPERTY AND A STREET OF THE STREET			**************************************	and the control of the state of					
Anesthesiology	169	127	<i>7</i> 5.1	26	15 4	0	0.0	16	9.5	
Cardiac & Cardiovascular Systems	169	48	28.4	115	68.0	0	0.0	6	3 6	
Clinical Neurology	54	25	46.3	26	48.1	0	0.0	3	5 6	
Critical Care Medicine	91	48	52.7	26	28 6	1	1.1	16	17.6	
Dentistry, Oral Surgery & Medicine	261	2	0.8	248	95.0	0	0.0	11	4.2	
Emergency Medicine	23	6	26.1	4	17.4	1	4.3	12	52.2	
Endocrinology & Metabolism	225	116	51.6	100	44.4	4	1.8	5	2.2	
Gastroenterology & Hepatology	280	88	31 4	162	57.9	0	0.0	30	10.7	
Geriatrics & Gerontology	30	21	70.0	6	20.0	0	0.0	3	10.0	
Hematology	129	26	20.2	<i>7</i> 5	58.1	1	0.8	27	20.9	
Immunology	93	41	44 1	47	50.5	4	4.3	1	1.1	
Infectious Diseases	68	22	32.4	32	47.1	1	1.5	13	19.1	
Medicine, General & Internal	333	160	48 0	128	38.4	3	0.9	42	12 6	
Microbiology	121	35	28.9	81	66.9	2	1.7	3	2.5	
Nutrition & Dietetics	82	35	42.7	34	41.5	11	13.4	2	2.4	
Obstetrics & Gynecology	306	178	58.2	112	36.6	2	07	14	4.6	
Oncology	542	163	30.1	284	52.4	38	7.0	5 <i>7</i>	10.5	
Ophthalmology	157	49	31.2	9	5.7	92	58.6	7	4.5	
Orthopedics	73	17	23 3	46	63.0	4	5.5	6	8.2	
Otorhinolaryngology	105	63	60.0	34	32.4	0	0.0	8	7.6	
Pathology	448	115	25.7	205	45.8	4	0.9	124	27.7	
Pediatrics	273	114	41.8	126	46.2	1	0.3	32	11.7	
Peripheral Vascular Disease	78	35	44.9	41	52.6	1	1 3	1	1.3	
Psychiatry	130	79	60.8	45	34.6	3	2.3	3	2.3	
Public, Environmental & Occ. Health	142	55	38.7	50	35.2	17	12.0	20	14 1	
Reproductive Biology	114	41	36 0	64	56.1	1	0.9	8	7.0	
Respiratory System	117	42	35.9	63	53.8	4	3.4	8	6.8	
Rheumatology	74	22	29.7	44	59.5	1	1.4	7	9.5	
Surgery	1079	439	40.7	486	45.0	5	0.5	149	13 8	
Transplantation	129	33	25.6	80	62.0	0	0.0	16	12.4	
Urology & Nephrology	235	94	40.0	99	42.1	1	0.4	41	17.4	
Virology	50	15	30.0	33	66.0	2	4.0	0	0.0	
Total	6180	2354	38.1	2931	47.4	204	3.3	691	11.2	
Pre-clinical Science										
Biochemistry & Molecular Biology	155	58	37.4	46	29.7	51	32.9	0	0.0	
Biotechnology & Applied Microbiology	42	3	7.1	9	21.4	29	69.0	1	2.4	
Cell Biology	167	60	35.9	57	34.1	50	29.9	0	0.0	
Genetics & Heredity	79	36	45.6	24	30.4	15	19.0	4	5.1	
Materials Science, Biomaterials	22	1	4.5	16	72.7	5	22 7	0	0.0	
Neurosciences	295	96	32.5	114	38.6	81	27.5	4	1.4	
Pharmacology & Pharmacy	574	327	57.0	214	37.3	26	4.5	7	1.2	
Physiology	112	45	40.2	58	51.8	9	8.0	0	0.0	
Radiology, Nuclear Medicine	471	224	47.6	150	31.8	29	6.2	68	14.4	
Toxicology	<i>7</i> 0	30	42.9	16	22.9	20	28.6	4	5.7	
Total	1987	880	44.3	704	35.4	315	15.9	88	4.4	
Grand Total	8167	3234	39.6	3635	44.5	519	6.4	779	9.5	

Table 9 provides the number of Medline publications with an impact factor published between January 1990 and November 2001 for The University of Hong Kong (HKU), compared with all Singaporean institutions taken together. Figure 12 highlights the main findings of this comparison -- that The University of Hong Kong had a higher publication rate during the 12 years of observation in Clinical Science than all Singaporean institutions taken together, 2,931 publications versus 2,630 publications. In the Pre-clinical Science area The University of Hong Kong had 704 versus 1,190 for all of Singapore.

Number of publications




Figure 12. The number of Medline publications with an impact factor published between January 1990 and November 2001 by The University of Hong Kong (HKU) compared with all Singaporean institutions taken together.

Table 9. The number of Medline publications with an impact factor published between January 1990 and November 2001 by The University of Hong Kong (HKU) compared with all Singaporean institutions taken together. Only life science areas are listed and are in two groups, namely Clinical Science and Pre-clinical Science.

Area	HKU N	Singapore N	Difterence %
Clinical Science		TOTAL STREET, AND	and the second s
Anesthesiology	26	61	-57 4
Cardiac & Cardiovascular Systems	115	41	180 5
Clinical Neurology	26	20	30 0
Critical Care Medicine	26	34	-23 5
Dentistry Oral Surgery & Medicine	248	151	64 2
Emergency Medicine	4	10	-60 0
Endocrinology & Metabolism	100	120	-16 7
Gastroenterology & Hepatology	162	94	72 3
Geriatrics & Gerontology	6	4	50 0
Hematology		29	158 6
mmunology	47	77	39 0
nfectious Diseases	32	41	-22 0
Medicine General & Internal	128	63	103 2
Microbiology	81	105	-22 9
Nutrition & Dietetics	34	23	47 8
Obstetrics & Gynecology	112	142	-21 1
Oncology	284	157	80 9
Ophthalmology	9	97	-90 <i>7</i>
Orthopedics	46	18	155 6
Otorhinolaryngology	34	52	34 5
Pathology	205	126	62 7
Pediatrics	126	132	-4 5
	41	25	64 0
Peripheral Vascular Disease	45	44	2 3
Psychiatry Public Environmental & Occ Health			60 3
	50	126 <i>7</i> 2	-11 1
Reproductive Biology	64 63	72 51	23 5
Respiratory System	44	42	23 3 4 8
Rheumatology			
Surgery	486	418	16 3
Fransplantation	80	68	17 6
Jrology & Nephrology	99	82	20 7
/irology	33	105	68 6
otal	2931	2630	11.4
re-clinical Science			
Biochemistry & Molecular Biology	46	200	-82 3
Biotechnology & Applied Microbiology	9	36	-75 O
Cell Biology	5 <i>7</i>	169	-66 3
Genetics & Heredity	24	124	-80 6
Naterials Science Biomaterials	16	44	-63 6
Veurosciences	114	169	-32 5
harmacology & Pharmacy	214	197	8 6
hysiology ,	58	18	222 2
Radiology Nuclear Medicine	150	82	82 9
oxicology	16	91	-82 4
Total Total	704	1190	-40.8
Grand Total	3635	3820	-4.8


Table 10 and Figure 13 indicate the number of Medline publications with an impact factor published between January 1990 and November 2001 for China, Hong Kong, Singapore and Taiwan. Only the total numbers of life science research areas were considered and are in two groups, namely Clinical Science and Pre-clinical Science. The figures are taken from Table 7 and the numbers have been divided by the total population of each region to produce a population-based adjusted (Adjusted) life science academic output; based on populations for China (1,261.5 million), Hong Kong (6.8 million), Singapore (4.1 million) and Taiwan (22.5 million). Table 10 and Figure 13 indicate that Hong Kong is the leader of the four when the number of publications is adjusted for the size of the population, both for Clinical Life Science and Pre-clinical Science. The runner-up is Singapore, followed by Taiwan. Based on the population-adjusted publication values, Hong Kong published 28% (1,202 versus 932 per million population) more publications in Clinical and Pre-clinical Science than Singapore and 48% (1,202 versus 811 per million population) more than Taiwan.


Table 10. The number of Medline publications with an impact factor published between January 1990 and November 2001 from China, Hong Kong, Singapore and Taiwan. Population-based adjusted life science academic output (Adjusted*); refers to the number of publications per million populations.

		China blications		ng Kong olications		ngapore Dications		aiwan Ilications
Area	Total N	Adjusted*	Total N	Adjusted*	Total N	Adjusted*	Total N	Adjusted*
Clinical Science	3946	3.1	6180	908.8	2630	641.5	12648	562.1
Pre-clinical Science	4453	3.5	1987	292.2	1190	290.2	5590	248.4
Total	8399	6.7	8167	1201.0	3820	931.7	18238	810.6


^{*} Based on tigures from Table 7 Population of the four regions are China | 261 5 million | Hong Kong 6 8 million | Singapore 4.1 million and Taiwan 22.5 million


Clinical Science






Pre-clinical Science





Clinical and Pre-clinical Science






Figure 13. The figure gives the total number of Medline publications with an impact factor published between January 1990 and November 2001 from China, Hong Kong, Singapore and Taiwan. The figures are taken from Table 1 and the numbers have been divided by the total population in each region to produce a population-based adjusted (Adjusted) life science academic output; based on the populations of China (1,261.5 million), Hong Kong (6.8 million), Singapore (4.1 million) and Taiwan (22.5 million). As a contrast, the total number of publications is also provided per region in the figure.

Summary

The single most important component of a biotech company is human resources. No biotechnology industry can exist or advance without universities and their research excellence in both Clinical Science and Pre-clinical Science. In the initial phase of establishing a biotechnology industry in an emerging region, universities and university hospitals are the breeding ground for growth. This was the case in all established biotechnology regions and will continue to be so.

By the year 2020 it is estimated that predominantly Chinese communities will be the leading consumers of life science products world-wide, which explains the rapidly increasing interest in this market. Against this background, this study describes the life science academic output in Asia's four predominantly Chinese communities: China, Hong Kong, Singapore and Taiwan. The findings should be of value to academic institutions, the biotechnology industry and government bodies in their effective apportionment and investment of resources in the life science field.

The findings clearly establish that all four areas – China, Hong Kong, Taiwan and Singapore – are important emerging research centres for life science. All four already produce a respectable academic life science output. From a global perspective, they rank among the top 20 to 30 countries, behind the more established life science / biotechnology leaders: North America, Europe and Australia/New Zealand. In Asia, Japan and Israel also have a higher academic life science output than any of the four predominantly Chinese communities.

Taiwan is here shown to be producing the highest number of life science publications, followed by China, Hong Kong and Singapore. However, Hong Kong is the leading location of the four when output is adjusted for the size of the populations, both for Clinical Science and Pre-clinical Science. Based on population-adjusted publication values, Hong Kong produces 28% more publications in Clinical and Pre-clinical Science than Singapore, and 48% more than Taiwan.

China is strongest in Pre-clinical Science than Clinical Science, while the reverse is true for Hong Kong, compared to Singapore and Taiwan. This trend was also noted when the number of publications in 'very high impact' journals were counted; among the four, China accounted for 55% of the 'very high impact' Pre-clinical Science publications, while Hong Kong produced 55% of the 'very high impact' Clinical Science publications. Life science research collaborations are already strong between China and Hong Kong, and further integration seems likely to ensure even greater and faster success.

The two Hong Kong institutions with medical faculties – The University of Hong Kong (HKU) and the Chinese University of Hong Kong (CUHK) – account for 85% of the Clinical and Pre-clinical publications in Hong Kong, with HKU producing 45% and CUHK producing 40%. However, the margin widens when Clinical Science is considered in isolation, with HKU taking a 9% lead over CUHK.

Over the past decade Hong Kong and Singapore have competed to attract international pharmaceutical companies and life science investment – and become the leading centre for biotechnology development in Asia (outside Japan). From this study it is clear that Singapore falls short of Hong Kong, which has a strikingly superior life science academic performance. To cite just one example, The University of Hong Kong, one of the two medical institutions in Hong Kong, has a higher Clinical Science academic output than all institutions, hospitals and private organizations in Singapore put together. One explanation, perhaps, is that Hong Kong has two competing medical faculties, while Singapore only has one medical faculty. Excellence does not tend to develop without competition.

It is possible to formulate many recommendations or proposals on the basis of this study, but only one is made here. Hong Kong is in an extremely competitive position in the medical life science academic area -- not only in the region but also globally -- together with a uniquely strategic position in respect to China. Medical life science innovations and discoveries are known to emerge from medical universities and university hospitals. The Hong Kong SAR Government could capitalise on this resource. Hong Kong clearly has the infrastructure and human resources in place, but cannot expect to advance without appropriate funding.

Appendix

This appendix includes selected areas listed with bold text in Table 6 (page 38-39), representing the major areas in life science research.


The information of five other areas are not given in Tables since the number of publications is too small to provide any useful information. The five areas are Allergy, Anesthesiology, Biochemical Research Methods, Medical Laboratory Technology and Medicine, Research and Experimental.


Journals sorted according to the impact factor provided by the *Journal Citation Reports* (JCR) 2000 version for Multidisciplinary Sciences JCR subject category. The Area Adjusted Impact Factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category: a journal with an adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW).

Multidisciplinary Sciences	Subject Category, Area	Impact	Adjusted	Publication	China	НК	SNG	TW	Total
SCIENCE 23.872 98.0 A 14 3 6 1 24 6 8 5 1 6 8 5 1 6 8 5 1 6 8 1 7 24 6 6 8 32 6 8 8 1 1 1 7 8 9 95.9 A 24 6 6 6 32 6 8 8 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Multidisciplinary Sciences	ractor	IF (%)	lype	n	n	n	n	n
PNATL ACAD SCI USA				Α	15	3	8	2	28
SCI AM 2.240 93.9 A				Α	14	3	6	1	24
IBM RES DEV	P NATL ACAD SCI USA	10.789	95.9	Α	24	6	6	32	68
RES NATL INST STAN		2.240	93 9	Α	0	0	0	0	0
PHILOS T ROY SOC A		1.944	91.8	Α	0	0	0	0	0
P ROY SOC LOND A MAT 1.403 85.7 A 0			89.8	Α	0			0	0
ANN NY ACAD SCI ANN NY ACAD SCI 1.381 83.7 A 78 13 4 18 113 ANN NATURWISSENSCHAFTEN 1.261 81 6 A 2 0 0 0 0 2 AM SCI 1.155 79.6 A 0 0 0 0 0 0 1 INT J BIFURCAT CHAOS 0.866 75.5 A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		1.493	87.8	Α	0	0	0	0	0
NATURWISSENSCHAFTEN AM SCI 1.155 79.6 A 0 0 0 0 1 NATURWISSENSCHAFTEN AM SCI 1.155 79.6 A 0 0 0 0 0 0 0 0 CR ACAD SCI III VIE 0.980 77.6 A 1 0 0 0 0 0 1 INT J BIFURCAT CHAOS 0.866 75.5 A 0 0 0 0 0 0 SUPRAMOL SCI 0.817 71.4 A 0 0 0 0 0 0 SUPRAMOL SCI 0.817 71.4 A 0 0 0 0 0 0 0 0 SUPRAMOL SCI 0.817 71.4 A 0 0 0 0 0 0 0 0 0 0 0 1 ROY SOC NEW ZEAL 0.736 67.3 A 0 0 0 0 0 0 1 ROY SOC NEW ZEAL 0.736 67.3 A 0 0 0 0 0 0 0 0 0 SCI ENG ETHICS 0.407 63.3 B 0 0 0 0 0 0 0 SCI ENG ETHICS 0.440 61.2 B 0 0 0 0 0 0 0 SAFR J SCI 0 1414 57.1 B 0 0 0 0 0 0 1 ROY SOC SOUTH AUST 0.405 53.1 B 0 0 0 0 0 0 1 ROY SOC SOUTH AUST 0.405 53.1 B 0 0 0 0 0 0 0 0 0 0 1 ROY SOC SOUTH AUST 0.405 53.1 B 0 0 0 0 0 0 0 0 0 0 0 0						-	-	-	0
AM SCI CR ACAD SCI III VIE 0.980 77.6 A 1 0 0 0 0 0 0 1 INT J BIFURCAT CHAOS 0.866 75.5 A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0								18	113
CR ACAD SCI III VIE	NATURWISSENSCHAFTEN	1.261	81 6	Α	2	0	0	0	2
INT J BIFURCAT CHAOS 0.866 75.5 A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	AM SCI	1.155	79.6	Α	0	0	0	0	0
FRACTALS SUPRAMOL SCI 0.817 71.4 A 0 0 0 0 0 0 ANN CARNEGIE MUS 0.789 69.4 A 0 0 0 0 0 0 0 NEW SCI 0.817 0.812 67.3 B 0 0 0 0 0 0 0 0 0 0 0 0	CR ACAD SCI III VIE	0.980	77.6	Α	1	0	0	0	1
SUPRAMOL SCI ANN CARNEGIE MUS O.789 69:4 A O O O O O O O O O O O O O O O O O O	INT J BIFURCAT CHAOS	0.866	75.5	Α	0	0	0	0	0
ANN CARNEGIE MUS ROY SOC NEW ZEAL 0.736 67 3 A 0 0 0 0 0 CURR SCI INDIA 0.512 65 3 B 0 0 0 0 0 CURR SCI INDIA 0.512 65 3 B 0 0 0 0 0 0 SCI ENG ETHICS 0.470 63.3 B 0 0 0 0 0 0 PJPN ACAD B PHYS 0.443 59.2 B 0 0 0 0 0 0 PJPN ACAD B PHYS 0.443 59.2 B 0 0 0 0 0 0 PJPN ACAD B PHYS 0.444 57.1 B 0 0 0 0 0 0 CHINESS ECI BULL 0.414 57.1 B 0 0 0 0 0 0 T ROY SOC SOUTH AUST 0.405 53.1 B 0 0 0 0 0 0 T ROY SOC SOUTH AUST 0.366 51.0 B 0 0 0 0 0 0 TECHNOL ANAL STRATEG 0.356 49.0 B 0 0 0 0 0 SCIENTIST 0.347 46.9 B 0 0 0 0 0 SCI CHINA SER A 0.309 44.9 B 0 0 0 0 0 SCI CHINA SER A 0.309 44.9 B 0 0 0 0 0 SCI CHINA SER A 0.296 42.9 B 0 0 0 0 0 SISUES SCI TECHNOL 0.296 42.9 B 0 0 0 0 0 0 DHOJ ISCI 0.273 38 8 B 0 0 0 0 0 0 J HOPKINS APL TECH D 0.232 34.7 B 0 0 0 0 0 J SCI IND RES INDIA 0.208 32.7 C 0 0 0 0 0 SENDEAVOUR 0.189 30.6 C 0 0 0 0 0 RECHERCHE 0.092 24.5 C 0 0 0 0 0 RECHERCHE 0.092 24.5 C 0 0 0 0 0 RECHERCHE 0.092 24.5 C 0 0 0 0 0 ARAB JI SCI TECH OL 0.099 18.4 C 0 0 0 0 0 ARAB JI SCI ENG 0.060 14.3 C 0 0 0 0 0 0 ARAB JI SCI ENG 0.060 14.3 C 0 0 0 0 0 0 ARAB JI SCI ENG 0.060 14.3 C 0 0 0 0 0 0 ARAB JI SCI ENG 0.049 8.2 C 0 0 0 0 0 0 ARAB GURL SCI	FRACTALS	0.852	<i>7</i> 3 5	Α	0	0	0	0	0
ROY SOC NEW ZEAL	SUPRAMOL SCI	0.817	71.4	Α	0	0	0	0	0
CURR SCI INDIA CURR SCI INDIA O.512 65 3 B 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	ANN CARNEGIE MUS	0.789	69.4	Α	0	0	0	0	0
SCI ENG ETHICS	J ROY SOC NEW ZEAL	0.736	67 3	Α	0	0	0	0	0
NEW SCI P JPN ACAD B PHYS O. 444 51.1 B O O O O O O O O O O O O O O O O O O	CURR SCI INDIA	0.512	65 3	В	0	0	0	0	0
P JPN ACAD B PHYS S AFR J SCI O 444 57.1 B 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	SCI ENG ETHICS	0.470	63.3	В	0	0	0	0	0
S ÁFR J SCI O 414 57.1 B 0 0 0 0 0 0 0 CHINESE SCI BULL O.414 55.1 B 0 0 0 0 0 0 0 0 0 CHINESE SCI BULL TROY SOC SOUTH AUST O.405 53.1 B 0 0 0 0 0 0 0 0 INTERCIENCIA O.366 51.0 B 0 0 0 0 0 0 0 TECHNOL ANAL STRATEG O.366 51.0 B 0 0 0 0 0 0 0 TECHNOL ANAL STRATEG O.356 49.0 B 0 0 0 0 0 0 0 SCIENTIST O.347 46.9 B 0 0 0 0 0 0 0 O O O O O O O O O O O O		0.464	61.2	В	0	0	0	0	0
CHINÉSE SCI BULL O.414 55.1 B O O O O O O O T ROY SOC SOUTH AUST O.405 53.1 B O O O O O O O O O O T ROY SOC SOUTH AUST O.366 51.0 B O O O O O O O O O O TECHNOL ANAL STRATEG O.356 49.0 B O O O O O O O O O O O O O O O O O O	P IPN ACAD B PHYS	0.443	59.2	В	0	0	0	0	Ö
CHINÉSE SCI BULL O.414 55.1 B O O O O O O O T ROY SOC SOUTH AUST O.405 53.1 B O O O O O O O O O O T ROY SOC SOUTH AUST O.366 51.0 B O O O O O O O O O O TECHNOL ANAL STRATEG O.356 49.0 B O O O O O O O O O O O O O O O O O O	S AFR I SCI	0 414	57.1	В	0	0	0	Ô	0
T ROY SOC SOUTH AUST 0.405 53.1 B 0 0 0 0 0 0 0 1 INTERCIENCIA 0.366 51.0 B 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	,				0	0	0	0	Ō
INTERCIENCIA					0	0	0		O.
SCIENTIST 0.347 46.9 B 0 0 0 0 SCI CHINA SER A 0.309 44.9 B 0									
SCIENTIST 0.347 46.9 B 0 0 0 0 SCI CHINA SER A 0.309 44.9 B 0	TECHNOL ANAL STRATEG	0.356	49.0	В	0	0	0	0	Ö
SCI CHINA SER A 0.309					Ō	Ō	0	0	Ō
ISSUES SCI TECHNOL							Ō		
ARCH SCI OHIO J SCI OH			42.9		0	0	0	0	0
OHIO J SCI OHIO J SCI OL273 OHIO J SCI OL249 OHIO J SCI OL247 OHIO J SCI OHIO J SCI OL247 OHIO J SCI OHIO J SCI OL247 OHIO J							0	0	Ö
PROG NAT SCI 0.249 36.7 B 0 0 0 0 J HOPKINS APL TECH D 0.232 34.7 B 0 </td <td></td> <td></td> <td></td> <td></td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>Ō</td>					0	0	0	0	Ō
J HOPKINS APL TECH D J SCI IND RES INDIA 0.208 32.7 C 0 0 0 0 0 ENDEAVOUR 0.189 30.6 C 0 0 0 0 0 TECHNOL REV 0.173 28.6 C 0 0 0 0 0 TEX J SCI RECHERCHE 0.092 24.5 C 0 0 0 0 0 RAN J SCI TECHNOL KUWAIT J SCI ENG J ENVIRON LAW 0.069 18.4 C 0 0 0 0 0 DEFENCE SCI J 0.060 16.3 C 0.073 20.4 C 0.09 0 0 DEFENCE SCI J 0.060 16.3 C 0.070 0 0.070		0.249	36.7	В	0	0	0	0	0
SCI IND RES INDIA					0	0	0	0	0
ENDEAVOUR 0.189 30.6 C 0 0 0 0 0 0 TECHNOL REV 0.173 28.6 C 0 0 0 0 0 0 TEX J SCI 0.157 26.5 C 0 0 0 0 0 0 RECHERCHE 0.092 24.5 C 0 0 0 0 0 0 IRAN J SCI TECHNOL 0.090 22.4 C 0 0 0 0 0 0 KUWAIT J SCI ENG 0.073 20.4 C 0 0 0 0 0 JENVIRON LAW 0.069 18.4 C 0 0 0 0 0 DEFENCE SCI J 0.060 16.3 C 0 0 0 0 ARAB J SCI ENG 0.060 14.3 C 0 0 0 0 0 NATL ACAD SCI LETT 0.059 12.2 C 0 0 0 0 INTERDISCIPL SCI REV 0.058 10.2 C 0 0 0 0 T ROY SOC S AFR 0.049 8.2 C 0 0 0 0 R&D MAG 0.033 4.1 C 0 0 0 0 R&D MAG 0.033 4.1 C 0 0 0 0 R&D MAG 0.033 4.1 C 0 0 0 0 DISCOV INNOVAT			-						
TECHNOL REV 0.173 28.6 C 0 0 0 0 0 TEX J SCI 0.157 26.5 C 0 0 0 0 0 RECHERCHE 0.092 24.5 C 0 0 0 0 0 IRAN J SCI TECHNOL 0.090 22.4 C 0 0 0 0 0 KUWAIT J SCI ENG 0.073 20.4 C 0	•			č	-	-			
TEX J SCI 0.157 26.5 C 0 0 0 0 0 RECHERCHE 0.092 24.5 C 0 0 0 0 0 IRAN J SCI TECHNOL 0.090 22.4 C 0 0 0 0 0 KUWAIT J SCI ENG 0.073 20.4 C 0				č					
RECHERCHE 0.092 24.5 C 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0				č	Ō		Ō		Ō
IRAN SCI TECHNOL 0.090 22.4 C 0 0 0 0 0	•			č	ō	Ō	Ō	Ō	Õ
KUWAIT J SCI ENG 0.073 20.4 C 0 <td></td> <td></td> <td></td> <td>č</td> <td></td> <td>-</td> <td>-</td> <td></td> <td>-</td>				č		-	-		-
J ENVIRON LAW 0.069 18.4 C 0 0 0 0 0 0 DEFENCE SCI J 0.060 16.3 C 0 0 0 0 0 ARAB J SCI ENG 0.060 14.3 C 0 0 0 0 0 NATL ACAD SCI LETT 0.059 12.2 C 0 0 0 0 0 INTERDISCIPL SCI REV 0.058 10.2 C 0 0 0 0 0 T ROY SOC S AFR 0.049 8.2 C 0 0 0 0 0 ARAB GULF J SCI RES 0.042 6.1 C 0 0 0 0 R&D MAG 0.033 4.1 C 0 0 0 0 DISCOV INNOVAT 0.023 2.0 C 0 0 0 0	•			č			_		
DEFENCE SCI J 0.060 16.3 C 0 0 0 0 0 ARAB J SCI ENG 0.060 14.3 C 0 0 0 0 0 NATL ACAD SCI LETT 0.059 12.2 C 0 0 0 0 0 INTERDISCIPL SCI REV 0.058 10.2 C 0 0 0 0 0 T ROY SOC S AFR 0.049 8.2 C 0 0 0 0 0 ARAB GULF J SCI RES 0.042 6.1 C 0 0 0 0 0 R&D MAG 0.033 4.1 C 0 0 0 0 0 DISCOV INNOVAT 0.023 2.0 C 0 0 0 0 0	•			č	_		-		
ARAB J SCI ENG NATL ACAD SCI LETT 0.059 12.2 C 0 0 0 0 0 1.01 1.02 C 0 0 0 0 0 0 0 0 0 0 0 0									-
NATL ACAD SCI LETT 0.059 12.2 C 0 0 0 0 0 INTERDISCIPL SCI REV 0.058 10.2 C 0 0 0 0 0 T ROY SOC S AFR 0.049 8.2 C 0 0 0 0 0 ARAB GULF J SCI RES 0.042 6.1 C 0 0 0 0 0 R&D MAG 0.033 4.1 C 0 0 0 0 0 DISCOV INNOVAT 0.023 2.0 C 0 0 0 0 0	•			č	-	_			
INTERDISCIPL SCI REV 0.058 10.2 C 0 0 0 0 0 0 T ROY SOC S AFR 0.049 8.2 C 0 0 0 0 0 0 ARAB GULF J SCI RES 0.042 6.1 C 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0				č		_	-		-
T ROY SOC S AFR 0.049 8.2 C 0 0 0 0 0 0 ARAB GULF J SCI RES 0.042 6.1 C 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0					-	-			
ARAB GULF J SCI RES 0.042 6.1 C 0 0 0 0 0 0 R&D MAG 0.033 4.1 C 0 0 0 0 0 0 DISCOV INNOVAT 0.023 2.0 C 0 0 0 0 0				č	_		-		
R&D MAG 0.033 4.1 C 0 0 0 0 0 DISCOV INNOVAT 0.023 2.0 C 0 0 0 0 0					-				-
DISCOV INNOVAT 0.023 2.0 C 0 0 0 0 0				č			-	-	_
				č	-	-	-		
Total 134 25 24 53 236		0.023		~	-	-		-	•
	Total				134	25	24	53	236

Biochemistry and Molecular Biology

Number of full papers (with impact factor) in Medline





Biochemistry and Molecular Biology subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).

Journals sorted according to the impact factor provided by the *Journal Citation Reports* (JCR) 2000 version for Biochemistry and Molecular Biology JCR subject category. The Area Adjusted Impact Factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category: a journal with an adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW). About 15 of the journals with the lowest IF with no publications have been omitted in the list.

ANNU REV BIOCHEM 43.429 100.0 A 0 0 0 0 0 0 0 0 CELL 32.440 99.7 A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Subject Category, Area Biochemistry and Molecular Biology	Impact Factor	Adjusted IF (%)	Publication Type	China n	HK n	SNG n	TW n	Total n
CELL			**************************************						
NAT MED ANNU REV CELL DEV BI ANNU REV ELL DEV BI ANNU REV BIOPH BIOM I6.194 98.4 A 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0									
ANNU REV CELL DEV BI MOL CELL 18.195 98.7 A 0 0 0 0 0 0 0 0 1 ANNU REV BIOPH BIOM 16.194 98.4 A 0 0 0 0 0 0 0 0 CURR OPIN CENET DEV 13.891 97.7 A 0 0 0 1 0 1 TRENDS BIOCHEM SCI 13.246 97.4 A 1 1 1 1 1 1 1 1 1 TRENDS BIOCHEM SCI 13.246 97.4 A 0 0 0 1 0 1 TRENDS BIOCHEM SCI 13.246 97.1 A 1 1 1 1 1 1 1 1 1 TRENDS BIOCHEM SCI 11.939 96.6 A 0 0 0 1 0 0 1 ANT STRUCT BIOL 11.58 96.1 11.939 96.6 A 0 0 0 1 0 0 1 ANT STRUCT BIOL 11.58 96.1 11.939 95.5 A 0 0 0 1 0 0 0 ANT STRUCT BIOL 11.033 95.8 A 0 0 0 0 0 0 0 0 ANT STRUCT BIOL 11.033 95.8 A 0 0 0 0 0 0 0 0 ANT STRUCT BIOL 11.033 95.8 A 0 0 0 0 0 0 0 0 ANT STRUCT BIOL 11.033 95.8 A 0 0 0 0 0 0 0 0 ANT STRUCT BIOL 11.033 95.8 A 0 0 0 0 0 0 0 0 ANT STRUCT BIOL 11.033 95.8 A 0 0 0 0 0 0 0 0 ANT STRUCT BIOL 11.033 95.8 A 0 0 0 0 0 0 0 0 ANT STRUCT BIOL 11.033 95.8 A 0 0 0 0 0 0 0 0 ANT STRUCT BIOL 11.033 95.8 A 0 0 0 0 0 0 0 0 ANT STRUCT BIOL 11.034 CURR OPIN STRUC BIOL 97.666 94.8 97.44 94.5 A 0 0 0 0 0 0 0 ANT STRUCT BIOL ANT STRUCT BIOL ANT STRUCT BIOL 10.427 95.5 A 0 0 0 0 0 0 0 ANT STRUCT BIOL ANT STRUCT BIOL ANT STRUCT BIOL ANT STRUCT BIOL 10.427 95.5 A 0 0 0 0 0 0 0 ANT STRUCT BIOL ANT STRUCT BIOL ANT STRUCT BIOL 10.427 95.5 A 0 0 0 0 0 0 0 ANT STRUCT BIOL ANT STRU	NAT MED								-
MOL CELL ANNU REV BIOPH BIOM ANNU REV BIOPH BIOM 16.194 98.7 A 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	ANNU REV CELL DEV BI	26.300	99.0		Ó				
ANNU REV BIOM BIOM ANNU REV BIOM BIOM ANNU REV PLANT PHYS 15.094 98.1 A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	MOL CELL	18.195							1
EMBO J 13.999 97.7 A 0 0 0 1 0 1 1 1 TRENDS BIOCHEM SCI 13.810 97.4 A 0 0 0 1 1 0 1 1 TRENDS BIOCHEM SCI 13.246 97.1 A 1 1 1 1 1 4 A NAT CELL BIOL 11.939 96.8 A 0 0 0 0 1 0 0 0 0 0 NAT STRUCT BIOL 11.158 96.5 A 0 0 0 0 0 0 0 0 0 NAT STRUCT BIOL 11.158 96.1 A 0 1 1 0 0 1 1 1 LANT CELL 11.158 96.1 A 0 0 0 0 0 0 0 0 0 NAT STRUCT BIOL 11.158 96.1 A 0 0 0 0 0 0 1 1 1 1 LANT CELL 11.093 95.8 A 0 0 0 0 0 1 1 1 1 LANT CELL 11.093 95.8 A 0 0 0 0 0 0 1 1 1 LANT CELL 11.093 95.8 A 0 0 0 0 0 0 0 0 0 0 NAT STRUCT BIOL 10.427 95.5 A 0 0 0 0 0 0 0 0 0 0 NAT STRUCT BIOL 10.427 95.5 A 0 0 0 0 0 0 0 0 0 NAT STRUCT BIOL 10.427 95.5 A 0 0 0 0 0 0 0 0 0 NAT STRUCT BIOL 10.427 95.5 A 0 0 0 0 0 0 0 0 NAT STRUCT BIOL 10.427 95.5 A 0 0 0 0 0 0 0 0 NAT STRUCT BIOL 10.427 95.5 A 0 0 0 0 0 0 0 0 NAT STRUCT BIOL 10.427 95.5 A 0 0 0 0 0 0 0 0 NAT STRUCT BIOL 10.427 95.5 A 0 0 0 0 0 0 0 0 NAT STRUCT BIOL 10.427 95.5 A 0 0 0 0 0 0 0 0 NAT STRUCT BIOL 10.427 95.5 A 0 0 0 0 0 0 0 0 NAT STRUCT BIOL 10.427 95.5 A 0 0 0 0 0 0 0 0 NAT STRUCT BIOL 10.427 95.5 A 0 0 0 0 0 0 0 0 NAT STRUCT BIOL 10.427 95.5 A 0 0 0 0 0 0 0 0 0 NAT STRUCT BIOL 10.427 95.5 A 0 0 0 0 0 0 0 0 0 0 NAT STRUCT BIOL 10.427 95.5 A 0 0 0 0 0 0 0 0 0 0 0 NAT STRUCT BIOL 10.427 95.5 A 0 0 0 0 0 0 0 0 0 0 0 0 NAT STRUCT BIOL 10.427 95.5 A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		16.194	98.4	Α	Ö		Ó		Ó
CURR OPIN GENET DEV			98.1	Α	0	0	0	0	0
TRENDS BIOCHEM SCI NAT CELL BIOL 11.939 96.8 A 0 0 1 0 1 11.539 96.8 A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 11.589 96.1 A 0 0 0 0 0 0 0 0 0 0 0 1 11.589 96.1 A 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1				Α	0	0	1	0	1
NAT CELL BIOL BBAR REV BIOMEMBRANES 11.645 96.5 A 0 0 0 0 0 0 0 NAT STRUCT BIOL 11.158 96.1 A 0 0 1 0 0 1 1 0 0 1 1 1.158 96.1 A 0 0 0 0 0 0 0 0 0 1 1 1.158 96.1 A 0 0 0 0 0 0 0 0 1 1 1.158 96.1 A 0 0 0 0 0 0 0 0 0 1 1 1.158 96.1 A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0					-		1	0	1
BBA REV BIOMEMBRANES							•		
NAT STRUCT BIOL 11.158 96.1 A 0 1 0 0 0 1 1 1 CURR OPIN STRUC BIOL 10.427 95.5 A 0 0 0 0 0 0 0 MOL CELL BIOL 9.666 94.8 A 0 0 0 0 0 0 0 MOL CELL BIOL 9.666 94.8 A 0 0 0 0 0 0 0 MOL CELL BIOL 9.666 94.8 A 0 0 0 0 0 0 0 HUM MOL GENET 9.048 94.2 A 0 0 0 0 1 1 1 MOL BIOL CELL (URR BIOL 8.897 93.9 A 1 0 0 0 1 0 1 MOL PSYCHIATR 8.927 93.9 A 0 0 0 1 0 1 MOL BIOL CELL (URR BIOL 8.393 93.2 A 0 0 0 1 0 1 PROG NUCLEIC ACID RE 8.373 92.9 A 0 0 0 1 0 1 PROG NUCLEIC ACID RE 8.373 92.9 A 0 0 0 1 0 1 PROG NUCLEIC ACID RE 8.373 92.9 A 0 0 0 1 0 1 PROG NUCLEIC MED							•		•
PLANT CELL CURR OPIN STRUC BIOL 10.427 95.5 A 0 0 0 0 0 0 BBA REV CANCER 9.714 95.2 A 0 0 0 0 0 0 0 0 0 0 0 0					-	-			
CURR OPIN STRUC BIOL 10.427 95.5 A							-	_	•
BBA REV CANCER									
MOL CELL BIOL FASEB J 9.249 94.5 A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0							-		
FASEB 92.49 94.5 A							-		
HUM MOL GENET MOL PSYCHIATR 8.927 93.9 A 1 0 0 0 1 1 0 1 CURR BIOL BIOL CELL B.482 93.5 A 0 0 1 1 0 1 0 1 PROG NUCLEIC ACID RE B.373 92.9 A 0 0 0 1 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0							-		
MOL BYCHIATR MOL BIOL CELL MOL BIOL CELL BOLL BASHS MOL BIOL CELL BOLL BASHS MOL BIOL CELL BASHS MOL BIOL CELL BASHS BOLL BASHS BOLL BIOESSAYS F.906 BIOESSAYS F.907 BIOESSAYS F.906 BIOESSAYS							-		
MOL BIOL CELL CURR BIOL BIOL BIOL BIOL BIOL BIOL BIOL BIOL									•
CURR BIOL PROG NUCLEIC ACID RE 8.373 92.9 A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0									
PROG NUCLEIC ACID RE 8.373 92.9							-		
BIOESSAYS	PROG NUCLEIC ACID RE						-		Ò
GENOME RES JBIOL CHEM JBIOL CHEM JBIOL CHEM JBIOL CHEM JBIOL CHEM JBIOL CHEM BIOL CYTOKINE GROWTH FR JBIOL CHEM BIOL CYTOKINE GROWTH FR JBIOL CHEM BIOL JBIOL CHEM JBIOL JBIOL CHEM JBIOL JBIOL CHEM JBIOL JBIOL CHEM JBIOL	BIOESSAYS								
BIOL CHEM	CELL DEATH DIFFER				0	Õ	1		1
CURR OPIN CHEM BIOL 5.70.44 91.3 A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	GENOME RES	7.615	91.9	Α	0	0	1	0	1
STRUCT FOLD DES		7.368	91.6	Α	39	30	118	165	352
ONCOGENE 6.490 90.6 A 0 0 0 1 1 BBA BIOENERGETICS 6.346 90.3 A 0			91.3	Α	0	0			0
BBA BIGENERGETICS									
MOL MICROBIOL 6.339 90.0 A 0 0 0 0 1 1 ADV MICROB PHYSIOL 6.095 89.7 A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0					-		_		
ADV MICROB PHYSIOL CYTOKINE GROWTH F R 6.049 89.4 A 0 0 0 0 0 0 0 0 0 TRENDS MICROBIOL 6.006 89.0 A 0 0 1 0 1 0 1 GENE THER 5.964 88.7 A 0 0 0 1 0 1 0 1 ADV PROTEIN CHEM 5.769 88.4 A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0									
CYTOKINE GROWTH F R 6.049 89.4 A 0 0 0 1 0 0 TRENDS MICROBIOL 6.006 89.0 A 0 0 1 0 1 GENE THER 5.964 88.7 A 0 0 0 1 0 1 ADV PROTEIN CHEM 5.769 88.4 A 0 0 0 0 0 0 CHEM BIOL 5.717 88.1 A 0 0 0 0 1 1 FOLD DES 5.700 87.7 A 0 0 0 0 0 0 MOL PHARMACOL 5.678 87.4 A 0 0 0 0 0 1 1 CURR OPIN LIPIDOL VITAM HORM 5.661 87.1 A 0 0 0 0 0 1 VITAM HORM 5.407 86.8 A 0 0 0 1 0 1 NUCLEIC ACIDS RES 5.396 86.5 A 20 10 13 29 72 REV PHYSIOL BIOCH P 5.389 86.1 A 0 0 0 0 0 0 J MOL BIOL FROG LIPID RES 5.379 85.5 A 0 1 0 0 0 0 TRENDS LIPID RES 5.379 85.5 A 0 1 0 0 0 0 TRENDS LIPID REP 5.298 85.2 A 0 1 0 0 0 0 1 NAT PROD REP 5.298 85.2 A 0 1 0 0 0 0 1 NAT PROD REP 5.295 84.8 A 0 0 0 0 0 0 0 CELL GROWTH DIFFER 5.295 84.8 A 0 0 0 0 0 0 0 RNA DOL MED TODAY 5.193 84.2 A 0 0 0 0 0 0 RNA CRIT REV BIOCHEM MOL 5.046 83.2 A 0 0 0 0 0 0 RNA FROG BIOPHYS MOL BIO CRIT REV BIOCHEM MOL 5.048 83.2 A 0 0 0 0 0 0 RNA FROG BIOPHYS MOL BIO CURR MED CHEM 4.900 82.3 A 0 0 0 0 0 0 MET IONS BIOL SYST 4.385 81.9 A 0 0 0 0 0 0 MET IONS BIOL SYST 4.385 81.9 A 0 0 0 0 0 0 MET IONS BIOL SYST 4.385 81.9 A 0 0 0 0 0 0 0 MET IONS BIOL SYST 4.385 81.9 A 0 0 0 0 0 0 0 MET IONS BIOL SYST 4.385 81.9 A 0 0 0 0 0 0 1 1 ROULEM J 115 195					-				•
TRENDS MICROBIOL 6,006 89.0 A 0 0 1 0 1 GENE THER 5.964 88.7 A 0 0 0 1 0 1 ADV PROTEIN CHEM 5.766 88.4 A 0 0 0 0 0 0 0 CHEM BIOL 5.717 88.1 A 0 0 0 0 0 0 0 0 0									
GENE THER ADV PROTEIN CHEM 5.769 88.4 A 0 0 0 1 1 0 1 ADV PROTEIN CHEM 5.769 88.4 A 0 0 0 0 0 1 1 1 FOLD DES 5.700 87.7 A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0									
ADV PROTEIN CHEM 5.769 88.4 A 0 0 0 0 0 CHEM BIOL 5.717 88.1 A 0 0 0 0 1 1 1 CURD DES 5.700 87.7 A 0 0 0 0 0 MOL PHARMACOL 5.678 87.4 A 0 0 0 0 1 1 CURR OPIN LIPIDOL 5.661 87.1 A 0 0 0 0 0 0 VITAM HORM 5.407 86.8 A 0 0 1 1 1 NUCLEIC ACIDS RES 5.396 86.5 A 20 10 13 29 72 REV PHYSIOL BIOCH P 5.389 86.1 A 0 0 0 0 0 0 J MOL BIOL PROG LIPID RES 5.379 85.5 A 0 1 0 1 NAT PROD REP 5.295 84.8 A 0 0 0 0 1 1 NAT PROD REP 5.295 84.8 A 0 0 0 0 0 CELL GROWTH DIFFER 5.235 84.5 A 0 0 0 0 0 CRIT REV BIOCHEM MOL S.083 83.5 A 0 0 0 0 0 0 0 0 0 0 0 0							•		
CHEM BIOL FOLD DES 5.717 88.1 A 0 0 0 1 1 FOLD DES 5.700 87.7 A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0									
FOLD DES MOL PHARMACOL CURR OPIN LIPIDOL TOWN MOL BIOL TOWN MOL BIOCH P TOWN MOL BIOL STATE MOL BIOL CELL GROWTH DIFFER MOL BIOL EVOL NAT PROD REP CELL GROWTH DIFFER MOL MED TODAY ADV ENZYMOL RAMB TOWN MOL BIOCH STATE TOWN MOL BIOCH									
MOL PHARMACOL 5.678 87.4 A 0 0 0 1 1 CURR OPIN LIPIDOL 5.661 87.1 A 0 0 0 0 0 VITAM HORM 5.407 86.8 A 0 0 1 0 1 NUCLEIC ACIDS RES 5.396 86.5 A 20 10 13 29 72 REV PHYSIOL BIOCH P 5.389 86.1 A 0 1 1 1 0 0 1 1 1 0 0 1 1 1 0 0 1 1 1 0 0									
CURR OPIN LIPIDOL VITAM HORM 5.407 86.8 A 0 0 1 1 0 1 NUCLEIC ACIDS RES 5.396 86.5 A 20 10 13 29 72 REV PHYSIOL BIOCH P 5.388 86.1 A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0									
VITAM HORM 5.407 86.8 A O 0 1 0 1 NUCLEIC ACIDS RES 5.396 86.5 A 20 10 13 29 72 REV PHYSIOL BIOCH P 5.389 86.1 A 0 1 1 1 0 0 1 1 NAT PROD REP 5.295 84.8 A 0 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>									
NUCLEIC ACIDS RES REV PHYSIOL BIOCH P S.389 86.1 A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	VITAM HORM					0	1	0	1
REV PHYSIOL BIOCH P J MOL BIOL 5.388 85.8 A 18 12 4 26 60 PROG LIPID RES 5.379 85.5 A 0 1 0 0 1 1 0 0 1 1 NAT PROD REP 5.295 84.8 A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	NUCLEIC ACIDS RES		86.5	Α	20	10	13	29	72
PROG LIPID RES 5.379 85.5 A 0 1 0 0 1 MOL BIOL EVOL 5.298 85.2 A 0 0 0 1 1 NAT PROD REP 5.295 84.8 A 0 0 0 0 0 CELL GROWTH DIFFER 5.235 84.5 A 0 <td>REV PHYSIOL BIOCH P</td> <td></td> <td></td> <td>Α</td> <td></td> <td></td> <td></td> <td></td> <td></td>	REV PHYSIOL BIOCH P			Α					
MOL BIOL EVOL 5.298 85.2 A 0 0 0 1 1 NAT PROD REP 5.295 84.8 A 0 0 0 0 0 CELL GROWTH DIFFER 5.235 84.5 A 0 0 0 1 1 MOL MED TODAY 5.193 84.2 A 0 <td></td> <td></td> <td></td> <td>Α</td> <td></td> <td>12</td> <td></td> <td></td> <td></td>				Α		12			
NAT PROD REP 5.295 84.8 A 0 0 0 0 0 0 CELL GROWTH DIFFER 5.235 84.5 A 0 0 0 1 1 MOL MED TODAY 5.193 84.2 A 0 0 0 0 0 0 ADV ENZYMOL RAMB 5.143 83.9 A 0 0 0 0 0 0 0 0 0 0 0 0									
CELL GROWTH DIFFER 5.235 84.5 A 0 0 0 1 1 MOL MED TODAY 5.193 84.2 A 0 0 0 0 0 ADV ENZYMOL RAMB 5.143 83.9 A 0 0 0 0 0 CRIT REV BIOCHEM MOL 5.083 83.5 A 0 0 0 0 0 RNA 5.046 83.2 A 0 0 0 0 0 PROG BIOPHYS MOL BIO 4.931 82.9 A 0 1 0 0 1 CURR MED CHEM 4.909 82.6 A 1 0 0 0 1 J NEUROCHEM 4.900 82.3 A 0 0 0 0 0 MET IONS BIOL SYST 4.385 81.9 A 0 0 0 0 0 AM J RESP CELL MOL 4.3553 81.6 A 0 0 0 1 1 BIOCHEM 4 8 24 115 195							-		
MOL MED TODAY 5.193 84.2 A 0 0 0 0 0 ADV ENZYMOL RAMB 5.143 83.9 A 0 0 0 0 0 CRIT REV BIOCHEM MOL 5.083 83.5 A 0 0 0 0 0 RNA 5.046 83.2 A 0 0 0 0 0 PROG BIOPHYS MOL BIO 4.931 82.9 A 0 1 0 0 1 CURR MED CHEM 4.909 82.6 A 1 0 0 0 1 J NEUROCHEM 4.900 82.3 A 0 0 0 0 0 MET IONS BIOL SYST 4.385 81.9 A 0 0 0 0 0 AM J RESP CELL MOL 4.353 81.6 A 0 0 0 1 1 1 15 195									
ADV ENZYMOL RAMB 5.143 83.9 A 0 0 0 0 0 0 RNA 5.083 83.5 A 0 0 0 0 0 0 RNA 5.046 83.2 A 0 0 0 0 0 0 0 0 0 0 0 0						-	-		
CRIT REV BIOCHEM MOL RNA 5.083 83.5 A 0 0 0 0 0 0 0 0 PROG BIOPHYS MOL BIO 4.931 82.9 A 0 1 0 1 0 1 0 1 0 1 0 1 1							-		
RNA 5.046 83.2 A 0 0 0 0 0 0 0 PROG BIOPHYS MOL BIO 4.931 82.9 A 0 1 0 0 1 0 0 1 0 1 CURR MED CHEM 4.909 82.6 A 1 0 0 0 0 1 1 NEUROCHEM 4.900 82.3 A 0 0 0 0 0 0 0 0 0 MET IONS BIOL SYST 4.385 81.9 A 0 0 0 0 0 0 0 1 1 BIOCHEM 4.280 81.3 A 48 8 24 115 195									
PROG BIOPHYS MOL BIO									
CURR MED CHEM 4.909 82.6 A 1 0 0 0 1 J NEUROCHEM 4.900 82.3 A 0 0 0 0 0 MET IONS BIOL SYST 4.385 81.9 A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 BIOCHEM J 4.280 81.3 A 48 8 24 115 195									1
J NEUROCHEM 4.900 82.3 A 0 0 0 0 0 MET IONS BIOL SYST 4.385 81.9 A 0 0 0 0 0 AM J RESP CELL MOL 4.353 81.6 A 0 0 0 1 1 BIOCHEM J 4.280 81.3 A 48 8 24 115 195							-		1
MET IONS BIOL SYST 4.385 81.9 A 0 0 0 0 0 0 AM J RESP CELL MOL 4.353 81.6 A 0 0 0 1 1 BIOCHEM J 4.280 81.3 A 48 8 24 115 195					-		-		
AM J RESP CELL MOL 4.353 81.6 A 0 0 0 1 1 BIOCHEM J 4.280 81.3 A 48 8 24 115 195							-		
BIOCHEM J 4.280 81.3 A 48 8 24 115 195	AM I RESP CELL MOL				-				_
							-	•	
BIOCHEMISTRY US 4.221 81.0 A 20 3 6 36 65	BIOCHEMISTRY US	4.221	81.0	Ä	20	3	6	36	65

(co	nti	nu	adi
lCO	HU	пu	eu,

(continued)	and the second s					0.10	77.1.1	7
Subject Category, Area Biochemistry and Molecular Biology	Impact Factor	Adjusted IF (%)	Publication Type	China n	HK n	SNG n	TW n	Total n
BBA MOL CELL BIOL L	4.160	80.6	Ą	0	0	0	0	0
FREE RADICAL BIO MED	4.116	80.3	A	1	0	0 0	0 0	1 0
DRUG DISCOV TODAY	4.105	80.0	A A	0 0	0	0	0	0
I MOL EVOL	3.984 3.869	79.7 79.4	Ä	8	1	Ő	11	20
PROTEIN SCI MOL MED	3.779	79.0	Ä	1	ò	ŏ	0	1
I LIPID RES	3.702	78.7	Â	Ó	0	1	1	2
BRIT I PHARMACOL	3.689	78.4	Α	0	0	0	0	0
CELL MOL LIFE SCI	3.668	78.1	Α	0	0	0	1	1
MATRIX BIOL	3.664	77.7	Ą	1	0	0	0	1 1
J BIOMOL NMR	3.592	77.4	A	0	0	0 0	Ó	1
PROTEINS	3.576 3.448	77.1 76.8	A A	Ó	Ö	0	1	i
MOL PLANT MICROBE IN FEBS LETT	3.440	76.5	Â	Ö	ŏ	Ŏ	ò	ò
GLYCOBIOLOGY	3.419	76.1	Â	ŏ	Ō	0	6	6
ADV CARBOHYD CHEM BI	3.400	75.8	A	0	0	0	0	0
MOL PHYLOGENET EVOL	3.345	75.5	Α	1	0	0	0	1
MOL MEMBR BIOL	3.339	75.2	Ą	0	0	1	0	1
CELL SIGNAL	3.294	74.8	Ą	0	0	0 0	0 1	0 1
J STRUCT BIOL	3.255	74.5	A A	0	0	1	Ó	1
PLANT MOL BIOL	3.226 3.181	74.2 73.9	Â	0	ő	Ó	ŏ	ó
BIOCHEM SOC SYMP EUR J HUM GENET	3.175	73.5	Â	Õ	ŏ	ĭ	ŏ	ĭ
BBA MOL CELL RES	3.171	73.2	Ä	Ŏ	ŏ	Ò	Õ	Ô
CHROMOSOMA	3.157	72.9	A	0	0	0	1	1
CURR PHARM DESIGN	3.110	72.6	Α	0	0	0	0	0
MOL CARCINOGEN	3.104	72.3	A	1	0	0	0	1
ACTA CRYSTALLOGR D	3.067	71.9	Ą	1	0	0	0	1
BIOCHEM BIOPH RES CO	3.055	71.6	A	0 1	0 0	0 0	0	0 1
J BIOL INORG CHEM	3.045 3.029	71.3 71.0	A A	Ó	0	0	0	ó
CELL MOTIL CYTOSKEL BIOL CHEM	2.978	71.0 70.6	Â	11	1	1	ŏ	13
ANTISENSE NUCLEIC A	2.976	70.3	Ä	0	ò	Ö	ĭ	1
BIOCHEM PHARMACOL	2.975	70.0	A	0	0	0	0	0
BBA LIPID LIPID MET	2.973	69 4	Α	0	0	0	0	Q
J MEMBRANE BIOL	2.973	69 7	Ą	0	1	0	0	1
AMYLOID	2.957	69.0	A	0	0	0	0	0
INT J BIOCHEM CELL B	2.910	68.7	A	1 30	0 15	0 11	0 36	1 92
EUR J BIOCHEM CRIT REV ONCOGENESIS	2 852 2 852	68 4 68 1	A A	30 1	0	0	0	1
YEAST	2 825	67 7	Ä	i	ő	Ö	Õ	i
J CELL BIOCHEM	2 775	67 +	Ä	ò	ŏ	Ö	1	i
MOL ECOL	2 769	67.1	Ä	Õ	Ō	Ō	1	1
J COMPUT AID MOL DES	2 739	66 8	Α	0	0	0	0	0
J INFLAMM	2 714	66 5	В	0	0	0	0	0
EXTREMOPHILES	2 688	66 1	В	0	0	0	0	0
NEUROCHEM INT	2 662	65 8	В	1	0	0	0	1
NEUROGENETICS	2 596	65 5 65 2	B B	0	0	0	0	0 0
ARCH BIOCHEM BIOPHYS INSECT MOL BIOL	2 576 2 574	64 8	В	0	0	Ö	1	1
BBA MOL BASIS DIS	2 557	64.5	В	Ö	Ő	ŏ	ò	ó
BIOCONJUGATE CHEM	2 550	64.2	B	Õ	ő	ŏ	ĭ	ĭ
MOL REPROD DEV	2 535	63.9	В	Ō	Ō	1	Ô	1
CELL PHYSIOL BIOCHEM	2 519	63.5	В	1	0	0	0	1
FREE RADICAL RES	2.493	63.2	В	5	2	13	5	25
CYTOKINE	2 490	62.9	В	0	0	0	1	1
CELL ADHES COMMUN	2.485	62.6	В	0	0	0	0	0
MOL GEN GENET PROTEIN ENG	2.462 2.442	62.3	В В	0	0	0	0 0	0
MOL BREEDING	2.442	61.9 61.6	В	1 0	0	0	0	1 0
BIOPOLYMERS	2.405	61.3	B	Ö	Ö	0	1	1
EXP CLIN IMMUNOGENET	2.400	61.0	В	1	0	0	ó	1
ANTIVIR CHEM CHEMOTH	2.386	60.6	B	i	ő	ŏ	ŏ	i
MOL GENET METAB	2.360	60.3	В	ó	ĭ	ŏ	ŏ	i
METHOD ENZYMOL	2.340	60.0	В	5	5	3	4	17
CHEM PHYS LIPIDS	2.328	59. <i>7</i>	В	0	0	1	0	1
BIOCHIMIE	2.324	59.4	В	3	1	2	2	8
BBA BIOMEMBRANES	2.313	59.0	В	0	0	0	0	0
COLD SPRING HARB SYM	2.301	58.7	В	0	0	1	0	1
PHOTOCHEM PHOTOBIOL	2.278	58.4	В	1	0	0	0	1

(continued)

Subject Category, Area Impact Adjusted Publication Chura HK SNC TW Total Total Total Total Type n n n n n n n n n	(continued)								
Biochemistry and Molecular Biology	Subject Category, Area	Impact	Adjusted	Publication	China	HK	SNG	TW	Total
BIOLSIGNAL RECEPT 2.278			,						
ADVENZYME REGUL	encomments of approximation and approximation of the comments		officering to the second specific and specification in		or or are arranged and are				
STEROID BIOCHEM 2.245 57.4 B									
MÖL IMMUNOL 2.244 57.1 B 0 1 0 0 1 NITRIC OXIDE BIOL CH 2.243 56.8 B 0 0 0 0 1 0 1 NITRIC OXIDE BIOL CH 2.243 56.8 B 0 0 0 1 0 1 NITRIC OXIDE BIOL CH 2.243 56.8 B 0 0 0 1 0 0 1 NITRIC OXIDE BIOL CH 2.243 56.8 B 0 0 0 0 1 0 1 NITRIC OXIDE BIOL CH 2.244 57.1 B 0 0 0 0 1 0 0 1 NITRIC OXIDE BIOL CH 2.245 56.8 B 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0									
BBA GENE STRUCT EXPR 1.243									-
NITRIC CAIDE BIOL CH NEW PHYTO NEW P									•
CROWTH FACTORS				B					
JCHEM NEUROANAT	NEW PHYTOL	2.149	56.1		0	0	0	Õ	Ó
MAMM GENOME								0	0
TRANSCENIC RES JUNUSCLE RES CELL M JENOCHEM TOXYO JENOCHEM JENOCHE	,				-				-
MUSCLE RES CELL M 2.117									•
BIDCHEM TOKYO	I MAI ISCLE DES CELL M								•
CELL MOL NEUROBIOL 2.093 53.9 B 0 0 0 1 1 MOL CELL BIOCHEM 2.054 53.5 B 0 0 0 0 0 0 0 1 1 MOL CELL BIOCHEM 2.054 53.5 B 0 0 0 0 0 0 1 1 TRECEPTOR RES 2.024 53.2 B 0 0 0 0 1 1 TRECEPTOR CHANNEL 2.019 52.9 B 0 0 0 0 0 0 0 0 1 1									
MOL CELL BIOCHEM									
RECEPTOR CHANNEL ANAL BIOCHEM 1.976 52.6 B 0 0 1 0 1 ANAL BIOCHEM 1.976 52.6 B 0 0 0 1 0 1 ANAL BIOCHEM 1.976 52.6 B 0 0 0 1 0 1 ANTI CANCER DRUG DES 1.937 51.6 B 0 0 1 1 BIOCHEM CELL BIOL 1.937 51.6 B 0 1 1 1 INCERPISIONAL TR R 1.915 51.0 B 0 1 1 1 INCERPISIONAL TR R 1.915 51.0 B 0 0 1 1 INCERPISIONAL TR R 1.915 51.0 B 0 0 0 0 0 1 INCERPISIONAL TR R 1.920 51.3 B 0 0 0 0 0 0 1 INCERPISIONAL TR R 1.915 51.0 B 0 0 0 0 0 0 0 1 INCERPISIONAL TR R 1.827 50.3 B 0 0 0 0 1 INCERPISIONAL TR R 1.827 50.3 B 0 0 0 1 INCERPISIONAL TR R 1.827 50.3 B 0 0 0 1 INCERPISIONAL TR R 1.827 50.3 B 0 0 0 1 INCERPISIONAL TR R 1.827 50.3 B 0 0 0 1 INCERPISIONAL TR R 1.827 50.3 B 0 0 0 1 1 INCERPISIONAL TR R 1.827 50.3 B 0 0 0 1 1 INCERPISIONAL TR R 1.827 50.3 B 0 0 0 0 1 1 INCERPISIONAL TR R 1.828 INCERPISIONAL TR R 1.828 INCERPISIONAL TR R 1.829 INCERPISIONAL TR R 1.829 INCERPISIONAL TR R 1.829 INCERPISIONAL TR R 1.820 INCERPISIONAL TR R 1.820 INCERPISIONAL TR R 1.821 INCERPISIONAL TR R 1.822 INCERPISIONAL TR R 1.824 INCERPISIONAL TR R 1.825 INCERPISIONAL TR R 1.826 INCERPISIONAL TR R 1.821 INCERPISIONAL TR R 1.821 INCERPISIONAL TR R 1.821 INCERPISIONAL TR R 1.824 INCERPISIONAL TR R 1.825 INCERPISIONAL TR R 1.826 INCERPISIONAL TR R INCERPISIONAL TR R INCERPISIONAL TR R INCERPISION			53.5	В		0			Ó
ANAL BIOCHEM 1.976 52.6 8 0 0 0 0 0 1 1 ANTI CANCER DRUG DES 1.937 51.6 8 0 0 0 1 1 0 1 1 ANTI CANCER DRUG DES 1.937 51.6 8 0 0 0 1 1 0 1 1 INSECT BIOCHEM MOLEC 1.920 51.3 8 0 0 1 0 1 1 INSECT BIOCHEM MOLEC 1.920 51.3 8 0 0 0 1 0 1 0 1 INSECT BIOCHEM MOLEC 1.920 51.3 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0							-		1
XENOBIOTICA								-	1
ANTI CANCER DRUG DES 1937 51.6 8 0 0 0 1 1 1 1 1 INSECT BIOCHEM MOLEC 1.937 51.9 8 0 0 1 0 0 1 1 RECEPT SIGNAL TR R 1.915 51.0 8 0 0 0 1 0 1 1 COMPUT BIOL 1.920 51.3 8 0 0 0 1 0 0 1 1 COMPUT BIOL 1.990 50.6 8 0 1 0 0 0 1 1 COMPUT BIOL 1.990 50.6 8 0 1 0 0 1 1 1 PEPTIDES 1.867 50.3 8 0 0 0 0 1 1 1 PEPTIDES 1.867 49.7 8 0 0 0 1 0 1 1 PEPTIDES 1.867 49.7 8 0 0 0 1 0 1 1 NEUROCHEM RES 1.858 49.4 8 0 0 1 0 0 1 1 NEUROCHEM RES 1.858 49.4 8 0 0 0 1 0 1 1 NEUROCHEM RES 1.858 49.4 8 0 0 0 1 0 1 1 NEUROCHEM RES 1.831 48.7 8 0 0 0 0 0 0 0 1 STEROIDS 1.831 48.7 8 0 0 0 0 0 0 0 1 STEROIDS 1.831 48.7 8 0 0 0 0 0 0 0 1 J I I I I I I I I I I I I I I I I I I				В					0
BIOCHEM CELL BIOL							-	-	1
NSECT BIOCHEM MOLEC 1.920 51.3 B 0 0 1 0 1 JRECEPT SIGNAL TR R 1.915 51.0 B 0 0 0 0 JCOMPUT BIOL 1.990 50.6 B 0 1 0 0 1 MECH ACEING DEV 1.897 50.3 B 0 0 0 1 1 PEPTIDES 1.867 50.0 B 177 2 1 8 28 METHODS 1.867 49.7 B 0 0 1 0 1 NEUROCHEM RES 1.858 49.4 B 0 0 1 0 1 NEUROCHEM RES 1.838 49.4 B 0 0 1 0 1 NEUROCHEM RES 1.838 49.4 B 0 0 0 0 0 STEROIDS 1.831 48.7 B 0 0 0 0 0 STEROIDS 1.831 48.7 B 0 0 0 0 0 ODNA CELL BIOL 1.827 48.4 B 0 0 0 0 0 0 STEROIDS 1.831 48.7 B 0 0 0 0 0 0 DIAC CELL BIOL 1.827 48.4 B 0 0 0 0 1 1 JBIOMOL STRUCT DYN 1.826 48.1 B 1 0 0 0 0 1 JBIONGRAMED CHEM 1.799 47.7 B 0 0 0 1 1 LIPIDS 1.769 47.4 B 0 0 0 1 0 1 LIPIDS 1.769 47.4 B 0 0 1 0 1 GIYCOCONIUGATE 1.757 46.8 B 5 0 0 0 5 BIOTECHNIQUES 1.756 46.5 B 7 11 10 18 46 MOL CELL PROBE 1.744 46.1 B 0 0 0 1 1 JENZYM INHIB 1.733 45.5 B 3 0 0 1 4 THER DRUG MONIT 1.732 44.8 B 1 0 0 0 0 CHAD BIOL INTERACT 1.707 44.5 B 0 0 0 0 0 CHAD BIOL INTERACT 1.707 44.5 B 0 0 0 0 0 EUR CYTOKINE NETW 1.693 44.2 B 1 0 0 0 0 DIAGON MOL PATHOL 1.697 43.5 B 0 0 0 0 0 JIMOL RECOGNIT 1.648 44.8 B 1 0 0 0 0 JIMOL RECOGNIT 1.649 44.9 B 0 0 0 0 0 JIMOL RECOGNIT 1.649 44.9 B 0 0 0 0 0 JIMOL RECOGNIT 1.649 44.8 B 0 0 0 0 0 JIMOL RECOGNIT 1.649 44.8 B 0 0 0 0 0 JIMOL RECOGNIT 1.649 44.8 B 0 0 0 0 0 JIMOL RECOGNIT 1.649 44.8 B 0 0 0 0 0 JIMOL RECOGNIT 1.449 44.8 B 0 0 0 0 0 JIMOL RECOGNIT 1.449				B R					1
RECEPT SIGNAL TR R				B					•
COMPUT BIOL									ò
PEPTIDES				В		1	0		
NETHODS 1.867									
NEUROCHEM RES 1.858									
BBA GEN SUBJECTS					-		-		
STEROIDS									
DNA CELL BIOL 1.827				B					
BIOMOL STRUCT DYN				B		-	-	-	
LIPIDS		1.826	48.1				-	0	1
MOL NEUROSCI									
GLYCOCONJUGATE J BIOTECHNIQUES 1.756 46.5 B 7 11 10 18 46 MOL CELL PROBE 1.744 46.1 B 0 0 0 0 1 1 CLIN CHEM LAB MED 1.744 45.8 B 4 5 0 1 1 10 LENZYM INHIB 1.733 45.5 B 3 0 0 0 1 4 THER DRUG MONIT 1.732 45.2 B 0 0 0 0 0 0 1 CHEM BIOL INTERACT 1.707 44.5 B 0 0 0 0 0 0 0 CHEM GLOW INTERACT 1.707 44.5 B 0 0 0 0 0 0 0 CHEM BIOL INTERACT 1.707 44.5 B 0 0 0 0 0 0 0 CHEM CYTOKINE NETW 1.693 44.2 B 1 0 0 0 0 1 BBA PROTEIN STRUCT M 1.687 43.9 B 0 0 0 0 0 0 0 DIAGN MOL PATHOL 1.679 43.5 B 0 0 0 0 0 1 J MOL RECOGNIT 1.614 43.2 B 1 0 0 0 1 1 J MOL RECOGNIT 1.614 43.2 B 1 0 0 0 1 1 ADV SEC MESS PHOSPH 1.591 42.6 B 1 0 0 0 0 1 BIOPHYS CHEM 1.578 42.3 B 0 0 0 1 1 0 1 BIOPHYS CHEM 1.578 42.3 B 0 0 0 0 0 0 1 BIOPHYS CHEM 1.568 41.6 B 0 0 0 0 0 1 BIOPHYS CHEM 1.569 41.9 B 0 0 1 0 0 1 BIOPHS CHEM 1.569 41.9 B 0 0 1 0 0 0 1 BIOPHOCH PHOTOBIO B 1.529 41.0 B 0 0 1 0 1 INFLAMM RES 1.560 41.3 B 0 0 0 0 0 0 1 INFLAMM RES 1.560 41.3 B 0 0 0 0 0 0 0 INT J BIOL MACROMOL 1.492 40.6 B 21 0 0 1 0 1 INFLAMM RES 1.560 41.3 B 0 0 0 0 0 0 0 0 INT J BIOL MACROMOL 1.492 40.6 B 21 0 0 10 31 J PEPT SCI 1.441 39.0 B 0 0 0 0 0 0 0 INT J BIOL MACROMOL 1.499 39.7 B 1 0 0 0 0 1 INT J BIOL MACROMOL 1.448 39.4 B 0 0 0 0 0 0 0 INT J BIOL MACROMOL 1.449 39.7 B 1 0 0 0 0 0 1 INT J BIOL MACROMOL 1.449 39.7 B 1 0 0 0 0 0 0 INT J BIOL MACROMOL 1.449 39.7 B 1 0 0 0 0 0 0 INT J BIOL MACROMOL 1.448 39.4 B 0 0 0 0 0 0 0 0 INT J BIOL MACROMOL 1.449 39.7 B 1 0 0 0 0 0 0 INT J BIOL MACROMOL 1.448 39.4 B 0 0 0 0 0 0 0 0 INT J BIOL MACROMOL 1.448 39.4 B 0 0 0 0 0 0 0 0 INT J BIOL MACROMOL 1.448 39.4 B 0 0 0 0 0 0 0 0 0 INT J BIOL MACROMOL 1.448 39.4 B 0 0 0 0 0 0 0 0 0 INT J BIOL MACROMOL 1.448 39.4 B 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0							-		
BIOTECHNIÓUES									
MOL CELL PROBE 1.744									
CLIN CHEM LAB MED									
THER DRUG MONIT 1.732				В			0	1	10
CHROMOSOME RES 1.725									
CHEM BIOL INTERACT 1.707							-		-
EUR CYTOKINE NETW 1.693									
BBA PROTEIN STRUCT M									
DIAGN MOL PATHOL 1.679 43.5 B 0 0 0 1 1 J MOL RECOGNIT 1.614 43.2 B 1 0 0 0 1 CARBOHYD RES 1.606 42.9 B 0 0 1 0 1 ADV SEC MESS PHOSPH 1.591 42.6 B 1 0 0 0 1 BIOPHYS CHEM 1.578 42.3 B 0 1 1 0 0									
MOL RECOGNIT							_		
CARBOHYD RES 1.606 42.9 B 0 0 1 0 1 ADV SEC MESS PHOSPH 1.591 42.6 B 1 0 0 0 1 BIOPHYS CHEM 1.578 42.3 B 0 0 0 0 0 PROTEIN EXPRES PURIF 1.569 41.9 B 0 0 1 0 1 BIOMETALS 1.568 41.6 B 0 0 1 0 1 INFLAMM RES 1.560 41.3 B 0 0 1 0 1 INFLAMM RES 1.560 41.3 B 0 1 0 0 1 INT J BIOL MACROMOL 1.492 40.6 B 21 0 0 10 31 J PEPT SCI 1.471 40.3 B 0 1 0 0 10 31 J INORG BIOCHEM 1.460 40.0 B 0 1 0 0 1 J INORG BIOCHEM 1.449 39.7 B 1 0 0 0 0 1 J CHEM ECOL 1.441 39.0 B 0 0 0 0 0 0 J CELL MOL BIOL 1.441 39.0 B 0 0 0 0 0 0 J CHEM ECOL 1.441 39.0 B 0 0 0 0 0 0 J CHEM ECOL 1.441 39.0 B 0 0 0 0 0 0 J CHEM ECOL 1.441 39.0 B 0 0 0 0 0 0 J CEXP MOL MED 1.411 38.1 B 0 0 0 0 0 0 EXP MOL MED 1.411 38.1 B 0 0 0 0 0 0 AMINO ACIDS 1.408 37.7 B 0 0 0 0 0 PHYSIOL GENOMICS 1.353 36.8 B 0 0 0 0 0 0 PHYSIOL GENOMICS					1	0	0	0	1
BIOPHYS CHEM	CARBOHYD RES				_				1
PROTEIN EXPRES PURIF BIOMETALS 1.569 41.9 BIOMETALS 1.568 41.6 B 0 0 1 0 1 0 1 INFLAMM RES 1.560 41.3 B 0 0 0 1 0 0 1 0 1 INFLAMM RES 1.560 41.3 B 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0								-	
BIOMETALS 1.568 41.6 B 0 0 1 0 1 INFLAMM RES 1.560 41.3 B 0 1 0 0 1 J PHOTOCH PHOTOBIO B 1.529 41.0 B 0 0 0 0 0 INT J BIOL MACROMOL 1.492 40.6 B 21 0 0 10 31 J PEPT SCI 1,471 40.3 B 0 1 0 0 1 J INORG BIOCHEM 1.460 40.0 B 0 1 0 0 1 J INORG BIOCHEM 1.449 39.7 B 1 0 0 0 0 0 CELL MOL BIOL 1.449 39.7 B 1 0 0 0 0 1 J CHEM ECOL 1.441 39.0 B 0 0 0 0 0 0 J CHEM ECOL 1.441 39.0 B 0 0 0 0 0 0 J PEPT RES 1.439 38.7 B 9 3 0 8 20 J LIPOSOME RES 1.439 38.7 B 9 3 0 8 20 J LIPOSOME RES 1.429 38.4 B 0 0 0 0 0 0 EXP MOL MED 1.411 38.1 B 0 0 0 0 0 AMINO ACIDS 1.408 37.7 B 0 0 0 0 0 J MOL GRAPH MODEL 1.407 37.4 B 0 0 0 0 0 PHYSIOL GENOMICS 1.354 37.1 B 0 0 0 0 0 PHYSIOL GENOMICS 1.353 36.8 B 0 0 0 0 0 0									
INFLAMM RES									
PHOTOCH PHOTOBIO B									
INT J BIOL MACROMOL 1.492									
J INORG BIOCHEM 1.460 40.0 B 0 0 0 0 0 CELL MOL BIOL 1.449 39.7 B 1 0 0 0 1 J MOL CATAL B ENZYM 1.448 39.4 B 0 0 0 0 0 J CHEM ECOL 1.441 39.0 B 0 0 0 0 0 J PEPT RES 1.439 38.7 B 9 3 0 8 20 J LIPOSOME RES 1.429 38.4 B 0 0 0 0 0 EXP MOL MED 1.411 38.1 B 0 0 0 0 0 AMINO ACIDS 1.408 37.7 B 0 0 0 0 0 J MOL GRAPH MODEL 1.407 37.4 B 0 0 0 0 0 0 FIBRINOLYSIS PROTEOL 1.354 37.1 B 0 0 0 0 0 0 0 0 0 0 0	•			В		0	-		
CELL MOL BIOL 1.449 39.7 B 1 0 0 0 1 J MOL CATAL B ENZYM 1.448 39.4 B 0 0 0 0 0 J CHEM ECOL 1.441 39.0 B 0 0 0 0 0 J PEPT RES 1.439 38.7 B 9 3 0 8 20 J LIPOSOME RES 1.429 38.4 B 0 0 0 0 0 EXP MOL MED 1.411 38.1 B 0 0 0 0 AMINO ACIDS 1.408 37.7 B 0 0 0 0 0 AMINO ACIDS 1.408 37.7 B 0 0 0 0 0 FIBRINOLYSIS PROTEOL 1.354 37.1 B 0 0 0 0 0 PHYSIOL GENOMICS 1.353 36.8 B 0 0 0 0 0 PHYSIOL GENOMICS 1.353 36.8			40.3			-	-		
MOL CATAL B ENZYM	J INORG BIOCHEM								
CHEM ECOL						-	-		-
PEPT RES									
J LIPOSOME RES 1.429 38.4 B 0 0 0 0 0 EXP MOL MED 1.411 38.1 B 0 0 0 0 0 AMINO ACIDS 1.408 37.7 B 0 0 0 0 0 J MOL GRAPH MODEL 1.407 37.4 B 0 0 0 0 0 FIBRINOLYSIS PROTEOL 1.354 37.1 B 0 0 0 0 0 PHYSIOL GENOMICS 1.353 36.8 B 0 0 0 0 0									-
EXP MOL MED 1.411 38.1 B 0 0 0 0 0 0 0 0 AMINO ACIDS 1.408 37.7 B 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0									
AMINO ACIDS 1.408 37.7 B 0 0 0 0 0 0 0 0 1 MOL GRAPH MODEL 1.407 37.4 B 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0									
J MOL GRAPH MODEL 1.407 37.4 B 0 0 0 0 0 FIBRINOLYSIS PROTEOL 1.354 37.1 B 0 0 0 0 0 PHYSIOL GENOMICS 1.353 36.8 B 0 0 0 0 0	AMINO ACIDS			В			-		
FIBRINOLYSIS PROTEOL 1.354 37.1 B 0<	J MOL GRAPH MODEL	1.407				-	-		
THISTOP GENOMICS	FIBRINOLYSIS PROTEOL				-	_			
DIOUNG CHEM 1.320 30.3 D 0 0 0 0						_			
	DIOUKU CHEM	1.328	20.3	U	· · · · · · · · · · · · · · · · · · ·				

					-15
(C	or	١TI	n	ue	d)


(continued)								
Subject Category Area	Impact	Adjusted IF (%)	Publication	China n	HK n	SNG n	TW n	Total n
Biochemistry and Molecular Biology	Factor	IF (70)	Туре		~~~~			
CLIN BIOCHEM	1 327	36 1	В	0	0	0 0	0 0	0
BIOMED CHROMATOGR	1 311 1 309	35 8 35 5	B B	0 0	0	0	0	Ö
BIOCATAL BIOTRANSFOR PLANT PHYSIOL BIOCH	1 292	35 2	В	Ö	ŏ	ŏ	ŏ	ŏ
PLANT SCI	1 259	34 8	B	Õ	Õ	Ō	0	0
COMP BIOCHEM PHYS C	1 249	34 5	В	0	0	0	0	0
FISH PHYSIOL BIOCHEM	1 240	34 2	В	0	0	0	0	0
PESTIC BIOCHEM PHYS	1 233	33 9	В	0	0	0 0	0	0 0
PROSTAG LEUKOTR ESS	1 226 1 216	33 5 33 2	В	0	0	0	0	0
BIOTECHNOL APPL BIOC PHYTOCHEM ANALYSIS	1 206	32 9	č	Ö	Õ	ő	ő	ŏ
MOL BIOL REP	1 200	32 6	č	2	1	Ō	1	4
INFLAMMATION	1 189	32 3	С	1	0	0	0	Ţ
J MOL MODEL	1 183	31 9	Č	0	0	0	0 1	0
ARCH INSECT BIOCHEM	1 159	31 6 31 3	C	0 1	0	0 0	0	1 1
J BIOCHEM MOL TOXIC ANN CLIN BIOCHEM	1 129 1 113	31 0	č	ó	ő	ŏ	ŏ	ò
ENANTIOMER	1 111	30 6	č	Ö	ŏ	ŏ	ŏ	ŏ
CAN I MICROBIOL	1 105	30 3	Č	Ō	0	0	0	0
J NUTR BIOCHEM	1 083	30 0	Č	0	0	0	0	0
ESSAYS BIOCHEM	1 077	29 7	C	0	0	0	0	0
GENES GENET SYST	1 074	29 4 29 0	<u> </u>	1	0	0	0	1 1
BIOELECTROCH BIOENER BIOCHEMISTRY MOSCOW+	1 052 1 050	29 0	2	12	0	Ö	Ö	12
CLIN CHIM ACTA	1 041	28 4	Č	0	ŏ	ŏ	ő	ō
BIOSCI BIOTECH BIOCH	1 039	28 1	Ĉ	0	0	0	1	1
PROSTAG OTH LIPID M	1 034	27 7	Č	0	0	0	0	0
J TRACE ELEM MED BIO	1 032	27 4	C	0	0 0	0 0	1 0	1 0
ADDICT BIOL COMP BIOCHEM PHYS B	1 023 1 015	27 1 26 8	C	0	0	0	1	1
CELL BIOCHEM FUNCT	1 000	26 1	Č	ő	ő	ő	i	i
I NAT TOXINS	1 000	26 5	č	Ŏ	Ö	Ō	1	1
MEDIAT INFLAMM	0 990	25 8		1	0	0	0	1
BIOCHEM SOC T	0 975	25 5	C	0	0	0	1 0	1
MOL CELLS I PHYSIOL BIOCHEM	0 968 0 958	25 2 24 8	C	0 0	1	0	0	1 0
J TRACE ELEM EXP MED	0 952	24 5	Ċ	Ö	ő	Ö	ő	ő
APOPTOSIS	0 949	24 2	č	1	Õ	Ō	Ō	Ĩ
J BIOCHEM BIOPH METH	0 926	23 9	C	0	0	0	0	0
COLLOID SURFACE B	0 888	23 5	Č	0	0	0	0	0
BIOCHEM MOL BIOL INT	0 888 0 884	23 2 22 9	C	98 0	25 0	19 0	84 0	226 0
SOMAT CELL MOLEC GEN COMP BIOCHEM PHYS A	0 883	22 6	Č	0	1	0	0	1
BIOTHERAPY	0 870	22 3	č	ő	ò	ŏ	Õ	ó
J CARBOHYD CHEM	0 855	21 9	С	0	0	0	0	0
MOL BIOTECHNOL	0 847	21 6	Č	0	0	1	0	1
APPL BIOCHEM BIOTECH	0 843	21 3	C	0	0	0	0	0
ARCH PHYSIOL BIOCHEM DRUG NEWS PERSPECT	0 841 0 835	21 0 20 6	Ċ	1	0	0 0	0	1 0
MAGNESIUM RES	0 825	20 3	-	Ö	ő	ő	ő	ŏ
BIOPHARM DRUG DISPOS	0 819	20 0	č	ŏ	ŏ	ŏ	ŏ	ŏ
GROWTH HORM IGF RES	0 788	19 <i>7</i>	C	0	0	1	0	1
BIOL TRACE ELEM RES	0 786	19 4	Č	0	0	0	0	0
ACTA CHEM SCAND	0 776	19 0	Ç	0	0	0	0	0
PROCESS BIOCHEM ACTA BIOCHIM POL	0 774 0 749	18 <i>7</i> 184	C	0 0	0	0	0	0
I PROTEIN CHEM	0 745	18 1	Č	56	2	1	47	106
J BIOCHEM MOL BIOL	0 742	17 7	č	0	ō	ò	ő	0
REDOX REP	0 717	174	Č	2	ŏ	Õ	ĭ	3
Z NATURFORSCH C	0 709	17 1	Č	0	0	0	0	0
BIOCHEM GENET CHEM SPEC BIOAVAILAB	0 694	168	C	Ŏ	0	0	0	0
BIOSCIENCE REP	0 690 0 678	16 5 16 1	C	0	0	0 0	0	0 0
I IMMUNOASSAY	0 676	15 8	č	0	1	0	0	1
NAT PROD LETT	0 662	15 5	č	Ö	ó	Ö	ŏ	ó
TRACE ELEM ELECTROLY	0 653	15 2	000000000000000000000000000000000000000	0	ŏ	0	ŏ	0
PLANT MOL BIOL REP	0 653	14 8	Č	0	0	0	0	0
J BIOLUM CHEMILUM	0 632	14 5	С	0	0	0	0	0


(continued)

Subject Category Area Biochemistry and Molecular Biology	Impact Factor	Adjusted IF (%)	Publication Type	China	НК	SNG	TW	Total
Diociticinisti y and an interest to a management broady	- 1000		iype	n	n	n	n _	n
HEMOGLOBIN	0 631	14 2	С	0	0	0	0	0
ARCH PHARM RES	0 629	13 9	С	1	0	0	Ō	i
NUCLEOS NUCLEOT NUCL	0 622	13 5	С	0	0	0	O	0
BIOCHEM SYST ECOL	0 599	13 2	С	0	0	0	0	Ō
DRUG DELIV	0 596	12 9	C	1	0	0	0	1
TRENDS GLYCOSCI GLYC	0 553	12 6	C	0	0	0	0	0
J FOOD BIOCHEM	0 547	12 3	C	0	0	0	0	0
CURR TOP MEMBR	0 530	11 9	С	0	0	0	0	0
res commun mol path	0 495	11 6	Ç	0	0	0	1	1
MOL BIOL+	0 477	11 3	С	0	0	0	0	0
GENET MOL BIOL	0 470	11 0	Č	О	0	0	0	0
PROTEIN PEPTIDE LETT	0 468	10 6	Ç	0	0	0	0	0
PREP BIOCHEM BIOTECH	0 467	10 3	Č	0	1	0	0	1
BIOGENIC AMINES	0 453	10 0	Č	Ō	0	0	0	0
ACTA BOT SIN	0 434	9 7	Č	0	0	O.	0	0
IUBMB LIFE	0 418	9 4	Ç	0	0	1	0	1
LUMINESCENCE	0 326	6 5	Č	3	0	0	0	3
INDIAN J BIOCHEM BIO	0 256	4 5	C	0	0	0	1	1
Total	Whitehillia halbankariaaaaaaaaaa	made madenate property	TRANS STREETMENT ASSISTANCE ASSIS	507	155	260	699	1621

Biotechnology and Applied Microbiology

Number of full papers (with impact factor) in Medline





Biotechnology and Applied Microbiology subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).

Journals sorted according to the impact factor provided by the *Journal Citation Reports* (JCR) 2000 version for Biotechnology and Applied Microbiology JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category: a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW). About 20 of the journals with the lowest IF with no publications have been omitted in the list.


Subject Category, Area	Impact	Adjusted	Publication	China	НК	SNG	TW	Total
Biotechnology and Applied Microbiology	Factor	IF (%)	Туре	n	n	n	n	n
CURR OPIN GENET DEV	13.810	100 0	Α	0	0	1	0	1
NAT BIOTECHNOL	11.542	99.3	Ą	1	1	2	3	7
GENOME RES	7.615	98.5	Ą	0	0	0	1	1
HUM GENE THER	6.796	97.8	A	1	0	0	0	1
GENE THER	5.964	97 O	A	Ŏ	0	1	0	!
TRENDS BIOTECHNOL	5.385	96.3	A	0 0	0 1	1	0 0	3
CURR OPIN BIOTECH PHARMACOGENETICS	4.711 4.465	95.5 94.8	A A	1	Ó	2 0	0	1
CRIT REV EUKAR GENE	4.383	94.0	Ä	Ó	Ö	ő	ŏ	ó
CANCER GENE THER	4.151	93.3	Â	1	ő	ŏ	ŏ	1
MUTAT RES REV MUTAT	4.129	92.5	Ä	ò	ŏ	Ö	ő	ó
MUTAT RES DNA REPAIR	3 515	91.8	Ä	ŏ	Ŏ	ŏ	ŏ	ŏ
MOL PLANT MICROBE IN	3,448	91.0	Α	1	Ō	Ō	0	1
GENOMICS	3.425	90.3	Α	1	0	0	0	1
APPL ENVIRON MICROB	3,389	89 6	Α	0	0	0	0	0
J GEN VIROL	3.126	88.8	A	Q	0	0	0	0
J BIOMOL SCREEN	3.034	88.1	Ą	0	0	0	0	0
BIOSENS BIOELECTRON	3.014	87.3	Ą	19	6	4	2	31
STEM CELLS	2 989	86.6	Ą	0	1	0	0	1
ANTISENSE NUCLEIC A	2 976	85.8	Ą	0	0 1	1 0	0	1
YEAST	2.825	85.1 84.3	A A	0	1	0	0	1
IMMUNOTECHNOLOGY PROTEIN ENG	2 697 2.442	83.6	Â	16	i	3	14	34
MOL BREEDING	2.442	82.8	Ä	0	ó	Ô	0	0
CRIT REV BIOTECHNOL	2 333	82.1	Ä	ŏ	ő	ŏ	ŏ	ŏ
MUTAT RES FUND MOL M	2 148	81.3	Â	ŏ	ŏ	Ŏ	ŏ	ŏ
MAMM GENOME	2.137	80.6	Â	ō	1	Ō	0	1
TRANSGENIC RES	2 132	79.9	Α	0	0	0	1	1
GENE EXPRESSION	2.100	79.1	Α	0	0	0	1	1
BIOTECHNOL BIOENG	2.081	78.4	Α	7	1	4	16	28
TISSUE ENG	2 073	77.6	Ą	0	0	1	Ŏ	1
SYST APPL MICROBIOL	2.060	76.9	A	1	0	0	0	1
MUTAT RES GENOMICS	1 952	76.1	A	0 0	0 1	0	0	0 1
J COMPUT BIOL	1 900	75.4 74.6	A A	0	Ó	0	1	1
BIOTECHNOL PROGR	1.897 1.828	74.6 73.9	Ä	0	Ö	Ő	ó	ó
BIOFOULING J FOOD PROTECT	1.820	73.3	Ä	ŏ	ŏ	ő	ĭ	ĭ
MOL CELL PROBE	1.744	72.4	Ä	ŏ	Ŏ	ī	Ó	1
DIAGN MOL PATHOL	1 679	71.6	Ä	Ō	Ō	0	1	1
MOL MAR BIOL BIOTECH	1,625	70.9	Α	0	0	0	1	1
GENOME	1 610	70.1	Α	0	0	0	0	0
CYTOKINES CELL MOL T	1.582	69.4	Α	0	0	0	1	1
PROTEIN EXPRES PURIF	1 569	68.7	Ą	21	3	1	5	30
J APPL MICROBIOL	1.511	67.9	A	0	0	0	1	1
MUTAT RES GEN TOX EN	1.506	67.2	A	0	0	0 0	0	0
J VIROL METHODS	1.505	66.4	B B	0 4	0 1	3	13	21
APPL MICROBIOL BIOT	1.505	65.7	В	0	Ó	0	0	0
MOL DIAGN	1.456 1.422	64.9 64.2	В	ŏ	ŏ	Õ	Õ	ŏ
GENET ANAL BIOMOL E	1.411	63.4	В	1	1	ĭ	10	13
ENZYME MICROB TECH J ANTIBIOT	1.347	62.7	B	ò	ò	ò	Õ	0
J BIOTECHNOL	1.311	61.9	B	14	ž	1	9	31
BIOCATAL BIOTRANSFOR	1.309	61.2	B	0	0	0	0	0
BIOL CONTROL	1.299	60.4	В	0	0	0	0	Ō
INT I BIOL MARKER	1.292	59.7	В	1	0	0	0	1
FOOD MICROBIOL	1.272	59.0	В	0	0	0	0	0
BIOTECHNOL GENET ENG	1.257	58.2	В	0	0	0	0	0
BIOTECHNOL APPL BIOC	1,216	5 <i>7</i> .5	В	17	0	2	22	41
LETT APPL MICROBIOL	1.154	56.7	В	0	0	0	1	1
BIODEGRADATION	1.109	56.0	В	0	0	1	0	1

(continued)

Subject Category Area	Impact	Adjusted	Publication	China	НК	SNG	TW	Total
Biotechnology and Applied Microbiology	Factor	IF (%)	Туре	n	n	n	n	n
CAN I MICROBIOL	1 105	55 2	В	0	0	0	0	0
I MICROBIOL BIOTECHN	1 083	54 5	В	0	0	0	0	0
MAR BIOTECHNOL	1 068	53 <i>7</i>	В	0	0	0	0	0
I IND MICROBIOL BIOT	1 052	53 0	В	0	1	0	1	2
BIOSCI BIOTECH BIOCH	1 039	52 2	В	0	0	0	1	1
BIOMARKERS	0 987	51 5	В	0	0	0	0	0
I FERMENT BIOENG	0 979	50 <i>7</i>	В	0	0	0	0	0
BIOTECHNOL LETT	0 967	50 0	В	0	0	0	0	0
CYTOTECHNOLOGY	0 925	49 3	В	0	0	0	1	1
FOOD CONTROL	0 903	48 5	В	0	0	0	0	0
MOL THER	0 897	47 8	В	0	0	1	0	1
BIOTECHNOL ADV	0 893	47 0	В	0	0	0	0	0
J CHEM TECHNOL BIOT	0 883	46 3	В	1	0	0	0	1
J AM SOC BREW CHEM	0 870	45 5	В	О	0	0	0	0
MOL BIOTECHNOL	0 847	44 8	В	5	3	0	0	8
APPL BIOCHEM BIOTECH	0 843	44 0	В	26	11	1	8	46
BIOLOGICALS	0 789	41 8	В	1	0	0	0	1
FOLIA MICROBIOL	0 752	38 8	В	0	0	0	1	1
anim biotechnol	0 725	37 3	В	2	0	0	0	2
BIORESOURCE TECHNOL	0 700	35 8	В	0	0	0	1	1
GENET COUNSEL	0 636	32 8	Ç	0	0	0	1	1
BIOTECH HISTOCHEM	0 605	30 6	C	0	0	1	0	1
HYBRIDOMA	0 587	29 9	С	1	0	0	0	1
DNA SEQUENCE	0 542	27 6	Č	0	0	1	0	1
PREP BIOCHEM BIOTECH	0 467	23 9	Č	10	Q	0	1	11
BIOMOL ENG	0 278	15 7	Č	1	0	0	0	1
AUSTRALAS BIOTECHNOL	0 062	4 5	С	1	0	2	0	3
Total				155	42	36	119	352

Cardiac and Cardiovascular Systems

Number of full papers (with impact factor) in Medline



Three year groups CUHK HKU Academia Other CUHK HKU Academia Other


Cardiac and Cardiovascular Systems subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).


Journals sorted according to the impact factor provided by the Journal Citation Reports (JCR) 2000 version for Cardiac and Cardiovascular Systems JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category: a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW).

Subject Category, Area Cardiac and Cardiovascular Systems	Impact Factor	Adjusted IF (%)	Publication Type	China n	HK n	SNG n	TW n	Tot n
CIRCULATION	10.893	100.0	A	0	0	0	0	0
CIRC RES	9.193	98.4	Â	ŏ	ő	ŏ	ĭ	1
AM COLL CARDIOL	7.082	96.8	Ä	2	13	1	37	53
EUR HEART I	3.840	95.2	Ä	Õ	7	i	10	18
		93.7	Ä	3	6	i	12	
CARDIOVASC RES	3.783	92.1	Â	0	0	Ó	0	22
MOL CELL CARDIOL	3.383							
M J PHYSIOL HEART C	3.243	90.5	Ą	0	0	0	1	1
THORAC CARDIOV SUR	3.057	88.9	Ą	0	0	0	0	C
RENDS CARDIOVAS MED	2.879	87.3	Ą	Q	0	0	0	C
CARDIOVASC ELECTR	2.789	85. <i>7</i>	Ą	Ō	6	0	37	4.
M J CARDIOL	2.762	84.1	Ą	7	26	6	98	13
HEART LUNG TRANSPL	2.526	82.5	Α	0	1	0	0	1
CHEST	2.451	81.0	Α	0	0	0	0	C
am heart j	2.419	79.4	Α	16	21	3	<i>7</i> 1	11
CARDIOVASC PHARM	2.396	<i>77</i> .8	Α	0	0	0	0	(
ROG CARDIOVASC DIS	2.375	76.2	Α	0	0	0	0	C
CARDIOV MAGN RESON	2.304	74.6	Α	0	0	0	Ó	(
HEART	2.144	73.0	Α	Õ	6	Ö	8	1.
NUCL CARDIOL	1.854	71.4	Α	1	Ō	Ō	Ö	1
ANN THORAC SURG	1.828	69.8	A	Ó	Ŏ	ŏ	ŏ	Ċ
AM SOC ECHOCARDIOG	1.636	68.3	Â	Ĩ	ŏ	ĩ	6	Š
ACE	1.600	66.7	Â	ò	ŏ	ò	ŏ	Č
CURR OPIN CARDIOL	1 515	65.1	B	ŏ	ĭ	1	ŏ	2
URR PROB CARDIOLOGY	1.500	63.5	В	ŏ	ó	ó	Ö	Ć
ASIC RES CARDIOL	1.490	61.9	В	0	ő	0	1	1
CATHETER CARDIO INTE	1.321	60.3	В					
RESP MED	1 254		D	0	5	7	11	2.
CAN I CARDIOL		58.7	В	0	0	0	0	0
UR J CARDIO THORAC	1.237	57.1	В	1	1	1	3	6
UR I HEART FAIL	1.187	55.6	B	0	0	1	0	1
HEART VALVE DIS	1.151	54.0	В	0	1	0	0	1
CLIN CARDIOL	1.119	52.4	В	3	1	4	1	9
CARDIOL	1.079	50.8	B	4	20	2	6	3
CARDIOVASC INTER RAD	1.029	49.2	В	0	0	0	0	C
NT J CARDIOL	0.973	47.6	В	39	38	8	105	19
HERZ	0.965	46.0	В	1	0	0	0	1
NUTR METAB CARDIOVAS	0.959	44.4	В	0	0	0	0	О
CARDIOVASC DRUG THER	0.951	42.9	В	0	0	0	0	0
CARDIOTHOR VASC AN	0.917	41.3	В	0	1	0	0	1
ARDIOVASC DRUG REV	0.881	39. <i>7</i>	В	0	0	0	0	C
KARDIOL	0.874	38.1	В	0	0	0	Ó	Ċ
PEDIATR CARDIOL	0.863	36.5	В	Ó	0	Ö	ī	1
CARDIOVASC SURG	0.862	34.9	В	1	Ō	Ō	Ó	1
HORAC CARDIOV SURG	0.850	33.3	В	ò	ŏ	ŏ	ŏ	ċ
INTERV CARD ELECTR	0.782	31.7	Č	2	4	ŏ	4	1
EV ESP CARDIOL	0.700	30.2	Ĉ	ō	Ö	ŏ	Õ	Ċ
ARDIOLOGY	0.678	28.6	Ĉ	ŏ	7	ŏ	48	5.
IEART LUNG	0.620	27.0	00000000	Ö	ó	Ő	0	0
ARDIOL YOUNG	0.615	25.4	č	Ö	1	Ö	ŏ	1
IEART VESSELS	0.595	23.8	č	ő	ί	ő	ő	i
ELECTROCARDIOL	0.586	22.2	č	1	Ó			
CARDIOVASC SURG	0.573	20.6	č			3	7	1
NT I CARDIAC IMAG	0.541	19.0		0	0	Õ	0	0
EX HEART I I	0.539	17.5	C	0	0	0	1	1
CAND CARDIOVASC I	0.508	15.9	č	3	0	1	7	1
CTA CARDIOL	0.450	14.3	č	0	0	0	5	5
UROPACE	0.430		Č	4	0	0	3	7
RCH MAL COEUR VAISS	0.440	12.7	Č	Ö	1	0	2	3
CHOCARDIOGR J CARD		11.1	Č	0	0	0	0	0
ARDIOVASC PATHOL	0.386	9.5	ر	1	Ō	0	11	12
N HEART I	0.347	7.9	۲	0	0	0	1	1
CARDIAC SURG	0.323	6.3	Č	3	1	0	64	68
ARDIOLOGIYA	0.224 0.205	4.8 3.2	0000000000	0	0	0	1	1
otal	0.203	٠.٤	C	-	_	•	0	0
52				93	169	41	563	86

Cell Biology

Number of full papers (with impact factor) in Medline





Cell Biology subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).

Journals sorted according to the impact factor provided by the Journal Citation Reports (JCR) 2000 version for Cell Biology JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category: a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW).

Subject Category, Area Cell Biology	Impact Factor	Adjusted IF (%)	Publication Type	China n	HK n	SNG n	TW n	Total n
THE PROPERTY OF THE PROPERTY O		100.0	A	0	0	3	1	4
CELL	32.440 27.905	99.3	Ä	ő	ŏ	ő	i	i
NAT MED ANNU REV CELL DEV BI	26.300	98.6	Ä	0	0	0	0	0
CURR OPIN CELL BIOL	22.754	98.0	Α	0	0	2	0	2
TRENDS CELL BIOL	18.815	97.3	Ą	0	0	1	0	1
MOL CELL	18.195	96.6	A	0 2	0 1	1 11	0 3	1 1 <i>7</i>
EMBOJ	13.999	95.9 95.2	A A	2	4	6	ő	12
I CELL BIOL	13.955 13.810	93.2	Â	Ó	Ŏ	ĭ	ŏ	1
CURR OPIN GENET DEV NAT CELL BIOL	11.939	93.9	Ä	ŏ	ŏ	2	Ō	2
NAT STRUCT BIOL	11.158	93 2	Α	0	1	0	0	1
PLANT CELL	11.093	92.5	A	0	0	0	1	1
CURR OPIN STRUC BIOL	10.427	91.8	A	0	0	0	0	0
MOL CELL BIOL	9.666	91.2	A	3 0	2 3	33 3	2 <i>7</i> 5	65 11
FASEB J	9.249 8.482	90.5 89.8	A A	0	1	4	ő	5
MOL BIOL CELL CELL DEATH DIFFER	7.785	89.1	Ä	Ŏ	ò	i	Ŏ	1
INT REV CYTOL	7.637	88.4	Ä	Ō	1	0	0	1
STRUCT FOLD DES	6.681	87.8	Α	0	0	0	1	1
ONCOGENE	6.490	87.1	Ą	1	0	0	0	1
CYTOKINE GROWTH F R	6.049	86.4	A	0	0 3	0 13	0 5	0 22
J CELL SCI	5.996 5 235	85 <i>.7</i> 85 0	A A	1 0	0	0	3	3
CELL GROWTH DIFFER MOL MED TODAY	5.193	84.4	Ä	ő	ŏ	Õ	Õ	ő
SEMIN CELL DEV BIOL	4.978	83.7	Ä	ŏ	Õ	Õ	Ō	0
GENES CELLS	4.885	83.0	A	0	0	0	0	Ō
AM J RESP CELL MOL	4.353	82 3	Α	1	Ō	0	0	1
J LEUKOCYTE BIOL	4.342	81.6	Ą	0	0	0	1	0
BBA MOL CELL BIOL L	4.160	81 0	A A	0 0	0 0	0 0	0 1	1
AM J PHYSIOL CELL PH EXP CELL RES	4.086 3.860	80.3 79.6	Ä	0	Ö	1	ó	i
MOL MED	3.779	78.9	Ä	1	ő	ò	ŏ	i
CELL CALCIUM	3.711	78.2	Α	1	1	0	6	8
CELL MOL LIFE SCI	3.668	77 6	Α	3	0	1	2	6
MATRIX BIOL	3.664	76 9	Ą	1	0	0	0	1 0
J CELL PHYSIOL	3.474	76 2 75 5	Ą	0 61	0 30	0 27	0 77	195
FEBS LETT CELL STRESS CHAPERON	3.440 3.436	75 5 74 8	A A	1	1	0	1	3
CELL MICROBIOL	3.409	74 1	Ä	ò	ò	ŏ	ó	Õ
I MOL CELL CARDIOL	3.383	73.5	A	4	11	0	10	25
J BIOENERG BIOMEMBR	3 355	72.8	Α	0	0	0	1	1
MOL MEMBR BIOL	3.339	72.1	Ą	1	0	0	0	1
CELL SIGNAL	3.294 3.255	71.4 70.7	A A	3 4	1 0	4 1	25 3	33 8
I STRUCT BIOL CELL MOTIL CYTOSKEL	3.029	70.7	Â	1	1	Ó	1	3
STEM CELLS	2.989	69.4	Ä	i	ó	Ŏ	ò	ī
DEV GENES EVOL	2.982	68.7	A	Ò	Õ	Ö	0	0
J MEMBRANE BIOL	2.973	68 0	Α	0	1	0	0	1
CELL TRANSPLANT	2.959	67.3	A	0	0	0	1	1 0
ADV ANAT EMBRYOL CEL INT I BIOCHEM CELL B	2.933 2.910	66.7 66.0	A B	0 12	0 13	0 2	0 1	28
CRIT REV ONCOGENESIS	2.852	65.3	В	1	0	Ó	Ó	1
EUR J CELL BIOL	2.801	64.6	В	ò	ŏ	8	5	13
J CELL BIOCHEM	2.775	63.9	В	12	17	0	76	105
JINFLAMM	2.714	63.3	В	0	0	0	0	0
TISSUE ANTIGENS	2.612	62.6	В	0	0	0	ō	0
J HISTOCHEM CYTOCHEM CYTOMETRY	2.610 2.557	61.9 61.2	B B	1 1	1	1	5 1	8 6
HISTOPATHOLOGY	2.554	60.5	В	0	2 0	2 0	0	0
MOL REPROD DEV	2.535	59.9	В	ŏ	ő	1	ő	1
CELL PHYSIOL BIOCHEM	2.519	59.2	В	ĭ	ŏ	ò	ŏ	1
CYTOKINE	2.490	58.5	В	1	Ō	0	0	1

(continued)


(continued)								
Subject Category, Area	Impact	Adjusted	Publication	China	HK	SNG	TW	Total
Cell Biology	Factor	IF (%)	Туре	n	n	n	n	n
CELL ADHES COMMUN	2.485	57.8	В	0	0			
METHOD CELL BIOL	2.395	57.0 57.1	В	0	0	0 1	0	0 1
MOL CELL ENDOCRINOL	2.369	56.5	B	ő	ő	ò	ő	ó
DIFFERENTIATION	2.353	55.8	B	Õ	ŏ	ő	ŏ	ŭ
PLANT CELL PHYSIOL	2.311	55.1	В	0	0	0	1	1
BIOL SIGNAL RECEPT	2.278	54.4	В	8	14	0	0	22
NITRIC OXIDE BIOL CH	2.225	53.7	В	0	0	1	Ú	1
CELL IMMUNOL IMMUNOL CELL BIOL	2.206 2.201	53.1	В	0	1	0	0	1
CELL TISSUE RES	2.192	52.4 51.7	B B	0 4	0 9	0 7	0 6	0 26
HISTOCHEM CELL BIOL	2.157	51.0	В	Ö	1	ó	0	1
GROWTH FACTORS	2.145	50.3	B	ŏ	ò	ő	ő	ò
J MUSCLE RES CELL M	2.117	49.7	В	0	0	0	1	1
CELL MOL NEUROBIOL	2.093	49.0	В	0	0	1	0	1
TISSUE ENG	2.073	48.3	В	0	0	1	0	1_
MOL CELL BIOCHEM I INTERF CYTOK RES	2.054 2.024	47.6	B B	13	15 0	1	8	37
RECEPTOR CHANNEL	2.024	46.9 46.3	В	0 0	0	0 1	1 0	1
BIOCHEM CELL BIOL	1.937	45.6	B	2	9	Ó	ő	11
I RECENT SIGNAL TR R	1.915	44.9	B	ō	ő	ŏ	ŏ	0
MECH AGEING DEV	1.897	44.2	В	1	0	0	0	1
PIGM CELL RES	1.866	43.5	В	0	2	0	0	2
DNA CELL BIOL	1.827	42.9	В	0	0	0	1	1
MOL CELL PROBE	1.744	42.2	В	0	0	1	1	2
DEV GROWTH DIFFER EUR CYTOKINE NETW	1.730 1.693	41.5 40.8	B B	0 1	1 0	0 0	0 0	1
BIOL CELL	1.670	40.1	В	1	ő	Ő	Ö	1
CYTOKINES CELL MOL T	1.582	39.5	B	Ò	Õ	ŏ	ĺ	1
endothelium new York	1.579	38.8	В	1	0	0	0	1
INFLAMM RES	1.560	38.1	В	0	1	0	0	1
HISTOL HISTOPATHOL	1.553	37.4	В	Ö	0	0	0	0
PROG HISTOCHEM CYTO	1.500 1.449	36. <i>7</i> 36.1	B B	0 1	0 1	0 3	0	0 5
CELL MOL BIOL CYTOGENET CELL GENET	1.449	35.4	В	0	Ó	0	1	1
ACTA CYTOL	1.391	34.7	В	ő	ŏ	ŏ	ó	ó
ZYGOTE	1.365	34.0	B	Ō	Ō	1	Ō	1
PHYSIOL GENOMICS	1.353	33.3	В	0	0	0	0	0
TRAFFIC	1.340	32.7	C C	0	0	1	0	1
PROTOPLASMA	1.333 1.252	32.0 31.3	Č	0 0	0	0 0	0 1	0 1
PATHOBIOLOGY J NEUROCYTOL	1.232	30.6	2	0	Ő	0	ó	ó
PROSTAG LEUKOTR ESS	1.226	29.9	č	ŏ	ŏ	ŏ	ŏ	ŏ
ARCH HISTOL CYTOL	1.202	29.3	Č	1	0	9	6	16
Inflammation	1.189	28.6	C	1	0	0	0	1
CELL BIOL TOXICOL	1.107	27.9	Ç	0	ō	0	0	0
HISTOCHEM J	1.078	27.2	Ç	2	5 0	0 0	1	8 1
IN VITRO CELL DEV AN EUR J HISTOCHEM	1.059 1.039	26.5 25.9	0000000000	0	0	0	Ö	Ó
PROSTAG OTH LIPID M	1.034	25.2	č	3	2	ŏ	4	ğ
INT J TISSUE REACT	1.030	24.5	Č	2	0	0	2	4
CELL BIOCHEM FUNCT	1.000	23.1	Ç	3	0	0	0	3
CYTOTHERAPY	1.000	23.8	Ç	0	0	0	0	0
MEDIAT INFLAMM	0.990	22.4	Č	1 0	0 1	0 0	0	1
MOL CELLS PLATELETS	0.968 0.965	21.8 21.1	Č	0	Ó	0	Õ	Ó
CELL STRUCT FUNCT	0.960	20.4	č	Ö	ĭ	ŏ	ő	1
CELL PROLIFERAT	0.955	19. <i>7</i>	č	Ö	ò	ŏ	Õ	Ó
CONNECT TISSUE RES	0.952	19.0	С	1	0	0	0	1
APOPTOSIS	0.949	18.4	Ç	Ō	1	2	2	5
ACTA HISTOCHEM	0.943	17.7	Č	5	0	0	0	5
CYTOTECHNOLOGY	0.925	17.0	Č	3 0	0	0	0	3
CELLS TISSUES ORGANS	0.896 0.884	16.3 15.6	ر ر	0	1	0	0	1
SOMAT CELL MOLEC GEN ACTA HISTOCHEM CYTOC	0.879	15.0	č	ŏ	ò	Ŏ	ŏ	ò
ANAL QUANT CYTOL	0.877	14.3	č	16	Ĭ	ŏ	ő	23
BIOTHERAPY	0.870	13.6	Č	0	0	Q	0	0
TISSUE CELL	0.864	12.9	000000000000000000000000000000000000000	1	0	2	2	5
ANAL CELL PATHOL	0.838	12.2	Ċ	1	0	0	0	11


(continued)

Subject Category, Area Cell Biology	Impact Factor	Adjusted IF (%)	Publication Type	China n	HK n	SNG n	TW n	Total n
GROWTH HORM IGF RES CYTOPATHOLOGY IN VITRO CELL DEV PL BIOSCIENCE REP CURR TOP CELL REGUL BIOTECH HISTOCHEM CELL BIOL INT IUBMB LIFE NAT IMMUN FOLIA HISTOCHEM CYTO BIOCELL BIOL MEMBRANY EMBO REP CYTOBIOS J HISTOTECHNOL ENDOCYT CELL RES NAT REV MOL CELL BIO	0.788 0.760 0.750 0.678 0.636 0.605 0.592 0.418 0.400 0.388 0.361 0.345 0.323 0.308 0.308	11.6 10.9 10.2 9.5 8.8 8.2 7.5 6.8 6.1 5.4 4.8 4.1 3.4 2.0 2.7 1.4		0 0 0 9 0 3 14 11 0 0 0 0	0 1 0 0 0 0 5 0 0 0 0 0 0 0 0 0 0 0 0 0	1 0 0 0 0 2 2 1 0 0 0 0 0 0 0 0	0 0 0 1 0 0 6 2 0 0 1 0 0 6 0 0	1 1 0 10 0 5 27 14 0 0 1 0 0 9 0
Total				231	167	169	326	893

Clinical Neurology

Number of full papers (with impact factor) in Medline





Clinical Neurology subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).

Journals sorted according to the impact factor provided by the *Journal Citation Reports* (JCR) 2000 version for Clinical Neurology JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category: a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW). About 20 of the journals with the lowest IF with no publications have been omitted in the list.


Subject Category, Area	Impact Factor	Adjusted IF (%)	Publication Type	China n	HK n	SNG n	TW n	Total n
Clinical Neurology	ractor	- IF (/0)	Турс		-		-	AND THE PROPERTY OF THE PERSON NAMED IN
ANN NEUROL	8.480	100.0	A	1	0	0 0	0	1 0
BRAIN	7.303	99.3	A	0 0	0 0	0	0	0
BRAIN PATHOL	6.435	98.5	A A	0	Ö	0	1	1
SCHIZOPHRENIA BULL	6.085	97 8 97.1	Â	0	ŏ	Ö	ò	ò
STROKE	6 008	96.4	Â	Ő	ŏ	ő	ĭ	1
I NEUROPATH EXP NEUR	5.565 5.052	95.6	Ä	ő	ŏ	ŏ	i	1
J CLIN PSYCHOPHARM	4.781	94.9	Ä	4	11	2	33	50
NEUROLOGY ARCH NEUROL CHICAGO	4.393	94.2	Â	4	3	1	5	13
PAIN FORUM	4.320	93.4	Ä	Ó	0	0	0	0
PAIN	3 853	92.7	A	0	0	0	0	O
EPILEPSIA	3.787	92.0	Α	2	1	2	15	20
MOVEMENT DISORD	3.655	91.2	Α	2	7	1	16	26
AMYOTROPH LATERAL SC	3.5 <i>7</i> 1	90.5	Α	0	0	0	0	0
NEUROSCI BIOBEHAV R	3 382	89.8	Ą	0	0	1	0	1
ELECTROEN CLIN NEURO	3 327	89.1	A	0	0	0	O O	0
CURR OPIN NEUROL	3.176	88.3	A	0	0	0	0 4	0 11
SLEEP	3 168	87.6	A	3 0	4 0	1	0	1
CEREBROVASC DIS	2 950	86.9	A A	0	0	Ó	0	Ó
J NEUROSURG	2 918 2 899	86.1 85.4	Ä	0	0	0	0	Ö
NEUROSURGERY	2 877	84.7	Â	0	ő	ő	1	i i
J NEUROTRAUM EPILEPSY RES	2 866	83.9	Ä	ĭ	ŏ	ĭ	2	4
J NEUROL NEUROSUR PS	2.846	83 2	Ä	ò	ŏ	Ó	ō	0
PSYCHOPHARMACOL BULL	2 809	82.5	A	Ö	Ō	0	0	0
HEADACHE	2.699	81.8	A	3	1	3	3	10
NEUROGENETICS	2 596	81 0	A	0	0	0	0	0
NEUROPATH APPL NEURO	2.523	80 3	Α	0	1	0	0	1
ACTA NEUROPATHOL	2 446	79 6	Α	0	0	0	1	1
CEPHALALGIA	2 391	78.8	Α	1	0	0	0	1
J INT NEUROPSYCH SOC	2 376	78 1	Ą	0	1	0	0	1
J PSYCHOPHARMACOL	2.328	77 4	A	0	0	0	0	0 1
J CLIN NEUROPHYSIOL	2.173	76.6	A	0	0	1 0	0 0	1
I NEUROPSYCH CLIN N	2 140	75 9 75.2	A	1 0	0	0	0	Ó
AM I NEURORADIOL	2 126 2 081	75.2 74.5	A A	0	0	0	1	1
NEUROGASTROENT MOTIL I NEUROL	2 061	73 7	Ä	Ö	1	Ő	12	13
EUR NEUROPSYCHOPHARM	2 045	73 0	Ä	ő	ò	ŏ	1	1
CLIN NEUROPHARMACOL	1 943	72 3	Ä	ŏ	ŏ	Ŏ	i	1
I AFFECT DISORDERS	1 938	71.5	A	Ō	Ō	0	0	0
PSYCHIAT RES NEUROIM	1 919	70 8	A	Ō	0	0	0	0
NEUROSCIENTIST	1 918	70 1	Α	0	0	0	0	0
CLIN J PAIN	1 900	69.3	Α	0	1	0	2	3
NEUROCASE	1.871	68 6	Α	0	0	0	0	0
SPINE	1 843	67 9	Ą	0	0	0	0	0
J PAIN SYMPTOM MANAG	1.837	67.2	A	0	Ŏ	0	1	1 3
ALZ DIS ASSOC DIS	1.837	66.4	B B	0	0	0 0	1 0	Ó
MULT SCLER I NEURAL TRANSM	1.807 1.785	65.7 65.0	В	0 0	0 0	0	0	Õ
DEV MED CHILD NEUROL	1.780	64.2	В	1	0	0	0	1
DEMENT GERIATR COGN	1.763	63.5	В	Ó	ő	ő	1	1
CLIN NEUROPHYSIOL	1.672	62.8	В	1	ő	ŏ	ò	i
NEUROEPIDEMIOLOGY	1.654	62.0	B	ò	ŏ	ŏ	Ő	Ò
SEMIN NEUROL	1.635	61.3	B	Ŏ	ŏ	ŏ	ŏ	Ō
I NERV MENT DIS	1.626	60.6	B	Ö	ŏ	ŏ	ŏ	Ō
NEUROPEDIATRICS	1.597	59.9	B	Ŏ	Ŏ	1	0	1
BRAIN TOPOGR	1.596	59.1	В	1	Õ	Ö	Ō	1
J NEURO ONCOL	1.581	58.4	В	0	0	0	0	0
CAN J NEUROL SCI	1.504	57.7	В	2	2	0	7	11
EUR ARCH PSY CLIN N	1.385	56.9	В	0	1	0	0	1


(continued)

Subject Category, Area Clinical Neurology	Impact Factor	Adjusted IF (%)	Publication Type	China n	HK n	SNG n	TW n	Total n
INT J NEUROPSYCHOPH	1.323	56.2	В	0	0	0	0	0
ACTA NEUROL SCAND	1.304	55.5	B	š	6	ĭ	42	52
NEUROSURG CLIN N AM	1.265	54.7	В	Ö	ŏ	Ò	o o	0
NEUROMODULATION	1.216	54.0	В	0	Ō	Ö	ō	ŏ
BRAIN DEV JPN	1.155	53.3	В	4	5	1	17	27
J CHILD NEUROL	1.134	52.6	В	0	1	0	0	1
SEIZURE EUR J EPILEP	1.127	51.8	В	0	1	0	0	1
J INTELL DISABIL RES	1.123	51.1	В	0	1	0	0	1
HUM PSYCHOPHARM CLIN	1.103	50.4	В	0	0	0	0	0
PROG NEURO PSYCHOPH	1.078	49.6	В	0	0	0	1	1
J CLIN EXP NEUROPSYC	1.067	48.9	В	0	0	0	0	0
J PERIPHER NERV SYST	1.038	48.2	В	0	0	1	0	1
ADV NEUROL	0.968	43.8	В	0	0	0	1	1
EUR J NEUROL	0.952	43 1	В	0	1	0	0	1
CLIN NEUROPSYCHOL	0.948	42.3	В	0	0	0	1	1
CLIN AUTON RES	0.942	40.9	В	0	0	0	1	1
J NEUROIMAGING	0.942	41.6	В	1	0	0	0	1
J NEUROSURG ANESTH	0.937	40.1	В	0	1	0	0	7
SPINAL CORD	0.913	39.4	В	3	1	3	6	13
J GERIATR PSYCH NEUR	0.909	38.7	В	0	0	0	1	1
NEUROPSY NEUROPSY BE	0.896	38.0	В	0	0	0	1	1
NEUROL RES	0.866	36.5	В	0	0	0	1	1
PEDIATR NEUROSURG	0.811	34.3	В	0	1	0	0	1
MINIM INVAS NEUROSUR	0.805	33.6	В	0	1	0	0	1
ACTA NEUROL BELG	0.697	29.9	Ç	0	0	0	1	1
PSYCHIAT CLIN NEUROS	0.452	18.2	CCC	0	1	0	0	1
J NEURO OPHTHALMOL	0.252	8.8	Č	0	0	0	1	1
J CLIN NEUROSCI	0.178	5.1	C	1	0	0	0	1
Total				39	54	20	184	297

Critical Care Medicine

Number of full papers (with impact factor) in Medline






Critical Care Medicine subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).


Journals sorted according to the impact factor provided by the *Journal Citation Reports* (JCR) 2000 version for Critical Care Medicine JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category: a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW).

Subject Category, Area Critical Care Medicine	Impact Factor	Adjusted IF (%)	Publication Type	China n	HK n	SNG n	TW n	Total n
CRIT CARE MED	3.824	93.3	Α	4	11	0	16	31
J NEUROTRAUM	2.877	86.7	Α	1	0	0	0	1
SHOCK	2.785	80 0	Α	1	0	0	0	1
INTENS CARE MED	2 098	<i>7</i> 3 3	Α	1	5	1	8	15
RESUSCITATION	1.760	66.7	Α	1	0	0	0	1
J TRAUMA	1,498	60 0	В	0	0	0	0	0
J CRIT CARE	1.407	53.3	В	0	0	0	0	0
BURNS	0.856	46.7	В	0	0	0	0	0
ANAESTH INTENS CARE	0.770	40.0	В	0	75	33	4	112
ANASTH INTENSIVMED	0.647	33.3	В	0	0	0	0	0
I INTENSIVE CARE MED	0.544	26.7	С	0	0	0	0	0
ANASTH INTENSIV NOTF	0 541	20.0	С	0	0	0	0	0
INJURY	0.363	13.3	С	0	0	0	0	0
SEM RESP CRIT CARE M	0.336	6.7	С	0	0	0	0	0
Total				8	91	34	29	162

Dentistry, Oral Surgery and Medicine

Number of full papers (with impact factor) in Medline






Dentistry, Oral Surgery and Medicine subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).


Journals sorted according to the impact factor provided by the *Journal Citation Reports* (JCR) 2000 version for Dentistry, Oral Surgery and Medicine JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category: a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW).

Subject Category, Area	Impact	Adjusted	Publication	 China	HK	SNG	TW	Total
Dentistry, Oral Surgery and Medicine	Factor	IF (%)	Туре	n	n	n	n	n
I DENT RES	4 438	100.0	Α	0	15	3	6	24
CRIT REV ORAL BIOL M	3 148	97.8	Α	0	0	0	0	0
EUR J ORAL SCI	1 808	95. <i>7</i>	Α	2	0	0	0	2
CARIES RES	1 708	93 5	Α	2	2	0	0	4
ORAL ONCOL	1 690	91 3	A	0	1	0	0	1
CLIN ORAL IMPLAN RES	1 680	89.1	Α	0	0	0	0	0
I DENT	1 594	87.0	A	1	24	3	4	32
J ORAL PATHOL MED	1.457	84.8	Α	0	0	0	0	0
AM I DENT	1 452	82 6	A	0	8	2	0	10
I CLIN PERIODONTOL	1 426	80 4	A	4	9	2	11	26
ORAL MICROBIOL IMMUN	1 419	78 3	A	0	1	0	0	1
OPER DENT	1 411	76 1	Α	0	1	20	1	22
PERIODONTOL 2000	1 391	73 9	A	0	0	0	0	0
COMMUNITY DENT ORAL	1 350	71 7	A	0	0	0	0	0
INT ORAL MAX IMPL	1 316	69.6	A	1	1	1	2	5
I OROFAC PAIN	1 288	67.4	A	1	2	0	1	4
J PERIODONTOL	1.215	65.2	В	1	3	1	32	37
INT I PROSTHODONT	1 182	63 0	В	0	4	8	3	15
DENT MATER	1 016	60 9	В	0	0	Ō	1	1
J PERIODONTAL RES	0.946	58.7	В	1	Ō	0	4	5
INT ENDOD J	0.933	56.5	В	2	1	0	1	4
INT J ORAL MAX SURG	0.932	54 3	B	0	Ô	Ö	0	0
SWED DENT I	0 914	52.2	В	o o	1	0	Ö	1
ORAL SURG ORAL MED O	0.865	50.0	В	ő	Ö	Õ	1	1
I AM DENT ASSOC	0.854	47.8	В	Ö	1	1	0	2
ARCH ORAL BIOL	0 845	45.7	В	6	17	5	7	35
BRIT DENT I	0.822	43.5	В	Ö	16	1	1	18
J PROSTHET DENT	0.022	41 3	В	12	11	13	30	66
J ORAL MAXIL SURG	0 773	39 1	В	30	15	7	20	72
BRIT J ORAL MAX SURG	0.771	37 0	В	0	0	0	0	0
ACTA ODONTOL SCAND	0.771	34.8	В	1	3	0	0	4
AM J ORTHOD DENTOFAC	0.757	32.6	č	2	17	2	17	38
CLEFT PALATE CRAN J	0.737	30.4	č	0	1	0	0	1
QUINTESSENCE INT	0.712	28.3	Č	7	26	22	7	62
ANGLE ORTHOD	0.704	26.1	Č	Ó	10	0	8	18
J ENDODONT	0.668	23.9	č	2	1	Ī	31	35
CRANIO	0.657	21.7	č	0	0	0	2	2
J PUBLIC HEALTH DENT	0.656	19 6	č	Õ	1	Ō	0	1
INT J PERIODONT REST	0.650	17.4	č	0	ò	0	3	3
J CRANIO MAXILL SURG	0.636	15.2	č	0	0	Ö	0	0
EUR J ORTHODONT	0.593	13.0	č	2	8	3	1	14
J ORAL REHABIL	0.565	10.9	č	17	10	27	26	80
ENDOD DENT TRAUMATOL	0.363	8.7	C	2	0	7	3	12
J DENT CHILD	0.496	6.5	Ċ	Õ	0	Ó	Õ	0
INT DENT J	0.419	4.3	C	3	19	5	Ö	27
AUST DENT I	0.373	2.2	Ċ	1	32	17	8	58
AUST DENT J	0.373	4.4	C	•	an	, ,	-	- ~
Total				100	261	151	231	743

Emergency Medicine

Number of full papers (with impact factor) in Medline





Emergency Medicine subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).

Journals sorted according to the impact factor provided by the *Journal Citation Reports* (JCR) 2000 version for Emergency Medicine JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category: a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW).

Subject Category, Area	Impact	Adjusted	Publication	China	НК	SNG	TW	Total
Emergency Medicine	Factor	IF (%)	Туре	n	n	n	n	n
ann emerg med	2.183	100 0	Α	0	2	3	8	13
RESUSCITATION	1.760	91.7	Α	2	6	1	1	10
ACAD EMERG MED	1.419	83 3	Α	0	1	1	3	5
CRIT CARE CLIN	1.143	<i>7</i> 5 0	Α	0	1	0	0	1
AM J EMERG MED	1.054	66.7	Α	2	2	4	45	53
J BURN CARE REHABIL	0.810	58 3	В	0	0	0	0	0
J ACCID EMERG MED	0 668	50.0	В	0	11	1	1	13
EMERG MED CLIN N AM	0.635	41.7	В	0	0	0	0	0
NEW HORIZ SCI PRACT	0 619	33 3	В	0	0	0	0	0
UNFALLCHIRURG	0.496	25 0	C	1	0	0	0	1
PEDIATR EMERG CARE	0.428	16 7	C	0	0	0	1	1
INJURY	0.363	8.3	С	0	0	0	0	0
Total				5	23	10	59	97

Endocrinology and Metabolism


Number of full papers (with impact factor) in Medline


Three year groups

Hong Kong Singapore Taiwan


12 year period - 1990 to 2001

China Hong Kong Singapore Taiwan






Three year groups



12 year period - 1990 to 2001

CUHK Academia



Endocrinology and Metabolism subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).

Journals sorted according to the impact factor provided by the *Journal Citation Reports* (JCR) 2000 version for Endocrinology and Metabolism JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category: a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW).


Subject Category, Area Endocrinology and Metabolism	Impact Factor	Adjusted IF (%)	Publication Type	China n	HK n	SNG n	TW n	Total n
ENDOCR REV	19 524	100.0	Α	0	0	0	0	0
FRONT NEUROENDOCRIN	8.375	98 9	Α	0	0	0	0	0
DIABETES	7.715	97 8	Α	1	2	1	4	8
MOL ENDOCRINOL	6.251	96 6	Α	0	0	5	5	10
J CEREBR BLOOD F MET	5.926	95 5	Α	0	0	0	1	1
J BONE MINER RES	5 877	94 4	Α	1	6	0	3	10
DIABETOLOGIA	5.721	93.3	Ą	3	4	1	5	13
CURR OPIN LIPIDOL	5.661	92 1	Ą	Q	0	0	0	0
J CLIN ENDOCR METAB	5.447	91 0	Ą	6	19	10	18	53
VITAM HORM	5.407	89 9	Ą	0	0	1	0	1
RECENT PROG HORM RES	5.306	88.8	Ą	ō	0	0	0	0
DIABETES CARE	4 992	87.6	A	5 2	28 9	2 13	17 22	52
ENDOCRINOLOGY OBEC DES	4 790 4.656	86 5 85.4	A	ő	1	0	0	46 1
OBES RES			A	10	7	7	35	59
FREE RADICAL BIO MED BONE	4 116 3 998	84.3 83.1	A A	1	7	ó	33 7	15
TRENDS ENDOCRIN MET	3 908	82.0	Ä	Ó	ó	Ö	ó	0
J PINEAL RES	3.779	80.9	Ä	Ö	ő	ő	ŏ	ő
PROSTATE	3.75 4	79.8	Ä	Ö	ŏ	ő	ŏ	ŏ
AM J PHYSIOL ENDOC M	3 183	78.7	Â	ŏ	ő	ŏ	ŏ	ŏ
PSYCHONEUROENDOCRINO	3 008	77.5	Ä	Ö	Ō	0	1	1
INT J OBESITY	2 982	76.4	Α	0	0	1	0	1
CLIN ENDOCRINOL	2.922	75.3	Α	1	20	5	10	36
NEUROENDOCRINOLOGY	2 744	74.2	Α	0	0	0	0	0
DIABETIC MED	2.732	73.0	Α	1	13	2	12	28
NEUROIMMUNOMODULAT	2.701	71.9	Α	1	0	0	0	1
J ENDOCRINOL	2 663	70.8	Α	3	18	1	8	30
BAILLIERE CLIN ENDOC	2.659	69.7	Α	Ō	0	0	0	0
J MOL ENDOCRINOL	2 654	68.5	A	0	2	2	0	4
REGUL PEPTIDES	2 634	67.4	A	0	0	0	1	1
OSTEOPOROSIS INT	2 613	66.3	В	3	18	3	3	27
J NEUROENDOCRINOL	2 598	65.2	B B	0 0	0	1 0	0 1	1 1
HORM BEHAV	2 553	64.0 62.9	В	0	0	0	ó	Ó
J MAMMARY GLAND BIOL	2.493 2.376	61.8	В	0	Ö	0	0	0
ENDOCRIN METAB CLIN MOL CELL ENDOCRINOL	2.369	60.7	В	3	7	10	14	34
EUR J ENDOCRINOL	2.315	59 6	В	3	1	5	5	14
J STEROID BIOCHEM	2.245	58.4	В	3	i	ő	5	9
CALCIFIED TISSUE INT	2.189	57.3	B	1	10	2	15	28
DIABETES METAB RES	2.155	56 2	B	Ò	Ō	ō	0	0
THYROID	2 047	55.1	B	1	7	5	8	21
METABOLISM	1.952	52.8	В	4	7	2	25	38
SEMIN REPROD ENDOCR	1.952	53.9	В	0	0	0	0	0
GEN COMP ENDOCR	1 912	51.7	В	6	15	13	15	49
DIABETES REV	1.886	50 6	В	0	0	0	0	0
STEROIDS	1 831	49.4	В	16	0	4	3	23
HORM METAB RES	1 707	48.3	В	2	1	5	5	13
DOMEST ANIM ENDOCRIN	1.679	47 2	В	1	0	0	0	1
PANCREAS	1.648	46 1	В	0	0	0	0	0
ENDOCRINE	1.609	44 9	В	0	0	2 1	2	4 1
J CLIN DENSITOM	1.523	43 8	В В	0	0	Ó	0	Ó
DIABETES METAB	1.464 1.413	42.7 41.6	В	0	0	0	0	Ö
NEUROPEPTIDES METAB BRAIN DIS	1.413	40.4	В	0	0	0	ő	ő
EXP CLIN ENDOCR DIAB	1.406	39.3	В	Ő	ŏ	Ő	ő	ő
I ENDOCRINOL INVEST	1.398	38.2	В	1	1	2	12	16
MINER ELECTROL METAB	1.350	37.1	В	ò	i	ō	8	9
I INHERIT METAB DIS	1.307	36.0	В	ő	ò	ŏ	ŏ	ó
HORM RES	1.301	34.8	B	7	2	2	2	13
COMP BIOCHEM PHYS C	1.249	33.7	В	Ó	ō	ō	ō	0
ENDOCR RELAT CANCER	1.239	32.6	C	Ŏ	ō	Ō	1	Ĩ
	1.226	31.5	č	Ö	3	ī	12	16


(continued)

Subject Category, Area	Impact	Adjusted	Publication	China	НК	SNG	TW	Total
Endocrinology and Metabolism	Factor	IF (%)	Туре	n	n	n	n	n
GYNECOL ENDOCRINOL	1.107	30.3	C	0	0	0	0	0
I TRACE ELEM MED BIO	1.032	29.2	C C C	Ō	0	Ö	i	1
ENDOCR RES	0.994	28.1	č	2	3	Õ	3	8
DIABETES RES CLIN PR	0.982	27.0	Ċ	1	9	7	24	41
DIABETES NUTR METAB	0.964	25.8	С	0	1	0	0	1
NUTR METAB CARDIOVAS	0.959	24.7	C	0	0	0	0	Ó
J TRACE ELEM EXP MED	0.952	23.6	С	0	0	0	0	0
J BONE MINER METAB	0.926	22.5	С	1	0	0	0	1
INT J PANCREATOL	0.924	21.3	С	0	0	0	0	0
J DIABETES COMPLICAT	0.851	20.2	. С	0	1	2	2	5
DIABETES EDUCATOR	0.837	19.1	С	0	0	0	0	0
MAGNESIUM RES	0.825	18.0	С	1	0	0	2	3
J BIOL REG HOMEOS AG	0.803	16.9	С	1	0	0	0	1
GROWTH HORM IGF RES	0.788	15. <i>7</i>	С	0	0	1	0	1
BIOL TRACE ELEM RES	0.786	14.6	С	0	0	0	0	0
ENDOCR J	0.779	13.5	С	1	0	0	7	8
ANN NUTR METAB	0.655	12.4	С	0	0	0	0	0
TRACE ELEM ELECTROLY	0.653	11.2	С	0	0	0	0	0
J PEDIATR ENDOCR MET	0.638	10.1	С	0	1	0	0	1
ACTA DIABETOL	0.519	9.0	С	1	0	0	0	1
ANN ENDOCRINOL PARIS	0.436	7.9	С	0	0	0	0	0
ENDOCR PATHOL	0.402	6.7	С	0	0	0	0	0
ENDOCRINOLOGIST	0.382	5.6	С	0	0	0	0	0
DIABETES OBES METAB	0.300	4.5	С	2	0	7	0	3
BEST PRACT RES CL EN	0.158	3.4	С	0	0	0	0	0
MAGNESIUM B	0.132	2.2	С	0	0	0	0	0
ITAL J MINER ELECT M	0.077	1.1	С	0	0	0	0	0
Total				96	225	120	324	765

Gastroenterology and Hepatology

Number of full papers (with impact factor) in Medline





Gastroenterology and Hepatology subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).

Journals sorted according to the impact factor provided by the Journal Citation Reports (JCR) 2000 version for Gastroenterology and Hepatology JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW)

Subject Category Area	Impact	Adjusted	Publication	China	НК	sng	TW	Total
Gastroenterology and Hepatology	Factor	IF (%)	Туре	n	n	n	n	n
GASTROENTEROLOGY HEPATOLOGY SEMIN LIVER DIS GUT J HEPATOL ALIMENT PHARM THERAP AM J PHYSIOL GASTR L AM J GASTROENTEROL GASTROINTEST ENDOSC HELICOBACTER J VIRAL HEPATITIS LIVER TRANSPLANT NEUROGASTROENT MOTIL SCAND J GASTROENTERO ENDOSCOPY HEPATOL RES INFLAMM BOWEL DIS	12 246 7 304 6 012 5 386 3 761 3 489 3 115 2 834 2 820 2 639 2 157 2 130 2 081 1 842 1 817 1 808 1 791	100 0 97 8 95 6 93 3 91 1 88 9 86 7 84 4 82 2 80 0 77 8 75 6 73 3 71 1 68 9 66 4	A A A A A A A A A A A A A A A A B B	4 8 0 5 3 0 0 6 1 0 0 3 0 0	14 25 0 9 8 0 0 41 47 1 0 7 0	0 1 0 14 1 0 1 3 10 0 0 0 0 0	31 85 1 16 62 0 0 96 69 0 0 0 1 38 0	49 119 1 44 74 0 1 146 127 1 1 1 50 0
DIGESTION GASTROENTEROL CLIN N LIVER BAILLIERE CLIN GASTR INT J COLORECTAL DIS DIS COLON RECTUM CAN J GASTROENTEROL J PEDIATR GASTR NUTR DIGEST DIS SCI ITAL J GASTROENTEROL EUR J GASTROENTEROL EUR J GASTROENTEROL J CLIN GASTROENTEROL J GASTROEN HEPAT J CLIN GASTROENTEROL J GASTROEN HEPATOL WORLD J GASTROENTERO J GASTROENTEROL GASTROEN CLIN BIOL HEPATO GASTROENTEROL Z GASTROENTEROL ABDOM IMAGING DIGEST SURG	1 780 1 774 1 739 1 733 1 707 1 690 1 645 1 580 1 498 1 142 1 127 1 116 0 993 0 990 0 927 0 905 0 887 0 866 0 810	62 2 60 0 57 8 55 6 53 3 51 1 48 9 46 7 44 2 40 0 37 8 35 6 33 1 28 9 26 7 24 4 22 0	888888888888888	2 0 4 0 0 0 0 0 0 4 0 1 1 1 3 1 0 0 0 0 1 1 0 0 0 1	11 0 2 1 0 0 2 0 2 0 2 0 6 7 63 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 1 0 1 1 0 0 0 6 0 5 10 31 0 0 0 0	5 0 15 0 0 0 0 6 7 0 6 53 190 0 21 0 0	18 1 21 2 1 0 2 0 100 0 18 71 315 0 38 0 0
DIGEST DIS ACTA GASTRO ENT BELG CURR OPIN GASTROEN REV ESP ENFERM DIG J DIARRHOEAL DIS RES CHIR GASTROENTEROL BEST PRACT RES CL GA Total	0 744 0 605 0 577 0 384 0 379 0 078 0 067	17 8 15 6 13 3 11 1 8 9 4 4 2 2	000000000000000000000000000000000000000	0 0 0 3 0 0	2 2 0 0 0 0 5	0 0 0 2 0 1	0 2 0 0 1 0 2	3 4 0 0 6 0 8


Genetics and Heredity


Number of full papers (with impact factor) in Medline

Three year groups China Hong Kong Singapore Taiwar

12 year period - 1990 to 2001

China Hong Kong Singapore Taiwan







Three year groups

CUHK HKU Academia Othe

12 year period - 1990 to 2001

CUHK HKU Academia Other





Genetics and Heredity subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).

Journals sorted according to the impact factor provided by the *Journal Citation Reports* (JCR) 2000 version for Genetics & Heredity JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category: a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW). About 20 of the journals with the lowest IF with no publications have been omitted in the list.


Subject Category, Area	Impact	Adjusted	Publication	China	НК	SNG	TW	Total
Genetics and Heredity	Factor	IF (%)	Туре	n	n	n	n	n
NAT GENET	30.910	100.0	Α	4	1	0	1	6
GENE DEV	19.676	99.1	Α	0	0	7	1	8
CURR OPIN GENET DEV	13.810	98.2	Α	0	0	1	0	1
ANNU REV GENET	13.450	97.4	Ą	1	0	0	0	1
TRENDS GENET	12.912	96.5	Ą	0	1	0	2	3
AM J HUM GENET	10.351	95.6	Ą	4	2	0	5	11
HUM MOL GENET	9.048	94.7	Ą	0	1	0	1	2
TRENDS ECOL EVOL	8.765	93.9	A	0	0	0	0	0
GENOME RES HUM GENE THER	7.615 6.796	93.0 92.1	Ą	2 0	1 0	1 0	0	4 1
EVOL BIOL	6.667	91.2	A A	0	0	0	1 0	0
ONCOGENE	6.490	90.4	Ä	1	0	0	0	1
GENE THER	5.964	89.5	Ä	ί	ő	ő	ŏ	1
ADV GENET	5.750	88.6	Ä	ò	ő	ŏ	ŏ	Ó
MOL BIOL EVOL	5.298	87.7	Â	4	ĭ	1	3	9
GENES CELLS	4.885	86.8	Ä	ó	ò	Ó	ő	ó
GENETICS	4.687	86.0	Ä	14	2	ī	3	20
GENE CHROMOSOME CANC	4.534	85.1	Α	1	0	0	0	1
PHARMACOGENETICS	4.465	84.2	Α	0	0	1	0	1
CRIT REV EUKAR GENE	4.383	83.3	Α	0	0	0	0	0
CANCER GENE THER	4.151	82.5	Α	0	1	0	0	1
MUTAT RES REV MUTAT	4.129	81.6	A	0	0	0	0	0
I MOL EVOL	3.984	80.7	A	6	2	1	4	13
HUM MUTAT	3.666	79.8	A	1	2	0	8	11
EVOLUTION Proteins	3.632	78.9	A	0	0	0	0	0
MUTAT RES DNA REPAIR	3.576	78.1	A	17	0	1	10	28
J MOL MED JMM	3.515 3.445	77.2 76.3	A	0	0	0	0	0
GENOMICS	3.425	75.4	A A	1 1 <i>7</i>	0 7	0 3	0 10	1 3 <i>7</i>
HUM GENET	3.422	74.6	Â	10	í	5 6	32	37 49
EVOL DEV	3.400	73.7	Ä	0	ó	0	0	0
MOL PHYLOGENET EVOL	3.345	72.8	Ä	6	2	1	1	10
J MED GENET	3.290	71.9	Â	10	4	2	9	25
GENES IMMUN	3.222	71.1	A	0	Ó	ō	ő	0
DEV GENET	3.220	70.2	Α	0	1	1	1	3
EUR J HUM GENET	3.175	69.3	Α	0	0	0	1	1
CHROMOSOMA	3.157	68.4	Α	2	0	0	0	2
J GENE MED	3 103	67.5	Ą	0	0	1	0	1
PSYCHIATR GENET NEUROGENETICS	2.609	66 7	A	0	0	1	0	1
FUNGAL GENET BIOL	2 596	65.8	В	Õ	0	0	0	0
AM J MED GENET	2.566 2.479	64.9 64.0	В	0	0	0	0	0
MOL GEN GENET	2.462	63.2	B B	14 7	9	2	25	50
GENE	2.461	62.3	В	22	3 15	8 25	12 43	30 105
EXP CLIN IMMUNOGENET	2.400	61.4	В	1	0	0	0	105
MOL GENET METAB	2.360	60.5	B	1	0	0	0	1
THEOR APPL GENET	2.358	59.6	B	ò	ŏ	Õ	ŏ	Ó
J EVOLUTION BIOL	2.357	58.8	B	ŏ	ŏ	ŏ	ŏ	ŏ
ENVIRON MOL MUTAGEN	2.278	57.9	B	ŏ	Ŏ	ŏ	ĭ	ĭ
MUTAGENESIS	2.226	57.0	В	6	Ŏ	ŏ	19	25
MUTAT RES FUND MOL M	2.148	56.1	В	Ō	ō	Õ	0	Õ
ANN HUM GENET	2.146	55.3	В	0	Ō	2	Ō	2
IMMUNOGENETICS	2.142	54.4	В	0	0	1	0	1
MAMM GENOME	2.137	53.5	В	0	1	0	0	1
GENE EXPRESSION HEREDITY	2.100	52.6	В	0	0	0	1	1
CURR GENET	2.009	51.8	В	4	0	0	1	5
MUTAT RES GENOMICS	1.977	50.9	В	0	0	0	3	3
J NEUROGENET	1.952 1.938	50.0	В	Ŏ	0	0	0	0
GENET RES	1.862	49.1 47.4	B B	0	0	0	0	0
	1.002	77.7	D	2	0	0	0	2


(continued)

Subject Category, Area	Impact	Adjusted	Publication	China	HK	SNG	TW	Total
Genetics and Heredity	Factor	IF (%)	Туре	n	n	n	n	n
THEOR POPUL BIOL	1.833	46.5	В	0	0	0	1	1
DNA CELL BIOL	1.827	45.6	В	3	0	4	38	45
HUM HERED	1.800	44.7	В	13	1	18	10	42
EVOL ECOL	1.762	43.9	В	0	0	0	0	0
CHROMOSOME RES	1.725	43.0	В	2	0	0	3	5
J HUM GENET	1.685	42.1	В	2	0	0	3	5
CLIN GENET	1.643	40.4	В	6	7	11	11	35
GENOME	1.610	38.6	В	5	1	1	4	11
HUM BIOL	1.532	37.7	В	1	0	4	1	6
BEHAV GENET	1.516	36.8	В	0	0	0	1	1
I HERED	1.511	36.0	В	1	1	1	3	6
GENETICA	1.440	34.2	В	2	0	0	0	2
J ASSIST REPROD GEN	1.416	32.5	Č	0	0	1	0	1
CYTOGENET CELL GENET	1.409	31.6	Č	11	6	1	2	20
EUR J IMMUNOGENET	1.385	30.7	Č	1	0	0	0	1
GENET EPIDEMIOL	1.313	28.9	Č	0	0	1	0	1
JINHERIT METAB DIS	1.307	28.1	Č	!	3	2	11	17
PLASMID	1.302	27.2	Č	6	0		/	16
J INTELL DISABIL RES	1.123	22.8	Č	Ü	1	0	0	1
GENES GENET SYST	1.074	21.1	<u> </u>	1	0	0	0	1
MOL THER	0.897	20.2	Č	0	0	0	0	1
SOMAT CELL MOLEC GEN	0.884	19.3	Č	1	1	0	0	<u> </u>
ANIM GENET	0.863 0.753	17.5	Č	4	0	0	Ó	5
HEREDITAS	0.733	15.8	000000000000000000000000000000000000000	0	0	0	2	4 2
GENESIS BLOCKETA CENET	0.694	14.9 14.0	5	21	1	0	2	24
BIOCHEM GENET GENET COUNSEL	0.636	13.2	Č	0	Ó	0	1	1
	0.542	10.5	Č C	4	0	9	6	19
DNA SEQUENCE BIOMOL ENG	0.342	4.4	Č	1	ő	0	ő	1
Total				249	79	124	305	757

Geriatrics and Gerontology


Number of full papers (with impact factor) in Medline






Three year groups Academia

12 year period - 1990 to 2001 Academia






Geriatrics and Gerontology subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).


Journals sorted according to the impact factor provided by the Journal Citation Reports (JCR) 2000 version for Geriatrics and Gerontology JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW)

Subject Category Area Geriatrics and Gerontology	Impact Factor	Adjusted IF (%)	Publication Type	China n	HK n	SNG n	TW n	Total n
NEUROBIOL AGING J AM GERIATR SOC AGE EXP GERONTOL DRUG AGING MECH AGEING DEV DEMENT GERIATR COGN	4 159 3 136 2 622 2 622 2 342 1 897 1 763	100 0 95 5 86 4 90 9 81 8 77 3 72 7	A A A A A A	0 0 0 3 0 16	1 6 0 1 1 0	0 0 0 0 0	0 7 0 0 0 2	1 13 0 4 1 18
AGE AGEING J GERONTOL A BIOL INT J GERIATR PSYCH GERONTOLOGY MATURITAS CLIN GERIATR MED	1 611 1 549 1 495 1 424 1 402 1 232	68 2 63 6 59 1 54 5 50 0 45 5	A B B B B	1 0 0 0 0	4 6 0 7 1	3 0 1 0 0	5 10 0 8 0	13 16 1 15 1 0
J GERONTOL B PSYCHOL GERIATRICS J GERIATR PSYCH NEUR AGING CLIN EXP RES EXP AGING RES BIOGERONTOLOGY Z GERONTOL GERIATR	1 102 0 919 0 909 0 781 0 581 0 469 0 458	40 9 36 4 31 8 27 3 22 7 18 2 13 6	B B C C C C C	0 0 0 0 0	1 0 1 1 0 0	0 0 0 0 0	0 0 0 0 0	1 0 1 1 0 0
ARCH GERONTOL GERIAT GROWTH DEVELOP AGING Total	0 269 0 143	9 1 4 5	C	0 1 21	0 0 30	0 0 4	0 0 33	0 1 88



Number of full papers (with impact factor) in Medline






Hematology subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).

Journals sorted according to the impact factor provided by the Journal Citation Reports (JCR) 2000 version for Hematology JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category, a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China. Hong Kong (HK). Singapore (SNG) and Taiwan (TW)

Subject Category Area Hematology	Impact Factor	Adjusted IF (%)	Publication Type	China n	HK n	SNG n	TW n	Total n
CIRCULATION CIRC RES BLOOD J CEREBR BLOOD F MET ARTERIOSCL THROM VAS THROMB HAEMOSTASIS J LEUKOCYTE BIOL TRANSFUSION LEUKEMIA SEMIN HEMATOL EXP HEMATOL BRIT J HAEMATOL STEM CELLS BLOOD CELL MOL DIS SHOCK J INFLAMM BLOOD REV MICROCIRCULATION HAEMATOLOGICA BONE MARROW TRANSPL J HEMATOTH STEM CELL SEMIN THROMB HEMOST VOY SANG TRANSFUS MED REV HEMATOL ONCOL CLIN N BLOOD COAGUL FIBRIN TRANSFUSION MED EUR J HAEMATOL LEUKEMIA RES AM J HEMATOL ANN HEMATOL ANN HEMATOL HAEMOPHILIA J PEDIAT HEMATOL ONC J CLIN APHERESIS FIBRINOLYSIS PROTEOL BAILLIERE CLIN HAEM THROMB RES BLOOD PURIFICAT LEUKEMIA LYMPHOMA INT J HEMATOL HAEMOSTASIS CRIT REV ONCOL HEMAT CYTOTHERAPY PLATELETS ACTA HAEMATOL LIFUR MIA LYMPHOMBOLYS CLIN LAB HAEMATOL INFUSIONSTHERAPIE HEMATOL ONCOL LINAB HAEMATOL LIFUR MIA LYMPHOMBOLYS CLIN LAB HAEMATOL LIFUR MIA LYMPHOMB HEM CLIN HEMORHEOL MICRO TRANSFUS CLIN BIOL HAEMATOL CELL THER HEMOGLOBIN PEDIATR HEMAT ONCOL CLIN APPL THROMB HEM CLIN HEMORHEOL MICRO TRANSFUS CLIN BIOL HAEMATOLOGIA TRANSFUS CLIN BIOL HAEMATOLOGIA TRANSFUS CLIN BIOL HAEMATOLOGIA TRANSFUS CLIN BIOL HAEMATOLOGIA TRANSFUS SCI COMP HAEMATOL INT INFUS THER TRANSFUS	10 893 9 193 9 193 8 977 5 9111 4 372 4 342 5 3 736 6 3 3 551 1 4 373 2 689 2 785 2 785 2 197 2 197 2 197 2 197 3 1 252 2 197 3 1 252 2 1 1019 1 252 2 1 1019 1 252 2 1 1019 1 252 2 1 1019 1 1000 1 1	100 3 7 0 3	у ААААААААААААААААААААААААВВВВВВВВВВВВВ	1010000020101111000100030000306110001320003711000160010000	0 0 9 0 0 0 1 9 0 0 0 0 1 0 1 0 4 0 0 0 5 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0	007000100030000000000000000000000000000	01 27 11 00 16 01 00 00 00 00 00 00 00 00 00 00 00 00	1 1 5 3 1 1 0 1 2 8 0 2 0 9 2 1 2 1 0 0 0 4 0 1 0 2 0 7 0 6 2 7 3 1 4 0 1 0 0 0 3 3 1 1 2 7 0 0 0 2 4 1 2 1 1 1 1 0 0 0 1 2 9 7 0 6 2 7 3 1 4 0 1 0 0 3 3 1 1 2 7 0 0 0 2 4 1 2 1 1 1 1 0 0 0 1 2 1 1 1 1 1 0 0 0 1 2 1 1 1 1
Total	aleaning the section of the section		parameter adaptorelatements become	89	129		211	458



Number of full papers (with impact factor) in Medline



Three year groups CUHK HKU Academia Other CUHK HKU Academia Other CUHK HKU Academia Other CUHK HKU Academia Other 12 years 13 years 14 years 15 years 16 years 16 years 17 years 18 years 18 years 18 years 18 years 19 years 1

Immunology subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).

Journals sorted according to the impact factor provided by the Journal Citation Reports (JCR) 2000 version for Immunology JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category, a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW). About 20 of the journals with the lowest IF with no publications have been omitted in the list


Subject Category Area Immunology	Impact Factor	Adjusted IF (70)	Publication Type	China n	HK n	SNG n	TW n	Total n
annu rev immunol	50 340	100 0	Α	0	0	0	0	O
IMMUNITY	21 083	99 1	Α	0	0	1	0	1
J EXP MED	15 236	98 3	Α	0	0	1	0	1
IMMUNOL TODAY	14 954	97 4	Ą	Ō	Ü	O.	0	0
ADV IMMUNOL	13 800	96 6	A	0	1	0	0	1
CURR OPIN IMMUNOL AIDS	12 549 8 018	95 7 94 8	A A	0 1	0	0 0	0	0 1
CRIT REV IMMUNOL	6 981	94 ()	Ä	ó	0	0	0	Ó
IMMUNOL	6 834	93 1	Ä	6	1	$\overset{\circ}{2}$	31	40
SEMIN IMMUNOL	6 544	92 2	A	õ	Ó	ō	0	0
immunol rev	5 961	91 4	4	0	0	0	0	0
EUR J IMMUNOL	5 240	90 5	Α	2	1	1	9	13
EMERG INFECT DIS	4 907	89 7	Ą	0	0	0	1	1
J LEUKOCYTE BIOL	4 342 4 204	88 8 87 9	A	0	0	0 0	5 0	5 0
INFECT IMMUN I ALLERGY CLIN IMMUN	4 179	87 1	A A)	3	2	19	26
TRANSPLANTATION	4 035	86 2	A	ō	õ	ō	ő	0
CURR TOP MICROBIOL	3 463	85 3	Â	ő	ŏ	1	ŏ	ĭ
J CLIN IMMUNOL	3 383	84 5	A	1	1	0	4	6
J NEUROIMMUNOL	3 355	83 6	Α	0	0	1	0	1
GENES IMMUN	3 222	82 8	Ą	0	0	Ó	0	0
EXERC IMMUNOL REV	3 200	81 9	A	0	0	0	0 5	0
INT IMMUNOL	3 130 3 046	81 U 80 2	A A	1 0	0	2 0	1	8 1
J ACQ IMMUN DEF SYND I IMMUNOTHER	3 046	79 3	Â	Ö	ő	0	ó	ó
CLIN INFECT DIS	2 972	78 4	Â	ŏ	ŏ	ő	ĭ	1
CLIN EXP ALLERGY	2 947	77 6	Ä	1	13	3	36	53
AIDS RES HUM RETROV	2 870	76 7	Α	0	0	0	1	1
CANCER IMMUNOL IMMUN	2 820	<i>7</i> 5 9	A	0	0	0	1	1
J INFLAMM	2 714	75 O	A	0	Ö	0	0	0
NEUROIMMUNOMODULAT	2 701 2 697	74 1 73 3	A A	1 0	0 1	0 0	0	1 1
IMMUNOTECHNOLOGY INFECT DIS CLIN N AM	2 631	73 3	Â	Ö	ò	ő	ŏ	ó
TISSUE ANTIGENS	2 612	71 6	Ä	ő	ŏ	ő	ŏ	ŏ
CLIN EXP IMMUNOL	2 544	70 7	Ą	5	12	Ö	12	29
CYTOKINE	2 490	69 8	Α	4	4	0	3	11
VACCINE	2 476	69 0	A	0	0	0	0	Ó
IMMUNOBIOLOGY	2 416	68 1	A	4	0	2	0 2	6 2
EXP CLIN IMMUNOGENET	2 400 2 396	67 2 66 4	A B	0	0	0 0	1	1
BONE MARROW TRANSPL ALLERGY	2 385	65 5	В	ŏ	ő	11	6	17
CLIN IMMUNOL	2 377	64 7	B	1	ŏ	1	ï	3
IMMUNOLOGY	2 292	63 8	В	6	2	5	16	29
MOL IMMUNOL	2 244	62 9	В	1	2	0	4	7
CELL IMMUNOL	2 206	62 1	В	2	0	4	8	14
DEV COMP IMMUNOL	2 205	61 2	B B	0	1 0	0	0 1	1 2
IMMUNOL CELL BIOL	2 201 2 198	60 3 59 5	В	1	0	0	1	2
IMMUNOL RES PEDIATR INFECT DIS J	2 190	58 6	В	Ó	Õ	ŏ	ò	ô
BRAIN BEHAV IMMUN	2 184	57 8	В	ĭ	ŏ	ŏ	Õ	ĩ
SPRINGER SEMIN IMMUN	2 176	56 9	В	0	0	0	0	0
J AUTOIMMUN	2 176	56 0	В	1	1	0	0	2
MICROB PATHOGENESIS	2 144	55 2	В	0	0	0	1	1
IMMUNOGENETICS	2 142	54 3	В	0	1	0	0	1
J INTERF CYTOK RES	2 024	53 4	B B	1 0	0	0 0	3 0	4 0
PARASITE IMMUNOL	2 000 1 995	52 6 51 7	В	12	4	4	6	26
J IMMUNOL METHODS HUM IMMUNOL	1 953	50 9	В	2	1	4	6	13
ANN ALLERG ASTHMA IM	1 889	49 1	B	Õ	ò	i	7	8
CLIN DIAGN LAB IMMUN	1 796	48 3	В	0	1	0	0	1


(continued)

Subject Category, Area	Impact	Adjusted	Publication	China	НК	SNG	TW	Total
Immunology	Factor	IF (%)	Туре	n	n	n	n	n
SCAND HMMUNOL	1.777	47.4	В	4	4	0	16	24
I REPROD IMMUNOL	1.771	46.6	В	0	1	0	0	1
EUR CYTOKINE NETW	1,693	44.0	В	1	0	0	0	1
PEDIATR ALLERGY IMMU	1.635	42.2	В	0	0	0	1	1
INT ARCH ALLERGY IMM	1.630	40.5	В	7	3	2	22	34
FISH SHELLFISH IMMUN	1.618	39. <i>7</i>	В	0	0	1	0	1
CYTOKINES CELL MOL T	1.582	38.8	B B	0	0	0	1	1
INFLAMM RES	1.560	37.9		3	13	0	3	19
IMMUNOL LETT	1.546	37.1	В	21	1	0	9	31
TRANSPL IMMUNOL	1.453	36.2	В	0	0	0	1	1
ORAL MICROBIOL IMMUN	1.419	35.3	В	0	1	0	0	1
EUR J IMMUNOGENET	1.385	34.5	В	2	1	0	0	3
VET IMMUNOL IMMUNOP	1.343	31.9	С	0	1	0	0	1
FEMS IMMUNOL MED MIC	1.244	31.0	С	0	0	0	1	1
AUTOIMMUNITY	1.204	30.2	С	1	2	2	1	6
INFLAMMATION	1.189	29.3	С	4	1	0	2	7
CAN I MICROBIOL	1.105	26.7	С	1	0	0	0	1
INT I STD AIDS	1.019	23.3	С	0	0	1	0	1
MEDIAT INFLAMM	0.990	22.4	С	1	0	0	0	1
VIRAL IMMUNOL	0.982	21.6	С	1	0	0	0	1
COMP IMMUNOL MICROB	0.902	19.8	С	0	0	0	1	1
I BIOL REG HOMEOS AG	0.803	18.1	С	1	0	0	0	1
CLIN REV ALLERG IMMU	0.741	16.4	С	0	1	0	0	1
LIMMUNOASSAY	0.676	13.8	С	1	0	0	0	1
IMMUNOL INVEST	0.635	12.9	C	5	3	0	9	17
HYBRIDOMA	0.587	11.2	С	12	2	1	7	22
I INVEST ALLERG CLIN	0.537	10.3	C	3	0	0	0	3
TRANSFUS CLIN BIOL	0.462	7.8	ввоооооооооо	0	1	0	0	1
ASIAN PAC J ALLERGY	0.186	1.7	С	6	8	24	19	5 <i>7</i>
Total				131	93	77	285	586

Infectious Diseases

Number of full papers (with impact factor) in Medline






Infectious Diseases subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).

Journals sorted according to the impact factor provided by the *Journal Citation Reports* (JCR) 2000 version for Infectious Diseases JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category: a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW).

Subject Category, Area	Impact	Adjusted	Publication	China	НК	SNG	TW	Total
Infectious Diseases	Factor	IF (%)	Туре	n	n	n	n	n
AIDS	8.018	100.0	Α	1	0	0	0	1
LINFECT DIS	4.988	97.2	Α	9	4	5	39	57
EMERG INFECT DIS	4.907	94.4	Α	0	1	0	2	3
ANTIVIR THER	4.510	91. <i>7</i>	Α	0	0	0	0	0
INFECT IMMUN	4.204	88.9	Α	2	3	2	23	30
MICROB DRUG RESIST	3.263	86.1	Α	0	0	0	1	1
J ACQ IMMUN DEF SYND	3.046	83.3	Α	0	0	0	2	2
SEX TRANSM DIS	3.021	80.6	Α	5	3	3	2	13
CLIN INFECT DIS	2.972	77.8	Α	0	0	1	0	1
J ANTIMICROB CHEMOTH	2.964	75.0	Α	0	0	0	0	0
AIDS RES HUM RETROV	2.870	72.2	Α	0	0	0	1	1
INFECT DIS CLIN N AM	2.631	69.4	Α	0	0	0	0	0
PEDIATR INFECT DIS J	2.190	66.7	Α	0	0	0	0	Ó
J VIRAL HEPATITIS	2.157	63.9	В	0	1	0	0	1
SEX TRANSM INFECT	2.136	61.1	. В	1	0	0	0	1
INFECT CONT HOSP EP	2.082	58.3	В	0	1	0	0	1
INT J TUBERC LUNG D	2.011	55.6	В	0	1	0	0	1
DIAGN MICR INFEC DIS	1.932	52.8	В	0	0	0	0	0
J HOSP INFECT	1.812	50.0	В	0	16	7	10	33
CLIN DIAGN LAB IMMUN	1.796	47.2	В	0	1	0	0	1
EPIDEMIOL INFECT	1. <i>77</i> 5	44.4	В	0	0	0	0	0
AM J INFECT CONTROL	1.561	41.7	В	0	2	0	4	6
LEPROSY REV	1.343	38.9	В	1	0	0	0	1
EUR J CLIN MICROBIOL	1.337	36.1	В	0	Ô	0	0	0
INFECTION	1.254	33.3	В	0	2	0	15	17
SCAND J INFECT DIS	1.241	30.6	С	1	12	2	29	44
J INFECTION	1.188	27.8	С	0	16	9	15	40
INT J ANTIMICROB AG	1.141	25.0	С	Ö	0	Ô	1	1
INT J STD AIDS	1.019	22.2	Ċ	1	5	12	3	21
CURR OPIN INFECT DIS	0.778	19.4	С	Ó	Ō	0	Ô	0
JPN J INFECT DIS	0.479	16.7	С	1	Ō	Ó	0	1
INFECT MED	0.420	13.9	С	Ó	Ö	Ŏ	Õ	Ó
ZBL HYG UMWELTMED	0.244	11.1	Č	ō	ŏ	Ŏ	ō	Ö
INFECT DIS CLIN PRAC	0.224	8.3	Č	Ö	Ŏ	Ö	ŏ	Ö
MED MALADIES INFECT	0.201	5.6	Č	ŏ	Ŏ	ŏ	Ö	Ŏ
INT J HYG ENVIR HEAL	0.080	2.8	Č	Ö	ŏ	Ö	Ö	Ö
Total				22	68	41	147	278

Materials Science, Biomaterials

Number of full papers (with impact factor) in Medline



Three year groups CUHK HKU Academia Other CUHK HKU Academia Other CUHK HKU Academia Other CUHK HKU Academia Other 12 years 13 years 14 years 14 years 15 years 16 years 16 years 16 years 16 years 17 years 18 years 1


Materials Science, Biomaterials subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).


Journals sorted according to the impact factor provided by the *Journal Citation Reports* (JCR) 2000 version for Materials Science, Biomaterials JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW)

Subject Category, Area Materials Science, Biomaterials	Impact Factor	Adjusted IF (%)	Publication Type	China n	HK n	SNG n	TW n	Total n
I BIOMED MATER RES	1 900	100 0	Α	33	3	15	70	121
BIOMATERIALS	1 796	90 0	Α	27	3	23	59	112
I BIOMAT SCI POLYM E	1 669	80 0	Α	0	0	0	1	1
DENT MATER	1 016	70 O	Α	0	9	5	7	21
ARTIF CELL BLOOD SUB	0 685	60 0	В	16	2	0	11	29
J MATER SCI MATER M	0 621	50 0	В	0	0	0	0	0
J BIOMATER APPL	0 533	40 0	В	3	0	1	1	5
J BIOACT COMPAT POL	0 426	30 0	С	0	0	0	0	0
CELL POLYM	0 368	20 0	С	0	0	0	0	0
BIO MED MATER ENG	0 277	10 0	C	10	5	0	7	22
Total				89	22	44	156	311

Medicine, General and Internal

Number of full papers (with impact factor) in Medline





Medicine, General and Internal subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).

Journals sorted according to the impact factor provided by the *Journal Citation Reports* (JCR) 2000 version for Medicine, General and Internal JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category: a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW). About 15 of the journals with the lowest IF with no publications have been omitted in the list.


Subject Category, Area Medicine, General and Internal	Impact Factor	Adjusted IF (%)	Publication Type	China n	HK n	SNG n	TW	Total n
	00.000	100.0	Λ	0	0	0	0	^
NOVART FDN SYMP	99.999 29.512	100.0 99.0	A A	2	15	Ö	6	0 23
NEW ENGL J MED JAMA J AM MED ASSOC	15.402	98.1	Â	3	7	1	4	15
LANCET	10.232	97.1	Â	4	30	9	9	52
ANNU REV MED	9.891	96.2	Â	ò	1	ŏ	ó	1
ANN INTERN MED	9.833	95.2	Ä	2	3	Õ	4	ġ
ARCH INTERN MED	6.055	94.3	Α	2	2	0	9	13
AM I MED	5.960	93.3	Α	0	10	1	2	13
BRIT MED J	5.331	92.4	Α	4	13	6	4	27
MEDICINE	4.623	91.4	Ą	0	0	0	2	2
AMYLOID	2.957	90.5	Ą	0	0	0	0	Ō
P ASSOC AM PHYSICIAN	2.881	89.5	Ą	1	0	0	0	1
J FAM PRACTICE	2.851	88.6	Ą	0	0	0	0	0
ANN MED	2.794	87.6	Ą	2	1	1	0	4
J GEN INTERN MED CAN MED ASSOC J	2.421 2.352	86. <i>7</i> 85. <i>7</i>	A A	0 1	0 1	0 0	0	0
JINTERN MED	2.273	84.8	Ä	1	4	0	7	2 12
ARCH FAM MED	2.273	83.8	Ä	Ó	0	1	ó	12
I INVEST MED	2.255	82.9	Ä	ő	ő	Ó	1	1
OIM MON LASSOC PHYS	2.252	81.9	Ä	ŏ	9	1	9	19
MAYO CLIN PROC	2.242	81.0	Ä	ŏ	ő	i	2	3
AM I PREV MED	2.192	80.0	Ä	ŏ	Õ	ó	ī	ĭ
EUR J CLIN INVEST	2.071	79.0	A	Ö	Ö	Ō	i	1
PALLIATIVE MED	1.989	78.1	A	Ö	1	0	Ó	1
J LAB CLIN MED	1.978	<i>77.</i> 1	Α	0	0	0	0	0
MED J AUSTRALIA	1.928	76.2	Α	1	8	0	0	9
BRIT MED BULL	1.869	75.2	Α	0	1	0	0	1
J PAIN SYMPTOM MANAG	1.837	74.3	Α	1	0	3	8	12
BRIT J GEN PRACT	1.627	73.3	A	Ō	0	1	0	1
PREV MED	1.557	72 4	Ą	0	0	0	1	1
AM J MED SCI MED CLIN N AM	1.520	71.4	A	0	1	0	8	9
J WOMENS HEALTH	1.486	70.5	A	0	1	0	0	1
NEW ZEAL MED	1.395 1 202	69.5 68.6	A A	0 0	0	0	0	0 4
FAM PRACT	1.078	67.6	Ä	1	4 12	0	0 7	20
CURR MED RES OPIN	1.000	66.7	Â	0	0	0	ó	0
DAN MED BULL	0.914	65.7	В	ŏ	0	Ö	ŏ	ŏ
AM FAM PHYSICIAN	0.888	64.8	B	ő	ő	ŏ	ĭ	ĭ
CLEV CLIN J MED	0.827	63 8	B	ŏ	ő	2	ò	2
DEUT MED WOCHENSCHR	0.788	62.9	В	Ö	ĭ	ō	ŏ	1
J ROY COLL PHYS LOND	0.759	61.9	В	0	2	0	0	2
MED CLIN BARCELONA	0.750	61.0	В	0	0	0	0	0
POSTGRAD MED	0.722	60.0	В	0	0	0	0	0
NETH J MED	0.721	59.0	В	0	0	0	0	0
PRIMARY CARE	0.720	58.1	В	0	0	0	0	0
AVIAT SPACE ENVIR MD WESTERN J MED	0.658	57.1	В	0	0	0	0	0
INTERNAL MED	0.643	56.2	В	1	5	0	0	6
AM J MANAGE CARE	0.643 0.642	55.2	B B	0	0	0	3	3
MT SINAI J MED	0.628	54.3 53.3	B B	0	0	0	0	0
SCAND J PRIM HEALTH	0.611	52.4	В	0	0	0	0	0
SOUTHERN MED I	0.593	51.4	В	0 1	0	0 1	0 6	0 8
AM J CHINESE MED	0.583	50.5	В	27	10	2	135	174
INT I CLIN PRACT	0.579	49.5	B	0	15	5	7	27
WIEN KLIN WOCHENSCHR	0.572	48.6	B	ŏ	0	Ö	ó	ő
J NATL MED ASSOC	0.555	47.6	B	ŏ	ŏ	Ö	ő	ŏ
DM DIS MON	0.548	46.7	B	ŏ	ŏ	ő	ŏ	ŏ
MIL MED	0.512	45.7	В	2	ŏ	10	ŏ	12
SCOT MED J	0.488	44.8	В	1	Õ			2


(continued)

(COntinued)	-		The second property with the property and		construction and on the sec-			manthiana was
Subject Category, Area	Impact	Adjusted	Publication	China	HK	SNG	TW	Total
Medicine, General and Internal	Factor	IF (%)	Туре	n	n	n	n	n
S AFR MED J	0.461	43.8	В	0	0	0	4	4
IPN I MED SCI BIOL	0.444	42.9	В	4	Ō	Ō	6	10
PRESSE MED	0.441	41.9	В	0	0	0	0	0
ann med interne	0.420	41.0	В	0	0	0	0	0
AUST NZ J MED	0.413	40.0	В	0	14	10	1	25
HOSP PRACT	0.412	39.0	В	0	0	0	0	0
CAN FAM PHYSICIAN	0.407	38.1	В	0	1	0	0	1
MED PROBL PERFORM AR	0.397	37.1	В	0	0	0	0	O
J WOMEN HEALTH GEN B	0.395	36.2	В	0	0	0	1	1
MED KLIN	0.390	35.2	В	0	0	0	0	0
Indian J med res	0.383	34.3	В	0	0	0	0	0
acta clin belg	0.381	33.3	В	0	0	0	0	0
REV MED INTERNE	0.375	32.4	С	0	0	0	0	0
IRISH J MED SCI	0.353	30.5	C	0	0	0	0	0
J FORMOS MED ASSOC	0.353	31.4	C	4	0	0	2009	2013
HOSP MED	0.348	29.5	C	0	9	1	0	10
medicina buenos aire	0.345	28.6	C	0	0	0	0	0
J URBAN HEAITH	0.345	27.6	C	0	0	0	0	0
POSTGRAD MED J	0.339	26.7	C	1	66	2	9	78
natl med J India	0.333	25. <i>7</i>	С	0	1	0	0	1
YONSEI MED J	0.332	24.8	С	1	0	0	0	1
TOHOKU J EXP MED	0.328	23.8	С	0	0	0	1	1
REV MED CHILE	0.290	22.9	С	0	0	0	0	0
IRISH MED J	0.280	21.9	C	0	0	0	0	0
INTERNIST	0.277	21.0	C	0	0	0	0	0
J ROY SOC MED	0.270	20.0	Ç	0	3	2	0	5
SCHWEIZ MED WSCHR	0.258	19.0		1	1	0	0	2
E AFR MED J	0.199	15.2	C	2	0	0	0	2_
CHINESE MED J PEKING	0.107	5.7	C	470	81	2	24	5 <i>77</i>
Total				540	333	63	2292	3228



Number of full papers (with impact factor) in Medline





Microbiology subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).

Journals sorted according to the impact factor provided by the *Journal Citation Reports* (JCR) 2000 version for Microbiology JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category: a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW).

Subject Category, Area Microbiology	Impact Factor	Adjusted IF (%)	Publication Type	China n	HK n	SNG n	TW n	Total n
MICROBIOL MOL BIOL R	20.639	100.0	Α	0	0	0	0	0
CLIN MICROBIOL REV	12.141	98.8	Α	0	1	0	0	1
ANNU REV MICROBIOL	9.238	97.6	Α	0	0	0	0	0
FEMS MICROBIOL REV	6.367	96.4	Α	0	0	0	0	0
MOL MICROBIOL	6.339	95.2	Α	2	0	3	11	16
ADV MICROB PHYSIOL	6.095	94.0	Α	0	0	0	0	0
TRENDS MICROBIOL	6.006	92.8	Α	0	0	1	0	1
CURR OPIN MICROBIOL	5.435	91.6	A	Q	0	0	0	0
ANTIMICROB AGENTS CH	3.954	90.4	A	0	0	0	0	0
J BACTERIOL	3.506	89.2	A	7	1	11	37	56
J CLIN MICROBIOL	3.503	88.0	Ą	23	39	8	91	161
CURR TOP MICROBIOL	3.463	86.7	Ą	1	0	0	0	1
CELL MICROBIOL	3.409	85.5	Ą	0	0	Ō	0	0
APPL ENVIRON MICROB	3.389	84.3	Ą	5	7	9	26	47
MICROB DRUG RESIST	3.263	83.1	Ą	0	0	ō	1	1
CLIN INFECT DIS	2.972	81.9	A	4	16	5	50	75
J ANTIMICROB CHEMOTH	2.964	80.7	Ą	0	0	0	0	0
YEAST	2.825	79.5	A	0	0	0	1	1
ENVIRON MICROBIOL	2.740	78.3	A	0	0 3	0 11	0 1 <i>7</i>	0 31
MICROBIOL UK	2.732	77.1	A	0	0	0	0	0
MICROBIAL ECOL	2.703	75.9	A	0	0	0	0	0
EXTREMOPHILES	2.688	74.7	A A	15	ő	5	5	25
INT J SYST BACTERIOL	2.675 2.639	73.5 72.3	Ä	1	3	1	0	5
HELICOBACTER	2.555	71.1	Â	3	ő	Ó	ő	3
ANTON LEEUW INT J G	2.439	69.9	Â	Ö	ő	ő	ŏ	ő
FEMS MICROBIOL ECOL PROTIST	2.351	68.7	Â	ő	ő	Ö	ŏ	ŏ
MICROB PATHOGENESIS	2.144	67.5	Ä	ő	ŏ	ŏ	6	6
SYST APPL MICROBIOL	2.060	66.3	B	1	ŏ	ŏ	ŏ	1
ARCH MICROBIOL	2.056	65.1	В	i	Ö	ĭ	5	ż
DIAGN MICR INFEC DIS	1.932	63.9	В	4	12	ó	29	45
CRIT REV MICROBIOL	1.917	62.7	B	Ó	0	Ō	0	0
INT J FOOD MICROBIOL	1.848	61.4	B	Ö	Õ	0	15	15
CLIN DIAGN LAB IMMUN	1.796	60.2	B	3	4	3	3	13
APMIS	1.713	59.0	В	Ó	1	0	0	1
MED MICROBIOL IMMUN	1.672	57.8	В	0	0	1	0	1
RES MICROBIOL	1.631	56.6	В	1	2	1	0	4
I MED MICROBIOL	1.625	55.4	В	4	12	5	11	32
FEMS MICROBIOL LETT	1,615	54.2	В	10	3	20	17	50
J EUKARYOT MICROBIOL	1.519	53.0	В	0	0	0	2	2
J MICROBIOL METH	1.512	51.8	В	1	1	0	1	3
J APPL MICROBIOL	1.511	50.6	В	6	2	4	13	25
VET MICROBIOL	1.428	49.4	В	0	0	0	0	0
ORAL MICROBIOL IMMUN	1.419	48.2	В	1	4	0	1	6
JANTIBIOT	1.347	47.0	В	0	0	0	0	0
EUR J CLIN MICROBIOL	1.337	45.8	В	0	3	1	12	16
FOOD MICROBIOL	1.272	44.6	В	0	0	0	0	0
FEMS IMMUNOL MED MIC	1.244	43.4	В	1	0	1	0	2
LETT APPL MICROBIOL	1.154	42.2	В	7	0	2	13	22
INT J ANTIMICROB AG	1.141	41.0	В	0	0	0	1	1
INT J LEPROSY	1.114	39.8	В	0	Ŏ	0	0	0
CAN J MICROBIOL	1.105	38.6	В	0	0	3	8	11
MICROBES INFECT	1.101	3 <i>7</i> .3	В	Ō	0	0	0	0
J MICROBIOL BIOTECHN	1.083	36.1	В	0	0	0	0	0
MICROBIOL IMMUNOL	1.070	34.9	В	10	0	0	16	26
B I PASTEUR	1.045	33.7	B	0	0	0	0	0
CURR MICROBIOL	1.029	32.5	Ç	13	0	0	26	39
ADV MICROB ECOL	1.000	31.3	Č	0	0	0	0	0
COMP IMMUNOL	0.902	30.1	Ċ C	0	0	0	1 0	1
MICROB	0.891	28.9	Ĺ	0	U	U	U	0

(continued)

Subject Category Area	Impact	Adjusted	Publication	China	НК	SNG	TW	Total
Microbiology	Factor	IF (%)	Туре	n	n	n	n	n
EUR J PROTISTOL	0 813	27 7	C	0	0	0	0	0
REV MED MICROBIOL	0 <i>7</i> 78	26 5	C	O.	0	0	0	0
FOLIA MICROBIOL	0 <i>7</i> 52	25 3	Č	O	Ŏ	0	1	1
ACTA PROTOZOOL	0 737	24 1	Ç	Ö	Ü	0	Ŏ	0
ASM NEWS	0 61 <i>7</i>	22 9	Ç	Ö	Ŏ	0	O O	0
I BASIC MICROB	0 613	21 <i>7</i>	Ç	Õ	0	0	2	2
ZBL BAKT INT J MED M	0 599	20 5	Č	O O	l	0	Ö	Ţ
I GEN APPL MICROBIOL	0 573	19 3	Č	O O	ō	0	0	0
MICROBIOS	0 508	18 1	C	0	5	6	18	29
METHOD MICROBIOL	0 484	16 9	Ç	O	O O	0	0	0
MICROBIOLOGICA	0 422	15 7	Č	O O	Õ	0	Õ	Õ
anaerobe	0 410	14 5	Č	0	Ō	0	0	0
J ENDOTOXIN RES	0 388	13 3	C	Õ	Ŏ	0	0	Ü
MICROBIOL RES	0 382	120	C	Ŏ.	Ŏ	0	ļ	1
MICROBIOLOGY+	0 338	10 8	C	0	Û	Ü	Ü	0
INT J SYST EVOL MICR	0 305	9 6	Č	8	Ŏ	3	1	12
APPL BIOCHEM MICRO+	0 244	7 2	Č	0	Ŏ	0	Ü	0
ZBL HYG UMWEITMED	0 244	8 4	Č	O O	Ŏ	0	Ŏ	Ů.
ANN MICROBIOL	0 237	6.0	C	Õ	Ŏ	0	0	0
J MICROBIOL	0 185	4 8	Č	O	Ō	0	Û	Ũ
INT J MED MICROBIOL	0 125	3 6	Ç	0	0	0	0	Ü
ADV APPL MICROBIOL	0 111	2 4	C	0	1	0	Ü	1
REV MICROBIOL	0 073	1 2	C	0	0	0	0	U
Total				132	121	105	442	800

Neurosciences


Number of full papers (with impact factor) in Medline


Three year groups

China Hong Kong Singapore Taiwa

12 year period - 1990 to 2001


China Hong Kong Singapore Taiwan






Three year groups

CUHK HKU Academia Othe



12 year period - 1990 to 2001

CUHK HKU Academia Other



Neurosciences subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).

Journals sorted according to the impact factor provided by the *Journal Citation Reports* (JCR) 2000 version for Neurosciences JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category: a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW).


Subject Category, Area Neurosciences	Impact Factor	Adjusted IF (%)	Publication Type	China n	HK n	SNG n	TW n	Total n
ANNU REV NEUROSCI	26.676	100.0	А	0	0	0	0	0
TRENDS NEUROSCI	17.417	99.5	Α	Ō	0	0	0	0
NEURON	15.081	99.0	Ą	0	0	1	3	4
BEHAV BRAIN SCI	14.250	98.5	Ą	0	0	0	0	0
NAT NEUROSCI	12.636	98.0	A	0 0	1 0	0	1	1
PROG NEUROBIOL	9.933	97.5 97.0	A A	0	ŏ	Ő	ó	ó
CURR OPIN NEUROBIOL	9.277 9.212	96.6	Ä	ĭ	2	Õ	ŏ	š
BRAIN RES REV MOL PSYCHIATR	8.927	96.1	Ä	Ö	ō	Ŏ	ĩ	ī
I NEUROSCI	8.502	95.6	A	3	2	1	12	18
ANN NEUROL	8.480	95.1	Α	2	0	1	6	9
FRONT NEUROENDOCRIN	8.375	94.6	Ą	0	0	Ö	0	0
CRIT REV NEUROBIOL	7.778	94.1	Ą	0	0	0 0	0	0 0
BRAIN	7.303	93.6 93.1	A A	0 0	0 1	0	0	1
NEUROIMAGE	6.857 6.435	93.1	Â	Õ	Ó	ŏ	ŏ	ò
BRAIN PATHOL I CEREBR BLOOD F MET	5.926	92.1	Â	ŏ	ŏ	ŏ	5	5
MOL CELL NEUROSCI	5.746	91.6	Â	ĭ	8	Ŏ	Õ	9
I NEUROPATH EXP NEUR	5,565	91.1	A	0	0	0	1	1
NEUROBIOL DIS	5.333	90.6	Α	0	0	0	0	0
HUM BRAIN MAPP	5.163	90.1	Ą	1	0	0	0	1
I COGNITIVE NEUROSCI	5.115	89.7	Ą	0	0	0	0	0
INEUROCHEM	4.900	89.2	A	6	18	1	52 0	77 4
CEREB CORTEX	4.822	88.7	A A	4 2	0	0	2	4
HIPPOCAMPUS	4.683 4.579	88 2 87,7	Ä	Ó	0	0	Ó	Õ
NEUROPSYCHOPHARMACOL MOL NEUROBIOL	4,382	87.7 87.2	Â	ő	1	ŏ	ŏ	1
PAIN FORUM	4.320	86.7	Â	ŏ	ò	ŏ	ŏ	Ó
BIOL PSYCHIAT	4.269	86.2	A	Ō	Ö	0	0	0
NEUROBIOL AGING	4.159	85 <i>7</i>	Α	1	0	0	0	1
NEUROPHARMACOLOGY	4.125	85.2	Α	0	0	0	0	Ō
LEARN MEMORY	4.011	84.7	Ą	3	0	0	1	4
GLIA	3.932	84 2	Ą	1	4	4 0	7 8	16 25
EUR J NEUROSCI	3.862	83 <i>7</i> 83 3	A A	12 1	5 2	4	12	19
EXP NEUROL J NEUROPHYSIOL	3.858 3.855	03 3 82 8	Ä	1	0	Õ	0	1
PAIN	3.853	82 3	Ä	14	ő	1	10	25
PINEAL RES	3.779	81 8	Ä	0	ŏ	ò	0	0
COMP NEUROL	3.772	81 3	A	ō	Ĩ	Ō	0	1
NEUROSCIENCE	3.563	80 8	Α	31	21	15	42	109
EVOKED POTENTIAL	3.470	80 3	Ą	0	0	0	0	0
NEUROBIOL	3.465	79.8	Ą	2	0	0	1	3 22
SYNAPSE	3.402 3.400	79 3 78.8	A A	2 0	0	0	20 1	1
REV NEUROSCI NEUROVIROL	3.397	78.3	Ä	0	0	0	Ó	Ó
NEUROSCI BIOBEHAV R	3.382	77.8	Ä	Õ	ŏ	í	ŏ	ĭ
NEUROIMMUNOL	3.355	77.3	Ä	4	Ŏ	Ó	4	8
NEUROSCI RES	3.207	76.8	A	11	5	4	13	33
CURR OPIN NEUROL	3.176	76.4	Α	0	0	0	0	0
NEUROBIOL LEARN MEM	3.040	75.9	Ą	0	0	0	0	0
PSYCHONEUROENDOCRINO	3.008	75.4	Ą	0	0	0	1	1
NT REV NEUROBIOL NEUROTRAUM	2.944	74.9	A	0	0	0	0	0
PSYCHOPHARMACOLOGY	2.877 2.804	74.4 73.9	A A	0 0	1 0	1 0	0 0	2 0
NEUROPSYCHOLOGIA	2.778	73.9	Â	1	0	0	2	3
BEHAV NEUROSCI	2.751	72.9	Ä	ó	ő	Ö	ī	í
NEUROENDOCRINOLOGY	2.744	72.4	Ä	9	15	1	14	39
COGNITIVE BRAIN RES	2.733	71.9	Â	ó	Õ	ó	0	0
NEUROMUSCULAR DISORD	2.718	71.4	Ä	ĺ	ĭ	ŏ	1	3
NEUROPSYCHOLOGY	2.702	70.9	Α	0	0	Ó	1	1
NEUROIMMUNOMODULAT	2.701	70.4	A	5	0	0	0	5
NEUROREPORT	2.696	70.0	Ą	67	31	10	28	136
NEUROCHEM INT MOL BRAIN RES	2.662	69.5	A	3	5	1	9	18
YIOL DRAIN RES	2.622	69.0	Α	7	3	4	12	26


(continued)

(continued)								
Subject Category Area	Impact	Adjusted	Publication	China	НК	SNG	TW	Total
Neurosciences	Factor	IF (%)	Туре	<u>n</u>	n	n	n	<u>n</u>
•	Impact Factor 1 038 1 0908 0 955 0 952 0 942 0 939 0 911 0 896 0 866 0 836 0 805 0 807 0 667 0 667 0 667 0 667 0 631 0 630 0 538 0 527 0 514 0 507 0 486 0 387 0 374 0 365 0 444 0 387 0 374 0 365 0 278 0 296 0 278 0 262 0 258 0 279 0 262 0 258 0 279 0 162 0 156 0 157 0 106 0 103 0 106 0 103 0 099 0 087 0 065 0 051	Adjusted IF (%) 33 5 33 5 33 7 30 32 5 31 0 30 0 6 29 1 28 6 29 1 28 6 29 1 26 1 6 20 27 1 6 21 27 20 2 7 21 27 20 7 21 19 7 21 16 3 8 21 1 3 8 21	Publication Type B C C C C C C C C C C C C C C C C C C	China n 1 4 0 0 0 0 1 0 0 0 1 0 0 1 0 0 1 0 0 1 0 0 0 1 0	HK n 0 0 0 0 1 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0	SNG n 011000000000000000000000000000000000	TW n 1 33 2 1 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Total n 2 388 3 1 1 1 5 0 0 1 1 2 0 0 0 1 1 0 0 0 1 1 0 0 0 0 0
CONFIN CEPHALALGICA ACTA NEUROPSYCHIATR NEUROPHYSIOLOGY+	0 045 0 036 0 027	2 5 2 0 1 5	C C	0	0	0 0 0	0	0
AUTON NEUROSCI BASIC GIORN NEUROPSICOFARM	0 012 0 000	1 0 0 5	C	1 0	0	0	7 0	8 0
Total				705	295	169	788	195 <i>7</i>

Nutrition and Dietetics

Number of full papers (with impact factor) in Medline






Nutrition and Dietetics subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).


Journals sorted according to the impact factor provided by the Journal Citation Reports (JCR) 2000 version for Nutrition and Dietetics JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category: a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW).

ANNU REV NUTR PROG LIPID RES AM J CLIN NUTR OBES RES NUTR REV INT J OBESITY J NUTR CRIT REV FOOD SCI	7.071 5.379 5.012 4.656 3.126 2.982 2.913 2.730 2.415 2.330	100.0 98.0 96.1 94.1 92.2 90.2 88.2 86.3 84.3	Type A A A A A A	0 0 9 0 3 0 4	0 1 4 0 0 6	0 0 3 0 3 3	0 0 6 1 0	0 1 22 1 6
PROG LIPID RES AM J CLIN NUTR OBES RES NUTR REV INT J OBESITY J NUTR CRIT REV FOOD SCI	5.379 5.012 4.656 3.126 2.982 2.913 2.730 2.415 2.330	98.0 96.1 94.1 92.2 90.2 88.2 86.3	A A A A	0 9 0 3 0	1 4 0 0 6	0 3 0 3	0 6 1	1 22 1
AM J CLIN NUTR OBES RES NUTR REV INT J OBESITY J NUTR CRIT REV FOOD SCI	5.012 4.656 3.126 2.982 2.913 2.730 2.415 2.330	96.1 94.1 92.2 90.2 88.2 86.3	A A A A	9 0 3 0	4 0 0 6	3 0 3	6 1	22 1
OBES RES NUTR REV INT J OBESITY J NUTR CRIT REV FOOD SCI	4.656 3.126 2.982 2.913 2.730 2.415 2.330	94.1 92.2 90.2 88.2 86.3	A A A	0 3 0	0 0 6	0	1	1
NUTR REV INT J OBESITY J NUTR CRIT REV FOOD SCI	3.126 2.982 2.913 2.730 2.415 2.330	92.2 90.2 88.2 86.3	A A A	3 0	0 6	3		
INT J OBESITY J NUTR CRIT REV FOOD SCI	2.982 2.913 2.730 2.415 2.330	90.2 88.2 86.3	A A	0	6		0	6
J NUTR CRIT REV FOOD SCI	2.913 2.730 2.415 2.330	88.2 86.3	Α	-	-	2		ъ
CRIT REV FOOD SCI	2.730 2.415 2.330	86.3		Δ)	8	17
	2.415 2.330		À		9	0	34	47
	2.330	84.3	Α	0	0	0	0	0
BRIT J NUTR			Α	6	5	2	6	19
P NUTR SOC	2 1 7 1	82.4	Α	0	1	0	0	1
EUR J CLIN NUTR	2.171	80.4	Α	6	14	1	2	23
NUTR RES REV	2.160	78.4	Α	0	0	0	0	0
EUR J NUTR	2.059	76.5	Α	0	1	0	0	1
NUTR CANCER	2.016	74.5	Α	0	0	0	0	0
LIPIDS	1.769	72.5	Α	1	21	1	6	29
JPEN PARENTER ENTER	1.580	70.6	Α	4	1	0	11	16
J PEDIATR GASTR NUTR	1.580	68.6	Α	0	0	0	0	0
J AM COLL NUTR	1.564	66.7	Α	1	1	0	9	11
NUTRITION	1.509	64.7	В	5	1	0	11	17
CLIN NUTR	1.387	62.7	В	1	0	0	4	5
REPROD NUTR DEV	1.351	60.8	В	0	0	1	0	1
INT J EAT DISORDER	1.336	58.8	В	0	1	0	0	1
INT J VITAM NUTR RES	1.299	56.9	В	0	0	0	5	5
FOOD REV INT	1.237	54.9	В	0	Ö	Ō	Ö	0
INT J SPORT NUTR	1,222	52.9	В	Õ	Õ	Õ	Ö	Õ
APPETITE	1.217	51.0	В	Õ	1	Õ	ő	1
Z ERNAHRUNGSWISS	1.179	49.0	В	1	ò	ő	Ö	i
J AM DIET ASSOC	1.142	47 1	В	i	1	1	4	7
J NUTR BIOCHEM	1.083	45.1	В	Ö	ò	ò	Ö	Ó
DIABETES NUTR METAB	0.964	43.1	В	ő	Õ	Õ	1	1
NUTR METAB CARDIOVAS	0.959	41.2	В	Õ	Ö	0	ò	ò
FOOD CHEM	0 921	39.2	B	Ő	0	Ö	Ö	ő
BIOL TRACE ELEM RES	0.786	37.3	В	74	11	7	36	128
FOOD DRUG LAW I	0 771	35.3	B	0	0	ó	0	0
NUTR RES	0.716	33.3	В	0	0	0	0	0
ANN NUTR METAB	0.655	31.4	Č	0	0	0	0	0
J NUTR SCI VITAMINOL	0.653	29 4	Č	1	0	0	9	10
INT I FOOD SCI NUTR	0.545	27.5	Č	Ó	3	1	1	5
ECOL FOOD NUTR	0.375	25.5	Ċ	0	0	Ó	0	0
FOOD POLICY	0.375	23.5	Ċ	0	0	0	0	0
I NUTR EDUC	0.298	21.6	C	0	-	0		0
I HUM NUTR DIET	0.275	19.6	C		0	_	0	
ACTA ALIMENT HUNG	0.246	17.6	C	0	0	0	0	0
ERNAHRUNGS UMSCHAU	0.213	17.6	C	-	0	0	0	-
J CLIN BIOCHEM NUTR	0.189	13.7	C	0	0	0	0	0
NIPPON NOGEIK KAISHI	0.169	11.8	C	0	0	0	0	0
PLANT FOOD HUM NUTR	0.132			0	0	0	0	0
OCL OL CORPS GRAS LI	0.133	9.8	C	0	0	0	0	0
ARCH LATINOAM NUTR	0.108	7.8 F.0	C	0	0	0	0	0
CAN J DIET PRACT RES	0.101	5.9 3.9	C C	0	0	0	0	0 0
Total	0.001	3.5	C	117	82	23	154	376

Obstetrics and Gynecology

Number of full papers (with impact factor) in Medline






Obstetrics and Gynecology subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).

Journals sorted according to the impact factor provided by the *Journal Citation Reports* (JCR) 2000 version for Obstetrics and Gynecology JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW)

alle deletele and security processing proces	manufer higher anything appears common				art shilling the support the shifter of			
Subject Category Area	Impact	Adjusted	Publication	China	HK	SNG	TW	Total
Obstetrics and Gynecology	Factor	IF (%)	Туре	<u>n</u>	n	<u>n</u>	<u>n</u>	n
HUM REPROD	2 997	100 0	Α	0	0	0	0	0
hum reprod update	2 887	98 2	Α	0	0	1	0	1
FERTIL STERIL	2 854	96 5	Α	0	0	0	0	0
PLACENTA	2 587	94 7	Α	0	1	0	0	1
AM J OBSTET GYNECOL	2 519	93 0	Α	1	11	2	22	36
BRIT J OBSTET GYNAEC	2 349	91 2	Α	1	21	10	9	41
MENOPAUSE	2 273	89 5	Α	0	0	0	1	1
J SOC GYNECOL INVEST	2 184	87 <i>7</i>	Α	0	1	0	0	1
OBSTET GYNECOL	2 091	86 0	Ą	4	13	12	28	57
GYNECOL ONCOL	1 972	84 2	A	0	0	0	0	0
SEMIN REPROD ENDOCR	1 952	82 5	A	0	0	0	0	0
SEMIN PERINATOL	1 808	80 7	Ą	0	1	0	0	1
ULTRASOUND OBST GYN	1 725	78 9	A	0	0	0	1	1
CONTRACEPTION	1 704	77 2 75 4	A	62	14	15	2	93
PRENATAL DIAG INT J GYNECOL PATHOL	1 647 1 508	75 4 73 7	A	1	26	3	62	92
I ASSIST REPROD GEN	1 416	73 / 71 9	A A	0 1	0 9	0 6	1 31	1 47
MATURITAS	1 402	70 2	Ä	Ó	7	6	1	14
CURR OPIN OBSTET GYN	1 387	68 4	Â	0	3	5	Ó	8
CLIN PERINATOL	1 360	66 7	Ä	0	Ö	1	0	1
INT J OBSTET ANESTH	1 274	64 9	В	0	Ö	ò	Ő	ó
I AM ASSOC GYN LAP	1 268	63 2	B	ő	2	ő	30	32
PAEDIATR PERINAT EP	1 265	61 4	B	ő	ī	ő	0	1
BIRTH ISS PERINAT C	1 250	59 6	В	ŏ	i	ő	Ŏ	i
GYNECOL ENDOCRINOL	1 107	57 9	B	1	ò	4	3	8
ACTA OBSTET GYN SCAN	1 028	56 1	В	2	34	5	54	95
ARCH GYNECOL OBSTET	1 000	54 4	В	0	9	Õ	7	16
EARLY HUM DEV	0 982	52 6	В	0	0	0	0	0
J PERINAT MED	0 950	50 9	В	0	1	0	0	1
BAILLIERE CLIN OB GY	0 944	49 1	В	0	1	0	0	1
FETAL DIAGN THER	0 879	47 4	В	0	0	1	8	9
J REPROD MED	0 820	45 6	В	1	9	0	54	64
CLIN OBSTET GYNECOL	0 810	43 9	В	0	0	0	0	0
HYPERTENS PREGNANCY	0 750	42 1	В	0	1	0	0	1
EUR J OBSTET GYN R B OBSTET GYN CLIN N AM	0 703	40 4	В	0	0	0	0	0
INT J GYNECOL CANCER	0 670	38 6	В	0	0	0	0	0
GYNECOL OBSTET INVES	0 663 0 662	36 8	В	0	0	0	1	1
INT J FERTIL WOMEN M	0 633	35 1 33 3	B B	2	35	13	17	67
AM J PERINAT	0 616	31 6	Č	1 0	1	1	1	4 1
BREAST	0 588	29 8	C	0	0 0	0 0	1 0	Ó
EUR J GYNAECOL ONCOL	0 551	28 1	Ċ	0	1	0	0	1
ANN CHIR GYNAECOL	0 550	26 3	č	0	i	0	Ö	1
PRENAT NEONAT MED	0 544	24 6	č	Ö	Ó	Ö	0	ò
J PSYCHOSOM OBST GYN	0 529	22 8	č	Ö	1	Ö	ő	1
AUST NZ J OBSTET GYN	0 523	21 1	č	Ő	83	40	Õ	123
ADV CONTRACEPT	0 509	19 3	Č	Ŏ	0	0	Ö	0
INT J GYNECOL OBSTET	0 490	17 5	C	16	18	17	54	105
GYNAECOL ENDOSC	0 485	15 8	С	0	0	0	0	0
J MATERN FETAL INVES	0 400	14 0	C	0	Ō	Ö	Õ	0
J WOMEN HEALTH GEN B	0 395	12 3	С	0	0	Ó	1	1
Z GEBURTSH NEONATOL	0 248	10 5	С	0	0	0	0	0
GYNAKOL GEBURT RUNDS GYNAKOLOGE	0 228	8 8	C	0	0	0	0	0
GEBURTSH FRAUENHEILK	0 206	70	Ç	0	0	0	0	0
CONTRACEPT FERTIL S	0 204	5 3	C	0	0	0	0	0
BEST PRACT RES CL OB	0 171	3 5	C	0	0	0	0	0
DEST FRACTINES OF OD	0 128	18	С	0	0	0	0	0
Total				93	306	142	200	930
				73	300	142	389	730

Oncology

Number of full papers (with impact factor) in Medline






Figure. Oncology subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).


Journals sorted according to the impact factor provided by the *Journal Citation Reports* (JCR) 2000 version for Oncology JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category: a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW). About 10 of the journals with the lowest IF with no publications have been omitted in the list.


Subject Category, Area	Impact	Adjusted	Publication	China	НК	SNG	TW	Total
Oncology	Factor	IF (%)	Туре	n	n	n	n	n
CA CANCER J CLIN	24.674	100.0	Α	0	0	0	0	0
ADV CANCER RES	21.680	99.0	Α	0	0	0	0	Ō
J NATL CANCER I	14.159	98.1	Α	7	2	1	6	16
J CLIN ONCOL	8.773	97.1	Ą	1	20	0	14	35
CANCER RES	8.460	96.1	Ą	10	23	6	66	105
ONCOGENE SEA VIA GANGER BIOL	6.490	95.1	Ą	2	18	5	26	51
SEMIN CANCER BIOL	5.841	94.2	A	0	0	1	0	1
CLIN CANCER RES GENE CHROMOSOME CANC	4.643 4.534	93.2 92.2	A A	2 5	11 6	6 1	17	36
CANCER EPIDEM BIOMAR	4.354	91.3	Â	3 1	0	Ó	8 0	20 1
CANCER GENE THER	4.151	90.3	Ä	4	ő	Ö	3	7
CARCINOGENESIS	4.031	89.3	Â	16	7	8	32	63
INT J CANCER	3.918	88.3	Ä	42	32	16	58	148
EXP CELL RES	3.860	87.4	Ä	1	4	4	15	24
LEUKEMIA	3 736	86.4	Α	12	10	0	12	34
BRIT J CANCER	3.489	84.5	Α	11	18	13	58	100
SEMIN ONCOL	3.365	83.5	Α	0	1	2	0	3
CANCER METAST REV	3.325	82.5	Α	0	0	0	0	0
ANN ONCOL	3.249	81.6	A	Ō	1	4	3	8
MOL CARCINOGEN INT I RADIAT ONCOL	3.104	80.6	Ą	0	0	0	15	15
J IMMUNOTHER	3 058	79.6	Ą	0	0	0	0	0
STEM CELLS	3.027 2.989	78.6	A	0	0	0	0	0
CRIT REV ONCOGENESIS	2.852	77.7 76.7	A A	1 1	0	0	1	2 1
STRAHLENTHER ONKOL	2.846	75.7 75.7	Â	Ó	0	0	0	0
CANCER IMMUNOL IMMUN	2.820	74.8	Ä	2	1	0	2	5
ANN SURG ONCOL	2 799	73.8	Ä	ō	Ó	1	0	1
EUR J CANCER	2.725	72.8	Ä	3	11	4	19	37
BREAST CANCER RES TR	2.720	71.8	A	4	2	i	10	17
ONCOLOGY BASEL	2.584	70.9	Α	4	15	i	22	42
RADIOTHER ONCOL	2.469	69.9	Α	0	1	0	0	1
CANCER CAUSE CONTROL	2.464	68.9	Α	1	0	0	0	1
SEMIN RADIAT ONCOL	2.427	68.0	A	0	0	0	0	0
BONE MARROW TRANSPL INT J ONCOL	2.396	67.0	A	0	0	0	1	1
JPN J CANCER RES	2.142	66.0	В	6	9	10	8	33
CANCER CHEMOTH PHARM	2.120 2.081	65.0 64.1	B B	6	0	1	17	24
CANCER TREAT REV	2.053	63.1	В	0 0	0	0	0	0
NUTR CANCER	2.016	62.1	В	5	0 2	0	0 15	0 22
CURR PROB CANCER	2.000	61.2	B	ő	0	0	0	0
HEMATOL ONCOL CLIN N	1.979	60.2	B	Ö	ŏ	Ö	1	1
GYNECOL ONCOL	1.972	59.2	B	11	29	3	73	116
ANTI CANCER DRUG DES	1.93 <i>7</i>	58.3	В	0	0	Õ	1	1
MELANOMA RES	1.862	57.3	В	0	Ö	Ō	Ô	0
CLIN EXP METASTAS	1.845	56.3	В	4	0	0	1	5
CANCER SURV J CANCER RES CLIN	1.824	55.3	В	0	0	0	0	0
CANCER CYTOPATHOL	1.789	54.4	В	65	1	0	4	70
ORAL ONCOL	1.716 1.690	53.4	В	31	80	14	101	226
SEMIN SURG ONCOL	1.650	52.4 51.5	В	0	5	0	1	6
TUMOR BIOL	1.626	50.5	В	0	0	0	0	0
CANCER GENET CYTOGEN	1.625	49.5	B B	0 25	1	Õ	0	1 20
J NEURO ONCOL	1.581	48.5	В	25 3	82 1	5 2	17 12	129 18
ANTI CANCER DRUG	1.570	47.6	В	0	Ó	0	12	10
J SURG ONCOL	1.541	46.6	В	0	0	0	Ó	Ó
CANCER INVEST	1.527	45.6	B	Ö	2	1	7	10
CANCER LETT	1.517	44.7	B	26	31	19	100	176
ONCOL RES LEUKEMIA RES	1.508 1.502	43.7	В	2	1	Ö	2	5
		42.7	В	24				

Subject Category, Area	Impact	Adjusted	Publication	China	HK	SNG	TW	Total
Oncology	Factor	IF (%)	Туре	<u>n</u>	n	n	n	n
UR J SURG ONCOL	1.434	41.7	В	0	0	0	1	1
LUNG CANCER J IASLC	1.401	40.8	В	1	0	0	0	1
I PEDIAT HEMATOL ONC	1.387	39.8	В	0	0	0	1	1
EUR J CANCER PREV	1.351	38.8	В	11	0	0	0	11
ANTICANCER RES	1.331	3 <i>7.</i> 9	В	21	36	7	153	217
MED ONCOL	1.318	35.9	В	0	1	2	0	3
MED PEDIATR ONCOL	1.301	35.0	В	0	1	0	0	1
INT I BIOL MARKER	1.292	34.0	В	1	0	0	0	1
ONCOL REP	1.290	33.0	С	3	5	3	11	22
CANCER DETECT PREV	1.258	32.0	С	1	3	2	2	8
LEUKEMIA LYMPHOMA	1.252	31.1	C	3	16	4	9	32
ENDOCR RELAT CANCER	1.239	30.1	С	0	0	0	1	1
SUPPORT CARE CANCER	1.174	29.1	С	0	0	1	0	1
TERATOGEN CARCIN MUT	1.106	28.2	С	0	1	0	0	1
CRIT REV ONCOL HEMAT	1.019	26.2	C C	1	6	2	1	10
CANCER BIOTHER RADIO	0.989	24.3	С	0	0	0	1	1
AM I CLIN ONCOL CANC	0.952	22.3	С	7	2	2	24	35
ONCOLOGY NY	0.933	21.4	С	0	0	0	1	1
I CHEMOTHERAPY	0.921	20.4	С	0	1	0	0	1
ACTA ONCOL	0.908	19.4	C	1	5	5	5	16
JPN J CLIN ONCOL	0.786	18.4	С	2	0	0	52	54
HEMATOL ONCOL	0.692	17.5	С	0	31	0	0	31
INVAS METAST	0.677	15.5	С	1	0	0	0	1
INT I GYNECOL CANCER	0.663	14.6	С	1	0	0	2	3
PEDIATR HEMAT ONCOL	0.601	10. <i>7</i>	С	0	0	0	1	1
NEOPLASMA	0.579	8.7	С	0	0	0	11	11
EUR I GYNAECOL ONCOL	0.551	7.8	С	0	1	0	6	7
LEXP CLIN CANC RES	0.540	6.8	С	14	0	0	0	14
TUMORI	0.485	5.8	С	2	0	0	1	3
SURG ONCOL	0.293	2.9	С	0	1	0	0	1
Total				408	542	157	1040	2147

Ophthalmology

Number of full papers (with impact factor) in Medline






Ophthalmology subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).


Journals sorted according to the impact factor provided by the *Journal Citation Reports* (JCR) 2000 version for Ophthalmology JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category: a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW).

Subject Category, Area	Impact	Adjusted	Publication	China	НК	SNG	TW	Total
Ophthalmology	Factor	IF (%)	Туре	n	n	n	n	n
PROG RETIN EYE RES	4.680	100.0	Α	0	1	0	0	1
INVEST OPHTH VIS SCI	4.373	97.6	A	1	13	4	9	27
OPHTHALMOLOGY	3.040	95.1	Α	8	12	17	8	45
SURV OPHTHALMOL	2,562	92.7	A	Ö	0	1	0	1
ARCH OPHTHALMOL CHIC	2.158	90.2	A	2	5	6	3	16
VISUAL NEUROSCI	2.149	87.8	Α	7	0	1	0	8
I CATARACT REFR SURG	2.071	85.4	A	0	0	1	0	1
I REFRACT SURG	2.061	82.9	Α	1	0	0	0	1
EXP EYE RES	2.014	80.5	A	3	1	0	2	6
VISION RES	2.000	78.0	A	1	4	0	1	6
BRIT I OPHTHALMOL	1.948	75.6	A	3	4	12	12	31
AM I OPHTHALMOL	1.941	73.2	A	6	6	11	15	38
CURR EYE RES	1.511	70.7	Ä	Ö	8	0	8	16
CORNEA	1.391	68.3	Ä	3	1	6	21	31
I GLAUCOMA	1.227	65.9	В	Ō	3	1	0	4
EYE	1.139	63.4	B	Ō	12	8	1	21
GRAEF ARCH CLIN EXP	1.112	61.0	B	7	4	0	2	13
OPTOMETRY VISION SCI	1.015	58.5	В	4	30	5	4	43
OCUL IMMUNOL INFLAMM	0.814	56.1	B	1	0	0	Ó	1
OPHTHALMIC SURG LAS	0.775	53.7	B	Ó	ŏ	Õ	Õ	Ö
OPHTHALMIC RES	0.773	51.2	B	3	1	0	6	10
I OCUL PHARMACOL TH	0.757	48.8	B	0	Ó	Õ	1	1
RETINA J RET VIT DIS	0.740	46.3	B	1	3	1	11	16
OPHTHALMIC PLAST REC	0.699	43.9	B	1	1	2	3	7
AUST NZ I OPHTHALMOL	0.578	41.5	B	3	1	10	2	16
CAN I OPHTHALMOL	0.543	39.0	B	0	1	0	3	4
EUR I OPHTHALMOL	0.541	36,6	В	Ō	Ó	0	0	0
OPHTHALMOLOGE	0.536	34.1	B	Õ	1	0	0	1
OPHTHAL PHYSL OPT	0.504	31.7	Č	Ö	40	Ō	Ō	40
OPHTHALMOLOGICA	0.494	29.3	č	4	1	1	10	16
ACTA OPHTHALMOL SCAN	0.490	26.8	č	1	3	3	7	14
JPN J OPHTHALMOL	0.479	24.4	č	2	1	1	8	12
I PEDIAT OPHTH STRAB	0.422	22.0	Č	0	0	0	1	1
I TOXICOL CUTAN OCUL	0.417	19.5	Č	Ō	0	0	0	0
KLIN MONATSBL AUGENH	0.406	17.1	č	Ō	0	0	0	0
NEURO OPHTHALMOLOGY	0.376	14.6	č	Ō	ō	0	0	0
I FR OPHTALMOL	0.318	12.2	č	Õ	Ö	0	0	0
I NEURO OPHTHALMOL	0.252	9.8	č	Ö	Ö	1	4	5
INT OPHTHALMOL CLIN	0.209	7.3	č	ŏ	ő	Ö	Ó	Ö
CLIN EXP OPHTHALMOL	0.084	4.9	Č	ő	ŏ	5	ŏ	5
ANN OPHTHALMOL	0.030	2.4	č	Ö	Ö	Ō	ō	Ō
-				62	157	97	142	458
Total				04	13/	7/	144	730

Orthopedics

Number of full papers (with impact factor) in Medline





Orthopedics subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).

Journals sorted according to the impact factor provided by the *Journal Citation Reports* (JCR) 2000 version for Orthopedics JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category: a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW).

Subject Category, Area	Impact	Adjusted	Publication	China	HK	SNG	TW	Total
Orthopedics	Factor	IF (%)	Туре	<u>n</u>	n	n	n	n
J ORTHOPAED RES	2.233	100.0	Α	0	3	0	9	12
J BONE JOINT SURG AM	2.222	97.4	Α	0	0	0	0	0
OSTEOARTHR CARTILAGE	2.080	94.9	Α	0	0	1	0	1
SPINE	1.843	92.3	Α	15	41	4	35	95
J BONE JOINT SURG BR	1.612	89.7	Α	0	0	0	0	0
J ORTHOP SPORT PHYS	1.424	87.2	Α	0	0	0	1	1
CLIN J SPORT MED	1.255	84.6	Α	0	0	0	0	0
PHYS THER	1.222	82.1	Α	0	0	0	1	1
ARTHROSCOPY	1.217	79.5	Α	0	0	0	0	0
CLIN ORTHOP RELAT R	1.182	76.9	Α	0	0	0	0	0
CLIN BIOMECH	1.056	74.4	Α	0	0	0	1	1
J ARTHROPLASTY	0.978	71.8	Α	1	10	1	15	27
ACTA ORTHOP SCAND	0.973	66.7	Α	2	1	5	24	32
J SHOULDER ELB SURG	0.973	69.2	Α	0	0	1	0	1
GAIT POSTURE	0.955	64.1	В	0	0	0	1	1
CONNECT TISSUE RES	0.952	61.5	В	0	1	0	0	1
ORTHOP CLIN N AM	0.874	59.0	В	0	0	0	0	0
J ORTHOP TRAUMA	0.843	56.4	В	0	0	0	0	0
J SPINAL DISORD	0.816	53.8	В	3	5	3	8	19
J HAND SURG AM	0.795	51.3	В	0	0	0	0	0
J PEDIATR ORTHOPED	0.636	48.7	В	0	0	0	0	0
HAND CLIN	0.571	46.2	В	0	0	1	8	9
ARCH ORTHOP TRAUM SU	0.507	43.6	В	0	0	0	1	1
J HAND SURG BRIT EUR	0.495	41.0	В	0	0	0	0	0
FOOT ANKLE INT	0.493	38.5	В	2	0	1	6	9
ISOKINET EXERC SCI	0.476	35.9	В	0	0	0	0	0
ORTHOPEDICS	0.472	33.3	В	2	1	0	6	9
Z ORTHOP GRENZGEB	0.446	30.8	C	0	0	0	0	0
INT ORTHOP	0.368	28.2	C	7	11	0	15	33
ORTHOPADE	0.364	25.6	С	0	0	0	0	0
NEURO ORTHOPEDICS	0.273	23.1	С	0	0	0	0	0
J BACK MUSCULOSKELET	0.261	20.5	С	0	0	0	0	0
KNEE	0.255	17.9	C	0	0	0	0	0
J PEDIATR ORTHOP B	0.217	15.4	С	1	0	0	0	1
REV CHIR ORTHOP	0.212	12.8	C	0	0	0	0	0
J AM PODIAT MED ASSN	0.189	10.3	С	0	0	0	0	0
PROSTHET ORTHOT INT	0.119	7.7	С	0	0	1	0	1
JNMS J NEUROMUSC SYS	0.103	5.1	С	0	0	0	0	0
CURR ORTHOPAED	0.099	2.6	С	0	0	0	0	0
Total				33	73	18	131	255

Otorhinolaryngology


Number of full papers (with impact factor) in Medline


Three year groups

China Hong Kong Singapore Taiwan

12 year period - 1990 to 2001

China Hong Kong Singapore Taiwan







Three year groups

UHK HKU Academia

12 year period - 1990 to 2001

CUHK HKU Academia Other






Otorhinolaryngology subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).


Journals sorted according to the impact factor provided by the *Journal Citation Reports* (JCR) 2000 version for Otorhinolaryngology JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category: a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW).

Subject Category, Area	Impact	Adjusted	Publication	China	НК	SNG	TW	Total
Otorhinolaryngology	Factor	IF (%)	Туре	n	n	n	n	n
AUDIOL NEURO OTOL	2.390	100.0	Α	0	0	0	1	1
HEAD NECK I SCI SPEC	1.917	96.6	Α	0	0	0	0	0
HEARING RES	1.753	93.1	Α	18	0	1	7	26
DYSPHAGIA	1.567	89.7	Α	0	0	1	0	1
ARCH OTOLARYNGOL	1.527	86.2	Α	0	0	0	0	0
EAR HEARING	1.506	82.8	Α	0	0	0	0	0
LARYNGOSCOPE	1.457	79.3	Α	15	10	0	24	49
AM J OTOL	1.199	75.9	Α	2	9	1	7	19
ANN OTO RHINOL LARYN	1.124	72.4	Α	19	4	3	28	54
I VESTIBUL RES EOUIL	1.116	69.0	Α	1	0	0	0	1
BRIT I AUDIOL	1.062	65.5	В	0	0	0	0	0
AM J RHINOL	1.021	62.1	В	1	0	2	7	10
OTÓLARYNG HEAD NECK	0.977	58.6	В	0	0	0	0	0
CLIN OTOLARYNGOL ALL	0.839	55.2	В	1	9	1	7	18
AUDIOLOGY	0.818	51.7	В	0	1	0	2	3
ACTA OTO LARYNGOL	0.812	48.3	В	15	3	2	12	32
SCAND AUDIOL	0.755	44.8	В	0	0	0	0	0
HNO	0.722	41.4	В	0	0	0	0	0
EUR ARCH OTO RHINO L	0.646	37.9	В	6	5	2	16	29
ORL I OTO RHINO LARY	0.624	34.5	В	7	0	3	6	16
LARYNGO RHINO OTOL	0.621	31.0	С	0	0	0	0	0
IVOICE	0.584	27.6	С	0	1	0	1	2
OTOLARYNG CLIN N AM	0.537	24.1	C	0	0	0	0	0
I LARYNGOL OTOL	0.482	20.7	C	17	48	34	20	119
INT I PEDIATR OTORHI	0.476	17.2	С	0	0	0	0	0
IOTOLARYNGOL	0.471	13.8	С	4	6	0	12	22
AM I OTOLARYNG	0.452	10.3	C	1	9	2	11	23
SKULL BASE SURG	0.185	6.9	C C	0	0	0	0	0
OTO RHINO LARYN NOVA	0.083	3.4	C	0	0	0	0	0
Total				107	105	52	161	425



Number of full papers (with impact factor) in Medline





Pathology subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).


Journals sorted according to the impact factor provided by the *Journal Citation Reports* (JCR) 2000 version for Pathology JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category: a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW).


AM J PATHOL BRAIN PATHOL J NEUROPATH EXP NEUR AM J SURG PATHOL LAB INVEST J PATHOL AM J CLIN PATHOL ACTA NEUROPATHOL ACTA NEUROPATHOL ACTA NEUROPATHOL ALZ DIS ASSOC DIS J SPRINGER SEMIN IMMUN ALZ DIS ASSOC DIS J CLIN PATHOL ALZ DIS ASSOC DIS J CLIN PATHOL ALZ DIS ASSOC DIS J COMP PATHOL APMIS VIRCHOWS ARCH J 1.713 VIRCHOWS ARCH DIAGN MOL PATHOL INT J GYNECOL PATHOL INT J GYNECOL PATHOL INT J GYNECOL PATHOL INT J LEGAL MED J ORAL PATHOL MED ACTA CYTOL VET PATHOL 1.362	100.0 98.5 97.0 95.5 94.0 92.5 91.0 89.6 88.1 86.6 85.1 83.6 82.1 80.6 79.1	A A A A A A A A A	0 0 3 0 0 2 0 5 2 3	13 0 3 0 5 10 15 37 40	1 0 0 0 0 5 1 2	10 0 4 0 17 11 3	24 0 10 0 22
NEUROPATH EXP NEUR	97.0 95.5 94.0 92.5 91.0 89.6 88.1 86.6 85.1 83.6 82.1 80.6	A A A A A A A	3 0 0 2 0 5 2	3 0 5 10 15 37	0 0 0 5	4 0 17 11	10 0 22
AM J SURG PATHOL LAB INVEST J PATHOL MODERN PATHOL AM J CLIN PATHOL 2.939 HUM PATHOL TISSUE ANTIGENS 2.612 HISTOPATHOLOGY AEUROPATH APPL NEURO 2.523 SEMIN DIAGN PATHOL 2.458 ACTA NEUROPATHOL TOXICOL PATHOL	95.5 94.0 92.5 91.0 89.6 88.1 86.6 85.1 83.6 82.1 80.6	A A A A A A	0 0 2 0 5 2	0 5 10 15 37	0 0 5 1	0 17 11	0 22
AM J SURG PATHOL LAB INVEST J PATHOL J PATHOL AN J CLIN PATHOL AN J CHIN P	94.0 92.5 91.0 89.6 88.1 86.6 85.1 83.6 82.1 80.6	A A A A A	0 2 0 5 2	5 10 15 37	0 5 1	17 11	22
LAB INVEST 4.165 J PATHOL 4.137 MODERN PATHOL 3.241 AM J CLIN PATHOL 2.939 HUM PATHOL 2.906 TISSUE ANTIGENS 2.612 HISTOPATHOLOGY 2.554 NEUROPATH APPL NEURO 2.553 SEMIN DIAGN PATHOL 2.458 ACTA NEUROPATHOL 2.329 SPRINGER SEMIN IMMUN 2.176 ALZ DIS ASSOC DIS 1.837 J CLIN PATHOL 1.755 APMIS 1.713 VIRCHOWS ARCH 1.713 DIAGN MOL PATHOL 1.679 HISTOL HISTOPATHOL 1.553 J COMP PATHOL 1.553 INT J GYNECOL PATHOL 1.508 INT J LEGAL MED 1.497 J ORAL PATHOL LAB MED 1.432 ACTA CYTOL 1.391	92.5 91.0 89.6 88.1 86.6 85.1 83.6 82.1 80.6	A A A A A	2 0 5 2	10 15 37	5 1	11	
MODERN PATHOL 3.241 AM J CLIN PATHOL 2.939 HUM PATHOL 2.906 TISSUE ANTIGENS 2.612 HISTOPATHOLOGY 2.554 NEUROPATH APPL NEURO 2.523 SEMIN DIAGN PATHOL 2.458 ACTA NEUROPATHOL 2.329 SPRINGER SEMIN IMMUN 2.176 ALZ DIS ASSOC DIS 1.837 J CLIN PATHOL 1.755 APMIS 1.713 VIRCHOWS ARCH 1.713 DIAGN MOL PATHOL 1.679 HISTOL HISTOPATHOL 1.553 J COMP PATHOL 1.510 INT J GYNECOL PATHOL 1.508 INT J LEGAL MED 1.497 J ORAL PATHOL MED 1.457 ARCH PATHOL LAB MED 1.432 ACTA CYTOL 1.391	91.0 89.6 88.1 86.6 85.1 83.6 82.1 80.6	A A A A	0 5 2	15 37	1		
MODERN PATHOL 3.241 AM J CLIN PATHOL 2.939 HUM PATHOL 2.906 TISSUE ANTIGENS 2.612 HISTOPATHOLOGY 2.554 NEUROPATH APPL NEURO 2.523 SEMIN DIAGN PATHOL 2.458 ACTA NEUROPATHOL 2.329 SPRINGER SEMIN IMMUN 2.176 ALZ DIS ASSOC DIS 1.837 J CLIN PATHOL 1.755 APMIS 1.713 VIRCHOWS ARCH 1.713 DIAGN MOL PATHOL 1.679 HISTOL HISTOPATHOL 1.553 J COMP PATHOL 1.510 INT J GYNECOL PATHOL 1.508 INT J LEGAL MED 1.497 J ORAL PATHOL MED 1.457 ARCH PATHOL LAB MED 1.432 ACTA CYTOL 1.391	89.6 88.1 86.6 85.1 83.6 82.1 80.6	A A A	0 5 2	37		3	28
AM J CLIN PATHOL 2.939 HUM PATHOL 2.906 TISSUE ANTIGENS 2.612 HISTOPATHOLOGY 2.554 NEUROPATH APPL NEURO 2.523 SEMIN DIAGN PATHOL 2.458 ACTA NEUROPATHOL 2.446 TOXICOL PATHOL 2.329 SPRINGER SEMIN IMMUN 2.176 ALZ DIS ASSOC DIS 1.837 J CLIN PATHOL 1.755 APMIS 1.713 VIRCHOWS ARCH 1.713 DIAGN MOL PATHOL 1.679 HISTOL HISTOPATHOL 1.553 J COMP PATHOL 1.553 J COMP PATHOL 1.550 INT J GYNECOL PATHOL 1.508 INT J LEGAL MED 1.497 J ORAL PATHOL LAB MED 1.432 ACTA CYTOL 1.391	88.1 86.6 85.1 83.6 82.1 80.6	A A A	2		2	.,	19
HUM PATHOL 2.906 TISSUE ANTIGENS 2.612 HISTOPATHOLOGY 2.524 NEUROPATH APPL NEURO 2.523 SEMIN DIAGN PATHOL 2.458 ACTA NEUROPATHOL 2.446 TOXICOL PATHOL 2.329 SPRINGER SEMIN IMMUN 2.176 ALZ DIS ASSOC DIS 1.837 J CLIN PATHOL 1.755 APMIS 1.713 VIRCHOWS ARCH 1.713 DIAGN MOL PATHOL 1.679 HISTOL HISTOPATHOL 1.553 J COMP PATHOL 1.553 J COMP PATHOL 1.508 INT J GYNECOL PATHOL 1.508 INT J LEGAL MED 1.497 J ORAL PATHOL MED 1.457 ARCH PATHOL LAB MED 1.432 ACTA CYTOL 1.391	88.1 86.6 85.1 83.6 82.1 80.6	A A A	2			8	52
TISSUE ANTIGENS 2.612 HISTOPATHOLOGY 2.554 NEUROPATH APPL NEURO 2.523 SEMIN DIAGN PATHOL 2.458 ACTA NEUROPATHOL 2.446 TOXICOL PATHOL 2.329 SPRINGER SEMIN IMMUN 2.176 ALZ DIS ASSOC DIS 1.837 J CLIN PATHOL 1.755 APMIS 1.713 VIRCHOWS ARCH 1.713 DIAGN MOL PATHOL 1.679 HISTOL HISTOPATHOL 1.553 J COMP PATHOL 1.510 INT J GYNECOL PATHOL 1.508 INT J LEGAL MED 1.497 J ORAL PATHOL MED 1.457 ARCH PATHOL LAB MED 1.432 ACTA CYTOL 1.391	86.6 85.1 83.6 82.1 80.6	A A			1	17	60
HISTOPATHOLOGY NEUROPATH APPL NEURO SEMIN DIAGN PATHOL ACTA NEUROPATHOL COLOR PATHOL SPRINGER SEMIN IMMUN ALZ DIS ASSOC DIS J CLIN PATHOL ALZ DIS ASSOC DIS 1.837 J CLIN PATHOL 1.755 APMIS VIRCHOWS ARCH DIAGN MOL PATHOL HISTOL HISTOPATHOL I.579 HISTOL HISTOPATHOL I.553 J COMP PATHOL INT J GYNECOL PATHOL INT J LEGAL MED J ORAL PATHOL MED ARCH PATHOL LAB MED 1.432 ACTA CYTOL	85.1 83.6 82.1 80.6	Α		2	8	6	19
NEUROPATH APPL NEURO 2.523 SEMIN DIAGN PATHOL 2.458 ACTA NEUROPATHOL 2.446 TOXICOL PATHOL 2.329 SPRINGER SEMIN IMMUN 2.176 ALZ DIS ASSOC DIS 1.837 J CLIN PATHOL 1.755 APMIS 1.713 VIRCHOWS ARCH 1.713 DIAGN MOL PATHOL 1.679 HISTOL HISTOPATHOL 1.553 J COMP PATHOL 1.510 INT J GYNECOL PATHOL 1.508 INT J LEGAL MED 1.497 J ORAL PATHOL MED 1.457 ARCH PATHOL LAB MED 1.432 ACTA CYTOL 1.391	83.6 82.1 80.6		5	66	7	22	100
SEMIN DIAGN PATHOL 2.458 ACTA NEUROPATHOL 2.446 TOXICOL PATHOL 2.329 SPRINGER SEMIN IMMUN 2.176 ALZ DIS ASSOC DIS 1.837 J CLIN PATHOL 1.755 APMIS 1.713 VIRCHOWS ARCH 1.713 DIAGN MOL PATHOL 1.679 HISTOL HISTOPATHOL 1.553 J COMP PATHOL 1.510 INT J GYNECOL PATHOL 1.508 INT J LEGAL MED 1.497 J ORAL PATHOL MED 1.457 ARCH PATHOL LAB MED 1.432 ACTA CYTOL 1.391	82.1 80.6		0	2	2	0	4
ACTA NEUROPATHOL TOXICOL PATHOL TOXICOL PATHOL SPRINGER SEMIN IMMUN ALZ DIS ASSOC DIS J CLIN PATHOL 1.755 APMIS VIRCHOWS ARCH DIAGN MOL PATHOL HISTOL HISTOPATHOL INT J GYNECOL PATHOL INT J GYNECOL PATHOL INT J LEGAL MED J ORAL PATHOL MED ARCH PATHOL LAB MED 1.432 ACTA CYTOL 1.3299	80.6	Α	Ō	2	0	0	2
TOXICOL PATHOL 2.329 SPRINGER SEMIN IMMUN 2.176 ALZ DIS ASSOC DIS 1.837 J CLIN PATHOL 1.755 APMIS 1.713 VIRCHOWS ARCH 1.713 DIAGN MOL PATHOL 1.679 HISTOL HISTOPATHOL 1.553 J COMP PATHOL 1.510 INT J GYNECOL PATHOL 1.508 INT J LEGAL MED 1.497 J ORAL PATHOL MED 1.457 ARCH PATHOL LAB MED 1.432 ACTA CYTOL 1.391		Ä	2	1	i	3	7
SPRINGER SEMIN IMMUN 2.176 ALZ DIS ASSOC DIS 1.837 J CLIN PATHOL 1.755 APMIS 1.713 VIRCHOWS ARCH 1.713 DIAGN MOL PATHOL 1.679 HISTOL HISTOPATHOL 1.553 J COMP PATHOL 1.510 INT J GYNECOL PATHOL 1.508 INT J LEGAL MED 1.497 J ORAL PATHOL MED 1.457 ARCH PATHOL LAB MED 1.432 ACTA CYTOL 1.391		A	ō	Ó	Ó	1	1
ALZ DIS ASSOC DIS 1.837 J CLIN PATHOL 1.755 APMIS 1.713 VIRCHOWS ARCH 1.713 DIAGN MOL PATHOL 1.679 HISTOL HISTOPATHOL 1.553 J COMP PATHOL 1.510 INT J GYNECOL PATHOL 1.508 INT J LEGAL MED 1.497 J ORAL PATHOL MED 1.457 ARCH PATHOL LAB MED 1.432 ACTA CYTOL 1.391	77.6	A	Ō	Ō	Ö	0	0
J CLIN PATHOL 1.755 APMIS 1.713 VIRCHOWS ARCH 1.713 DIAGN MOL PATHOL 1.679 HISTOL HISTOPATHOL 1.553 J COMP PATHOL 1.510 INT J GYNECOL PATHOL 1.508 INT J LEGAL MED 1.497 J ORAL PATHOL MED 1.457 ARCH PATHOL LAB MED 1.432 ACTA CYTOL 1.391	76.1	A	1	Ō	Ō	4	5
APMIS 1.713 VIRCHOWS ARCH 1.713 DIAGN MOL PATHOL 1.679 HISTOL HISTOPATHOL 1.553 J COMP PATHOL 1.510 INT J GYNECOL PATHOL 1.508 INT J LEGAL MED 1.497 J ORAL PATHOL MED 1.457 ARCH PATHOL LAB MED 1.432 ACTA CYTOL 1.391	74.6	Ä	9	63	9	11	92
VIRCHOWS ARCH 1.713 DIAGN MOL PATHOL 1.679 HISTOL HISTOPATHOL 1.553 J COMP PATHOL 1.510 INT J GYNECOL PATHOL 1.508 INT J LEGAL MED 1.497 J ORAL PATHOL MED 1.457 ARCH PATHOL LAB MED 1.432 ACTA CYTOL 1.391	71.6	A	4	17	Ŏ	1	22
DIAGN MOL PATHOL 1.679 HISTOL HISTOPATHOL 1.553 J COMP PATHOL 1.510 INT J GYNECOL PATHOL 1.508 INT J LEGAL MED 1.497 J ORAL PATHOL MED 1.457 ARCH PATHOL LAB MED 1.432 ACTA CYTOL 1.391	73.1	Ä	ó	2	ŏ	3	5
HISTOL HISTOPATHOL 1.553 J COMP PATHOL 1.510 INT J GYNECOL PATHOL 1.508 INT J LEGAL MED 1.497 J ORAL PATHOL MED 1.457 ARCH PATHOL LAB MED 1.432 ACTA CYTOL 1.391	70.1	Ä	ŏ	õ	ŏ	ĭ	ī
J COMP PATHOL 1.510 INT J GYNECOL PATHOL 1.508 INT J LEGAL MED 1.497 J ORAL PATHOL MED 1.457 ARCH PATHOL LAB MED 1.432 ACTA CYTOL 1.391	68.7	Ä	3	ő	17	15	41
ÎNT J GYNECOL PATHOL1.508INT J LEGAL MED1.497J ORAL PATHOL MED1.457ARCH PATHOL LAB MED1.432ACTA CYTOL1.391	67.2	Ä	ő	Ö	ő	ő	0
INT J LEGAL MED 1.497 J ORAL PATHOL MED 1.457 ARCH PATHOL LAB MED 1.432 ACTA CYTOL 1.391	65.7	В	2	5	4	3	14
J ORÁL PATHOL MED 1.457 ARCH PATHOL LAB MED 1.432 ACTA CYTOL 1.391	64.2	B	ī	1	ò	1	3
ARCH PATHOL LAB MED 1.432 ACTA CYTOL 1.391	62.7	В	5	13	ŏ	43	61
ACTA CYTOL 1.391	61.2	В	3	22	ő	10	35
	59.7	В	5	27	13	27	72
	58.2	В	1	ő	0	õ	1
	56.7	B	1	0	ő	ŏ	1
LEPROSY REV 1.343 INT I EXP PATHOL 1.321	55.2	В	Ó	0	1	ŏ	i
	53.7	В	Ö	ŏ	ò	1	i
	52.2	В	Õ	Ö	ŏ	ò	ò
PEDIATR PATHOL LAB M 1.182 INT I IMMUNOPATH PH 1.174	50.7	В	ŏ	ŏ	ŏ	ŏ	Õ
	49.3	В	1	3	ő	10	14
J CUTAN PATHOL 1.171	47.8	В	2	Õ	1	1	4
MOL CHEM NEUROPATHOL 1.163	46.3	В	Ó	ő	ó	ò	Ō
INT J LEPROSY 1.114	44.8	B	ŏ	1	2	3	6
EXP MOL PATHOL 1.085		В	3	3	Õ	3	9
PATHOL RES PRACT 1.075	43.3	В	0	0	ŏ	1	í
CLIN NEUROPATHOL 1.012	41.8 40.3	В	0	0	ŏ	ò	Ó
J MOL DIAGN 1.000		В	5	61	29	Ö	95
PATHOLOGY 0.994	38.8 37.3	В	Õ	14	0	4	18
DIAGN CYTOPATHOL 0.937		В	0	1	Õ	Ō	1
SCI JUSTICE 0.909	35.8	В	0	1	ŏ	ő	1
ORAL SURG ORAL MED O 0.865	34.3	Č	1	ó	Ŏ	ő	1
ANAL CELL PATHOL 0.838	32.8	<u> </u>	4	0	3	3	10
PATHOL INT 0.830	31.3	Ĉ C	Ö	3	0	1	4
CYTOPATHOLOGY 0.760	29.9	Č		0	0	Ó	Õ
APPL IMMUNOHISTO M M 0.747	28.4	C	Õ		0	0	4
ULTRASTRUCT PATHOL 0.745	26.9	Č	2	2			
PEDIATR DEVEL PATHOL 0.723	25.4	<u> </u>	0	0	0	0	0
EXP TOXICOL PATHOL 0.689	23.9	<u> </u>	0	0	Õ	0	0
AM J FOREN MED PATH 0.595	22.4	Č	1	3	5	0	9
PATHOL BIOL 0.546	20.9	Č	0	Õ	0	0	0
DIS MARKERS 0.539	19.4	Č	0	0	0	0	0
RES COMMUN MOL PATH 0.495	17.9	Č	0	0	0	1	1
NEUROPATHOLOGY 0.487		C	0	0	0	0	0
ANN PATHOL 0.473	16.4	~		0	-		
MED SCI LAW 0.472	14.9		Ö	0	0	0	0
INT J SURG PATHOL 0.463		C C C			-		

Subject Category, Area Pathology	Impact Factor	Adjusted IF (%)	Publication Type	China n	HK n	SNG n	TW n	Total n
ENDOCR PATHOL	0.402	10.4	С	0	0	0	0	0
PATHOLOGE	0.363	9.0	С	0	0	0	0	0
CARDIOVASC PATHOL	0.347	75	C	0	0	0	1	1
FOLIA NEUROPATHOL	0 258	6 0	С	0	0	0	0	0
B SOC PATHOL EXOT	0.151	4.5	С	0	0	0	0	0
ZH NEVROPATOL PSIKH	0.109	3.0	С	0	0	0	0	0
PEDIATR PATHOL MOL M	0 000	1 5	С	0	0	0	0	0
Total				78	448	126	251	903

Pediatrics

Number of full papers (with impact factor) in Medline





Pediatrics subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).


Journals sorted according to the impact factor provided by the *Journal Citation Reports* (JCR) 2000 version for Pediatrics JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category: a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW).


Subject Category, Area	Impact	Adjusted	Publication	China	HK	SNG	TW	Total
Pediatrics	Factor	IF (%)	Туре	n	n	n	n	n
PEDIATRICS J PEDIATR J AM ACAD CHILD PSY PEDIATR RES PEDIATR RES PEDIATR INFECT DIS I J CHILD ADOL PSYCHOP ARCH DIS CHILD SEMIN PERINATOL DEV MED CHILD NEUROL ARCH PEDIAT ADOL MED PEDIATR ALLERGY IMMU NEUROPEDIATRICS J PEDIATR GASTR NUTR PEDIATR PULM J ADOLESCENT HEALTH J PEDIAT HEMATOL ONC PEDIATR NEPHROL CLIN PERINATOL EUR J PEDIATR ACTA PAEDIATR MED PEDIATR ONCOL PAEDIATR PERINAT C J PEDIATR SURG PEDIATR SURG PEDIATR CLIN N AM J CHILD NEUROL PAEDIATR NEUROL PAEDIATR NEUROL PAEDIATR NEUROL PEDIATR CLIN N AM J DEV BEHAV PEDIATR PEDIATR NEUROL PAEDIATR NEUROL PAEDIATR ANAESTH EARLY HUM DEV J PERINAT MED PEDIATR CARDIOL CLIN PEDIATR PEDIATR CARDIOL CLIN PEDIATR PEDIATR CHILD H PEDIATR RENCOL PEDIATR NEUROSURG MENT RETARD DEV D R PEDIATR ANN PEDIATR EXERC SCI PEDIATR EXERC SCI PEDIATR REDIOCR MET J PEDIATR CHILD H PEDIATR RADIOL J PAEDIATR CHILD H PEDIATR RADIOL J PAEDIATR CHILD H PEDIATR RADIOL J PAEDIATR CHILD H PEDIATR RADIOCL J PEDIATR ORTHOPED	3.742 3.467 3.175 2.794 2.190 1.982 1.866 1.808 1.701 1.635 1.597 1.580 1.545 1.415 1.387 1.370 1.360 1.318 1.315 1.301 1.265 1.258 1.250 1.216 1.182 1.134 1.054 1.041 1.007 1.005 0.982 0.950 0.863 0.834 0.812 0.811 0.800 0.739 0.732 0.723 0.698 0.636	100.0 98.6 97.2 95.8 94.4 93.0 91.5 90.1 88.7 87.3 85.9 84.5 83.1 80.3 78.9 77.5 76.1 73.2 71.8 67.6 66.2 64.8 63.4 62.0 66.2 64.8 63.4 62.0 65.3 55.7 56.3 57.7 56.3 56.3 57.7 56.3 57.7	. AAAAAAAAAAAAAAAAAAAAAABBBBBBBBBBBBBBB	1 1 1 1 2 8 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	1 5 0 9 6 0 16 0 5 0 0 0 8 31 12 1 9 1 0 0 3 0 0 0 0 0 8 4 0 1 13	1603 1050 12013 00101352 06000 00113602 110000 07	10 16 0 7 39 0 8 2 4 11 7 0 0 25 0 0 3 0 0 0 25 2 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	13 28 1 21 54 0 31 2 10 13 8 1 30 1 9 0 1 36 65 16 1 20 3 0 0 7 0 1 0 0 1 1 8 1 0 0 0 1 1 0 0 0 0 0 0 1 0 0 0 0
CHILD CARE HITH DEV AM J PERINAT CARDIOL YOUNG PEDIATR HEMAT ONCOL CHILD NERV SYST PRENAT NEONAT MED ACTA PAEDIATR JAPON KLIN PADIATR J DENT CHILD PEDIATR SURG INT INT J PEDIATR OTORHI J TROP PEDIATRICS PEDIATR EMERG CARE CHILD PSYCHIAT HUM D J PEDIAT OPHTH STRAB	0.636 0.636 0.616 0.615 0.601 0.563 0.544 0.523 0.496 0.491 0.476 0.447 0.428 0.422	36.0 36.6 35.2 33.8 32.4 31.0 29.6 28.2 26.8 25.4 23.9 22.5 21.1 19.7 16.9 18.3	вввоссоссоссосс	1 0 2 0 2 0 0 1 0 0 0 1 0 0	13 1 3 0 12 0 0 5 0 2 0 0 2 0 0 0	7 1 0 1 0 0 7 0 3 0 2 1 0 0 5 5	11 0 16 0 7 0 0 3 0 11 1 5 0	32 21 1 21 0 0 16 0 16 1 11 1 1

Subject Category, Area Pediatrics	Impact Factor	Adjusted IF (%)	Publication Type	China n	HK n	SNG n	TW n	Total n
ANN TROP PAEDIATR	0.413	15.5	С	0	0	0	0	0
EUR I PEDIATR SURG	0.350	14.1	C	0	1	0	0	1
PEDIATR INT	0.327	12.7	С	1	1	0	2	4
ARCH PEDIATRIE	0.303	11.3	С	0	0	0	0	0
Z GEBURTSH NEONATOL	0.248	9.9	С	0	0	0	0	0
I PEDIATR ORTHOP B	0.217	8.5	Ċ	0	1	0	Ó	1
MONATSSCHR KINDERH	0.140	7.0	C	0	0	0	0	0
SAGGI	0.111	5.6	Ċ	0	Õ	Ö	Ö	0
ANN PEDIATR PARIS	0.106	4.2	Č	0	Ō	Ö	Ô	0
TURKISH I PEDIATR	0.089	2.8	Ċ	Ō	Ó	1	1	2
PEDIATR PATHOL MOL M	0.000	1.4	Č	Ō	0	0	0	0
Total				53	272	132	326	783

Peripheral Vascular Disease

Number of full papers (with impact factor) in Medline






Peripheral Vascular Disease subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).

Journals sorted according to the impact factor provided by the *Journal Citation Reports* (JCR) 2000 version for Peripheral Vascular Disease JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW)

C.L. and Calabara Area	less s est	Adjusted	Dullant	Ch		(NC	T) 4 /	~1
Subject Category Area	Impact	Aajustea IF (%)	Publication	China	HK	SNG	TW	Total
Peripheral Vascular Disease	Factor	IF (%)	Туре	n	_ n	n	n	n —
CIRCULATION	10 893	100 0	Α	2	6	1	43	52
CIRC RES	9 193	97 8	Α	2	1	0	6	9
STROKE	6 008	95 6	Α	5	15	0	33	53
CURR OPIN LIPIDOL	5 661	93 3	Α	0	0	0	0	0
HYPERTENSION	5 311	91 1	Α	1	4	0	23	28
ARTERIOSCL THROM VAS	5 111	88 9	Α	0	2	0	11	13
THROMB HAEMOSTASIS	4 372	86 7	Α	5	1	5	27	38
I HYPERTENS	3 640	84 4	A	11	4	2	9	26
ATHEROSCLEROSIS	3 386	82 2	A	10	13	6	31	60
I ENDOVASC SURG	3 276	80 0	A	0	1	0	0	1
AM I PHYSIOL HEART C	3 243	77 8	A	Ŏ	Ö	Ö	Ĭ	1
I VASC SURG	3 114	75 6	A	Ŏ	Õ	Ō	ò	Ó
CEREBROVASC DIS	2 950	73 3	A	1	4	2	1	8
SHOCK	2 785	71 1	Ä	i	Ó	ō	ò	1
I VASC RES	2 710	68 9	Ä	i	ŏ	Ö	ŏ	1
AM I HYPERTENS	2 685	66 7	Ä	i	3	1	27	32
MICROCIRCULATION	2 667	64 4	В	ò	õ	ó	0	Ü
CURR OPIN NEPHROL HY	2 544	62 2	В	0	0	0	ő	Õ
SEMIN THROMB HEMOST	2 179	60 0	В	0	Õ	Ö	ŏ	Ő
HYPERTENS RES	2 17 3	57 8	В	18	ő	ő	ő	18
MICROVASC RES	2 016	55 6	В	3	1	0	5	9
I VASC INTERV RADIOL	1 729	53 3	В	0	ò	ő	1	í
•	1 596	51 1	В	8	7	1	8	24
J HUM HYPERTENS	1 579	48 9	В	1	ó	ó	ő	1
ENDOTHELIUM NEW YORK	1 565	46 7	В	Ó	1	0	0	i
EUR J VASC ENDOVASC	1 378	44 4	В	0	Ó	0	1	i
KIDNEY BLOOD PRESS R	1 323	42 2	В	13	0	1	42	56
THROMB RES	1 266	40 0	В	0	1	Ó	0	1
CLIN EXP HYPERTENS	1 073	37 8	В	1	ó	0	Ö	1
ANN VASC SURG			В	Ó	1	2	1	4
CORONARY ARTERY DIS	1 028	35 6	В	0	Ó	0	1	1
J CARDIOTHOR VASC AN	0 917	33 3	Č	2	0	0	Ó	2
INT ANGIOL	0 802	31 1	Ċ	1	0	0	0	1
J THROMB THROMBOLYS	0 785	28 9	C	0	1	0	0	1
HYPERTENS PREGNANCY	0 750	26 7	C	0	ó	0	0	Ó
VASA J VASCULAR DIS	0 675	24 4	Ċ	6	12	3	34	55
ANGIOLOGY	0 628	22 2	C	1	0	0	1	2
HEART VESSELS	0 595	20 0	C	0	0	0	Ô	0
PHLEBOLOGY	0 571	17 8	C	30	0	0	1	31
CLIN HEMORHEOL MICRO	0 553	15 6	Č		0	1	12	14
JPN CIRC J	0 536	13 3	C	1 0	0	Ó	0	0
J ENDOVASC THER	0 425	11 1	C	_	0	0	0	0
ARCH MAL COEUR VAISS	0 403	8 9	C	0	-	0	0	0
J MAL VASCUL	0 337	6.7	C	0	0	-	-	0
HERZ KREISLAUF	0 159	4 4	C	0	0	0 0	0	0
PERFUSION GERMANY	0 130	22	С	0	0	U	U	U
Total				125	78	25	319	547
IVIAI			garage angujuranounus bertreitumoni Mo					

Pharmacology and Pharmacy

Number of full papers (with impact factor) in Medline



Pharmacology and Pharmacy subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).

Journals sorted according to the impact factor provided by the *Journal Citation Reports* (JCR) 2000 version for Pharmacology and Pharmacy JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category: a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW).


PHARMACOL REV 25.381 100.0 A 0 0 0 0 0 ANNU REV PHARMACOL 19.289 99.4 A 0 0 0 0 0 TRENDS PHARMACOL 19.289 99.4 A 0 0 0 0 0 PHARMACOL THERAPEUT 6.487 98.3 A 1 0 1 0 1 0 PHARMACOL THERAPEUT 6.487 98.3 A 1 0 1 0 1 0 REVER PHARMACOL 5.678 97.8 A 6 8 1 1.3 REVER PHARMACOL 6.487 98.3 A 1 0 0 1 0 REVER PHARMACOL 6.487 98.3 A 1 0 0 1 0 REVER PHARMACOL 6.487 98.3 A 1 0 0 1 0 REVER PHARMACOL 6.487 98.3 A 1 0 0 1 0 REVER PHARMACOL 6.487 98.3 A 1 0 0 1 0 REVER PHARMACOL 6.487 98.3 A 1 0 0 1 0 REVER PHARMACOL 6.487 98.3 A 1 0 0 1 0 REVER PHARMACOL 6.487 98.3 A 1 0 0 1 0 REVER PHARMACOL 6.487 98.3 A 1 0 0 0 0 REVER PHARMACOL 6.487 98.3 A 1 0 0 0 0 REVER PHARMACOL 6.487 98.3 A 1 0 0 0 0 REVER PHARMACOL 6.487 98.3 A 1 0 0 0 0 REVER PHARMACOL 6.487 98.3 A 1 0 0 0 0 0 REVER PHARMACOL 6.487 98.3 A 1 0 0 0 0 0 REVER PHARMACOL 6.487 99.5 A 0 0 0 0 0 1 REVER PHARMACOL 6.485 93.9 A 5 1 6 6 6 REVER PHARMACOL 7.485 93.9 A 5 1 6 6 7 REVER PHARMACOL 7.485 93.9 A 5 1 6 6 7 REVER PHARMACOL 7.485 93.9 A 5 1 6 7 REVER PHARMACOL 7.485 93.9 A 5 1 6 7 REVER PHARMACOL	ubject Category, Area harmacology and Pharmacy	Impact Factor	Adjusted IF (%)	Publication Type	China n	HK n	SNG n	TW n	Total n
ANNU REV PHARMACOL TRENDS PHARMACOL TENDS PHARMACOL SCI 10 377 98.9 A 0 0 0 0 0 PHARMACOL THERAPEUT 6.487 98.3 A 1 0 1 0 1 0 PHARMACOL THERAPEUT 6.487 98.3 A 1 0 0 0 0 0 0 PHARMACOL THER S. 5.678 97.8 A 6 6 8 1 4.3 REV PHYSIOL BIOCH P 5.389 97.2 A 0 0 0 0 0 0 CLIN PHARMACOL THER 5.275 96.7 A 4 2 2 1 6 JCLIN PSYCHOPHARM CURR MED CHEM 4.909 95 6 A 1 0 1 0 0 NEUROPSYCHOPHARMACOL 4.579 95 0 A 0 0 0 0 1 NEUROPSYCHOPHARMACOL 4.579 95 0 A 0 0 0 0 1 NEUROPSYCHOPHARMACOL 4.579 95 0 A 0 0 0 0 0 NEUROPSYCHOPHARMACOL 4.579 95 0 A 0 0 0 0 0 NEUROPSYCHOPHARMACOL 4.579 95 0 A 0 0 0 0 0 NEUROPSYCHOPHARMACOL 4.579 95 0 A 0 0 0 0 0 NEUROPSYCHOPHARMACOL 4.579 95 0 A 0 0 0 0 0 NEUROPSYCHOPHARMACOL 4.579 95 0 A 0 0 0 0 0 NEUROPSYCHOPHARMACOL 4.125 93.4 A 6 0 0 0 0 0 NEUROPSYCHOPHARMACOL 5.678 93.9 A 5 1 6 6 NEUROPHARMACOLOGY 4.125 93.4 A 6 0 0 0 0 0 NEUROPHARMACOLOGY 4.125 93.4 A 6 0 0 0 0 0 NEUROPHARMACOLOGY 4.105 92.8 A 0 0 0 0 0 0 NEUROPHARMACOLOGY 4.105 92.8 A 0 0 0 0 0 0 NEUROPHARMACOLOGY 4.105 92.8 A 0 0 0 0 0 0 NEUROPHARMACOLOGY 4.105 92.8 A 0 0 0 0 0 0 NEUROPHARMACOLOGY 4.105 92.8 A 0 0 0 0 0 0 NEUROPHARMACOLOGY 4.105 92.8 A 0 0 0 0 0 0 NEUROPHARMACOLOGY 4.105 92.8 A 0 0 0 0 0 0 NEUROPHARMACOLOGY 4.105 92.8 A 0 0 0 0 0 0 NEUROPHARMACOLOGY 4.105 92.8 A 0 0 0 0 0 0 NEUROPHARMACOLOGY 4.105 92.8 A 0 0 0 0 0 0 NEUROPHARMACOLOGY 4.105 92.8 A 0 0 0 0 0 0 NEUROPHARMACOLOGY 4.105 92.8 A 0 0 0 0 0 0 NEUROPHARMACOLOGY 4.105 92.8 A 0 0 0 0 0 0 NEUROPHARMACOLOGY 4.105 92.8 A 0 0 0 0 0 0 0 NEUROPHARMACOLOGY 4.105 92.8 A 0 0 0 0 0 0 0 NEUROPHARMACOLOGY 4.105 92.8 A 0 0 0 0 0 0 0 0 NEUROPHARMACOLOGY 4.105 92.8 A 0 0 0 0 0 0 0 0 NEUROPHARMACOLOGY 4.105 92.8 A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0							an demonstration also extend to		0
TRENDS PHARMACOL SCI 10377 98.9 A 0 2 0 0 0 PHARMACOL THERAPEUT 6.487 98 3 A 1 0 1 0 1 0 MOL PHARMACOL 5.678 97.8 A 6 6 8 1 43 MOL PHARMACOL THER 5.275 96.7 A 4 2 1 1 6 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0									ő
MOL PHARMACOL REV PHYSIOL BIOCH P 5.389 97.2 A 0 0 0 0 0 CLIN PHARMACOL THER 5.275 96.7 A 4 2 1 6 CLIN PHARMACOL CURR MED CHEM 4.909 95 6 A 1 0 0 1 0 CURR MED CHEM 4.909 95 6 A 1 0 0 1 0 CURR MED CHEM 4.909 95 6 A 1 0 0 1 0 CURR MED CHEM 4.510 94 5 A 0 0 0 0 0 1 ANTIVIR THER 4.510 94 5 A 0 0 0 0 0 1 ANTIVIR THER 4.510 94 5 A 0 0 0 0 0 0 PHARMACOLOGY 4.125 93.9 A 5 1 6 6 NEUROPHARMACOLOGY 4.125 93.4 A 6 0 0 0 0 21 CURR PHARMACOLOGY 4.125 93.4 A 6 0 0 0 0 21 CURR PHARMACOKINET 3.992 92 3 A 2 2 1 0 CRIT REV THER DRUG 3.766 91 7 A 0 1 0 0 ANTIMICROB AGENTS CH 3.954 91.2 A 4 19 9 19 CRIT REV THER DRUG 3.769 90.6 A 0 0 0 0 BRIT J PHARMACOL 3.689 90 1 A 16 33 3 138 ALIMENT PHARM THERAP 3.489 89.5 A 5 5 31 7 4 J PHARMACOL EXP THER 3.452 89 0 A 111 8 2 27 MED RES REV 3.417 88 4 A 1 0 0 0 DRUG METABREV 3.385 87 8 A 1 1 0 0 0 DRUG METABREV 3.385 87 8 A 1 1 0 0 0 DRUG METABREV 3.385 87 8 A 1 0 0 0 0 DRUG METABREV 3.385 87 8 A 1 1 0 0 0 DRUG METABREV 3.385 87 8 A 1 0 0 0 0 DRUG METABREV 3.385 87 8 A 1 0 0 0 0 DRUG METABROLL 2.964 85 6 A 1 1 0 0 0 DRUG METABREV 3.385 87 8 A 1 0 0 0 0 DRUG METABREV 3.385 87 8 A 1 0 0 0 0 DRUG METABREV 3.385 87 8 A 1 0 0 0 0 DRUG METABREV 3.385 87 8 A 1 1 0 0 0 0 DRUG METABREV 3.385 87 8 A 1 1 0 0 0 0 DRUG METABREV 3.386 87 8 A 1 0 0 0 0 1 DRUG METABREV 3.386 87 8 A 1 1 0 0 0 0 DRUG METABREV 3.386 87 8 A 1 1 0 0 0 0 DRUG METABREV 3.297 88 4 A 1 0 0 0 0 0 DRUG METABREV 3.386 87 8 A 1 1 0 0 0 0 DRUG METABREV 3.297 88 4 A 1 0 0 0 0 0 DRUG METABREV 3.297 88 4 A 1 0 0 0 0 0 DRUG METABREV 3.297 88 4 A 1 0 0 0 0 0 DRUG METABREV 3.297 88 4 A 1 0 0 0 0 0 DRUG METABREV 3.297 88 4 A 1 0 0 0 0 0 DRUG METABREV 3.297 88 4 A 1 0 0 0 0 0 DRUG METABREV 3.297 88 4 A 1 0 0 0 0 0 DRUG METABREV 3.297 88 4 A 1 0 0 0 0 0 DRUG METABREV 3.297 88 4 A 1 0 0 0 0 0 DRUG METABREV 3.297 88 4 A 1 0 0 0 0 0 DRUG METABREV 3.297 88 4 A 1 0 0 0 0 0 DRUG METABREV 3.297 88 4 A 1 0 0 0 0 0 DRUG METABREV 3.298 89 0 A 111 8 8 2 2 27 DRUG METABREV 3.298 89 0 A 111 8 8 2 2 27 DRUG METABREV 3.298 89 0 A 11 8 8 2 2 27 DRUG METABREV 3.298						2			2
MOL PHARMACOL S.678 97.8 A 6 B 1 43 REV PHYSIOL BIOCH P 5.389 97.2 A 0 0 0 0 0 0 CLIN PHARMACOL THER 5.275 96.7 A 4 2 1 6 CLIN PSYCHOPHARM 5.052 96 1 A 0 1 0 0 0 CURR MED CHEM 4.909 95 6 A 1 0 0 0 0 0 CURR MED CHEM 4.909 95 6 A 1 0 0 0 0 0 1 0 NEUROPSYCHOPHARMACOL 4.579 95 0 A 0 0 0 0 0 1 0 NEUROPSYCHOPHARMACOL 4.579 95 0 A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0						ñ			2
REV PHYSICU BIOCH P CINI PHARMACOL THER 5.275 96.7 A 4 2 1 1 6 ICLIN PSYCHOPHARM 5.052 96.1 A 0 1 1 0 0 NEUROPSYCHOPHARMACOL 4.579 95.6 A 1 0 0 0 0 1 NEUROPSYCHOPHARMACOL 4.579 95.0 A 0 0 0 0 1 NEUROPSYCHOPHARMACOL 4.579 95.0 A 0 0 0 0 1 NEUROPSYCHOPHARMACOL 4.579 95.0 A 0 0 0 0 0 1 NEUROPHARMACOLOGY 4.105 93.9 A 5 1 6 6 NEUROPHARMACOLOGY 4.125 93.4 A 6 0 0 0 0 0 NEUROPHARMACOLOGY 4.105 92.8 A 0 0 0 0 0 0 NEUROPHARMACOLOGY 5.10 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1					•				58
CLIN PHARMACOL THER 5.275 96.7 A 4 2 1 6 JCLIN PSYCHOPHARM 5.052 96 1 A 0 1 0 0 CURR MED CHEM 4.909 95 6 A 1 0 1 0 NEUROPSYCHOPHARMACOL 4.579 95 0 A 0 0 0 0 PHARMACOGUOGY 4.125 93.9 A 5 1 6 6 NEUROPHARMACOKINET 3.992 92.3 A 2 2 1 0 DRUGS 3.966 91.7 A 0 0 0 0 CRIT REV THER DRUG 3.769 90.6 A 0 0 0 0 RIT IPHARMACOLI 3.689 90.1 A 4 1.99 9 19 9 19 9 19 9 19 9 19 9 19 9 19 9 19 9 19									0
ICLIN PSYCHOPHARM CURR MED CHEM					-				13
CURR MED CHEM 4,909 95 6 A 1 0 1 0 NEUROPSYCHOPHARMACOL 4,579 99 50 A 0 0 0 0 1 PHARMACOGENETICS 4,465 93,9 A 5 1 6 6 NEUROPHARMACOLOGY 4,125 93,4 A 6 0 0 21 DRUG DISCOV TODAY 4,105 92.8 A 0 0 0 0 CLIN PHARMACOKINET 3,992 92.3 A 2 2 1 0 DRUCS 3,966 91.7 A 0 1 0 0 CRIT REV THER DRUG 3,269 90.6 A 0 0 0 0 RALIMENT PHARM THERAP 3,489 89.0 A 1 16 33 3 138 138 1 4 1 9 9 1 A 16 33 3 138 138 1 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>1</td>									1
NEUROPSYCHOPHARMACOL					-				2
ANTIVIR THER 4.510 94 5 A 0 0 0 0 0 PHARMACOCENETICS 4.465 93.9 A 5 1 6 6 NEUROPHARMACOLOGY 4.125 93.4 A 6 0 0 0 21 DRUG DISCOV TODAY 4.105 92.8 A 0 0 0 0 0 CLIN PHARMACOKINET 3.992 92.3 A 0 0 0 0 CLIN PHARMACOKINET 3.992 92.3 A 0 0 0 0 DRUGS 3.966 91.7 A 0 1 1 0 0 ROBRIT PHARMACOKINET 3.995 90.6 A 0 0 0 0 0 RITERY THER DRUG 3.769 90.6 A 0 0 0 0 0 RITERY THER DRUG 4.10 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1									1
PHARMACOGENETICS									ò
NEUROPHARMACOLOGY									18
DRÜG DISCOV TODAY									27
CLIN PHARMACOKINET 3.992 22 3 A 2 2 1 0 DRUGS 3.966 91 7 A 0 1 0 0 ANTIMICROB AGENTS CH 3.954 91.2 A 4 19 9 19 CRIT REV THER DRUG 3.769 90.6 A 0 0 0 0 0 BRIT J PHARMACOL 3.689 90.1 A 16 33 3 138 ALIMENT PHARM THERAP 3.489 89.5 A 5 31 7 4 J PHARMACOL EXP THER 3.452 89.0 A 11 8 2 27 MED RES REV 3.3417 88 4 A 1 0 0 0 DRUG RESIST 3.263 87.3 A 0 0 0 0 GURR PHARMACOL 2.975 86 2 A 12 14 26 52 J ANTIMIR GES 2.964 85 6									ő
SPUCS 3.966 91 7									5
ANTIMICROB ACENTS CH 3,954 91.2 A 4 19 9 19 CRIT REV THER DRUG 3,769 90.6 A 0 0 0 0 O DRIT J PHARMACOL 3.689 90.1 A 16 33 3 138 ALIMENT PHARM THERAP 3,489 89.5 A 5 31 7 4 J PHARMACOL EXP THER 3,452 89 0 A 11 8 2 27 MED RES REV 3,417 88 4 A 1 0 0 0 O DRUG METAB REV 3,335 87.8 A 1 0 0 0 O DRUG METAB REV 3,335 87.3 A 0 0 0 0 I CURR PHARM DESIGN 3,110 86.7 A 0 0 0 0 I CURR PHARM DESIGN 3,110 86.7 A 0 0 0 0 I CURR PHARMACOL 2,975 86 2 A 12 14 26 52 J ANTIMICROB CHEMOTH 2,964 85.1 A 6 1 0 45 SYCHOPHARMACOL BULL 2,869 84.5 A 0 0 0 0 DRUG SAFETY 2,763 83.4 A 0 0 0 0 DRUG SAFETY 2,763 83.4 A 0 0 0 0 O DRUG SAFETY 2,763 83.4 A 0 0 0 0 O DRUG SAFETY 2,763 83.4 A 0 1 0 0 O DRUG SAFETY 2,763 83.4 A 0 1 0 0 O DRUG SAFETY 2,763 83.4 A 0 1 0 0 O DRUG SAFETY 2,763 83.4 A 0 1 0 0 O DRUG SAFETY 2,763 83.4 A 0 1 0 0 O DRUG METAB DISPOS 2,513 80.7 A 1 2 0 1 2 0 1 2 0 1 2 0 1 2 0 1 2 0 1 2 0 1 2 0 1 2 0 1 2 0 1 2 0 1 2 0 1 2 0 1 2 0 1 2 0 1 2 0 0 0 0 0 0 0 0 0									ĭ
CRIT REV THER DRUG 3.769 90.6 A 0 0 0 0 0 BRIT J PHARMACOL 3.689 90.1 A 16 33 3 138 ALIMENT PHARM THERAP 3.489 89.5 A 5 31 7 4 J PHARMACOL EXP THER 3.489 89.5 A 5 31 7 4 J PHARMACOL EXP THER 3.489 89.5 A 5 31 7 4 J PHARMACOL EXP THER 3.489 89.5 A 5 31 7 4 J PHARMACOL EXP THER 3.489 89.5 A 5 31 7 4 J PHARMACOL EXP THER 3.480 89.5 A 5 31 7 4 J PHARMACOL EXP THER 3.481 88 4 A 1 0 0 0 0 DRUG METAB REV 3.385 87 8 A 1 0 0 0 0 1 RUCRO BRUG RESIST 3.263 87.3 A 0 0 0 0 0 1 CURR PHARM DESIGN 3.110 86.7 A 0 0 0 0 0 0 BIOCHEM PHARMACOL 2.975 86 2 A 12 14 26 52 J ANTIMICROB CHEMOTH 2.964 85 6 A 1 22 1 7 N S ARCH PHARMACOL BULL 2.869 85.1 A 6 1 0 45 PSYCHOPHARMACOL BULL 2.809 84 5 A 0 0 0 0 0 DRUG SAFETY 2.763 83 4 A 0 0 0 0 0 DRUG SAFETY 2.763 83 4 A 0 0 0 0 0 DRUG SAFETY 2.763 83 4 A 0 0 0 0 0 DRUG SAFETY 2.763 83 4 A 0 0 0 0 0 DRUG SAFETY 2.763 83 4 A 0 0 0 0 0 DRUG SAFETY 2.763 83 4 A 0 0 0 0 0 DRUG SAFETY 2.763 83 4 A 0 0 0 0 0 DRUG SAFETY 2.763 83 4 A 0 0 0 0 0 DRUG SAFETY 2.768 82.9 A 0 0 0 0 0 DRUG SAFETY 2.768 82.9 A 0 0 0 0 0 DRUG SAFETY 2.768 82.9 A 0 0 0 0 0 DRUG SAFETY 2.768 82.9 A 0 0 0 0 0 DRUG SAFETY 2.768 82.9 A 0 0 0 0 0 DRUG SAFETY 2.779 81.8 A 0 1 0 0 0 DRUG METAB DISPOS 2.513 80.7 A 1 2 0 12 PHARMACOPSYCHIATRY 2.681 81.2 A 0 1 0 0 DRUG METAB DISPOS 2.513 80.7 A 1 2 0 12 PHARMACOL SULL 2.896 79.0 A 18 12 2 2 DRUG METAB DISPOS 2.513 80.7 A 1 2 0 0 DRUG METAB DISPOS 2.513 80.7 A 1 2 0 0 DRUG METAB DISPOS 2.513 80.7 A 1 2 0 0 DRUG METAB DISPOS 2.513 80.7 A 1 2 0 0 DRUG METAB DISPOS 2.513 80.7 A 1 2 0 0 DRUG METAB DISPOS 2.513 80.7 A 1 2 0 0 DRUG METAB DISPOS 2.513 80.7 A 1 0 0 0 DRUG METAB DISPOS 2.513 80.7 A 1 0 0 0 DRUG METAB DISPOS 3.514 A 6 0 0 0 0 0 DRUG METAB DISPOS 3.515 A 1 0 0 0 0 DRUG METAB DISPOS 3.516 A 0 0 0 0 0 0 DRUG METAB DISPOS 3.517 A 1 0 0 0 0 DRUG METAB DISPOS 3.518 A 0 0 0 0 0 0 DRUG METAB DISPOS 3.518 A 0 0 0 0 0 0 DRUG METAB DISPOS 3.518 A 0 0 0 0 0 0 DRUG METAB DISPOS 3.518 A 0 0 0 0 0 0									51
BRIT PHARMACOL 3.689 90 1									Ô
ALIMÉNT PHARM THERAP 3.489 3.489 3.489 3.489 3.489 3.482 3.4852 3.489 3.4852 3.489 3.4852 3.489 3.4852 3.489 3.4852 3.489 3.4852 3.489 3.4852 3.489 3.4852 3.489 3.4852 3.487 3.487 3.4884 4 1 0 0 0 0 0 0 0 0 0 0 0 0									190
JPHARMACOL EXP THER									47
MED RES REV 3.417 88 4 A 1 0 0 0 0 DRUG METAB REV 3.385 87 8 A 1 0 0 0 0 MICROB DRUG RESIST 3.263 87.3 A 0 0 0 0 1 CURR PHARM DESIGN 3.110 86.7 A 0 0 0 0 0 BIOCHEM PHARMACOL 2.975 86.2 A 12 14 26 52 JANTIMICROB CHEMOTH 2.964 85.6 A 1 22 1 7 N S ARCH PHARMACOL 2.869 85.1 A 6 1 0 45 PSYCHOPHARMACOL PSYCHOPHARMACOL 2.809 84.5 A 0 0 0 0 0 DRUG SAFETY 2.763 83.4 A 0 0 1 0 0 DRUG SAFETY 2.763 83.4 A 0 0 1 0 0 ANTIVIR RES 2.758 82.9 A 0 0 0 0 0 TOXICOL APPL PHARM 2.730 82.3 A 1 0 0 0 0 CONTROL CLIN TRIALS 2.770 81.8 A 0 1 0 0 0 PHARMACOPSYCHIATRY 2.681 81.2 A 0 1 0 0 DRUG METAB DISPOS 2.513 80.7 A 1 2 0 12 PHARMACEUT RES 2.475 80.1 A 4 5 1 13 ADV DRUG DELIVER REV 2.406 79.6 A 0 0 0 0 0 J CARDIOVASC PHARM 2.396 79.0 A 18 12 2 25 ANTIVIR CHEM CHEMOTH 2.386 78.5 A 1 0 0 0 0 DRUG AGING 2.342 77.9 A 0 3 2 0 COMB C HEM HIGH T SCR 2.341 77.3 A 0 0 0 0 DRUG AGING 2.342 77.9 A 0 3 2 0 COMB C HEM HIGH T SCR 2.341 77.3 A 0 0 0 0 DRUG AGING 2.342 77.9 A 0 3 2 0 COMB C HEM HIGH T SCR 2.341 77.3 A 0 0 0 0 DRUG AGING 2.342 77.9 A 0 3 2 0 COMB C HEM HIGH T SCR 2.341 77.3 A 0 0 0 0 DRUG AGING 2.342 77.9 A 0 3 2 0 COMB C HEM HIGH T SCR 2.341 77.3 A 0 0 0 0 DRUG AGING 2.342 77.9 A 0 3 2 0 COMB C HEM HIGH T SCR 2.341 77.3 A 0 0 0 0 DRUG AGING 2.342 77.9 A 0 3 2 0 COMB C HEM HIGH T SCR 2.341 77.3 A 0 0 0 0 DRUG AGING 2.342 77.9 A 0 3 2 0 COMB C HEM HIGH T SCR 2.341 77.3 A 0 0 0 0 DRUG AGING 2.342 77.9 A 0 3 2 0 COMB C HEM HIGH T SCR 2.341 77.3 A 0 0 0 0 DRUG AGING 2.342 77.9 A 0 3 2 0 COMB C HEM HIGH T SCR 2.341 77.3 A 0 0 0 0 DRUG AGING 2.342 77.9 A 0 3 2 0 COMB C HEM HIGH T SCR 2.341 77.3 A 0 0 0 0 DRUG AGING 2.342 77.9 A 0 3 2 0 COMB C HEM HIGH T SCR 2.341 77.3 A 0 0 0 0 DRUG RESIST UPDATE 2.065 71.8 A 0 0 0 0 0 EUR J PHARMACOL 2.111 74.6 A 1 0 0 0 DRUG RESIST UPDATE 2.065 71.8 A 0 0 0 0 0 EUR NEUROPSYCHOPHARM 2.065 71.8 A 0 0 0 0 0 EUR NEUROPSYCHOPHARM 2.065 71.8 A 0 0 0 0 0 EUR NEUROPSYCHOPHARM 2.065 71.8 A 0 0 0 0 0 DRUG RESIST UPDATE								27	48
DRUC METAB REV 3.385 87 8									1
MICROB DRUG RESIST 3.263 87.3 A 0 0 0 1 CURR PHARM DESIGN 3.110 86.7 A 0 0 0 0 0 0 1 SIGNIER PHARMACOL 2.975 86.2 A 12 14 26 52 1 ANTIMICROB CHEMOTH 2.964 85.6 A 1 22 1 7 N S ARCH PHARMACOL 2.869 85.1 A 6 1 0 0 0 0 0 0 0 0 0 0 0 0								_	i
CURR PHARM DESIGN 3.110 86.7 A 0 0 0 0 0 0 0 BIOCHEM PHARMACOL 12.975 86 2 A 12 14 26 52 1 7 7 N S ARCH PHARMACOL 12.964 85 6 A 1 22 1 7 7 N S ARCH PHARMACOL 12.869 85.1 A 6 1 0 45 PSYCHOPHARMACOL BULL 12.809 84 5 A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0									i
BIOCHEM PHARMACOL 2.975 86 2 A 12 14 26 52 JANTIMICROB CHEMOTH 2.964 85 6 A 1 22 1 7 N SARCH PHARMACOL 2.869 85.1 A 6 1 0 45 PSYCHOPHARMACOL BULL 2.809 84 5 A 0 0 0 0 PSYCHOPHARMACOLOGY 2.804 84 0 A 0 0 0 0 PSYCHOPHARMACOLOGY 2.804 84 0 A 0 0 0 0 DRUG SAFETY 2.763 83 4 A 0 1 0 0 ANTIVIR RES 2.758 82 9 A 0 0 0 0 TOXICOL APPL PHARM 2.730 81.8 A 0 1 0 0 0 CONTROL CLIN TRIALS 2.707 81.8 A 0 1 0 0 0 PHARMACOPSYCHIATRY 2.681 81.2 A 0 1 0 0 0 PHARMACEUT RES 2.475 80.1 A 4 5 1 13 ADV DRUG DELIVER REV 2.406 79.6 A 0 0 0 0 0 DAUG DELIVER REV 2.406 79.0 A 18 12 2 25 ANTIVIR CHEM CHEMOTH 2.386 78.5 A 1 0 0 0 DRUG MEIM HIGH T SCR 2.341 77.3 A 0 0 0 0 DRUG AGING 2.342 77.9 A 0 3 2 0 COMB CHEM HIGH T SCR 2.341 77.3 A 0 0 0 0 DRUG AGING 2.328 76.8 A 0 0 0 0 0 DRUG AGING 2.236 76.2 A 47 48 14 141 J CONTROL RELEASE 2.151 75.7 A 12 0 4 20 BRIT J CLIN PHARMACOL 2.151 75.7 A 12 0 4 20 DRIAN SCI 2.095 74.0 A 7 4 3 26 CANCER CHEMOTH PHARM 2.076 72.9 A 1 0 0 0 DRUG RESIST UPDATE 2.069 72.4 A 0 3 0 2 DRUG RESIST UPDATE 2.069 72.4 A 0 0 0 DRUG RESIST UPDATE 2.065 71.3 A 0 0 0 0 DUR ON THE REVOLUTION 15 15 15 15 DRUG RESIST UPDATE 2.065 71.3 A 0 0 0 DRUG RESIST UPDATE 2.065 71.3 A 0 0 0 0 DRUG RESIST UPDATE 2.065 71.3 A 0 0 0 0 DRUG RESIST UPDATE 2.065 71.3 A 0 0 0 0 DRUG RESIST UPDATE 2.065 71.3 A 0 0 0 0 DRUG RESIST UPDATE 2.006 72.9 A 1 5 0 0 DRUG RESIST UPDATE 2.006 72.9 A 1 5 0 0 DRUG RESIST UPDATE 2.006 72.9									ò
JANTIMICROB CHEMOTH 2.964 85.6 A 1 22 1 7 N S ARCH PHARMACOL 2.869 85.1 A 6 1 0 0 0 0 PSYCHOPHARMACOL 2.869 85.1 A 0 0 0 0 0 PSYCHOPHARMACOL 2.809 84.5 A 0 0 0 0 0 DRUG SAFETY 2.763 83.4 A 0 1 0 ANTIVIR RES 2.758 82.9 A 0 0 0 0 0 TOXICOL APPL PHARM 2.730 82.3 A 1 0 0 0 0 CONTROL CLIN TRIALS 2.707 81.8 A 0 1 0 0 DRUG METAB DISPOS 2.513 80.7 A 1 2 0 DRUG METAB DISPOS 2.513 80.7 A 1 2 0 1 DRUG METAB DISPOS 2.513 80.7 A 1 2 0 1 2 DRUG METAB DISPOS 2.513 80.7 A 1 2 0 1 2 DRUG METAB DISPOS 2.513 80.7 A 1 2 0 1 2 DRUG METAB DISPOS 2.513 80.7 A 1 2 0 1 2 DRUG METAB DISPOS 2.513 80.7 A 1 2 0 1 2 DRUG METAB DISPOS 2.513 80.7 A 1 2 0 1 2 DRUG METAB DISPOS 2.513 80.7 A 1 2 0 1 2 DRUG METAB DISPOS 2.513 80.7 A 1 2 0 1 2 DRUG METAB DISPOS 2.513 80.7 A 1 2 0 1 2 DRUG METAB DISPOS 2.513 80.7 A 1 2 0 1 2 DRUG METAB DISPOS 2.513 80.7 A 1 2 0 1 2 0 1 2 DRUG METAB DISPOS 2.513 80.7 A 1 2 0 1 2 0 0 0 0 0 0 0 0 0 0 0 0									104
N S ARCH PHARMACOL PSYCHOPHARMACOL BULL 2.809 84 5 A 0 0 0 0 0 PSYCHOPHARMACOLOGY 2.804 84 0 A 0 0 0 0 0 DRUG SAFETY 2.763 83 4 A 0 1 0 0 ANTIVIR RES 2.758 82 9 A 0 0 0 0 0 CONTROL CLIN TRIALS 2.707 81.8 A 0 1 0 0 0 CONTROL CLIN TRIALS 2.707 81.8 A 0 1 0 0 0 PHARMACOPSYCHIATRY 2.681 81.2 A 0 1 0 0 PHARMACOPSYCHIATRY 2.681 81.2 A 0 1 0 0 PHARMACOPSYCHIATRY 3.681 81.2 A 0 1 0 0 PHARMACOPSYCHIATRY 3.781 81.8 A 0 0 1 0 0 PHARMACOPSYCHIATRY 3.781 81.8 A 0 0 0 0 0 0 PHARMACOPSYCHIATRY 3.781 81.8 A 0 0 0 0 0 PHARMACOPSYCHOPHARM 3.206 78.5 A 1 0 0 0 0 PHARMACOL 2.111 74.6 A 1 0 0 0 PHARMACOL 2.111 74.6 A 1 0 0 0 PHARMACOL 3.111 74.6 A 1 0 0 0 0 PHARMACOL 3.111 74.6 A 1 0 0 0 0 PHARMACOL 3.111 74.6 A 1 0 0 0 0 PHARMACOL 3.111 74.6 A 1 0 0 0 0 PHARMACOL 3.111 74.6 A 1 0 0 0 0 PHARMACOL 3.111 74.6 A 1 0 0 0 0 PHARMACOL 3.111 74.6 A 1 0 0 0 0 0 PHARMACOL 3.111 74.6 A 1 0 0 0 0 0 PHARMACOL 3.111 74.6 A 1 0 0 0 0 0 PHARMACOL 3.111 74.6 A 1 0 0 0 0 0 0 PHARMACOL 3.111 74.6 A 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0									31
PSYCHOPHARMACOL BULL 2.809 84 5 A 0 0 0 0 0 PSYCHOPHARMACOLOGY 2.804 84 0 A 0 0 0 0 0 DRUG SAFETY 2.763 83 4 A 0 1 0 0 ANTIVIR RES 2.758 82 9 A 0 0 0 0 CONTROL CLIN TRIALS 2.707 81.8 A 0 1 0 0 0 PHARMACOPSYCHIATRY 2.681 81.2 A 0 1 0 0 DRUG METAB DISPOS 2.513 80.7 A 1 2 0 12 PHARMACEUT RES 2.475 80.1 A 4 5 1 13 ADV DRUG DELIVER REV 2.406 79.6 A 0 0 0 0 0 J CARDIOVASC PHARM 2.396 79.0 A 18 12 2 25 ANTIVIR CHEM CHEMOTH 2.386 78.5 A 1 0 0 0 DRUG AGING COMB CHEM HIGH T SCR 2.341 77.3 A 0 3 2 0 COMB CHEM HIGH T SCR 2.341 77.3 A 0 0 0 0 1 J PSYCHOPHARMACOL 2.328 76.8 A 0 0 0 0 0 EUR J PHARMACOL 2.236 76.2 A 47 48 14 141 J CONTROL RELEASE 2.151 75.7 A 12 0 4 20 BRIT J CLIN PHARMACOL 2.151 75.7 A 12 0 4 20 BRIT J CLIN PHARMACOL 2.151 75.7 A 12 0 4 20 BRIT J CLIN PHARMACOL 2.151 75.7 A 12 0 4 20 BRIT J CLIN PHARMACOL 2.151 75.7 A 12 0 4 20 BRIT J CLIN PHARMACOL 2.151 75.7 A 12 0 4 20 BRIT J CLIN PHARMACOL 2.151 75.7 A 12 0 4 20 BRIT J CLIN PHARMACOL 2.151 75.7 A 12 0 4 20 BRIT J CLIN PHARMACOL 2.151 75.7 A 12 0 4 20 BRIT J CLIN PHARMACOL 2.151 75.7 A 12 0 4 20 BRIT J CLIN PHARMACOL 2.151 75.7 A 12 0 4 20 BRIT J CLIN PHARMACOL 2.151 75.7 A 12 0 4 20 BRIT J CLIN PHARMACOL 2.151 75.7 A 12 0 4 20 BRIT J CLIN PHARMACOL 2.151 75.7 A 12 0 4 20 BRIT J CLIN PHARMACOL 2.151 75.7 A 12 0 4 20 BRIT J CLIN PHARMACOL 2.151 75.7 A 12 0 4 20 BRIT J CLIN PHARMACOL 2.151 75.7 A 12 0 4 20 BRIT J CLIN PHARMACOL 2.151 75.7 A 12 0 4 20 BRIT J CLIN PHARMACOL 2.005 74.0 A 7 4 3 26 CANCER CHEMOTH PHARM 2.081 73.5 A 2 115 2 12 INT CLIN PSYCHOPHARM 2.066 72.4 A 0 3 0 0 0 0 EUR NEUROPSYCHOPHARM 2.066 72.4 A 0 3 0 0 0 0 EUR NEUROPSYCHOPHARM 2.067 72.4 A 0 3 0 0 0 0 EUR NEUROPSYCHOPHARM 2.045 77.3 A 0 0 0 0 0 EUR NEUROPSYCHOPHARM 2.045 77.3 A 0 0 0 0 0 I SLIN PHARMACOL 2.003 70.7 A 1 1 5 0 15 CHILD DADOL PSYCHOP									52
PSYCHOPHARMACOLOGY 2.804 84 0 A 0 0 0 0 0 DRUG SAFETY 2.763 83 4 A 0 0 0 0 0 DRUG SAFETY 2.758 82 9 A 0 0 0 0 0 TOXICOL APPL PHARM 2.730 82.3 A 1 0 0 0 CONTROL CLIN TRIALS 2.707 81.8 A 0 1 0 0 0 PHARMACOPSYCHIATRY 2.681 81.2 A 0 1 0 0 DRUG METAB DISPOS 2.513 80.7 A 1 2 0 12 PHARMACEUT RES 2.475 80.1 A 4 5 1 13 ADV DRUG DELIVER REV 2.406 79.6 A 0 0 0 0 0 DRUG ASC PHARM 2.396 79.0 A 18 12 2 25 ANTIVIR CHEM CHEMOTH 2.386 78.5 A 1 0 0 0 0 DRUG AGING 2.342 77.9 A 0 3 2 0 COMB CHEM HIGH T SCR 2.341 77.3 A 0 0 0 1 J PSYCHOPHARMACOL 2.328 76.8 A 0 0 0 0 1 J PSYCHOPHARMACOL 2.328 76.8 A 0 0 0 0 0 EUR J PHARMACOL 2.328 76.8 A 0 0 0 0 0 BRIT J CLIN PHARMACOL 2.151 75.7 A 12 0 4 20 BRIT J CLIN PHARMACOL 2.151 75.7 A 12 0 0 0 0 BRUG RESIST UPDATE 2.069 72.4 A 0 3 0 0 0 0 BURUG RESIST UPDATE 2.069 72.4 A 0 0 3 0 0 0 0 BURUG RESIST UPDATE 2.069 72.4 A 0 0 3 0 0 0 0 BURUG RESIST UPDATE 2.069 72.4 A 0 0 3 0 0 0 0 BURUG RESIST UPDATE 2.069 72.4 A 0 0 3 0 0 0 0 BURUG PSYCHOPP									o o
DRUG SAFETY 2.763 83 4 A 0 1 0 0 ANTIVIR RES 2.758 82 9 A 0 0 0 0 0 TOXICOL APPL PHARM 2.730 82.3 A 1 0 0 0 0 CONTROL CLIN TRIALS 2.707 81.8 A 0 1 0 0 DRUG METAB DISPOS 2.513 80.7 A 1 2 0 DRUG METAB DISPOS 2.513 80.7 A 1 2 0 12 DRUG METAB DISPOS 2.5475 80.1 A 4 5 1 13 ADV DRUG DELIVER REV 2.406 79.6 A 0 0 0 0 1 CARDIOVASC PHARM 2.396 79.0 A 18 12 2 5 ANTIVIR CHEM CHEMOTH 2.386 78.5 A 1 0 0 0 0 DRUG AGING 2.342 77.9 A 0 0 0 0 DRUG AGING 2.342 77.9 A 0 0 0 0 0 0 0 0 0 0 0 0							-		ő
ANTIVIR RES 2.758 82 9 A 0 0 0 0 0 TOXICOL APPL PHARM 2.730 82.3 A 1 0 0 0 0 CONTROL CLIN TRIALS 2.707 81.8 A 0 1 0 0 0 PHARMACOPSYCHIATRY 2.681 81.2 A 0 1 0 0 DRUG METAB DISPOS 2.513 80.7 A 1 2 0 12 PHARMACEUT RES 2.475 80.1 A 4 5 1 13 ADV DRUG DELIVER REV 2.406 79.6 A 0 0 0 0 0 J CARDIOVASC PHARM 2.396 79.0 A 18 12 2 25 ANTIVIR CHEM CHEMOTH 2.386 78.5 A 1 0 0 0 DRUG AGING 2.342 77.9 A 0 3 2 0 COMB CHEM HIGH T SCR 2.341 77.3 A 0 0 0 1 J PSYCHOPHARMACOL EUR J PHARMACOL EUR J PHARMACOL 2.328 76.8 A 0 0 0 0 EUR J PHARMACOL EUR J PHARMACOL 2.326 76.2 A 47 48 14 141 J CONTROL RELEASE 2.151 75.7 A 12 0 4 20 BRIT J CLIN PHARMACOL SEHAV PHARMACOL 2.151 75.7 A 12 0 4 20 BRIT J CLIN PHARMACOL SEHAV PHARMACOL 2.151 75.7 A 12 0 4 20 BRIT J CLIN PHARMACOL 2.151 75.7 A 12 0 4 20 BRIT J CLIN PHARMACOL 2.151 75.7 A 12 0 4 20 BRIT J CLIN PHARMACOL 2.151 75.7 A 12 0 4 20 BRIT J CLIN PHARMACOL 2.151 75.7 A 12 0 4 20 BRIT J CLIN PHARMACOL 2.151 75.7 A 12 0 4 20 BRIT J CLIN PHARMACOL 2.151 75.7 A 12 0 4 20 BRIT J CLIN PHARMACOL 2.151 75.7 A 12 0 0 0 0 DRUG RESIST UPDATE 2.066 72.9 A 1 0 0 0 0 CUN THER 2.067 72.9 A 1 0 0 0 CLIN THER 2.069 72.4 A 0 0 3 0 2 DRUG RESIST UPDATE 2.056 71.8 A 0 0 0 0 1 J CLIN PHARMACOL 2.003 70.7 A 1 1 5 0 15 J CHILD ADOL PSYCHOPP							_		1
TOXICOL APPL PHARM 2.730 82.3 A 1 0 0 0 CONTROL CLIN TRIALS 2.707 81.8 A 0 1 0 0 DHARMACOPSYCHIATRY 2.681 81.2 A 0 1 0 0 DRUG METAB DISPOS 2.513 80.7 A 1 2 0 12 PHARMACEUT RES 2.475 80.1 A A A D DRUG DELIVER REV 2.406 79.6 A DRUG DELIVER REV 2.406 79.6 A DRUG AGING COMB CHEM CHEMOTH 2.386 78.5 A 1 0 0 0 DRUG AGING COMB CHEM HIGH T SCR 2.341 DRUG AGING COMB CHEM HIGH T SCR 2.342 DRUG AGING COMB CHEM HIGH T SCR 2.056 DRUG RESIST UPDATE 2.057									Ó
CONTROL CLIN TRIALS 2.707 81.8 A 0 1 0 0 PHARMACOPSYCHIATRY 2.681 81.2 A 0 1 0 0 DRUG METAB DISPOS 2.513 80.7 A 1 2 0 12 PHARMACEUT RES 2.475 80.1 A 4 5 1 13 ADV DRUG DELIVER REV 2.406 79.6 A 0 0 0 0 0 J CARDIOVASC PHARM 2.396 79.0 A 18 12 2 25 ANTIVIR CHEM CHEMOTH 2.386 78.5 A 1 0 0 0 0 DRUG AGING COMB CHEM HIGH T SCR 2.341 77.9 A 0 3 2 0 COMB CHEM HIGH T SCR 2.341 77.3 A 0 0 0 1 J PSYCHOPHARMACOL 2.328 76.8 A 0 0 0 0 0 EUR J PHARMACOL 2.326 76.2 A 47 48 14 141 J CONTROL RELEASE 2.151 75.7 A 12 0 4 20 BRIT J CLIN PHARMACOL 2.111 74.6 A 1 0 0 0 J PHARM SCI CANCER CHEMOTH PHARM 2.081 73.5 A 2 15 CANCER CHEMOTH PHARM 2.086 72.9 A 1 0 0 0 CLIN THER 2.069 72.4 A 0 3 0 2 DRUG RESIST UPDATE 2.069 72.4 A 0 0 0 0 0 CLIN THER 2.069 72.4 A 0 0 0 0 0 CLIN PHARMACOL 2.015 71.3 A 0 0 0 0 CLIN PHARMACOL 2.016 71.3 A 0 0 0 0 0 CLIN PHARMACOL 2.017 71.3 A 0 0 0 0 0 CLIN PHARMACOL 2.018 71.3 A 0 0 0 0 0 CLIN PHARMACOL 2.019 72.4 A 0 0 0 0 0 CLIN PHARMACOL 2.019 72.4 A 0 0 0 0 0 CLIN PHARMACOL 2.019 72.4 A 0 0 0 0 0 CLIN PHARMACOL 2.019 72.4 A 0 0 0 0 0 CLIN PHARMACOL 2.019 72.4 A 0 0 0 0 0 CLIN PHARMACOL 2.019 72.4 A 0 0 0 0 0 CLIN PHARMACOL 2.019 72.4 A 0 0 0 0 0 CLIN PHARMACOL 2.019 72.4 A 0 0 0 0 0 CLIN PHARMACOL 2.019 72.4 A 0 0 0 0 0 CLIN PHARMACOL 2.019 72.4 A 0 0 0 0 0 CLIN PHARMACOL 2.019 72.4 A 0 0 0 0 0 CLIN PHARMACOL 2.019 72.4 A 0 0 0 0 0 CLIN PHARMACOL 2.019 72.4 A 0 0 0 0 0 CLIN PHARMACOL 2.019 72.4 A 0 0 0 0 0 CLIN PHARMACOL 2.019 72.4 A 0 0 0 0 0 CLIN PHARMACOL 2.019 72.4 A 0 0 0 0 0 CLIN PHARMACOL 2.019 72.4 A 0 0 0 0 0 CLIN PHARMACOL 2.019 72.4 A 0 0 0 0 0 CLIN PHARMACOL 2.019 72.4 A 0 0					-				1
PHARMACOPSYCHIATRY 2.681 81.2 A 0 1 0 0 DRUG METAB DISPOS 2.513 80.7 A 1 2 0 12 PHARMACEUT RES 2.475 80.1 A 4 5 1 13 ADV DRUG DELIVER REV 2.406 79.6 A 0 0 0 0 0 J CARDIOVASC PHARM 2.396 79.0 A 18 12 2 25 ANTIVIR CHEM CHEMOTH 2.386 78.5 A 1 0 0 0 0 0 DRUG AGING 2.342 77.9 A 0 3 2 0 COMB CHEM HIGH T SCR 2.341 77.3 A 0 0 0 1 J PSYCHOPHARMACOL 2.328 76.8 A 0 0 0 0 0 0 EUR J PHARMACOL 2.328 76.8 A 0 0 0 0 0 0 EUR J PHARMACOL 2.326 76.2 A 47 48 14 141 J CONTROL RELEASE 2.151 75.7 A 12 0 4 20 BRIT J CLIN PHARMACOL 2.111 74.6 A 1 0 0 0 0 J PHARM SCI CANCER CHEMOTH PHARM 2.095 74.0 A 7 A 3 26 CANCER CHEMOTH PHARM 2.095 74.0 A 7 A 1 0 0 0 0 CLIN THER 2.069 72.4 A 0 0 0 0 1 5 DRUG RESIST UPDATE 2.069 72.4 A 0 0 0 0 1 5 CHILD ADOL PSYCHOPHARM 2.045 71.3 A 0 0 0 0 1 5 1 5 1 5 1 5 1 5 1 5 1 5 1 5									i
DRUG METAB DISPOS 2.513 80.7 A 1 2 0 12 PHARMACEUT RES 2.475 80.1 A 4 5 1 13 ADV DRUG DELIVER REV 2.406 79.6 A 0 0 0 J CARDIOVASC PHARM 2.396 78.5 A 1 0 0 0 0 DRUG AGING 2.342 77.9 A 0 0 0 1 DRUG AGING COMB CHEM HIGH T SCR 2.341 77.3 A 0 0 0 1 J PSYCHOPHARMACOL 2.328 76.8 A 0 0 0 0 0 EUR J PHARMACOL J CONTROL RELEASE 2.151 BRIT J CLIN PHARMACOL BRIT J CLIN PHARMACOL J PHARMACOL J PHARMACOL J PHARMACOL J PHARMACOL J PHARMACOL J CONTROL RELEASE 2.151 75.7 A 12 0 4 20 BRIT J CLIN PHARMACOL J PHARMACOL J PHARM SCI CANCER CHEMOTH PHARM 2.095 74.0 A 7 4 3 26 CANCER CHEMOTH PHARM 2.081 73.5 A 2 DRUG RESIST UPDATE 2.069 72.4 A 0 0 0 0 1 J CHILD ADOL PSYCHOP 1.982 70.2 A 0 0 0 0 0 15 15 0 0 0 0 15 15					-			_	i
PHARMACEUT RES 2.475 80.1 A 4 5 1 13 ADV DRUG DELIVER REV 2.406 79.6 A 0 0 0 0 0 J CARDIOVASC PHARM 2.396 79.0 A 18 12 2 25 ANTIVIR CHEM CHEMOTH 2.386 78.5 A 1 0 0 0 DRUG AGING 2.342 77.9 A 0 3 2 0 COMB CHEM HIGH T SCR 2.341 77.3 A 0 0 0 0 J PSYCHOPHARMACOL 2.328 76.8 A 0 0 0 0 EUR J PHARMACOL 2.236 76.2 A 47 48 14 141 J CONTROL RELEASE 2.151 75.7 A 12 0 4 20 BRIT J CLIN PHARMACOL 2.151 75.7 A 12 14 6 6 BEHAV PHARMACOL 2.151 75.1 A 12 14 6 6 BEHAV PHARMACOL 2.151 75.1 A 12 14 6 6 CANCER CHEMOTH PHARM 2.095 74.0 A 7 4 3 26 CANCER CHEMOTH PHARM 2.081 73.5 A 2 15 2 12 INT CLIN PSYCHOPHARM 2.076 72.9 A 1 0 0 0 CLIN THER 2.069 72.4 A 0 3 0 2 DRUG RESIST UPDATE EUR NEUROPSYCHOPHARM 2.045 71.3 A 0 0 0 0 I JCHIN PHARMACOL 2.003 70.7 A 1 5 0 15 J CHILD ADOL PSYCHOP 1.982 70.2 A 0 0 0									15
ADV DRUG DELIVER REV J CARDIOVASC PHARM 2.396 79.0 A 18 12 2 25 ANTIVIR CHEM CHEMOTH 2.386 78.5 A 1 0 0 0 0 DRUG AGING 2.342 77.9 A 0 3 2 0 COMB CHEM HIGH T SCR J PSYCHOPHARMACOL EUR J PHARMACOL J CONTROL RELEASE 2.151 75.7 A 12 0 4 20 BRIT J CLIN PHARMACOL J PHARMACOL 2.151 75.7 A 12 14 6 6 BEHAV PHARMACOL J PHARMACOL J PHARMACOL 2.151 75.1 A 12 14 6 6 BEHAV PHARMACOL J PHARM SCI CANCER CHEMOTH PHARM 2.081 73.5 A 2 15 2 12 INT CLIN PSYCHOPHARM 2.081 73.5 A 2 15 2 12 INT CLIN PSYCHOPHARM 2.069 72.4 A 0 3 0 2 DRUG RESIST UPDATE EUR NEUROPSYCHOPHARM 2.045 71.3 A 0 0 0 D 1 J CHILD ADOL PSYCHOP 1.982 70.2 A 0 0									23
CARDIOVASC PHARM 2.396 79.0 A 18 12 2 25									0
ANTIVIR CHEM CHEMOTH 2.386 78.5 A 1 0 0 0 DRUG AGING COMB CHEM HIGH T SCR 2.341 77.9 A 0 0 1 1 1 1 1 1 1 1 1 1 1									57
DRUG AGING COMB CHEM HIGH T SCR J PSYCHOPHARMACOL LUR J PHARMACOL LUR	NITIVID CHEM CHEMOTH								1
COMB CHEM HIGH T SCR J PSYCHOPHARMACOL LUR J PHARMACOL									5
PSYCHOPHARMACOL 2.328 76.8 A 0 0 0 0								1	1
EUR J PHARMACOL 2.236 76.2 A 47 48 14 141 J CONTROL RELEASE 2.151 75.7 A 12 0 4 20 BRIT J CLIN PHARMACO 2.151 75.1 A 12 14 6 6 BEHAV PHARMACOL 2.111 74.6 A 1 0 0 0 0 J PHARM SCI 2.095 74.0 A 7 4 3 26 CANCER CHEMOTH PHARM 2.081 73.5 A 2 15 2 12 INT CLIN PSYCHOPHARM 2.081 73.5 A 2 15 2 12 INT CLIN PSYCHOPHARM 2.069 72.4 A 0 3 0 2 DRUG RESIST UPDATE 2.069 72.4 A 0 3 0 2 DRUG RESIST UPDATE 2.056 71.8 A 0 0 0 0 0 EUR NEUROPSYCHOPHARM 2.045 71.3 A 0 0 0 0 1 CLIN PHARMACOL 2.003 70.7 A 1 5 0 15 J CHILD ADOL PSYCHOP							Ö	0	0
J CONTROL RELEASE 2.151 75.7 A 12 0 4 20 BRIT J CLIN PHARMACO 2.151 75.1 A 12 14 6 6 BEHAV PHARMACOL 2.111 74.6 A 1 0 0 0 J PHARM SCI 2.095 74.0 A 7 4 3 26 CANCER CHEMOTH PHARM 2.081 73.5 A 2 15 2 12 INT CLIN PSYCHOPHARM 2.076 72.9 A 1 0 0 0 CLIN THER 2.069 72.4 A 0 3 0 2 DRUG RESIST UPDATE 2.056 71.8 A 0 0 0 EUR NEUROPSYCHOPHARM 2.045 71.3 A 0 0 0 J CLIN PHARMACOL 2.003 70.7 A 1 5 0 15 J CHILD ADOL PSYCHOP 1.982 70.2 A 0 0 0 O CHILD ADOL PSYCHOP 1.982 70.2 A 0 0 0 CHILD ADOL PSYCHOP 1.982 70.2 A 0 0 0 CLIN THER 2.003 70.7 A 1 5 0 15 J CHILD ADOL PSYCHOP 1.982 70.2 A 0 0 0 0 CLIN THER 2.003 70.7 A 1 5 0 15 J CHILD ADOL PSYCHOP 1.982 70.2 A 0 0 0 CLIN THER 2.003 70.7 A 0 0 0 CLIN THER 2.004 70.7 A 0 0 0 0 CLIN THER 2.005 71.8 A 0 0 0 0 CLIN THER 2.005 71.8 A 0 0 0 0 CLIN THER 2.005 71.8 A 0 0 0 0 CLIN THER 2.005 71.8 A 0 0 0 0 CLIN THER 2.005 71.8 A 0 0 0						48	14	141	250
BRIT J CLIN PHARMACO 2.151 75.1 A 12 14 6 6 BEHAV PHARMACOL J PHARM SCI CANCER CHEMOTH PHARM 2.095 74.0 A 7 4 3 26 CANCER CHEMOTH PHARM 2.081 73.5 A 2 15 2 12 INT CLIN PSYCHOPHARM 2.076 72.9 A 1 0 0 0 CLIN THER 2.069 72.4 A 0 3 0 2 DRUG RESIST UPDATE 2.069 72.4 A 0 3 0 2 DRUG RESIST UPDATE EUR NEUROPSYCHOPHARM 2.045 71.3 A 0 0 0 0 J CLIN PHARMACOL J CLIN PHARMACOL J CLIN PHARMACOL 1.982 70.2 A 0 0 0							4	20	36
BEHAV PHARMACOL 2.111 74.6 A 1 0 0 0 0 1 PHARM SCI 2.095 74.0 A 7 4 3 26 CANCER CHEMOTH PHARM 2.081 73.5 A 2 15 2 12 INT CLIN PSYCHOPHARM 2.076 72.9 A 1 0 0 0 CLIN THER 2.069 72.4 A 0 3 0 2 DRUG RESIST UPDATE 2.069 72.4 A 0 3 0 2 DRUG RESIST UPDATE 2.056 71.8 A 0 0 0 0 0 EUR NEUROPSYCHOPHARM 2.045 71.3 A 0 0 0 0 1 J CLIN PHARMACOL 2.003 70.7 A 1 5 0 15 J CHILD ADOL PSYCHOP	RIT I CLIN PHARMACO					14	6	6	38
J PHARM SCI 2.095 74.0 A 7 4 3 26	HAV DHADAACOI						Ó	0	1
CANCER CHEMOTH PHARM 2.081 73.5 A 2 15 2 12 INT CLIN PSYCHOPHARM 2.076 72.9 A 1 0 0 0 CLIN THER 2.069 72.4 A 0 3 0 2 DRUG RESIST UPDATE 2.056 71.8 A 0 0 0 0 EUR NEUROPSYCHOPHARM 2.045 71.3 A 0 0 0 0 JCLIN PHARMACOL 2.003 70.7 A 1 5 0 15 J CHILD ADOL PSYCHOP 1.982 70.2 A 0 0 0									40
INT CLIN PSYCHOPHARM 2.076 72.9 A 1 0 0 0 CLIN THER 2.069 72.4 A 0 3 0 2 DRUG RESIST UPDATE 2.056 71.8 A 0 0 0 EUR NEUROPSYCHOPHARM 2.045 71.3 A 0 0 0 J CLIN PHARMACOL 2.003 70.7 A 1 5 0 15 J CHILD ADOL PSYCHOP 1.982 70.2 A 0 0 0									31
CLIN THER 2.069 72.4 A 0 3 0 2 DRUG RESIST UPDATE 2.056 71.8 A 0 0 0 0 EUR NEUROPSYCHOPHARM 2.045 71.3 A 0 0 0 1 J CLIN PHARMACOL 2.003 70.7 A 1 5 0 15 J CHILD ADOL PSYCHOP 1.982 70.2 A 0 0 0 0								0	1
DRUG RESIST UPDATE 2.056 71.8 A 0 0 0 0 0 EUR NEUROPSYCHOPHARM 2.045 71.3 A 0 0 0 1 1 J CLIN PHARMACOL 2.003 70.7 A 1 5 0 15 J CHILD ADOL PSYCHOP 1.982 70.2 A 0 0 0 0									5
EUR NEUROPSYCHOPHARM 2.045 71.3 A 0 0 0 1 J CLIN PHARMACOL 2.003 70.7 A 1 5 0 15 J CHILD ADOL PSYCHOP 1.982 70.2 A 0 0 0 0					Õ	0	0	0	0
J CLIN PHARMACOL 2.003 70.7 A 1 5 0 15 J CHILD ADOL PSYCHOP 1.982 70.2 A 0 0 0 0									1
J CHILD ADOL PSYCHOP 1.982 70.2 A 0 0 0 0					-			15	21
) CITED ADDITION							0		0
ACOULDS 1400 D70 /1 U V) V	ENOBIOTICA	1.968	69.6	Ä	ŏ	ō	1	Ô	1
CLIN NEUROPHARMACOL 1.943 69.1 A 1 0 0 2					-	-	0		3
ANTI CANCER DRUG DES 1.937 68.5 A 1 0 0 3					-	-			4
PERSPECT DRUG DISCOV 1.934 68.0 A 0 0 0 0						-			0
J NAT PROD 1.878 67.4 A 0 0 0							-	Ó	Ō


Subject Category, Area Pharmacology and Pharmacy	Impact Factor	Adjusted IF (%)	Publication Type	China n	HK n	SNG n	TW n	Total n
ANN PHARMACOTHER	1.868	66.9	A	1	7	0	3	11
PLANTA MED	1.831	66.3	В В	1 72	0 126	0 16	0 1 <i>7</i> 1	1
LIFE SCI EXP CLIN PSYCHOPHARM	1.808 1.747	65. <i>7</i> 65.2	В	0	0	0	0	385 0
NEUROTOXICOLOGY	1.740	64.6	B	Ö	Ŏ	ī	ŏ	ĭ
PHARMACOL BIOCHEM BE	1.732	63.5	В	7	1	2	13	23
THER DRUG MONIT	1.732	64.1	В	0	0	Õ	0	0
EUR J CLIN PHARMACOL	1.729 1.724	63.0 62.4	B B	0	6 0	5 0	4 0	15 0
PHARMACOTHERAPY CHEM BIOL INTERACT	1.707	61.9	В	Ö	ŏ	ő	1	1
PHARM SCI TECHNOL TO	1.671	61.3	В	0	0	0	0	0
CHIRALITY	1.603	60.8	В	1	1	0	3	5
J DRUG TARGET	1.582 1.570	60.2 59.7	B B	0	0 5	0	0 16	0 21
ANTI CANCER DRUG CNS DRUGS	1.562	59.1	В	ŏ	ŏ	ő	0	0
CLIN EXP PHARMACOL P	1.519	58.6	В	0	0	0	0	0
ALCOHOL	1.495	58.0	В	0	0	0	1	1
BIOMED PHARMACOTHER	1.483 1.459	57.5 56.9	B B	4 1	2 1	1 0	0	7 2
PHARMACOECONOMICS TOXICON	1.445	56.4	В	ò	Ó	0	Õ	ő
DRUG DEVELOP RES	1.442	55.8	В	Ŏ	Ō	Ö	Ō	Ō
J LIPOSOME RES	1.429	55.2	В	0	0	0	0	0
TOXICOLOGY	1.427	54.7	B B	0	0	0	0	0
QUANT STRUCT ACT REL IMMUNOPHARMACOLOGY	1.397 1.370	54.1 53.6	В	1	6	0	7	14
JANTIBIOT	1.347	53.0	B	2	ŏ	ŏ	4	6
INT J NEUROPSYCHOPH	1.323	52.5	В	0	0	0	0	0
INVEST NEW DRUG	1.322	51.9	В	Ò	0	0	0 1 <i>7</i>	0
JPN J PHARMACOL BIOMED CHROMATOGR	1.31 <i>7</i> 1.311	51.4 50.8	B B	1 65	2	9 3	5	29 73
MED LETT DRUGS THER	1.279	50 3	B	0	ŏ	ő	õ	Ő
CLIN EXP HYPERTENS	1.266	49.7	В	0	4	2	10	16
FUNDAM CLIN PHARM	1.265	49.2	В	0	0	0	2	2
COMP BIOCHEM PHYS C CAN J PHYSIOL PHARM	1 249 1.245	48.6 48.1	B B	0	0	0 0	0	0
J PHARM PHARMACOL	1 229	47.5	B	14	14	ĭ	72	101
INT J CLIN PHARM TH	1 222	47.0	В	0	5	0	3	8
EUR J PHARM SCI	1.212	46.4	В	1	0	2	2	5
PHARMACOL TOXICOL CHEM PHARM BULL	1.189 1.177	45.9 45.3	B B	0 1 <i>7</i>	0 1	0 11	0 30	0 59
INT I IMMUNOPATH PH	1.174	44.8	В	0	Ó	0	0	0
EXPERT OPIN THER PAT	1.156	44 2	В	Ö	Ō	Ō	Ö	0
AM J HEALTH SYST PH INT I IMMUNOPHARMACO	1.154	43.6	В	ō	1	2	Õ	3
INT J ANTIMICROB AG	1.142 1.141	43.1 42.5	B B	5 1	2	0 0	5 3	12 4
GEN PHARMACOL VASC S	1.140	42.0	В	5	1 <i>7</i>	1	1 <i>7</i>	40
HUM PSYCHOPHARM CLIN	1.103	41.4	В	0	0	0	0	0
PULM PHARMACOL THER PROG NEURO PSYCHOPH	1.094	40.9	В	1	0	0	0	1
EUR J PHARM BIOPHARM	1.078 1 077	40.3 39.8	B B	0 0	0	0 0	1 2	1 2
MICROENCAPSUL	1.076	39.2	В	11	0	11	26	48
ENVIRON TOXICOL PHAR	1.071	38.7	B	0	ŏ	0	Õ	Ö
REGUL TOXICOL PHARM	1.042	38.1	В	0	1	0	0	1
INT J PHARM CHEMOTHERAPY	1.024 1.021	37.6 37.0	B B	15	1	3	1 <i>7</i> 7	36
J PHARMACEUT BIOMED	1.013	36.5	B B	4 30	14 6	0 4	12	25 52
CANCER BIOTHER RADIO	0.989	35.9	B	0	ŏ	ó	1	1
CARDIOVASC DRUG THER	0.951	35.4	В	1	2	0	3	6
SKIN PHARMACOL APPL ARCH PHARM	0.940 0.923	34.8 34.3	В	0	0	0	1	1
I CHEMOTHERAPY	0.923	34.3 33.7	В В	4 0	0 5	0 1	1 1	5 7
CLIN PHARM THER	0.902	33.1	č	Ö	8	6	4	18
DRUG EXP CLIN RES	0.897	32.6	C C	6	4	0	0	10
ADV THER PHARMACOLOGY	0.896	32.0	Č C	0	0	0	6	6
CLIN DRUG INVEST	0.893 0.888	31.5 30.9	C	3 0	12 0	2 0	36 0	53 0
REV CONTEMP PHARMACO	0.887	30.4	ž	ő	0	0	Ö	ő

(continued)								
Subject Category, Area	Impact	Adjusted	Publication	China	HK	SNG	TW	Total
Pharmacology and Pharmacy	Factor	IF (%)	Туре	n	n	n	n	n
BIOL PHARM BULL	0.885	29.8	С	7	2	1	12	22
CARDIOVASC DRUG REV	0.881	29.3	č	ó	õ	ò	ō	0
PHARMACOEPIDEM DR S	0.867	28.7	Č C C	Õ	Õ	Ō	ŏ	ō
AM I PHARM EDUC	0.852	28.2	C	0	0	0	0	0
J PHARMACOKINET BIOP	0.848	27.6	C	0	0	0	0	0
DRUG NEWS PERSPECT	0.835	27.1	С	0	0	0	0	0
BIOPHARM DRUG DISPOS	0.819	26.5	Č	0	0	0	11	11
PHARMACOL RES	0.805	26.0	C C	12	7	3	3	25
BIOLOGICALS	0.789	25.4	Č	2	0	0	0	2
PHYTOMEDICINE	0.779	24.9	Č	1 0	0 7	0 4	0 8	1 19
J AUTON PHARMACOL PHARM WORLD SCI	0. <i>777</i> 0. <i>774</i>	24.3 23.8	Č	0	ó	0	1	1
FOOD DRUG LAW I	0.771	23.2	CCC	Õ	ő	Õ	ò	ò
IMMUNOPHARM IMMUNOT	0.761	22.7	č	ő	ŏ	Ŏ	ŏ	ŏ
I OCUL PHARMACOL TH	0.757	22.1	č	3	ŏ	ī	39	43
LABELLED COMPD RAD	0.756	21.5	Č	Ö	Ō	0	0	0
ARZNEIMITTEL FORSCH	0.671	21.0	С	5	0	0	2	7
J VET PHARMACOL THER	0.648	20.4	00000	1	0	0	0	1
ARCH PHARM RES	0.629	19.9	Č	0	0	1	0	1
J INT MED RES	0.620	19.3	Č	2	1	0	1	4
DRUG CHEM TOXICOL	0.619	18.2	Č	1	0	0	0	1
DRUG DEV IND PHARM	0.619	18.8	Č	10 0	0	1 0	14 0	25 0
DRUG INF J	0.616 0.614	1 <i>7.7</i> 17.1	Č	0	0	0	0	0
BIODRUGS	0.596	16.6	Č	1	0	0	Ő	1
DRUG DELIV J ETHNOPHARMACOL	0.575	16.0	č	ó	ő	ŏ	Õ	ò
FARMACO	0.565	15.5	000000000000000000000000000000000000000	ŏ	Ŏ	Ŏ	ŏ	Õ
PDA J PHARM SCI TECH	0.564	14.9	Č	0	0	1	0	1
FORMULARY	0.547	14.4	С	0	0	0	0	0
METHOD FIND EXP CLIN	0.543	13.8	С	36	20	5	3	64
CURR THER RES CLIN E	0.519	13.3	Č	0	0	0	0	0
STP PHARMA SCI	0.496	12.7	Č	0	0	0 0	0 10	0 1 <i>7</i>
RES COMMUN MOL PATH	0.495	12.2	Č	4 0	3 0	0	0	0
EUR J DRUG METAB PH	0.488	11.6	Č	1249	13	0	1	1263
ACTA PHARMACOL SIN	0.485 0.471	11.0 10.5	č	13	2	1	2	18
PHARMAZIE POL I PHARMACOL	0.456	9.9	č	ő	ō	ó	ō	0
THERAPIE	0.432	9.4	č	ŏ	Õ	0	0	0
PHYTOTHER RES	0.422	8.8	Č	2	1	2	5	10
INT J TOXICOL	0.416	8.3	C	0	0	0	0	0
INT J CLIN PHARM RES	0.410	7.7	C	1	4	0	0	5
J PHÁRMACOL TOXICOL	0.350	7.2	Č	0	1	0	0	1 0
DRUGS TODAY	0.339	6.6	C	0	0	0	0	0
PHARM IND	0.314	6.1	Č	0 1	0	0	0	1
YAKUGAKU ZASSHI	0.301	5.5 5.0	000000000000000000000000000000000000000	Ó	0	0	0	ò
PSYCHOPHARMAKOTHERAP	0.301	5.0 4.4	č	1	ő	ő	ŏ	ĭ
J ASIAN NAT PROD RES	0.294 0.278	3.9	č	12	ő	ŏ	Ö	12
FITOTERAPIA J FOOD DRUG ANAL	0.227	3.3	č	Õ	Ŏ	Ō	0	0
BIOPHARM APPL T BIO	0.200	2.8	Č	Ö	0	0	0	0
CLIN RES REGUL AFF	0.138	2.2	C	0	0	0	0	0
PHARM BIOL	0.132	1.7	Č	0	0	0	0	0
DRUG FUTURE	0.015	1.1	ç	0	0	0	0	0
GIORN NEUROPSICOFARM	0.000	0.6	С	0	0	0	0	U
Total				1830	574	197	1268	3869
Total				1000	J, T			

Physiology

Number of full papers (with impact factor) in Medline





Physiology subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).


Journals sorted according to the impact factor provided by the *Journal Citation Reports* (JCR) 2000 version for Physiology JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category: a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW).


Subject Category, Area Physiology	Impact Factor	Adjusted IF (%)	Publication_ Type	China n	HK n	SNG n	TW n	Total n
Approximate control of the control o	27.677	100.0		0	0	0	0	0
PHYSIOL REV ANNU REV PHYSIOL	18.848	98 7	A A	0	Ö	0	0	0
I GEN PHYSIOL	6.082	97 4	Ä	ŏ	ŏ	ő	3	3
REV PHYSIOL BIOCH P	5.389	96.1	Ä	ŏ	ŏ	Õ	Ö	ō
I PHYSIOL LONDON	4.455	94 7	Α	5	17	0	20	42
ÁM J PHYSIOL RENAL	4.129	93 4	Α	0	0	0	1	1
AM J PHYSIOL CELL PH	4 086	92.1	Ą	0	4	0	2	6
J NEUROPHYSIOL	3.855	90 8	Ą	5	0	0	7	12
J PINEAL RES	3.779	89 5	A	1	17	2 0	5 15	25 18
J CELL PHYSIOL	3.474 3.303	88.2 86 8	A A	1 0	2 0	0	13	1
AM J PHYSIOL LUNG C AM J PHYSIOL HEART C	3.243	85 5	Ä	1	3	ő	3	ż
AM J PHYSIOL ENDOC M	3.183	84 2	Â	ò	ŏ	Ŏ	ŏ	Ó
AM I PHYSIOL GASTR L	3.115	82.9	A	0	2	0	1	3
PSYCHOPHYSIOLOGY	3.106	81.6	Α	1	0	0	0	1
J MEMBRANE BIOL	2.973	80 3	A	1	5	0	2	8
J BIOL RHYTHM	2.867	78 9	A	0	0	0	0	0
AM J PHYSIOL REG I	2 765	77 6	A	1	2	0	1	4 1
J VASC RES	2.710	76 3	A A	1 0	0	0	0	Ó
EXERCISE SPORT SCI R REGUL PEPTIDES	2.667 2.634	75 0 73.7	Ä	12	3	2	14	31
PHYSIOL ZOOL	2.543	72.4	Ä	1	ő	õ	0	1
J MAMMARY GLAND BIOL	2.493	71.1	Ä	ò	Ŏ	Õ	ō	Ó
I APPL PHYSIOL	2 297	69.7	Ä	Ō	0	0	0	0
PFLUG ARCH EUR J PHY	2.203	68.4	Α	4	5	0	10	1 9
CHEM SENSES	2.176	67.1	A	0	1	0	0	1
NEWS PHYSIOL SCI	2 060	65.8	В	0	0	0	0	0
J SLEEP RES	2 022	64.5	В	0 0	1 0	0	0 1	1 1
CHRONOBIOL INT	1.883	63.2	B B	0	0	0	6	6
ACTA PHYSIOL SCAND PANCREAS	1.764 1.648	61.8 60.5	В	3	ŏ	1	14	18
RESP PHYSIOL	1.575	59.2	B	ŏ	ŏ	Ò	0	0
CRYOBIOLOGY	1.532	57.9	B	9	Ō	0	2	11
CLIN EXP PHARMACOL P	1.519	56.6	В	23	36	8	29	96
J COMP PHYSIOL A	1.496	55 3	В	1	0	0	0	1
INT J PSYCHOPHYSIOL	1.489	53.9	В	0	Ŏ	0	0	0
J INSECT PHYSIOL	1.468	52.6	В	0	0 1	0	0	0 1
EUR J APPL PHYSIOL	1.404	51.3	B B	0	ò	0	1	i
KIDNEY BLOOD PRESS R	1.378 1.366	50.0 48. <i>7</i>	В	ő	ŏ	Õ	ó	ò
PHYSIOL RES JPN J PHYSIOL	1.351	47.4	B	4	ĭ	1	9	15
J PHYSIOL PARIS	1.339	46.1	B	ĺ	0	0	0	1
J COMP PHYSIOL B	1.324	44.7	В	1	0	0	0	1
CLIN J SPORT MED	1.255	43.4	В	0	0	0	0	0
CAN J PHYSIOL PHARM	1.245	42.1	В	3	2	3	7	15 0
FISH PHYSIOL BIOCHEM	1.240	40.8	В	0	0	0	0	0
PESTIC BIOCHEM PHYS	1.233	39.5	B B	1	0	Ö	ŏ	1
ARCH INSECT BIOCHEM	1.159	38.2 36.8	В	Ó	1	Õ	ŏ	i
J ELECTROMYOGR KINES PHYSIOL BIOCHEM ZOOL	1.146 1.135	35.5	В	ŏ	ò	ŏ	ĩ	i
CAN J APPL PHYSIOL	1.119	34.2	B	Ĭ	0	0	0	1
EXP PHYSIOL	1.057	32.9	Č	0	5	0	0	5
CRYO LETT	1.053	31.6	000000000	0	0	0	0	0
J PHYSIOL PHARMACOL	1.025	30.3	Ç	Ö	0	0	0	0
Q J EXP PSYCHOL B	1.000	28.9	C	0	0	0	0	0 1
CLIN PHYSIOL	0.984	27.6	ر	1 11	0	0	1	12
LYMPHOLOGY	0.974	26.3	2	0	0	0	Ò	0
J PHYSIOL BIOCHEM	0.958	25.0 23.7	č	Ö	1	ŏ	1	2
INT J PANCREATOL PHYSIOL MEAS	0.924 0.905	22.4	č	Ö	ò	ĺ	ò	1
TITISIOL MEAS	0.705					,,		


Subject Category, Area	Impact	Adjusted	Publication	China	НК	SNG	TW	Total
Physiology	Factor	IF (%)	Type	n	n	n	n	n
COMP BIOCHEM PHYS A	0 883	21 1	С	0	0	0	1	1
ARCH PHYSIOL BIOCHEM	0 841	19 7	С	1	0	0	0	1
I BIOL REG HOMEOS AG	0 803	18 4	C	1	0	0	0	1
HYPERTENS PREGNANCY	0 750	17 1	С	0	1	0	0	1
PEDIATR EXERC SCI	0.732	15 8	C	0	0	0	0	0
INT I BIOMETEOROL	0 652	14 5	С	1	0	0	0	1
CURR TOP CELL REGUL	0 636	13 2	С	0	0	0	0	0
NEUROPHYSIOL CLIN	0 516	11 8	С	0	0	0	0	0
CHINESE I PHYSIOL	0 422	10 5	С	3	2	0	284	289
GEN PHYSIOL BIOPHYS	0 417	9 2	C	0	0	0	0	0
ZH VYSSH NERV DEYAT+	0 374	79	С	0	0	0	0	0
BIOL RHYTHM RES	0 320	6 6	С	0	0	0	0	0
I EVOL BIOCHEM PHYS+	0 205	5 3	С	0	0	0	0	0
KLIN NEUROPHYSIOL	0 203	3 9	С	0	0	0	0	0
JPN J PHYS FIT SPORT	0 135	2 6	С	0	0	0	0	0
ADV PHYSIOL EDUC	0 037	1 3	С	0	0	0	0	0
Total				99	112	18	442	671


Psychiatry

Number of full papers (with impact factor) in Medline









Psychiatry subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).


Journals sorted according to the impact factor provided by the *Journal Citation Reports* (JCR) 2000 version for Psychiatry JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category, a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW)


Subject Category Area	Impact	Adjusted	Publication	China	HK	SNG	TW	Total
Psychiatry	Factor	IF (%)	Туре	n	n	n	<u>n</u> _	n
ARCH GEN PSYCHIAT	11 778	100 0	A	0	1	0	1	2
MOL PSYCHIATR	8 927	98 8	Ą	0	Õ	0	3	3
AM J PSYCHIAT	6 577	97 6	A	4	3	0	3	10
SCHIZOPHRENIA BULL	6 085	96 3 95 1	A A	0	1 2	1	0	2
J CLIN PSYCHOPHARM BRIT I PSYCHIAT	5 052 4 827	93 9	Ä	7	12	6	8	4 33
NEUROPSYCHOPHARMACOL	4 579	92 7	Ä	1	0	Ö	2	3
I CLIN PSYCHIAT	4 454	91 5	Ä	Ó	ŏ	ŏ	6	6
BIOL PSYCHIAT	4 269	90 2	A	1	1	1	14	17
SCHIZOPHR RES	3 506	89 0	Α	0	3	3	8	14
PSYCHOL MED	3 412	87 8	Ą	0	0	0	0	0
PSYCHOSOM MED	3 246	86 6	Ą	1	0	0	0	1
J AM ACAD CHILD PSY	3 175	85 4	A	4	2	0	2	8
J NEUROL NEUROSUR PS PSYCHOPHARMACOL BULL	2 846 2 809	84 1 82 9	A A	0 0	0	0	0	0
PSYCHOPHARMACOLOGY	2 804	81 7	Ä	Ö	2	0	5	7
DRUG ALCOHOL DEPEN	2 689	80 5	Ä	1	Õ	Õ	ő	í
PHARMACOPSYCHIATRY	2 681	79 3	Â	ó	ĭ	Õ	ŏ	i
ADDICTION	2 494	78 0	Α	0	1	0	0	1
J INT NEUROPSYCH SOC	2 376	<i>7</i> 6 8	Α	0	1	0	0	1
PSYCHOTHER PSYCHOSOM	2 372	75 6	Ą	0	0	0	0	0
J PSYCHIAT RES	2 330	74 4	Ą	0	0	0	0	0
J PSYCHOPHARMACOL	2 328	73 2 73 0	A	0	0	0	0	0
J NEUROPSYCH CLIN N INT CLIN PSYCHOPHARM	2 140 2 076	72 0 70 7	A A	1 0	0	0	0 2	2
EUR NEUROPSYCHOPHARM	2 0/6	69 5	Ä	0	0	0	1	1
I PSYCHIATR NEUROSCI	2 039	68 3	Ä	Ö	ő	ŏ	ò	ò
J CHILD ADOL PSYCHOP	1 982	67 1	Ä	ŏ	ŏ	ŏ	ŏ	ŏ
AM J ORTHOPSYCHIAT	1 939	65 9	В	0	Ō	Ō	Ō	0
J AFFECT DISORDERS	1 938	64 6	В	0	11	1	6	18
PSYCHIAT RES NEUROIM	1 919	63 4	В	0	0	0	0	0
NEUROCASE LECT	1 871	62 2	В	0	0	0	0	0
PSYCHIATR SERV	1 817 1 795	61 0 59 8	B B	0	0	0	0	0
ACTA PSYCHIAT SCAND	1 774	58 5	В	0 5	0 16	0 7	1 11	1 39
DEMENT GERIATR COGN	1 763	57 3	В	0	0	ó	1	39 1
EXP CLIN PSYCHOPHARM	1 747	56 1	B	ŏ	ŏ	Ö	ò	ó
I NERV MENT DIS	1 626	54 9	B	Ö	8	ĭ	3	12
CAN J PSYCHIAT	1 623	53 <i>7</i>	В	1	4	0	0	5
NEUROPSYCHOBIOLOGY	1 560	52 4	В	0	0	0	1	1
PSYCHIAT RES PSYCHOSOMATICS	1 557	51 2	В	3	2	3	10	18
GEN HOSP PSYCHIAT	1 555 1 512	50 0 48 8	B B	0 0	0 5	0	0	0
INT J GERIATR PSYCH	1 495	47 6	В	0	5 11	1 3	6 1	12 15
J PSYCHOSOM RES	1 446	46 3	B	Ö	4	0	4	8
COMPR PSYCHIAT	1 400	45 1	B	ĭ	i	ŏ	Ö	2
EUR ARCH PSY CLIN N	1 385	43 9	В	Ó	i	Ŏ	Ö	ī
INT J EAT DISORDER	1 336	42 7	В	0	1	0	0	1
INT J NEUROPSYCHOPH	1 323	41 5	В	0	0	0	0	0
AUST NZ J PSYCHIAT J INTELL DISABIL RES	1 265	40 2	В	0	25	15	3	43
HUM PSYCHOPHARM CLIN	1 123 1 103	39 0	В	0	2	0	1	3
PROG NEURO PSYCHOPH	1 078	37 8 36 6	B B	0 2	0 1	0	0	Ō
INT I PSYCHIAT MED	1 033	35 4	В	0	Ó	0	2	5 3
BEHAV MED	1 000	34 1	В	1	0	0	3 0	ა 1
J GERIATR PSYCH NEUR	0 909	32 9	Č	Ó	2	0	0	2
NEUROPSY NEUROPSY BE	0 896	31 7	č	ŏ	Õ	Ô	1	ī
PSYCHIATRY	0 827	30 5	C	ŏ	1	ő	Ó	i
MENT RETARD DEV D R	0 800	29 3	C	0	ò	ŏ	ŏ	Ó
STRESS MEDICINE	0 759	28 0	С	0	0	0	0	0

Subject Category Area	Impact	Adjusted	Publication	China	НК	SNG	TW	Total
Psychiatry	Factor	IF (%)	Туре	n	n	n	n	n
EUR PSYCHIAT	0 748	26 8	С	0	0	0	0	0
SUBST USE MISUSE	0 687	25 6	C	1	0	0	0	1
FORTSCHR NEUROL PSYC	0 636	23 2	C	0	0	0	0	0
BRIT J MED PSYCHOL	0 562	22 0	Ç	0	1	0	0	1
PSYCHOPATHOLOGY	0 547	20 7	C	0	0	0	1	1
J PSYCHOSOM OBST GYN	0 529	19 5	C	0	1	0	0	1
Z PSYCHOSOM MED PSYC	0 490	18 3	С	0	0	0	0	0
PSYCHIAT CLIN NEUROS	0 452	17 1	C	17	3	1	15	36
CHILD PSYCHIAT HUM D	0 422	15 9	С	0	0	0	1	1
NEUROPSYCHIATRIE	0 387	14 6	Ç	0	0	0	0	0
VERHALTENSTHERAPIE	0 311	13 4	Ç	0	0	О	0	0
ACTAS LUSO ESP NEUR	0 302	12 2	С	0	0	0	0	0
PSYCHOPHARMAKOTHERAP	0 301	11 0	Ç	0	0	0	0	0
NEUROL PSYCHIAT BR	0 278	98	Ç	Ō	0	Q.	0	0
nervenheilkunde	0 276	8 5	Č	Q.	Ō	Q.	0	0
ENCEPHALE	0 262	7 3	Č	0	0	0	0	0
ANN MED PSYCHOL	0 236	6 1	Ç	Ō	0	0	0	0
ARQ NEURO PSIQUIAT	0 197	4 9	Č	Q	0	0	Ō	0
ZH NEVROPATOL PSIKH	0 109	3 7	Č	0	0	0	0	0
ACTAS ESP PSIQUIATRI	0 098	2 4	Č	0	Ü	0	0	0
ACTA NEUROPSYCHIATR	0 036	1 2	C	0	0	0	0	0
Total				52	130	44	126	352

Public, Environmental and Occupational Health

Number of full papers (with impact factor) in Medline





Public, Environmental and Occupational Health subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).


Journals sorted according to the impact factor provided by the *Journal Citation Reports* (JCR) 2000 version for Public, Environmental and Occupational Health JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category: a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW).


Subject Category, Area Public, Environmental and Occupational Health	Impact Factor	Adjusted IF (%)	Publication Type	China n	HK n	SNG n	TW	Total n
ANNU REV PUBL HEALTH	4.524	100.0	A	0	0	0	0	0
CANCER EPIDEM BIOMAR	4.354	98.9	Â	10	2	3	5	20
AM I EPIDEMIOL	3.870	97.7	Ä	7	4	Ó	17	28
EPIDEMIOLOGY	3.632	96.6	Α	4	0	0	3	7
AM J PUBLIC HEALTH	3.269	95.5	Α	2	1	1	4	8
ENVIRON HEALTH PERSP	3.033	94.3	Α	7	0	4	10	21
DRUG SAFETY	2.763	93.2	Α	0	1	0	0	1
MED CARE	2.535	92 0	Ą	1	0	0	0	1
CANCER CAUSE CONTROL	2.464	90.9	Ą	3	0	3	3	9
J TOXICOL ENV HEAL B	2.360	89.8	A	0 4	0	0 8	0 18	0 31
OCCUP ENVIRON MED	2.262	88.6 87.5	A A	0	1 0	0	0	0
EPIDEMIOL REV AM I PREV MED	2.250 2.192	86.4	Â	ő	1	ő	2	3
QUAL LIFE RES	2.192	85.2	A	1	ó	1	1	ź
TOXICOL IND HEALTH	2.151	84.1	Â	i	ŏ	Ó	ò	1
INFECT CONT HOSP EP	2.082	83.0	Â	Ó	4	i	8	13
I CLIN EPIDEMIOL	2.075	81.8	A	2	3	0	8	13
PALLIATIVE MED	1.989	80.7	Α	0	3	0	1	4
J MED SCREEN	1.986	79.5	A	2	0	0	0	2
B WORLD HEALTH ORGAN	1.937	78.4	Ą	13	1	2	0	16 0
WHO TECH REP SER	1.900	77.3	A	0	0 7	0 9	0 22	66
INT J EPIDEMIOL	1.892	76.1 75.0	A	28 11	ó	3	22	36
ENVIRON RES	1.845 1.844	75.0 73.9	A A	1	2	ő	1	4
ANN EPIDEMIOL J EPIDEMIOL COMMUN H	1.827	72.7	Ä	i	13	7	3	24
PSYCHIATR SERV	1.795	71.6	Ä	ò	4	Ó	Ō	4
EPIDEMIOL INFECT	1.775	70.5	A	4	14	7	11	36
AM J TROP MED HYG	1.765	69.3	Α	0	0	0	Ō	Ō
THER DRUG MONIT	1.732	68.2	Α	0	0	0	0	0
STAT MED	1.717	65.9	В	0	1	0 1	0	1 1
TOB CONTROL	1.717	67.0	A	0 4	0 9	Ó	11	24
NEUROEPIDEMIOLOGY	1.654	64.8	B B	8	0	1	36	45
ARCH ENVIRON HEALTH	1.613 1.574	63.6 62.5	В	2	ŏ	7	3	12
SCAND J WORK ENV HEA PREV MED	1.557	61.4	В	ō	2	2	6	10
PUBLIC HEALTH REP	1.517	60.2	B	Ō	1	0	0	1
J EXPO ANAL ENV EPID	1.489	59.1	В	0	0	0	1	1
T ROY SOC TROP MED H	1.485	58.0	В	0	0	0	0	0
J ADOLESCENT HEALTH	1.415	56.8	В	0	3	0	4	7
J WOMENS HEALTH	1.395	55.7	В	0	0	0	0 3	0 36
COMMUNITY DENT ORAL	1.350	53.4	B B	6 0	20 0	7 1	0	1
TROP MED INT HEALTH	1.350	54.5 52.3	В	1	ŏ	3	2	6
GENET EPIDEMIOL	1.313 1.277	51.1	B	17	ĭ	12	8	38
AM J IND MED PAEDIATR PERINAT EP	1.265	50.0	B	ő	1	0	0	1
J OCCUP ENVIRON MED	1.251	48.9	B	2	2	1	9	14
SCAND I SOC MED	1.250	47.7	В	0	1	0	0	1
EUR J PÚBLIC HEALTH	1.165	46.6	В	0	0	0	0	0
ANN OCCUP HYG	1.064	45.5	В	1	0	0	0	1 0
QUAL HEALTH CARE	1.026	44.3	В	0	0 3	0 3	2	9
J PUBLIC HEALTH MED	1.015	43.2	B B	Ó	0	0	1	1
J TOXICOL ENV HEAL A	1.009	42.0 40.9	В	Ö	ŏ	ŏ	ò	ó
ANN TROP MED PARASIT	0.988 0.984	39.8	В	Ö	ŏ	ŏ	ŏ	ŏ
INT J TECHNOL ASSESS J AEROSOL MED	0.904	38.6	B	ŏ	ŏ	Ō	0	0
INT ARCH OCC ENV HEA	0.928	37.5	B	6	0	7	14	27
EUR J EPIDEMIOL	0.918	36.4	В	3	1	0	5	9
J OCCUP HEALTH	0.892	35.2	B	0	0	0	O O	0
PATIENT EDUC COUNS	0.875	34.1	' B	0	1	0	0	1 15
ANN HUM BIOL	0.835	33.0	С	10	2	3	<u> </u>	13

Subject Category, Area	Impact	Adjusted	Publication	China	HK	SNG	TW	Total
Public, Environmental and Occupational	Factor	IF (%)	Туре	n	n	n	n	n
I SCHOOL HEALTH	0 789	31 8	С	1	0	0	0	1
FLUORIDE	0 690	30.7	С	0	0	0	0	0
J PUBLIC HEALTH POL	0 674	29 5	С	0	0	0	0	0
J ENVIRON SCI HEAL B	0 673	28 4	С	0	0	1	15	16
AVIAT SPACE ENVIR MD	0 658	27.3	С	0	0	0	0	0
J PUBLIC HEALTH DENT	0 656	26.1	С	0	4	0	0	4
PUBLIC HEALTH	0 600	25 0	C	2	12	0	13	27
AM IND HYG ASSOC J	0.565	23 9	С	2	0	1	10	13
OCCUP MED OXFORD	0 531	22 7	С	0	5	18	5	28
IND HEALTH	0 500	20 5	С	0	1	0	0	1
REV EPIDEMIOL SANTE	0 500	21 6	С	0	0	0	0	0
BIOMED ENVIRON SCI	0.400	19 3	Ç	167	11	1	1	180
J WOMEN HEALTH GEN B	0.395	18.2		0	0	0	1	1
OCCUP MED STATE ART	0.387	17 0	Ç	0	0	1	0	1
ENVIRON GEOCHEM HLTH	0.351	15.9	Ç	0	0	0	0	0
J URBAN HEALTH	0.345	14 8	Ç	0	0	0	0	0
SCAND J PUBLIC HEALT	0.340	13 6	Č	Q	0	0	0	0
WORLD HEALTH FORUM	0.315	12 5	Č	6	0	7	0	13
TROP DOCT	0.282	11.4	Č	1	0	0	0	1
ZBL HYG UMWELTMED	0 244	10 2	Č	0	0	0	0	0
INDOOR BUILT ENVIRON	0.243	9.1	Č	0	0	0	0	0
SOZ PRAVENTIV MED	0 238	8.0	Ç	0	0	0	0	0
J ENVIRON HEALTH	0 188	6.8	Ç	0	0	0	0	0
INT J ENVIRON HEAL R	0 172	5 7	Č	Q	0	Ō	0	0
B SOC PATHOL EXOT	0 151	4.5	Č	O.	0	0	0	0
WILD ENVIRON MED	0 098	3 4	Č	1	0	0	0	1
INT J HYG ENVIR HEAL	0 080	2 3	CCC	0	0	0	0	0
J HEALTH POPUL NUTR	0.037	1 1	C	0	0	0	0	0
Total				343	142	126	289	900

Radiology, Nuclear Medicine and Medical Imaging

Number of full papers (with impact factor) in Medline





Radiology, Nuclear Medicine and Medical Imaging subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).

Journals sorted according to the impact factor provided by the *Journal Citation Reports* (JCR) 2000 version for Radiology, Nuclear Medicine and Medical Imaging JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category: a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW).


Subject Category, Area Radiology, Nuclear Medicine and Medical Imaging	Impact Factor	Adjusted IF (%)	Publication Type	China n	HK n	SNG n	TW n	Total n
$- \frac{1}{2} \left(\frac{1}{2}$							***************************************	
NEUROIMAGE	6.857	100.0	A	0	0	1	0	1
HUM BRAIN MAPP	5.163	98.8	A	1	0	0	0	1
RADIOLOGY	4.130	97.5	Ą	6	8	1	31	46
EUR J NUCL MED	3.772	96.3	A	3	5	0	34	42
J NUCL MED	3.617	95.0	Ą	8	3	1	37	49
MAGNET RESON MED	3.121	93.8	A	0	- 1	0	4	5
INT J RADIAT ONCOL	3.058	92.5	Ą	18	37	2	32	89
STRAHLENTHER ONKOL	2.846	91.3	Ą	0	0	0	0	0
RADIAT RES	2.752	90.0	Ą	9	0	0	7	16
INT J RADIAT BIOL	2.586	88.8	Ą	11	1	0	11	23
IEEE T MED IMAGING	2.573	87.5	Ą	2	1	0	6	9
RADIOTHER ONCOL	2.469	86.3	Ą	1	8	0	5	14
MED PHYS	2.428	85.0	. A	5	3	0	10	18
SEMIN RADIAT ONCOL	2.427	83.8	Α	0	0	0	0	0
J CARDIOV MAGN RESON	2.304	82.5	Α	О	0	0	0	0
SEMIN NUCL MED	2.143	81.3	Α	0	0	0	12	12
AM J NEURORADIOL	2.126	80.0	Α	3	13	2	34	52
PHYS MED BIOL	2.013	78.8	Α	8	13	1	3	25
NMR BIOMED	1.914	77.5	Α	0	0	0	0	0
Q J NUCL MED	1.910	76.3	Α	0	0	0	0	0
AM J ROENTGENOL	1.863	75.0	Α	7	29	4	27	67
J NUCL CARDIOL	1.854	73.8	Α	2	0	1	3	6
ULTRASOUND MED BIOL	1.822	72.5	Α	6	7	0	30	43
ULTRASONIC IMAGING	1.794	71.3	Α	0	0	Ö	4	4
J VASC INTERV RADIOL	1.729	70.0	Α	4	2	1	4	11
ULTRASOUND OBST GYN	1.725	68.8	A	Ó	18	4	27	49
BRAIN TOPOGR	1.596	67.5	Ä	$\tilde{2}$	0	Ö	0	2
NUCL MED BIOL	1.580	66.3	В	8	ĭ	ŏ	8	17
RADIOL CLIN N AM	1.529	65.0	B	Ö	ò	2	1	3
J COMPUT ASSIST TOMO	1.484	63.8	В	2	2	4	23	31
MAGN RESON IMAGING	1.452	62.5	B	6	õ	ò	5	11
INVEST RADIOL	1.410	61.3	B	4	í	1	2	8
RADIOGRAPHICS	1.396	60.0	B	Ö	4	ò	3	7
JMRI J MAGN RESON IM	1.302	58.8	В	ő	1	4	5	10
EUR RADIOL	1.119	57.5	B	Ö	2	2	2	6
I RADIAT RES	1.111	56.3	B	9	0	0	3	12
RADIAT ENVIRON BIOPH	1.110	55.0	В	2	0	ő	0	2
NEUROIMAG CLIN N AM	1.095	53.8	В	Ô	Ö	1	0	1
NUCL MED COMMUN	1.039	52.5	В	9	1	4		82
CARDIOVASC INTER RAD	1.029	51.3	В	7	1	0	68 6	14
ROFO FORTSCHR RONTG	1.005	50.0	В	ó	Ó	0	0	0
NEURORADIOLOGY	0.997	48.8	В	3	4	1		5 <i>7</i>
CANCER BIOTHER RADIO	0.989	47.5	В	0	0		49	
HEALTH PHYS	0.988	46.3	В			0	1	1
I ULTRAS MED	0.966	45.0		18	19	0	14	51
NUKLEARMED NUCL MED	0.965		В	2	19	2	66	89
INT HYPERTHER	0.952	43.8	В	0	0	0	3	3
BRIT J RADIOL		42.5	В	8	0	2	0	10
NEUROIMAGING	0.951	41.3	В	3	71	2	24	100
CLIN RADIOL	0.942	40.0	В	1	1	0	5	7
ULTRASCHALL MED	0.934	38.8	В	2	101	23	4	130
ACAD RADIOL	0.925	37.5	В	0	0	0	0	0
ABDOM IMAGING	0.912	36.3	В	3	0	2	2	7
EUR J RADIOL	0.866	35.0	В	1	4	0	34	39
	0.822	33.8	В	2	11	. 3	21	37
SEMIN ULTRASOUND CT	0.797	32.5	Č	0	1	1	1	3
ACTA RADIOL	0.785	31.3	C	6	5	0	7	18
DENTOMAXILLOFAC RAD	0.780	30.0	C	4	3	- 0	4	1.1
DIGIT IMAGING APPL RADIAT ISOTOPES	0.722	28.8	C	. 0	0	2	3	5
APPL KALIJALISCIJI IDES	0.716	27.5	C	17	10	0	21	48

Subject Category, Area	Impact	Adjusted	Publication	China	HK	SNG	TW	Total
Radiology, Nuclear Medicine and Medical Imaging	Factor	IF (%)	Туре	n	n	n	n	n
ULTRASONICS	0.711	26.3	С	7	0	1	2	10
SKELETAL RADIOL	0.695	25.0	C	1	11	3	5	20
PEDIATR RADIOL	0.684	23.8	C	1	15	2	27	45
J THORAC IMAG	0.663	22.5	С	0	0	0	3	3
RADIOLOGE	0.608	21.3	C	0	0	0	0	0
SEMIN ROENTGENOL	0.5 <i>97</i>	20.0	C	0	1	0	0	1
J CLIN ULTRASOUND	0.596	18.8	C	8	14	2	98	122
INTERV NEURORADIOL	0.585	1 <i>7</i> .5	Ç	0	0	0	0	0
RADIAT PROT DOSIM	0.581	16.3	C	1	0	0	0	1
INT J CARDIAC IMAG	0.541	15.0	C	0	0	0	2	2
COMPUT MED IMAG GRAP	0.500	13.8	С	2	1	0	13	16
J NEURORADIOLOGY	0.451	12.5	. C	0	0	0	0	0
CLIN NUCL MED	0.399	11.3	C	9	8	0	129	146
CLIN IMAG	0.368	10.0	Ç	1	10	0	28	39
J RADIOL	0.345	8.8	Č	1	0	0	0	1
SURG RADIOL ANAT	0.314	7.5	Ç	0	0	0	0	0
CRIT REV DIAGN IMAG	0.312	6.3	Č	0	0	0	0	0
CAN ASSOC RADIOL J	0.268	5.0	Č	0	0	O.	0	0
SEMIN INTERVENT RAD	0.160	3.8	Č	0	0	0	0	0
INT J NEURORADIOL	0.139	2.5	Ç	0	0	0	0	0
RIV NEURORADIOL	0.051	1.3	С	0	0	0	0	0
Total				244	471	82	1013	1810

Reproductive Biology

Number of full papers (with impact factor) in Medline

Academia



12 year period - 1990 to 2001 Three year groups CUHK


Reproductive Biology subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).

Journals sorted according to the impact factor provided by the *Journal Citation Reports* (JCR) 2000 version for Reproductive Biology JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category: a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW).

Subject Category, Area Reproductive Biology	Impact Factor	Adjusted IF (%)	Publication Type	China	HK	SNG	TW	Total
Reproductive biology	racioi	11 (70)	Type	n	n	n	n	n
REV REPROD	3.938	100.0	Α	0	0	1	0	1
BIOL REPROD	3.605	95. <i>7</i>	Α	12	19	0	9	40
MOL HUM REPROD	3.232	91.3	- A	4	3	5	7	19
hum reprod	2.997	87.0	Α	14	49	24	50	137
hum reprod update	2.887	82.6	Α	0	0	1	0	1
FERTIL STERIL	2.854	78.3	Α	7	19	18	40	84
PLACENTA	2.587	73.9	Α	2	3	1	1	7
MOL REPROD DEV	2.535	69.6	Α	14	1	5	19	39
SEX PLANT REPROD	2.260	65.2	В	0	0	0	0	0
THERIOGENOLOGY	2.062	60.9	В	0	0	0	1	1
J REPROD FERTIL	1.970	56.5	В	7	1	2	2	12
SEMIN REPROD ENDOCR	1.952	52.2	В	0	0	0	0	0
AM J REPROD IMMUNOL	1.932	47.8	В	0	0	0	0	0
I REPROD IMMUNOL	1. <i>77</i> 1	43.5	В	1	0	0	1	2
ZYGOTE	1.365	39.1	В	1	0	0	0	1
REPROD NUTR DEV	1.351	34.8	В	0	0	0	1	1
REPROD TOXICOL	1.347	30.4	С	1	0	0	0	1
REPROD FERT DEVELOP	1.098	26.1	С	0	1	0	0	1
ANIM REPROD SCI	1.080	21.7	C	1	0	0	2	3
INVERTEBR REPROD DEV	0.733	17.4	С	0	0	0	0	0
EUR J OBSTET GYN R B	0.703	13.0	· C	2	17	3	12	34
REPROD DOMEST ANIM	0.521	8. <i>7</i>	С	1	0	0	0	1
ADV CONTRACEPT	0.509	4.3	C	13	1	12	0	26
Total				80	114	72	145	411

Respiratory System

Number of full papers (with impact factor) in Medline




Respiratory System subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).


Journals sorted according to the impact factor provided by the *Journal Citation Reports* (JCR) 2000 version for Respiratory System JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK). Singapore (SNG) and Taiwan (TW)

Subject Category Area Respiratory System	Impact Factor	Adjusted IF (%)	Publication Type	China	HK	SNG	TW	Total
Respiratory System	i actor	11 (70)	Type	<u>n</u>	<u>n</u>	<u>n</u>	n	n_
AM J RESP CRIT CARE	5 443	100 0	Α	5	11	3	24	43
AM J RESP CELL MOL	4 353	96 6	Α	1	0	0	3	4
THORAX	3 979	93 1	Α	3	5	6	23	37
am j physiol lung C	3 303	89 <i>7</i>	Α	1	1	1	1	4
J THORAC CARDIOV SUR	3 057	86 2	Α	0	0	0	0	0
EUR RESPIR J	2 590	82 8	Α	1	13	11	20	45
J HEART LUNG TRANSPL	2 526	<i>7</i> 9 3	Α	1	0	0	0	1
CHEST	2 451	75 9	Α	6	42	13	111	172
INT J TUBERC LUNG D	2 011	72 4	Α	6	5	3	6	20
ANN THORAC SURG	1 828	69 0	Α	0	0	0	0	0
EXP LUNG RES	1 760	65 5	В	0	0	0	0	0
TOB CONTROL	1 <i>717</i>	62 1	В	0	0	0	1	1
SARCOIDOSIS VASC DIF	1 690	58 6	В	0	0	0	0	0
CLIN CHEST MED	1 627	55 2	В	0	0	0	1	1
RESP PHYSIOL	1 575	51 7	В	4	0	0	6	10
PEDIATR PULM	1 545	48 3	В	2	2	1	13	18
J ASTHMA	1 419	44 8	В	1	5	0	11	17
LUNG CANCER J IASLC	1 401	41 4	В	20	4	0	6	30
RESP MED	1 254	37 9	В	1	15	7	14	37
LUNG	1 188	34 5	В	1	5	0	7	13
EUR J CARDIO THORAC	1 187	31 0	С	0	0	1	0	1
PULM PHARMACOL THER	1 094	27 6	C	1	0	0	0	1
J AEROSOL MED	0 929	24 1	С	0	0	0	0	0
J CARDIOTHOR VASC AN	0 917	20 7	С	1	0	5	0	6
THORAC CARDIOV SURG	0 850	17 2	С	1	0	0	0	1
HEART LUNG	0 620	13 8	C	0	0	0	3	3
RESPIRATION	0 556	10 3	C C C	1	9	0	8	18
SEM RESP CRIT CARE M	0 336	6 9	С	0	0	0	0	0
REV MAL RESPIR	0 192	3 4	С	0	0	0	0	0
Total				57	117	51	258	483

Rheumatology

Number of full papers (with impact factor) in Medline






Rheumatology subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).

Journals sorted according to the impact factor provided by the *Journal Citation Reports* (JCR) 2000 version for Rheumatology JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category: a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW).

Subject Category, Area	Impact	Adjusted	Publication	China	HK	SNG	TW	Total
Rheumatology	Factor	IF (%)	Туре	n	n	n	n	n
ARTHRITIS RHEUM	6 841	100.0	Α	1	9	1	4	15
BRIT J RHEUMATOL	3 949	95. <i>7</i>	Α	1	7	4	6	18
SEMIN ARTHRITIS RHEU	3.066	91 3	Α	0	2	0	0	2
J RHEUMATOL	2 910	87 O	Α	1	14	14	23	52
RHEUMATOLOGY	2.537	82.6	Α	0	4	1	3	8
LUPUS	2 514	78.3	Α	0	14	15	10	39
ANN RHEUM DIS	2 444	73 9	Α	0	7	5	13	25
RHEUM DIS CLIN N AM	2 257	69.6	Α	0	1	0	0	1
OSTEOARTHR CARTILAGE	2.080	65.2	В	0	0	1	0	1
CLIN EXP RHEUMATOL	1 638	60.9	В	1	4	1	9	15
BAILLIERE CLIN RHEUM	1.436	56.5	В	0	0	0	0	0
ARTHRIT CARE RES	1 398	52.2	В	0	0	0	0	0
SCAND J RHEUMATOL	1 396	47.8	В	0	8	0	17	25
RHEUMATOL INT	1 162	43.5	В	2	0	0	3	5
B RHEUM DIS	1 115	39 1	В	0	0	0	0	0
Z RHEUMATOL	0 730	34.8	В	0	0	0	0	0
CLIN RHEUMATOL	0.724	30.4	С	1	2	0	24	27
REV RHUM	0.681	26.1	С	0	0	0	0	0
I MUSCULOSKELET PAIN	0.464	21.7	С	0	0	0	0	0
ICR I CLIN RHEUMATOL	0 384	17.4	С	0	0	0	0	0
AKTUEL RHEUMATOL	0 260	8. <i>7</i>	С	0	0	0	0	0
BEST PRACT RES CL RH	0 260	13.0	С	0	2	0	0	2
JOINT BONE SPINE	0 022	4.3	С	0	0	0	0	0
Total				7	74	42	112	235

Surgery


Number of full papers (with impact factor) in Medline



1990 2001 1990 2001 1990 2001

Three year groups

CUHK



12 year period - 1990 to 2001

CUHK

Surgery subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).


Journals sorted according to the impact factor provided by the *Journal Citation Reports* (JCR) 2000 version for Surgery JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category: a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW).


Subject Category, Area
AM SURC PATHOL 4.269 99.3 A 2 45 O 13 60 TRANSPANTATION 4.036 98.5 A O O O O O TRANSPANTATION 4.036 98.5 A O O O TRANSPANTATION 4.036 98.5 O TRANSPANTATION 4.036 98.5 O TRANSPANTATION 4.036 98.5 O TRANSPANTATION 4.036 98.5 O O TRANSPANTATION 4.036 O TRANSPANTATION 4.036 O O TRANSPANTATION 4.036
DIGEST SURG 0.810 50.0 B 2 2 0 2 6

Subject Category, Area Surgery	Impact Factor	Adjusted IF (%)	Publication Type	China n	HK n	SNG n	TW n	Total n
I BURN CARE REHABIL	0.810	50.7	В	0	2	0	1	3
MINIM INVAS NEUROSUR	0.805	49.3	В	0	1	0	0	1
I HAND SURG AM	0.795	48.5	В	11	14	9 0	11 5	45
LAPAROENDOSC ADV A	0.783	47.8	В В	0 2	2	2	5	7 9
OPHTHALMIC SURG LAS	0.775 0.771	47.1 46.3	В	7	14	2	2	25
BRIT J ORAL MAX SURG J INVEST SURG	0.756	45.6	B	ó	0	ō	ī	1
EUR SURG RES	0.754	44.9	В	0	0	0	8	8
CHIRURG	0.721	44.1	В	0	0	0	0	0
CLEFT PALATE CRAN J	0.718	43.4	В	3 0	6 9	2 6	8 5	19 20
SURG LAPARO ENDO PER	0.691	42.6 41.9	B B	0	0	0	0	0
TRANSPLANT P	0.678 0.675	41.2	В	9	9	4	53	75
BRIT J PLAST SURG EUR J SURG	0.663	40.4	B	Õ	9	1	25	35
STEREOT FUNCT NEUROS	0.657	39.7	В	7	1	4	8	20
I CRANIO MAXILL SURG	0.636	39.0	В	1	6	2	0	9
AUST NZ J SURG	0.627	38.2	В	2	113	53	1 5	169
J RECONSTR MICROSURG	0.621	37.5	B B	1 <i>7</i> 0	3 0	5 0	0	30 0
LASER MED SCI	0.620 0.619	36.8 36.0	В	3	11	4	20	38
CLIN NEUROL NEUROSUR OPER TECHN SPORT MED	0.606	35.3	B	ő	0	Ó	0	0
I CARDIOVASC SURG	0.573	34.6	B	4	3	1	9	17
PHLEBOLOGY	0.571	33.8	В	0	0	0	0	0
CHILD NERV SYST	0.563	33.1	C	0	4	0	14	18
ANN CHIR GYNAECOL	0.550	32.4	C	0 1	1 0	0	0 0	1 1
ANN CHIR	0.545 0.541	31.6 30.9	C	1	0	1	4	6
J CRANIOFAC SURG BRIT J NEUROSURG	0.539	30.1	Č	2	8	2	4	16
MICROSURG	0.517	29.4	č	36	4	1	27	68
J ROY COLL SURG EDIN	0.510	28.7		3	27	22	0	52
ARCH ORTHOP TRAUM SU	0.507	27.9	Ç	1	9	0	27	37
NEUROSURG QUART	0.500	27.2	C	0 1	0	0	0 0	0 1
UNFALLCHIRURG	0.496 0.495	26.5 25.7	C	15	0 23	16	11	65
I HAND SURG BRIT EUR PEDIATR SURG INT	0.491	25.7	Č	1	10	0	22	33
INT SURG	0.488	24.3	č	3	4	3	37	47
GYNAECOL ENDOSC	0.485	23.5	C	0	0	0	0	0
INT J SURG PATHOL	0.463	22 8	C	0	0	0	1	1
SCAND I PLAST RECONS	0.450	22 1	C	2	1	0	3 0	6 4
ANN ROY COLL SURG I ENDOVASC THER	0.439 0.425	21.3 20 6	<u></u>	0 0	4 0	0	0	ō
CAN J SURG	0.423	19.9	Č	Ö	15	ő	4	19
AESTHET PLAST SURG	0.414	19.1	č	4	0	ŏ	Ť	11
NEUROCHIRURGIE	0.390	18 4	С	0	0	0	0	0
NEUROL MED CHIR	0.387	17.6	Č	0	0	0	0	0
INJURY	0.363	16.9	C	10	20	6	18	54 2
NEUROSURG REV SURG TODAY	0.358 0.356	16.2 15.4	C C	0 7	1 0	0 2	1 9	18
EUR J PEDIATR SURG	0.350	14.7	Č	ó	2	ō	ő	2
SURG RADIOL ANAT	0.314	14.0	č	19	ō	Õ	Ŏ	19
ZBL CHIR	0.302	13.2	C	0	0	0	0	0
SURG ONCOL	0.293	12 5	Ç	2	6	1	0	9
MINIM INVASIV THER	0.291	11.8	C	0	0	0	0	0
ACTA CHIR BELG KNEE	0.270 0.255	11.0 10.3	C	0 0	0	0	0	0
CRIT REV NEUROSURG	0.233	9.6	Č	0	ŏ	Õ	Ö	ő
CLIN TECH SMALL AN P	0.228	8.8	č	ŏ	ŏ	ŏ	ŏ	ŏ
I CARDIAC SURG	0.224	8.1	Ċ	Ó	1	0	9	10
TECH NEUROSURG	0.215	7.4	C	0	0	0	0	0
J CHIR PARIS	0.213	6.6	č	0	0	0	0	0
REV CHIR ORTHOP Skull base surg	0.212 0.185	5.9	<u> </u>	0 0	0	0	1 0	1 0
SKULL BASE SURG S AFR J SURG	0.165	5.1 4.4	Č	0	0 1	0	2	3
EUR I PLAST SURG	0.159	3.7	č	0	Ó	0	Õ	0
NEUROL SURG TOKYO	0.156	2.9	č	ő	ŏ	ŏ	ŏ	ő
NEUROCIRUGIA	0.154	2.2	Č	ŏ	ŏ	ŏ	Ŏ	0
CHIR GASTROENTEROL	0.078	1.5	000000000000000000000000000000000000000	0	Ō	0	0	0
CESK SLOV NEUROL N	0.059	0.7	С	0	0	0	0	0
Total				623	1078	418	1727	384

Toxicology

Number of full papers (with impact factor) in Medline





Toxicology subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).

	Appendix - Toxicology
	•
	was a funder or consistent of the control of the co
~	


Journals sorted according to the impact factor provided by the *Journal Citation Reports* (JCR) 2000 version for Toxicology JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category: a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW).


(continued)

Subject Category, Area	Impact	Adjusted	Publication	China	HK	SÑG	TW	Total
Toxicology	Factor	IF (%)	Туре	n	n	n	n	n
CHEM SPEC BIOAVAILAB	0.690	22.1	С	0	0	0	0	0
EXP TOXICOL PATHOL	0.689	20.8	C	0	0	0	0	0
J APPL TOXICOL	0.659	18.2	C	2	0	3	6	11
J HEALTH SCI	0.659	19.5	С	0	0	0	0	0
DRUG CHEM TOXICOL	0.619	16.9	C	0	0	0	4	4
B ENVIRON CONTAM TOX	0.513	15.6	С	109	8	12	62	191
IND HEALTH	0.500	14.3	C	4	0	0	7	11
VET HUM TOXICOL	0.463	13.0	C	0	0	0	0	0
FOOD AGR IMMUNOL	0.431	11 <i>.7</i>	С	0	0	0	0	0
IN VITRO MOL TOXICOL	0.418	10.4	C	0	0	0	0	0
I TOXICOL CUTAN OCUL	0.417	9.1	С	0	0	O	0	0
INT J TOXICOL	0.416	7.8	C	0	0	0	0	0
TOXICOL METHOD	0.375	6.5	C	0	0	0	0	0
TOX SUBST MECH	0.367	5.2	C	0	0	О	0	0
J PHARMACOL TOXICOL	0.350	3.9	C	2	0	2	0	4
ARCH LEBENSMITTELHYG	0.327	2.6	C	0	0	0	0	O
JPN J TOX ENV HEALTH	0.166	1.3	С	0	0	0	0	0
Total				344	70	91	474	979

Transplantation

Number of full papers (with impact factor) in Medline






Transplantation subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).


Journals sorted according to the impact factor provided by the *Journal Citation Reports* (JCR) 2000 version for Transplantation JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category: a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW).

Subject Category, Area	Impact	Adjusted	Publication	China	НК	SNG	TW	Total
Transplantation	Factor	IF (%)	Туре	n	n	n	n	n
TRANSPLANTATION	4.035	100.0	Α	6	18	1	17	42
XENOTRANSPLANTATION	3.268	93 8	Α	1	0	0	0	1
CELL TRANSPLANT	2.959	87 5	Α	1	1	0	3	5
I HEART LUNG TRANSPL	2.526	81.3	Α	0	0	0	3	3
BONE MARROW TRANSPL	2.396	<i>7</i> 5 0	Α	6	29	3	12	50
NEURAL PLAST	2.333	68.8	Α	0	0	0	0	0
I HEMATOTH STEM CELL	2.194	62 5	В	0	1	0	0	1
LIVER TRANSPLANT	2.130	56 3	В	0	0	1	0	1
NEPHROL DIAL TRANSPL	2.056	50.0	В	0	0	0	0	0
TRANSPLANT INT	2.049	43.8	В	0	0	0	2	2
CLIN TRANSPLANT	1.841	37 5	В	0	4	0	8	12
TRANSPL IMMUNOL	1.453	31.3	С	0	0	0	1	1
ASAIO I	1.152	25.0	C	5	0	1	11	17
INT LARTIF ORGANS	0.931	18.8	С	2	11	0	2	15
TRANSPLANT P	0.678	12.5	С	66	65	62	269	462
DIALYSIS TRANSPLANT	0.474	6.3	С	0	0	0	0	0
Total				87	129	68	328	612

Urology and Nephrology

Number of full papers (with impact factor) in Medline






Urology and Nephrology subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).


Journals sorted according to the impact factor provided by the *Journal Citation Reports* (JCR) 2000 version for Urology and Nephrology JCR subject category. The Area Adjusted impact factor (Adjusted IF) corresponds to the impact factor position in percentage of an individual journal among all the journals listed under the subject category a journal with an Adjusted IF between 67% to 100% represents a type A publication, 33% to 67% to a type B and 0% to 33% to a type C publication. The number of Medline publications published between January 1990 to November 2001 is quoted per journal for China, Hong Kong (HK), Singapore (SNG) and Taiwan (TW)

Subject Category Area	Impact	Adjusted	Publication	China	НК	SNG	T\V	Total
Urology and Nephrology	Factor	IF (%)	Туре	n	n	n	n_	n
J AM SOC NEPHROL	5 <i>7</i> 45	100 0	Α	0	4	2	7	13
KIDNEY INT	4 371	97 7	Ä	9	13	7	28	57
AM J PHYSIOL RENAL	4 129	95 3	Α	0	0	0	1	1
PROSTATE	3 754	93 0	A	3	15	0	1	19
AM I KIDNEY DIS	3 646	90 7	Ä	0	38	2	25	65
LUROLOGY	2 896	88 4	Ä	17	7	10	117	151
CURR OPIN NEPHROL HY	2 544	86 0	A	0	0	0	0	0
UROLOGY	2 489	83 7	A	1	2	5	22	30
CONTRIB NEPHROL	2 417	81 4	Ä	1	3	2	1	7
INT J IMPOT RES	2 413	79 1	A	Ò	0	3	1	4
SEMIN NEPHROL	2 304	76 7	A	Ö	ō	1	Ú	1
EUR UROL	2 058	74 4	A	2	2	Ó	44	48
NEPHROL DIAL TRANSPL	2 056	72 1	Ä	6	21	3	66	96
NEUROUROL URODYNAM	1 968	69 8	A	ő	1	ı̈́	3	5
PERITON DIALYSIS INT	1 842	67 4	Ä	3	30	8	21	62
NEPHRON	1 818	65 1	В	2	23	3	60	88
EXP NEPHROL	1 762	62 8	В	0	0	Õ	0	0
UROL CLIN N AM	1 710	60 5	B	Ő	Ö	õ	Ŏ	ŏ
BRIT I UROL	1 690	58 1	B	11	27	14	37	89
CLIN NEPHROL	1 638	55.8	В	4	8	5	6	23
KIDNEY BLOOD PRESS R	1 378	53 5	В	o O	0	Õ	1	1
PEDIATR NEPHROL	1 370	51 2	В	9	6	4	15	34
INEPHROL	1 289	48 8	В	ó	Ö	Ó	0	0
BLOOD PURIFICAT	1 276	46 5	B	Õ	ŏ	ŏ	8	8
J ENDOUROL	1 227	44 2	В	4	2	2	4	12
WORLD J UROL	1 119	41 9	B	o O	ō	ō	3	3
UROL RES	0 993	39 5	В	12	ĭ	ž	10	25
AM I NEPHROL	0 936	37 2	B	0	16	5	36	57
SEMIN DIALYSIS	0 902	34 9	В	1	0	Ö	0	1
MOL UROL	0 822	32 6	Č	ó	Ö	ŏ	Ő	Ö
BIU INT	0 817	30 2	č	3	4	Õ	18	25
PROSTATE CANCER P D	0 646	27 9	č	õ	ó	Õ	0	0
RENAL FAILURE	0 617	25 6	č	6	5	Õ	21	32
NEPHROLOGIE	0 488	23 3	č	ő	Õ	Ö	0	0
DIALYSIS TRANSPLANT	0 474	20 9	č	Õ	Ö	Ö	Õ	ő
SCAND J UROL NEPHROL	0 448	18 6	č	Ö	7	3	8	18
NEPHROLOGY	0 447	16 3	č	Õ	Ó	Ő	Õ	0
UROL INT	0 394	14 0	Č	2	ŏ	Ő	31	33
	0 333	11 6	Č	õ	ő	Ő	0	0
UROLOGE A	0 333	93	Č	0	Ö	ő	0	ő
NEFROLOGIA AKTUEL UROL	0 181	7 O	C	0	0	Ő	Ö	ő
	0 151	47	Č	0	0	ő	ő	ŏ
ANN UROL	0 067	2 3	C	0	0	0	ő	õ
NIEREN HOCHDRUCK	0 007	ر ہ		5	9	9	~	•
Total				96	235	82	595	1008

Virology

Number of full papers (with impact factor) in Medline






Virology subject category. The number of Medline publications with an Impact Factor listed in the Journal Citation Reports 2000 version from 1990 to 2001 (12 year period) and for four three-year groups (1990-1992, etc). The upper panel is for China, Hong Kong, Singapore and Taiwan. The lower panel is for Hong Kong institutions; the Chinese University of Hong Kong (CUHK), The University of Hong Kong (HKU), other academic institutions (Academia) and non-academic institutions or organizations (Other).



X18650949

570.7205 K18
Karlberg, J. (Johan)
Life science academic output
in predominantly Chinese
communities, 1990 to 2001:
China, Hong Kong, Singapore
and Taiwan





About the Author:

Professor Johan PE Karlberg (BSc, MD, PhD) completed his undergraduate BSc. studies in Statistics and Education at the University of Goteborg, Goteborg, Sweden in 1970. This was followed by undergraduate and PhD studies in Medicine, and a period of 17 years of employment at the same institution. Professor Karlberg has published extensively on child growth and development research. He has also been a visiting researcher at Universities in England, US and Pakistan before taking up a post in the Department of Paediatrics, The University of Hong Kong in 1993. Professor Karlberg is the founder, and the current full-time Director, of the Clinical Trials Centre, The University of Hong Kong. The Centre is the first, and at present, the only faculty based central clinical trial organisation in Asia. During the first four years of the Centre's operation (1998-2002) around 100 trial contracts with most of the largest 25 international pharmaceutical companies have been signed. The Centre is also responsible for trial quality assurance issues as well as marketing activities. In addition, the Centre has also developed other clinical trial support services such as Project Management, Monitoring, Data Management, Medical Statistics and Central Laboratory Services.

Clinical Trials Centre

Faculty of Medicine
The University of Hong Kong
Hong Kong SAR, PR China

Tel: (852) 2855 4664 , Fax: (852) 2974 1248 , E-mail: ctcentre@hkucc.hku.hk http://www.hku.hk/ctc